









McQuaker, Stephen (2013) Functional molecules to test the free radical 







Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 



















Functional Molecules to Test the 





Supervisor : Dr Richard Hartley 
 
 
Thesis submitted in part fulfilment of the requirements for the degree of Doctor of 




School of Chemistry 







  2 
Abstract 
 
Oxidative stress at a cellular level resulting from reactive oxygen species (ROS) has been 
implicated as a key factor in the ageing process and the development of age-related 
diseases.  Mitochondria are the primary source of endogenously generated ROS through 
the leakage of electrons from the respiratory chain to molecular oxygen.  Therefore there is 
a lot of interest in investigating ROS production and their biological impacts on both a 
cellular level and whole organism level. 
 
A mitochondria-targeted hydrogen peroxide (H2O2) probe (MitoB) i and a mitochondria-
targeted nitric oxide (
•
NO) probe (MitoDA) iii have been prepared to allow the detection 
and quantification of mitochondrial concentrations of these species in vitro and in vivo.  
These utilise the selective reactivity of boronic acids with H2O2 and 1,2-dianilines with the 
combination of 
•
NO and oxygen respectively to afford specific reaction products.  These 





The mitochondrial membrane potential (ΔΨm) is directly linked to levels of ROS 
production, with an elevated ΔΨm resulting in increased ROS production.  Mitochondrial 
membrane potential moderators that release uncoupling molecules from caged precursors 
selectively in the presence of H2O2 were developed.  Two untargeted analogues, DNP-
SUM v and FCCP-SUM viii were prepared to release 2,4-dinitrophenoxyl anions (DNP
–
, 
vi) or carbonyl cyanide-p-trifluoromethoxyphenylhydrazonyl anions (FCCP
–
, ix) 
respectively and their pseudo-first order kinetics assessed.   
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Two mitochondria-targeted analogues, MitoDNP-SUM(1) x and MitoDNP-SUM(2) xi 
designed to release DNP
–
 vi inside the mitochondrial matrix were prepared.  Their abilities 
to lower the ΔΨm and therefore the ROS producing capabilities in isolated rat skeletal 






Work was also conducted towards the development of mitochondria-targeted photo-
activatable probes that could potentially release small functional bioactive compounds 
from caged precursors inside individual mitochondria upon selective irradiation. 
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Chapter 1:  The free radical theory of ageing 
1.1 Mitochondria and the electron transport chain 
 
Mitochondria (Fig.1) are organelles found in the majority of eukaryotic cells (including 
human cells) inside which an array of biosynthetic reactions occur central to many 
biological processes.  Mitochondria play a number of key biological roles including the 
harnessing of dietary energy from fats and sugars, maintaining calcium and redox 
homeostasis as well as being critically involved in apoptotic and necrotic cell death.  These 
organelles comprise two semi-permeable phospholipid bilayer membranes, the 
mitochondrial outer membrane (MOM) enclosing the entire organelle and the 
mitochondrial inner membrane (MIM).  Embedded in the MIM are a number of specialised 
proteins that perform the various redox reactions of the respiratory chain (electron 
transport chain).
1,2
  The primary function of mitochondria uses the respiratory chain to 
produce the cellular “energy currency” adenosine triphosphate (ATP) by ATP synthase 
(ATPase, E.C. 3.6.3.14) inside the mitochondrial matrix.  A number of MIM infolds 
(cristae) maximise the surface area to maximise the number of potential reaction sites and 






The energy released from the oxidation of dietary energy sources such as sugars and fatty 
acids, leads to the flow of electrons along the four discrete, sequential protein complexes of 
the respiratory chain with concomitant pumping of protons out of the mitochondrial matrix 
(Fig.2).   
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Fig.2: MIM supported electron transport chain proteins and electron carriers
1,4 
 
Electrons can enter the electron transport chain via a number of points depending on the 
specific energy source.  NADH dehydrogenase (complex I, E.C. 1.6.5.3) or succinate 
dehydrogenase (complex II, E.C. 1.3.5.1) where NADH and succinate are converted into 
NAD
+
 and fumarate respectively are two of the key electron entry points although others 
exist such as mitochondrial glycerol phosphate dehydrogenase (GPDH-M, E.C. 1.1.5.3). 
 
The oxidation of NADH at complex I occurs in a single two electron transfer process 
which reduces flavin mononucleotide (FMN) into FMNH2.
1
  Two subsequent single 
electron transfers (SET) to Fe-S centres in complex I occur before the electrons are passed 
on to reduce the lipid-soluble electron-carrier ubiquinone 1 (coenzyme Q) into ubiquinol 3 
(QH2) via a semiquinone intermediate 2. 
 
 
Scheme 1: Reduction/oxidation of coenzyme Q/ubiquinol 
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Complex I translocates four protons from the matrix into the intermembrane space (with a 
further two protons entering the Q-pool), helping to establish the MIM membrane 
protomotive force which comprises electrochemical potential (ΔΨm) and pH gradient 
components. 
 
Succinate dehydrogenase (complex II, E.C. 1.3.5.1) obtains electrons following the 
reduction of flavin adenine dinucleotide (FAD) to FADH2 by succinate (which itself is 
oxidised to fumarate) before being passed to coenzyme Q via three Fe-S centres.  Minor 
contributors of electrons to the Q-pool such as fatty acid metabolism (acyl-CoA-
dehydrogenase, E.C. 1.3.99.3) or from GPDH-M are also passed to co-enzyme Q via FAD/ 
FADH2 co-factors.  Complex II is not involved in proton pumping across the MIM. 
 
In the cytochrome bc1 complex (complex III, E.C. 1.10.2.2), cytochrome b sequentially 
binds two molecules of QH2 from the quinone pool (Q-pool) which are then divergently 
oxidised (Fig.3) at the Qo site.
1
  One electron from each of the two QH2 molecules is 
passed sequentially to water-soluble electron-carrier cytochrome c in the intermembrane 
space (IMS) via a Rieske iron-sulphur centre with four protons being released into the 
IMS.  The other electron from each QH2 molecule is passed to the Qi site (via the 
cytochrome bL and cytochrome bH hemes) where one molecule of coenzyme Q is reduced 
to QH2 taking two protons from the mitochondrial matrix.  In total four protons enter the 
IMS from the Q-pool, with two protons from the mitochondrial matrix partially 




Fig.3: Overall cytochrome bc1 complex cycle (complex III)
1
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Cytochrome c oxidase (complex IV, E.C. 1.9.3.1) transfers one electron each from four 
molecules of cytochrome c to molecular oxygen generating two molecules of water in the 
mitochondrial matrix.
1
  Eight protons are removed from the matrix with four forming water 
and four protons entering the IMS per O2 molecule fully reduced. 
 
MIM supported transmembrane protein ATPase harnesses the energy of ΔΨm established 
by complexes I, III and IV by allowing protons to flow back down the gradient into the 
mitochondrial matrix.
1
  ATPase uses this energy to convert adenosine diphosphate 4 
(ADP) into the high energy molecule ATP 5 through oxidative phosphorylation with the 
stepwise reduction of oxygen to water as a by-product (Scheme 2).  ATPase comprises a 
membrane pore with a rotating head group of subunits on the matrix side which is where 
ADP 4 is converted into ATP 5.  For each full head group rotation of mitochondrial 
ATPase, nine protons are taken from the IMS and three molecules of ATP 5 are produced.  
ATP 5 is then transported around the body and used as the energy source to power a 
plethora of biochemical reactions before being transported back to a mitochondrial matrix 
as ADP 4 to once again be converted into ATP 5.  Signalling molecule guanosine-5'-
triphosphate produced in the citric acid (Krebs) cycle can also be converted into ATP 5 by 
nucleoside-diphosphate kinases, however this is generally not a major contributing factor 
to overall ATP 5 levels. 
 
 
Scheme 2: Synthesis of ATP 5 from ADP 4 by ATPase 
 
A number of MIM uncoupling proteins that regulate the controlled dissipation of ΔΨm 
have been identified.  The first known as thermogenin or uncoupling protein 1 (UCP1) was 
discovered by Nicholls et al in 1978.
5
  Since then a further four uncoupling proteins have 
been confirmed.  This energy-dissipation mechanism serves a number of functions 
including thermogenesis, maintaining redox homeostasis and the reduction of reactive 
oxygen species (ROS) production.  The concept of mitochondrial uncoupling and in 
particular its impact on ROS levels will be discussed in further detail in chapter 6. 
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1.2 Oxidative stress, ROS production 
 
The term oxidative stress describes an imbalance between a biological systems production 
of ROS and its ability to readily detoxify the species produced or to repair the resulting 
damage.
6
  Alterations to the normal redox state of cells can lead to toxic effects through the 
production of free radicals and peroxides that can damage all components of the cell, 
including proteins, lipids and DNA. 
 
Molecular oxygen (O2) exists predominantly as a diradical or “triplet” state but also as the 
much shorter lived electron-paired or “singlet” state resulting from spin flipping of one 
electron in the highest occupied molecular orbital (Fig.4).  Oxygen availability is highly 
controlled in the body and is transported tightly bound to iron-based metalloproteins 
hemoglobin in the blood and myoglobin in muscle tissue.  These give the body a high level 
of control ensuring that oxygen is delivered when and where it is needed by the body.  
Perhaps more importantly, although necessary for the vast majority of life, oxygen can be 
toxic and so highly efficient sequestering of oxygen within an organism is vital to prevent 
cytotoxicity.  If triplet oxygen gains an electron it becomes the superoxide radical anion 
(O2
•−
).  If a second electron is gained the oxygen-oxygen bond order is reduced to one with 




formed.  In an aqueous medium this will pick up one or two 
protons depending on the pH to form hydroperoxide anions (HO2
−
) or hydrogen peroxide 
(H2O2, pKa = 11.62 at 25 °C).  Addition of a further electron causes oxygen-oxygen bond 
cleavage giving a hydroxide anion (HO
−







Fig.4: Oxygen orbital filling – In all diagrams, the lower energy σ1s, σ1s*, σ2s and σ2s* 
molecular orbitals are all fully occupied 
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Despite the electron transport chain being a highly efficient process, during its many redox 
reactions, occasionally electrons are prematurely leaked to molecular oxygen from 
complexes I and III of the respiratory chain or directly from the Q-pool to produce O2
•−
, 
particularly if normal cellular redox states have been altered.  Evidence from studies in 





Although mitochondria are thought to be the main endogenous source of ROS, other 
biological sources have been identified including xanthine oxidoreductase (XOR).  XOR 
exists as one of two interconvertable enzymatic forms, xanthine oxidase (XO, E.C. 
1.17.3.2) and xanthine dehydrogenase (XDH, E.C. 1.17.3.4).  XO catalyses the two step 
catabolism of purine residues such as the oxidation of hypoxanthine 6 to uric acid 8 
(Scheme 3) and is often reported as a producer of superoxide.  However under 
physiological conditions hydrogen peroxide has recently been reported to be the major 







Scheme 3: Xanthine oxidase oxidation of purine residues produce ROS 
 
Additional ROS sources include the body’s immune system which uses ROS such as 
hypochlorous acid (HOCl) generated by neutrophils to eradicate bacterial infections and 
background ionising radiation that can lead to ROS formation through homolytic cleavage 
of oxygen-hydrogen bonds in water. 
 
1.3 ROS proliferation and biological defence mechanisms 
 
The human body has developed a range of defence mechanisms to protect against 
oxidative stress.  Superoxide dismutase (SOD, E.C. 1.15.1.1) rapidly converts superoxide 
into H2O2 and O2 in the mitochondrial matrix via a disproportionation reaction mechanism 
(Scheme 4).  In eukaryotic cells, SOD predominantly use Cu/Zn co-factors.  Prokaryotes 
and protists utilise Mn or Fe co-factors while prokaryotic cells may also use Ni as a co-
factor.  
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 → M(n+1)+−SOD + H2O2 
Half Reaction   :  M
(n+1)+−SOD + O2
•−
 → Mn+−SOD + O2 




 → H2O2 + O2 
where M = Cu (n=1) ; Mn, Fe or Ni (n=2) 
Scheme 4: SOD disproportionation reaction 
 
Catalase enzymes (CAT, E.C. 1.11.1.6) catalyse the disproportionation reaction that 
converts H2O2 into O2 and water (Scheme 5) without the formation of radical by-products 
and are found in the cells of almost all living organisms that utilise aerobic respiration as 
well as certain anaerobic organisms.
11
  CAT is present to minimise ROS damage resulting 
from H2O2 generated by SOD.  Human CAT targeted to the mitochondrion of transgenic 
mice can lead to a significant increase in both maximum and average murine lifespan by 




Proposed Half Reaction : H2O2 + Fe(III)−CAT → H2O + O=Fe(IV)−CAT(
.
+) 
Proposed Half Reaction : H2O2 + O=Fe(IV)−CAT(
.
+) → H2O + Fe(III)−CAT + O2 
Overall CAT Disproportionation Reaction  :  2H2O2 → 2H2O + O2 
Scheme 5: Catalase disproportionation Reactions 
 
A family of glutathione peroxidases (GPx, E.C. 1.11.1.9) utilise a selenocysteine residue in 
their active sites to convert H2O2 into water via the dimerisation of tripeptide glutathione 9 
(GSH) into glutathione disulfide 11 (GSSG, Scheme 6).  Glutathione reductase (GSR, E.C. 
1.8.1.7) regenerates both molecules of GSH 9 using a stoichiometric NADPH co-factor. 
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Scheme 6: GPx reaction with H2O2 and the reversible dimerisation of GSH 9 
 
Any H2O2 which manages to evade CAT or GPx breakdown exists sufficiently as a neutral 
molecule at physiological pH to freely diffuse away from the matrix.  In contact with redox 
active metal ions throughout the body, including but not exclusively the first row transition 
metals [eg. iron(II)] used as enzyme co-factors, H2O2 forms highly reactive and damaging 
hydroxyl radicals (HO
•
).  This mechanism was originally reported by Fenton in 1894 as a 
method for oxidising organic molecules using H2O2 in the presence of iron(II) salts 
(Scheme 7).
13
  The toxicity associated with many highly poisonous metals such as 





Scheme 7: Reaction of H2O2 with biologically important metal ions 
 
Hydroxyl radicals initiate damaging radical cascades, reacting with DNA, lipid 
membranes, proteins, etc. at rates close to diffusion control.  Phospholipids are the major 
component of lipid membranes comprising polar head groups lined up on the membrane 
interior and exterior faces with hydrophobic tails embedded within the membrane.  The 
head groups usually comprise a phosphate group and a simple organic molecule such as 
choline (Fig.5), while tail groups generally contain diglycides which can vary in length and 
degree of unsaturation. 
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Fig.5: Bis-linoleic acid and choline derived phospholipid 
 
Lipid peroxidation by ROS starts with hydrogen atom abstraction by hydroxyl radicals 
(Schemes 8 and 9).
15
  Polyunsaturated fatty acid tails are more susceptible to oxygen-
centred radical induced hydrogen atom abstraction as the lipid radicals generated are more 
stable.  The lipid radicals (L
•
) generated can react with molecular oxygen to give lipid 
peroxyl radicals (LOO
•
) which can undergo further hydrogen atom abstraction from other 
fatty acid tails in the membrane, resulting in radical propagation. 
 
 
Scheme 8: Lipid (LH) peroxidation radical cascade overview 
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Scheme 9: Lipid peroxidation radical cascade initiation and propagation 
 
Lipid peroxides can further oxidise, cyclise intramolecularly or cross-link with other lipids.  
These can then fragment by a number of mechanisms including Hock cleavage to give 
non-radical products including isoprostanes 13, aldehydes 14 and isofurans (Scheme 10).  
This leads to lipid membrane instability and potentially cellular or organelle collapse. 
 
  25 
 
Scheme 10: Radical induced breakdown of arachidonic acid 12 
 
ROS damage to DNA and RNA occurs predominantly through reaction with hydroxyl 
radicals or their lipid derived radical products.  Superoxide and hydrogen peroxide do not 
react directly with DNA.  A number of potential oxidative modifications to base-pairs can 
occur which can lead to base-pair mismatches, mutations and DNA strand breakages 
through the breakdown of the sugar backbone.
16
   
 
Proteins can also be severely damaged by hydroxyl radicals.  All amino acids are 
susceptible to ROS damage with tryptophan, tyrosine, histidine and cysteine noted as 
particularly vulnerable.  ROS damage has been seen to cause significant structural 





The human body also utilises antioxidants, either endogenously produced or obtained 
through diet, to inhibit the oxidation of sensitive biomolecules by terminating radical 
cascades.  These may behave in a stoichiometric manner such as melatonin or undergo 
redox cycling to regenerate the antioxidants, as is the case for ascorbic acid (vitamin C) 
and the family of tocotrienyls and tocopherols 16 (vitamin E) (Scheme 11).  Vitamin E is 
lipophilic so embeds itself in phospholipid membranes and primarily protects against lipid 
peroxidation.  
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Scheme 11: Vitamin E redox cycling by vitamin C.  R = 2,6,10-trimethylundecane 
 
Hydroxyl, lipid peroxyl or carbon-centred radicals can abstract the phenolic hydrogen atom 
from α-d-tocopherol 16 to generate radical 15.  Ascorbic acid monoanion 17 donates an 
electron to reform the neutral α-d-tocopherol antioxidant 16.  Unlike vitamin E, vitamin C 
is water soluble and so this electron transfer must occur at the lipid-water interface.  The 
semihydroascorbate (ascorbyl radical) 18 is a relatively inert radical which loses an 
electron to form dehydroascorbate 19.  This final electron transfer can paradoxically lead 
to pro-oxidant behaviour of vitamin C as it may reduce free Fe(III) to Fe(II), which can 
then participate in the Fenton mechanism of ROS production (Scheme 7).  Similarly Cu(II) 




Endogenous antioxidants GSH 9 and uric acid 8 can react directly with hydroxyl radicals.  
GSH 9 undergoes hydrogen abstraction followed by dimerisation (Scheme 12) while uric 
acid 8 (pKa = 3.1, predominantly urate at physiological pHs) donates an electron to give 
hydroxide and a more stable, longer lived radical 21 which is then quenched by GSH 9 or 
ascorbic acid (Scheme 13). 
 
 
Scheme 12: Glutathione reaction with hydroxyl radicals 
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Scheme 13: Uric acid reaction with hydroxyl radicals 
 
Lipoic acid (LA) 23 behaves as an anti-oxidant in vitro by rapidly reacting with ROS such 
as H2O2 and hypochlorous acid (HOCl) in its reduced form dihydrolipoic acid 22 (DHLA, 
Scheme 14).  The ability of LA 23 to directly scavenge ROS in vivo has been widely 
debated with much of the antioxidant behaviour of LA 23 potentially coming from DHLA 
22 after reduction by the endogenous thioredoxin (Trx(SH)2)/thioredoxin reductase (TrxR, 





Scheme 14: Lipoic acid reduction/oxidation 
 
(R)-Lipoic acid [(R)-LA] 23 is a more efficient antioxidant than the unnatural enantiomer 
(S)-LA as the former is enzymatically recycled while the latter appears to reversibly inhibit 
the enzymes involved in the recycling process.
25
  (R)-LA 23 and (S)-LA will however react 
with achiral ROS at the same rate.  The mechanism for the antioxidant activity of LA 23 
may be more complex than simple direct ROS scavenging.  Recently the impact of LA 23 
on a number of biological processes including modulation of signal transduction and gene 
transcription was observed.  These processes can improve the antioxidant status of the cell 
(eg. activation of phase II detoxification via the transcription factor Nrf2) and it is possible 




The ability of antioxidants to protect the body relies heavily on their bioavailabilities and 
how well they can accumulate in sites of high ROS production.  The abilities of other in 
vitro antioxidants (Fig.5) obtained through diet such as polyphenols (eg. quercetin 24 and 
cathecin 25) and carotenoids (eg. β-carotene 26) to protect in vivo has been widely debated 
due to bioavailability issues, rapid metabolism and observed pro-oxidant behaviour.
27,28
  
Research into the area of antioxidant behaviour and protective mechanisms is ongoing. 
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Fig.5: In vitro antioxidants may not protect in vivo 
 
1.4 Free radical theory of ageing 
 
As an organism ages, oxidative damage accumulates at the cellular level over time.  This is 
the basis for one of the leading theories on ageing and age-related disease known as the 
free radical theory of ageing (FRTA).  First proposed in the mid 1950’s by Professor 
Denham Harman,
29
 FRTA describes how the effects of ageing and the resultant diseases 
can be attributed to the accumulation of lipid, protein and nucleic acid damage from free 
radicals, leading to a decline in function and ultimately disease with age.  The FRTA arose 
from a number of supporting observations.  In particular, exposure to ultraviolet light was 
known to generate oxygen-centred radical ROS in cells as well as cause signs of premature 
ageing.  This coupled with the knowledge that biological systems generate low levels of 
oxygen-centred radical ROS under normal conditions led to the basis for the FRTA. 
 
The production of ROS in mitochondria as a by-product of aerobic respiration is the main 
endogenous source of oxidative stress in the body.  It is important to reduce oxidative 
stress as strong evidence exists implicating it as a contributing factor in the development of 
a wide range of age-related diseases, including arteriosclerosis, neoplasia, stroke and 
cataracts as well as neurodegenerative diseases
6,30,31
 such as Alzheimer’s and Parkinson’s.  
Initially focussed strictly upon free radicals, the FRTA has been expanded to include other 
ROS and reactive nitrogen species (RNS).  Direct evidence for the FRTA was provided by 
the overexpression of human catalase targeted to murine mitochondria which extended 
lifespan by 20% and reduce signs of ageing in mice.
12
  Furthermore, human Trx(SH)2 
expression in transgenic mice showed protection against oxidative stress and extended 
median lifespan by 35%
32
 while overexpression of SOD can extend the lifespan of fruit 
flies (Drosophila melanogaster) by up to 48%.
33 
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1.5 RNS Production and proliferation 
 
Reactive nitrogen species (RNS) are a class of compounds including nitric oxide (
•
NO) and 
products derived thereof such as its reaction products with molecular oxygen (nitrite 
radical, 
•





 and thiols (S-nitrosothiols, RSNO).  Nitric oxide is an important intercellular 
signalling molecule produced by nitric oxide synthases (NOSs, E.C. 1.14.13.39) through 
the oxidation of L-arginine 27 into L-citrulline 28, requiring a number of co-factors 
including hemes, flavins and calmodulins (Scheme 15).  Once generated 
•
NO rapidly 
diffuses (average lifetime ranges from ms to s) from the point of origin and reacts with 
other biomolecules, often modifying their function. 
 
 
Scheme 15: Nitric oxide production by nitric oxide synthase 
 
In humans, the NOS family includes neuronal NOS (nNOS), a constitutive enzyme found 
in many different cell types, inducible NOS (iNOS) found in macrophages and endothelial 
NOS (eNOS) used to modulate vascular tone.  A debate as to whether or not mitochondrial 
NOS (mtNOS) or mitochondrial NOS-like enzymes exist is ongoing.  However current 
evidence suggests this is unlikely as the mitochondrial genome does not contain any NOS-
like sequences.  If mtNOS was synthesised in the nucleus, import mechanisms for it and all 
of the necessary co-factors would have to be in place.
35,36
  To date no conclusive evidence 
supporting the existence of mtNOS has been reported. 
 
Nitric oxide plays an important role in a number of biological processes including 
angiogenesis, insulin secretion, vasodilation, central nervous system development as well 
as cytotoxic immune responses.  Nitric oxide also directly regulates the functions of a 
whole host of proteins including glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
E.C. 1.2.1.12), creatine kinase (CK, E.C. 2.7.3.2), cytoskeletal proteins (tubulin and S-
actin), receptors (ryanodine receptor), transcription factors (TF cJun), thioredoxin 
[Trx(SH)2] and glutaredoxin (Grx).
37
  Despite this the entirety of 
•
NO roles in biology has 
not yet been fully elucidated. 
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Regardless of whether mtNOS exists or not, and although 
•
NO presence is evidently 
necessary in mitochondrial biology, it is clear that elevated levels of 
•
NO in mitochondria 
can produce a number of potentially detrimental biological effects in this organelle and as a 
result in the organism as a whole. 
 
•
NO itself is known to be a potent reversible competitive inhibitor of complexes III and IV 
as well as mitochondrial actinase at physiological nanomolar concentrations linking it as a 
potential moderator of physiological respiration.
38
  iNOS activated in response to 
inflammation signals produce sufficient 
•
NO to inhibit not only their own respiration, but 
also that of surrounding cells.  However it is likely that inhibition of the respiratory chain 
can protect cells in vivo under hypoxia conditions by slowing oxygen consumption, 
preventing anoxia which would cause apoptosis.
39
  Reversible inhibition of cytochrome c 
oxidase occurs when the 
•
NO binds to the reduced copper or iron centres in the catalytic 
centre leading to the exclusion of oxygen.  When 
•
NO binds to the oxidised form, 
inhibitory nitrite can be produced via hydration.  Nitrite radicals can oxidise ferrous iron in 
haemoglobin to ferric iron, preventing it from binding oxygen which combined with the 
•
NO inhibitory effects could potentially sensitise cells to hypoxia.  As a result, whether or 
not 
•
NO has an overall beneficial or detrimental effect on respiration is unclear.  It is likely 
at normal physiological concentrations 
•
NO has a beneficial effect but is detrimental at 
elevated levels, particularly as this leads to elevated concentrations of secondary RNS 
species (Scheme 16). 
 
 




  31 
Biological RNS can also cause nitration and S-nitrosation of proteins leading to direct and 
indirect changes to function and turnover efficiency.  For example it has been observed 
that nitrosation of complex IV subunit II results in a decline in levels of mitochondrial 
glutathione (GSH 9) and its dimer (GSSG 11).
42,43,44
   
 
Peroxynitrite can inhibit a number of mitochondrial components including complex I, 





NO2, N2O3 and S-nitrosothiols have also been seen to cause weak 
non-selective irreversible inhibition of a number of mitochondrial components.
46,47
  
Furthermore RNS such as 
•
NO2, N2O3, HNO2 and peroxynitrite can damage DNA through 
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Chapter 2:  Methods of targeting mitochondria 
 
As mitochondria have been strongly linked as the major cause of oxidative stress in the 
body, it is important to be able to selectively target potential therapeutic agents to this 
organelle over other compartments of the cell.  A number of methods for the selective 
delivery of biologically active molecules to mitochondria have been studied and have been 
recently reviewed.
49
  In particular, conjugation of desired payload molecules to delocalised 
lipophilic cations (DLCs) such as alkyl triphenylphosphonium (TPP)
50
 and quaternary 
ammonium salts,
51
 or to short peptide sequences comprising alternating lipophilic and 
basic side chains (the latter of which are predominantly cationic at physiological pHs) have 
been utilised.
52,53
  The key features of both approaches is to balance the incorporation 
cationic moieties so as to take advantage of ΔΨp and the large ΔΨm established by aerobic 
respiration to drive compound uptake with the need for sufficient lipophilic character to 
enable the traversing of the cellular phospholipid membrane, MOM and MIM. 
 
2.1 Delocalised lipophilic cations as a mitochondrial targeting strategy 
 
TPP compounds were originally developed by the groups of Murphy and Smith to 
investigate ΔΨm, but since have been employed be a number of groups to deliver a plethora 
of compounds to mitochondria.
49,54
  Utilising TPP salts as a mitochondria-targeting group 
has a number of advantages and disadvantages.  Firstly, it is relatively easy to synthetically 
introduce TPP groups (Chapter 7.4) and if introduced late in the synthesis, it gives a 
convenient handle for the synthesis of analogues containing radio- or stable deutero-
labelled TPP moieties for use in uptake, metabolism or mass spectrometry studies (Chapter 
6). 
 
The synthetic disadvantage of TPP moieties is that once incorporated into a molecule, the 
TPP group often dominates the physical characteristics.  If only one TPP species is present 
this can be advantageous as they can readily be precipitated from ethereal solvents or 
readily separated by silica column chromatography.  However if multiple TPP compounds 
are present, this can make separation of closely related synthetic products and by-products 
very difficult.  Therefore this limits the reactions that can be easily used after TPP has been 
introduced as it is vital to obtain high, selective conversion.  The scope of available 
reactions is also narrowed by the possibility of generating undesired phosphonium ylides 
or oxidation of phosphorous to give diphenylphosphine oxides under certain basic 
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conditions.  The latter is a rapid transformation driven by the formation of the strong 
phosphorus-oxygen double bond (Scheme 17).  This transformation does not occur 
significantly at physiological pHs. 
 
 
Scheme 17: Undesirable oxidation of TPP compounds to phosphine oxides 
 
The extent to which TPP-conjugates accumulate in the mitochondrial matrix is heavily 
dependant upon the magnitudes of the potential gradients across the MIM (ΔΨm, 150-180 
mV in healthy cells) and to the cellular plasma membrane potential (ΔΨp, 30-60 mV), both 
of which are negative on the internal membrane face (Fig.6).  The Nernst equation (Fig.7) 
can be used to calculate the concentrations of charged species across these membranes and 
indicates that singly charged cationic molecules should display a ten-fold increase in 
accumulation for every 61.5 mV at 37 °C assuming no other significant external factors, 
such as active molecular transport mechanisms or rapid irreversible binding to cellular 
components are taking place.  TPP compounds generally behave as predicted by the Nernst 
equation and are known to accumulate in the mitochondrial matrix in concentrations many 
hundred-fold higher than in the cytosol as a result of the large ΔΨm.
55
  Toxicity of TPP 
compounds is not usually a problem as the compounds are reversibly equilibrated between 
all intracellular and extracellular regions.  For example, a number of mice studies and a 
year-long phase II trials of MitoQ 29 (Chapter 3.1) in humans have been conducted with 
no adverse effects observed.
56
  As metabolism and excretion occur from circulation, TPP 
compounds from within the mitochondria diffuse back into the circulation so that the 
equilibrium is maintained.  However, this is not possible if the TPP compound is converted 
into a cell impermeable compound within the mitochondria or if it forms irreversible 
covalent attachment to an intracellular macromolecule. 
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Fig.7: Nernst equation and its simplified version converted to log10. 
Where EV and EmV = ΔΨm (in V and mV respectively), R = gas constant (J K
-1
),  
T = temperature (K), z = ion charge, F = Faraday constant (C mol
-1
),  
[Ion]o and [Ion]i = ion concentration outside and inside of the membrane respectively. 
 
Studies to assess the uptake by TPP dications found that although uptake was higher than 
the analogous TPP monocations, the uptake levels predicted by the Nernst equation (10-
fold increase for each ~30 mV) were not reached.  The exact reasons for this are currently 
unclear but it was understandably found that the lipophilic character had to be higher for 




It is not sufficient that TPP-conjugates accumulate in mitochondria; they must also not 
disrupt the cellular or mitochondrial membranes or otherwise adversely affect biological 
pathways (other than those deliberately targeted by the molecule linked to the TPP group), 
as this can lead to toxicity and cell death.  At low concentrations DLCs have been 
repeatedly found to be non-toxic, but at elevated concentrations the build up of charge 
inside the mitochondrial matrix has been seen to inhibit respiration and oxidative 
phosphorylation and ultimately induce the mitochondrial permeability transition, a trigger 
of apoptosis.  However it must be noted that the concentrations in question are usually 
significantly higher than therapeutic doses.  Incubating cells with micromolar 
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concentrations of TPP compounds allows for millimolar concentrations to be achieved in 
the mitochondrial matrix, levels at which no disruption of membranes or inhibition of 




TPP compounds are rapidly taken up (within 5 min) by energised mitochondria after 
intravenus administration
60
 and clearance profiles fit well to the Nernstian distribution of 
cationic compounds.  TPP compounds are also readily distributed throughout the body 
through oral administration as long as they can withstand the high acidity of the stomach 
and first pass effects.  As compounds are metabolised and excreted via liver and kidneys, 
redistribution from high concentrations to circulation maintains equilibrium with half lives 




Extensive work has been conducted on TPP compound uptake by isolated energised 
mitochondria.  However when studying intact cell systems it is more difficult to clearly 
illustrate TPP-derivatives have successfully accumulated in mitochondria over other 
cellular compartments as mitochondria depolarise and as a result release lipophilic cations 
during cell subfractionation.  Iodoacetamide-TPP 30 (IAM-TPP, Fig.8) has been used to 
label mitochondrial thiols such as membrane protein cysteine residues.  IAM-TPP 30 
accumulates in the mitochondrial matrix in the standard TPP manner but the reactive 
iodoacetamide moiety undergoes SN2 displacement of iodide by protein thiols in the matrix 
to form stable thioethers that cannot be cleared.  Localisation of IAM-TPP 30 can 





Fig.8: IAM-TPP 30 alkylates mitochondrial protein thiols 
 
2.2 Mitochondria-penetrating peptides 
 
An alternative approach for the selective delivery of molecules to mitochondria is through 
the use of mitochondria-targeted peptides.  These are comprised of a short peptide chains 
of alternating lipophilic and basic (protonated at physiological pH) side-chains.
52
  Initial 
studies by Schiller, Szeto and co-workers indicated that uptake of tetra-peptides (SS-
peptides) into cells followed by localisation to mitochondria was largely independent of 
ΔΨm, although other studies suggest a significant ΔΨm dependence.
63
  One such example is 
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SS-31 31 (Fig.9) which is comprised of D-Arg–Dmt (dimethyltyrosine)–Lys–Phe–NH2.  A 
number of analogues have been made with similar side chains with alternating 
arrangements and the C-terminus is often amidated to improve stability.  Observations 
during fluorescence tagging studies indicated that SS-peptides may selectively bind to the 
MIM, however the exact nature of any such interactions remain unclear. 
 
 
Fig.9: Mitochondria-targeting by peptides with lipophilic and cationic side chains 
 
To date no comprehensive in vivo studies have been reported that look at potential 
metabolism issues which arise from using a peptide targeting system, however 
incorporation of unnatural D-amino acids and unnatural side chains like Dmt should slow 
metabolism due to mismatching with enzymatic binding sites. 
 
This concept has been developed further by Kelley and co-workers who have looked to 
optimise peptide chain properties through the adaption of peptide length, side-chain type 
and ordering of amino acids to deliver of bioactives to mitochondria.
53,63,64
  Mitochondria-
targeting of chemotherapy drug chlorambucil 32 led to a significant increase in potency 
resulting from targeted cross-linking of mitochondrial DNA by the nitrogen mustard 
(Fig.10).  The therapeutic window was maintained through elevated uptake by chronic 
lymphocytic leukaemia cells compared to normal healthy cells as the mitochondria of 
cancer cells often have elevated ΔΨm.  Combined with the reduced uptake to HL60 cells in 
the presence of mitochondrial uncoupler carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP 33, Fig.11), ΔΨm appears to play a role in 
compound uptake.  A thiazole orange fluorophore was incorporated to enable compound 
monitoring by confocal microscopy.  Despite thiazole orange being a lipophilic cation 
itself, no comment was made as to the effect that this unit had on uptake but it is highly 
likely that this would have assisted uptake in this study.  However, it has since been 
reported that anionic fluorophores can also be delivered by this approach due to the 
  37 
molecule maintaining a net positive charge, something not possible for singly cationic TPP 
molecules.
65
  As in SS-peptides, unnatural amino acid residues are incorporated to slow 
metabolism. 
 
This study is one of many that highlights the fact that mitochondria-targeting of 
therapeutics is a realistic strategy for improving both new and existing disease treatments 
including chemotherapy agents.
63,66
   
 
 
Fig.10: Mitochondria-targeted chlorambucil 32 
 
 
Fig.11: Mitochondrial uncoupler FCCP 33 (Chapter 7 for further discussion) 
 
2.3   Alternative mitochondria-targeting approaches 
 
Alternative approaches for targeting materials to mitochondria to date have found limited 
usage but are in principle viable targeting mechanisms.  Harnessing some of the 
mitochondrial active transport machinery is one potential route that may be explored 
further in time.  Recently a patent has been granted related to the use of the carnitine-
acylcarnitine translocase (CACT) system for the mitochondria-targeted delivery of cis-
platin anti-cancer agents.
67
  The molecule L-carnitine 34 is used by the body to recognise 
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and actively transport fatty acids into the mitochondrial matrix for catabolism.  
Incorporating an L-carnitine 34 like moiety into a prodrug molecule could potentially 
allow delivery of molecules by the CACT system with prodrug release by carnitine 
palmitoyltransferase II (E.C. 2.3.1.21) embedded on the inside wall of the MIM.  The 
Hartley group recently published work towards a mitochondria-targeted spin-trap 





Fig.12: L-Carnitine 34 derivatives are potential mitochondria-targeting agents 
 
This method may be particularly suited to targeting cancerous cells as these rapidly 
dividing cells require an elevated uptake of raw materials including fatty acids.  Thus 
harnessing the up-regulated CACT system may allow some degree of selectivity to be 
achieved.  However to exploit active transport machinery the compounds used must retain 
binding properties to enzymatic active sites which in certain cases may not be accessible to 
molecules of substantially altered size, lipophilicity, number of rotatable bonds, etc. 
 
Targeting to mitochondria-specific binding sites has also been considered.  It has been 
suggested that the accumulation of 10-N-nonylacridine orange 36 (Fig.13) results from 
binding mitochondria-specific phospholipid cardiolipins.
69
  However this molecule is itself 
a lipophilic cation and therefore some (if not a large) degree of uptake would be expected 
to result via the same passive mechanism as other DLC compounds. 
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Chapter 3:  Small molecules targeted to mitochondria 
3.1  Mitochondria-targeted antioxidants 
 
A wide range of antioxidants, dyes, molecular probes and sensors have been made to 
accumulate in mitochondria utilising lipophilic TPP cations.  Conventional antioxidants are 
ineffective as they lack the ability to accumulate in sufficient concentrations where ROS 
are produced and most lack the ability to penetrate mitochondria.  Therefore mitochondria-
targeted antioxidants have been designed to protect against all components of 
intramitochondrial ROS cascades and many are known to protect against markers of 
oxidative stress in vitro and in vivo (Figs.14 and 15).
49
  In the literature discussion that 
follows the anionic counterion is arbitrary as this will rapidly exchange in vitro or in vivo. 
 
 
Fig.14: Mitochondria-targeted antioxidants 
 
 
Fig.15: Mitochondria-targeted antioxidants can target all aspects of mitochondrial ROS
57
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By far the most extensively studied TPP antioxidant is MitoQuinone 29 (MitoQ).  It was 
studied in vivo to assess the distribution properties of the TPP compounds throughout an 




H] Radiolabelled MitoQ 29 and 
controls were administered via either oral or intravenous (IV) tail vein injections in mice 
and concentrations in various organ tissues assessed at differing time points.  It was found 
that blood concentrations fell rapidly with a substantial uptake by kidney and liver tissues 
within 5 min of IV administration.  A lesser uptake to heart tissue and very little uptake by 
brain or adipose tissue were seen.  MitoQ 29 clearance from liver, kidneys and heart were 
2, 4 and 15 h respectively with almost complete loss of MitoQ 29 after 48 h.  Due to the 
lipophilicity of MitoQ 29 it is predominantly found adsorbed to the mitochondrial 




When the quinol form of MitoQ 29 acts as an antioxidant it is oxidized to the quinone 
form, which is then rapidly reduced by complex II back to the quinol, restoring its 
antioxidant efficacy.  Using a reverse driven ATPase system to establish ΔΨm (Chapter 
8.2.2) enables MitoQ 29 uptake but lacks the ability for the respiratory chain to reduce 
MitoQ 29 and so efficacy is lost.  Furthermore it was found that the reduced form MitoQ 
29 is not oxidized by complex III and therefore cannot act as an electron carrier to restore 
respiration in mitochondria deficient in coenzyme Q.  Quinols have been seen to undergo 
redox cycling in vitro under certain conditions which can lead to O2
•−
 formation however 




MitoPeroxidase 38 (MitoPrx, Fig.14) is a mitochondria-targeted version of the 
isoselenazole derivative ebselen 43, which is a mimetic of glutathione peroxidase (E.C. 
1.11.1.9, Scheme 18).  Ebselen 43 uses a selenium atom to reduce H2O2 to water and 
converts lipid hydroperoxides into the corresponding alcohols.
71,72
  Selenol 46 is the 
catalytically active species which can be formed from ebselen 43 by reaction with two 
equivalents of glutathione or by reduction by either thioredoxin [Trx(SH)2] or thioredoxin 
reductase (TrxR).  Oxidation of selenol 46 by hydroperoxides regenerates ebselen 43 via 
selenenic acid 47, which rapidly undergoes an intramolecular condensation reaction. 
 
Ebselen 43 itself can be directly oxidised slowly by hydroperoxides or rapidly by 
peroxynitrite to selenoxide 42.  However this is readily re-reduced by GSH 9 or TrxR.  
Diselenide 44 is also readily reduced to the active selenol 46 by TrxR or Trx(SH)2 and 
slowly by GSH. 
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Scheme 18: Ebselen mimetic catalyses the detoxification of peroxides. R = H or lipid. 
 
MitoPrx 38 uptake into energised, isolated mitochondria was confirmed as well as its 
activation in cells by intracellular GSH 9 and thioredoxin systems.  Additionally it was 
successful in reducing oxidative damage by hydroperoxides in cells.  However, unlike 
MitoQ 29 and MitoE 40, no significant improvement in efficacy over ebselen 43 itself 
through TPP conjugation was found.  The reason for this is currently unclear. 
 
MitoE 40 is a mitochondria-targeted version of α-d-tocopherol (the main component of 
vitamin E) found to accumulate rapidly in mitochondria, approximately 80-fold greater 
than endogenous vitamin E.
59
  As a result of elevated mitochondrial concentrations, MitoE 
40 was found to protect against oxidative stress, reducing lipid peroxidation and protein 
damage significantly better than the natural antioxidant.  MitoE 40 protects against 
oxidative stress by exactly the same mechanism as vitamin E (Chapter 1.3, Scheme 11), 
involving redox cycling by ascorbic acid.  Like vitamin E, MitoE 40 is lipophilic so 
embeds itself in phospholipid membranes and primarily protects against lipid peroxidation.  
 
  42 
Mitochondria-targeted lipoic acid 41 (MitoLip) was synthesised and assessed for its ability 
to protect against oxidative stress by the groups of Murphy and Smith.
24
  It was found that 
although uptake by energised mitochondria occurred, no protection against ROS was 
observed.  This was due to the minimal reduction (5-10%) of MitoLip 41 to the active 
reduced form, dithiol MitoLipH2 compared to endogenous (R)-lipoic acid 23.  In particular 
TrxR was unable to reduce MitoLA 41 in vitro. 
 
A mitochondria-targeted version of the superoxide dismutase mimetic (M40403) 
developed by Salvemini et al
73
 has also been developed by the group of Smith (MitoSOD 
37) with results appearing in abstracts but currently unpublished. 
 
Stable piperidine and pyrrolidine nitroxides 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl 
(TEMPO) and the analogous 3-carboxy proxyl (CP) can scavenge radicals in vitro and in 
vivo and mitochondria-targeted analogues MitoTEMPO 48 and MitoCP 49 have been 
developed (Fig.16).
74,75,76
  These can directly scavenge radicals, act as SOD mimetics 
(Scheme 19) and oxidise Fe(II) to Fe(III) preventing radical formation via the Fenton 
mechanism (Chapter 1.3, Scheme 7).   
 
 
Fig.16: Mitochondria-targeted radical scavengers act as SOD mimetics 
 
 
Scheme 19: Nitroxides as SOD mimetics and direct radical scavengers 
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Nitroxides behave as SOD mimetics through redox cycling between the nitroxide radical 
and the oxidised oxoammonium cation forms.  Nitroxide redox potentials are tuneable by 
modification of ring sizes and substituent effects.
77
  For each complete redox cycle two 
molecules of superoxide are disproportionated into one molecule of molecular oxygen and 
one molecule of hydrogen peroxide. 
 
A potential limitation of nitroxide usage as antioxidants in biological systems is that they 
are rapidly reduced to hydroxylamines by species such as ubiquinol in the MIM.  However 
in studies of MitoTEMPOL 48 and MitoCP 49, protection against oxidative stress was 
maintained even in the hydroxylamine forms.
78,79
  Hydroxylamines protect against radicals 
through hydrogen atom abstraction to reform a nitroxide radical species in a stoichiometric 
manner.  Murphy and co-workers found hydroxylamines to be significantly better at 
protecting against lipid peroxidation and DNA damage than the parent nitroxide. 
 
The above examples show that targeting materials to mitochondria can yield improved 
selectivity and/or efficacy (MitoQ 29, MitoE 40, MitoTEMPOL 48) demonstrating the 
viability of mitochondria as a potential therapeutic target.  However, in dealing with 
complex biological systems in which many pathways and their interactions are still not 
fully understood, success is not guaranteed (MitoLip 41).  Nonetheless, targeting by TPP 
provides a robust and reliable approach to deliver materials to mitochondria, allowing the 
roles of ROS/RNS and various bioactive molecules to be probed and understanding of their 
effects to be developed. 
 
3.2 Mitochondria-targeted bioactives 
 
A number of biologically active molecules other than antioxidants have been targeted to 
mitochondria using DLCs as a targeting mechanism.  These can be broadly split into two 
classes.  The first class like the antioxidants previously discussed retain a covalent 
attachment to their TPP moiety throughout usage while a second class undergo specific 
fragmentations to release active molecules in situ. 
 
Mitochondria-targeted S-nitrosothiol 50 (MitoSNO) selectively delivers 
•
NO to the 




NO release from MitoSNO 50 by reaction with 
glutathione (or other mitochondrial thiols) was found to reversibly inhibit complex III, 
cause vasodilation and protect against heart ischemia-reperfusion (I/R) injury (through S-
nitrosation of mitochondrial proteins), consistent with the known behaviour of 
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endogenously produced 
•
NO (Chapter 1.5).  Thus MitoSNO 50 can be used to study the 
reversible modulation of respiration and protection against I/R by 
•
NO.  The S-nitrosation 
occurred in approximately 1% of mitochondrial protein thiols despite the presence of a 
fully reduced GSH 9 pool.  Therefore it is possible that certain thiols are particularly 




Scheme 20: MitoSNO 50 delivers nitric oxide to mitochondria 
  
Spin traps react selectively with free radicals such as HO
•
 to give longer-lived radicals that 
can then be detected using electroparamagnetic resonance (EPR) spectroscopy (Scheme 
21).  The high selectivity of spin traps overcomes a number of problems inherent with 
using the commonly used fluorescent sensors for identifying ROS in biological systems 
(discussed further in Chapter 4).  However, despite being longer-lived species than the 
highly reactive free radicals, the spin trap adducts formed are themselves often 
decomposed or metabolised relatively quickly to EPR silent products, limiting their use as 
an identification and quantification tool.
80
  Furthermore reactions of free radicals with 
nitrone spin traps are often slow, leading to elevated concentrations of the probes being 







 and MitoDEPMPO 55
80,84
 have been 
developed but due to low sensitivities of these probes combined with adduct 
decomposition, none have been successfully used to quantify ROS in vivo.  Spin traps may 
be developed in the future with improved stability and reactivity but until then a better 




Scheme 21: Radical trapping by nitrone spin traps 
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Fig.17: Mitochondria-targeted spin traps 
 
A range of photosensitisers such as MitoPorphyrin 56 have been targeted to mitochondria 
using DLCs with the view to developing photodynamic therapy (PDT) agents to treat 
cancer (Fig.18).
85,86,87  
PDT uses photoreactions mediated by photosensitisers activated by 
light to produce bursts of ROS such as singlet oxygen in specific cells or cellular 
compartments.  The localised ROS generated damage the cell sufficiently so that apoptosis 
occurs.  As mitochondria are key regulators of damage signalling and apoptosis through 
the activation of the mitochondria outer membrane permeability (MOMP) transition pores, 




Fig.18: Mitochondria-targeted photosensitisers are potential PDT agents 
 
Cyclosporin A (CsA) is a lipophilic undecapeptide inhibitor of cyclophilins (CyPs), a 
family of peptidylprolyl cis-trans isomerases.
88
  CyP-D localised in mitochondria 
facilitates MOMP through the formation of permeability transition (PT) pores.  Inhibition 
of CyP-D by CsA can protect against much of the mitochondrial damage caused by I/R 
injury and subsequent necrosis by preventing PT pore formation.  In targeting CsA to 
mitochondria (Fig.19), although binding affinity was partially reduced, its selectivity 
towards CyP-D over cytosolic CyP-A was markedly increased leading to an improvement 
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in cytoprotection against I/R induced necrosis.  In contrast to the many small functional 
molecules previously discussed, this study displays the abilities of TPP targeting to deliver 
relatively large, complex molecules to mitochondria and the possibilities of modulating 
function through selective inhibition of mitochondrial enzymes. 
 
 
Fig.19: Mitochondria-targeted cyclosporine A 
 
3.3 Mitochondria staining 
 
Although TPP targeting has been extensively studied, other non-phosphorus based 
lipophilic cations can also accumulate selectively in mitochondria.  For example, 
rhodamine, rosamine and carbocyanine cationic fluorescent dyes such as the MitoTracker 
series have been widely used to stain energised mitochondria in vitro (Fig.20).  These not 
only allow the position and quantity of mitochondria present to be observed, but also can 
allow the effects that various stimuli such as UV or oxidative bursts have on the respiratory 
chain to be monitored. 
 
All of the probes in the MitoTracker series (58 to 64, Fig.20) use non-phosphorus based 
DLCs to drive accumulation in mitochondria with modifications to fluorophore 
substituents and spacers optimising fluorescence properties.  Rosamine-type probes 61 and 
63 require oxidation into lipophilic cations 62 and 64 inside the cell before mitochondrial 
uptake can occur which can give information regarding the redox state of cells under study.  
Once in the mitochondrial matrix, the benzylic chloride moieties react with membrane-
bound protein thiols giving covalent attachment through stable thioether linkages.  The 
concentrated localisation of fluorescence allows mitochondria to be imaged.  One problem 
with the MitoTracker series (Invitrogen) beyond inherent fluorescence limitations (Chapter 
4.5), is that they are known to photosensitize cells which can lead to depolarisation of 
ΔΨm, mitochondrial swelling and apoptosis.
89
  Covalently binding to cysteine residues also 
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prevents clearance from cells increasing toxicity profiles and can potentially impact protein 
function by modifying structure or by blocking either active or co-factor binding sites. 
 
 
Fig.20: MitoTracker dye series used to stain energised mitochondria 
 
Carbocyanine dye 65 (JC-1, Invitrogen) is a fluorescent dye that allows the ΔΨm status of 
individual mitochondrion to be monitored (Fig.21).  As a lipophilic cation, JC-1 65 
accumulates in energised mitochondria as previously discussed.  Mitochondria with 
elevated ΔΨm will uptake higher concentrations of JC-1 65, as defined by the Nernst 
equation.  Under these conditions JC-1 65 forms aggregates within the mitochondrial 
matrix which modify its fluorescent properties.  Above a critical concentration, J-
aggregates form.  This stains mitochondria red-fluorescent with λem maximum at 590 nm.  
If ΔΨm collapses (a key sign of apoptosis), monomeric JC-1 65 is released into the 
cytoplasm where it is green-fluorescent with λem maximum at 527 nm.  Thus clear 
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differentiation between mitochondria of varying ΔΨm can be made, in particular in the 
study of apoptotic or necrotic cell death in which ΔΨm becomes dissipated.  Furthermore, 
JC-1 65 monomers and J-aggregates both can be visualised simultaneously by fluorescence 
microscopy using a wide band-pass filter exciting at 488 nm. 
 
 
Fig.21: ΔΨm sensitive fluorescent probes 
 
The fluorescent dye Safranin O 66 (Fig.21) can also be used to monitor ΔΨm of isolated 
mitochondria.  Safranin O 66 fluoresces when used in dilute solutions but upon uptake into 
the small volume of the mitochondrial matrix, the elevated concentration causes self-
quenching to occur.  Thus ΔΨm and perturbations thereof can be monitored.  However, 
Safranin O 66 is not suited for studying mitochondria in intact cells as it will readily stain 
cell nuclei and can also be used to stain cartilage, mucins and mast cell granules. 
 
An alternative approach to mitochondrial staining is to employ mitochondria-targeted 
photoproteins such as aequorin or green fluorescent proteins (GFPs).  GFPs refer to a 
number of natural and artificially modified proteins obtained from marine organisms, 
traditionally from the jellyfish aequorea victoria.  These have been expressed in a number 
of transgenic organisms and cell lines with mitochondria-targeted versions expressed in 
plants.
90
  However modification of gene expression is not a robust, versatile tool for 
studying mitochondria and altering gene expression can lead to many unpredicted 
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Chapter 4:  Fluorescent ROS and RNS sensors 
 
ROS and RNS are central to pathological oxidative stress, cellular redox signalling 
pathways and a host of other metabolic functions ranging from stimulating cell growth to 
defence.  As previously discussed (Chapter 1) the exact biological roles of the individual 
ROS and RNS are poorly understood due to difficulties in measuring their individual 
concentrations in vivo.  Thus it is vital to develop techniques that allow the selective and 
accurate measurement of these dynamic species and to be able to make these 
measurements with confidence. 
 
In recent years a vast array of small molecule sensors have been developed to detect and 
quantify ROS and RNS as well as probe many other biological systems including calcium 
and protein binding.
91
  Chemical sensors designed to probe biological ROS or RNS must 
display high sensitivity and selectivity towards specific ROS/RNS, give a measureable 
response and ideally in a ratiometric manner (ie. the unreacted and reacted probes can both 
be detected so that a ratio of these can be determined and quantification of the ROS/RNS is 
not distorted by the concentration of the probe).  All reaction products must be clearly 
distinguishable from both the starting probe molecules and any by-products/breakdown 
products.  The probes must also be stable to the environments under study, be non-toxic 
and ideally cell permeable. 
 
The majority of sensors have been developed to detect changes in fluorescence resulting 
from direct reaction between the probe and ROS/RNS.  These are extensively used as they 
are generally simple, user-friendly assays that can be monitored with a range of 
fluorescence-based techniques such as confocal microscopy and flow cytometry. 
 
Sensors can be categorised as reversible or irreversible.  The output signal of a reversible 
sensor is directly related to the concentration of the species being detected at any given 
time and can go down if the concentration of that species drops.  Ion sensors are generally 
reversible and use ligands to bind an ion of interest.  The resulting complex has different 
fluorescent properties from the free sensor that can be detected.  An increase or decrease in 
the ion concentration leads to an increase or decrease in the complex concentration and so 
leads to a corresponding amplification or drop in the emission signal of the complex.  On 
the other hand, the output signal of irreversible sensors (or detectors) always increases as 
the sensor is irreversibly converted into another compound by the species being detected.  
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The concentration of the species being detected affects the rate of this conversion and 
therefore the rate of the output signal change.  As the incubation time of the sensor affects 
the magnitude of the signal, the sensor outputs are determined as the total change in output 
after a given period of time.  Almost all ROS/RNS sensors are irreversible sensors. 
 
One of the most widely employed sensors to monitor intracellular oxidative stress is 
dichlorodihydrofluorescein diacetate 67 (DCFH-DA) and its analogues (Scheme 22).
92,93
  
This cell permeable probe is hydrolysed by intracellular esterases to give DCFH 68 which 
can be retained by the cell.  Two electron oxidation of DCFH 68 gives fluorescent reporter 
molecule dichlorofluorescein 69 (DCF). 
 
 
Scheme 22: DCFH-DA 67 hydrolysis and oxidation 
 
Although an extensively used assay, a number of significant limitations exist with DCFH-
DA 67 as with many other fluorescence-based assays.  Firstly DCFH 68 does not react 
directly with H2O2 (which it is often used to measure), but instead the products of its 
interactions with peroxidases and hemes (eg. cytochrome c) such as HO
•
 radicals.  
Furthermore a host of other single-electron oxidising species can oxidise DCFH 68 to DCF 
69 such as peroxynitrite, 
•
NO2, HOCl and redox-active metals in the presence of O2 or 
H2O2.
92,94
  The intermediate radical DCF
•−






) to give 
O2
•−
 which after SOD disproportionation produces H2O2, ultimately leading to self-
propagating redox cycling and therefore fluorescence signal amplification.  In using 
DCFH-DA 67 a number of reactions are being monitored simultaneously including the rate 
of acetate hydrolysis by esterase enzymes, which in certain cell lines is insufficient to 
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4.1 Hydrogen peroxide detection and boronate caging 
 
One way to overcome the above issues is to detect chemoselective transformations such as 
the conversion of boronic acids and boronate esters by H2O2 under basic conditions to give 
the corresponding alcohols or phenols (Scheme 23).
95
  Initial attack on the vacant p-orbital 
of boron by the hydroperoxide anion is followed by a carbon migration to oxygen 
displacing a hydroxide anion.  This anion then attacks boron atom in an identical manner to 
the first step and the alkoxy or phenoxy groups (depending on R) are displaced with 




Scheme 23: Reaction of boronic acids/boronate esters with hydrogen peroxide 
R = alkyl, aryl or vinyl           R’ = H, alkyl or aryl 
 
This reaction has been widely employed synthetically in Brown hydroboration-oxidation of 
alkenes and terminal alkynes to generate anti-Markovnikov alcohols and aldehydes 
respectively.
96
  More recently the mechanism has be used as a trigger in sensors designed 
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Conversion of the electron-withdrawing boronate 70 to an electron-donating 
phenol/phenoxide 72 allows electron redistribution resulting in fragmentation and release 
of a reporter molecule such as a fluorophore 73.  Release from the caging linker will 
modify fluorophore electronics and therefore fluorescence.  Thus the presence of H2O2 in 
the system under study acts as a fluorescence “on switch”, identifying the presence of this 
species.  The quinone methide by-product 74 will be rapidly trapped by water to form 
benzylic alcohol 75.
99
   
 
In 2003, Lu and Chu reported the synthesis of two such boronate-containing H2O2 sensors 
76 and 77 (Fig.22) that release reporter molecules p-nitroaniline or 7-amino-4-
methylcoumarin respectively (measured by fluorescence or UV/Vis spectrometry), to be 
used as diagnostic tools for the presence of H2O2.
97
  A linear response of reporter molecule 
release with H2O2 addition was observed.  Furthermore the potential relevance of this 
approach towards use in biological systems was demonstrated in the indirect measurement 
of glucose levels when the substrate was pre-digested with glucose oxidase (E.C. 1.1.3.4) 
which is known to produce H2O2 as a by-product. 
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Fig.22: Lo and Chu’s H2O2 sensitive boronate probes 
 
Chang and co-workers subsequently reported the synthesis of Peroxy Lucifer 1 (PL1) 78 
(Fig.23).
100
  PL1 reacts with endogenously generated H2O2 from macrophages as well as 
being selective over other ROS tested including superoxide, nitric oxide, hydroxyl radicals 
and hypochlorite.  The probe was cell permeable and ratiometric with a 12-fold increase in 
the ratio of fluorescence maxima for the released aminonaphthalimide dye after reaction 
with H2O2 over PL1 (F540/F475, λex = 410 nm), a blue-fluorescent to green-fluorescent shift.  
However Lo and Chu’s probes, along with PL1 all release cell permeable dyes which 




Fig.23: PL1 78 R = (CH2)2O(CH2)2OAc 
 
Thus families of xanthene and phenoxazine based H2O2 sensing fluorescent probes have 
been produced by Chang and co-workers (79 to 88, Fig.24, Table 1) with structural 
modifications used to tune fluorescent properties.  The use of a lactone pendant group in 
fluorescein derivatives (79 to 85) is opened after phenol generation forming a caboxylate 
anion at physiological pHs resulting in the probe becoming trapped inside the cell 
analogous to DCFH 68.  These probes further differ from the boronate based probes 
previously discussed as they do not rely upon molecular fragmentation after reaction with 
H2O2.  They do however maintain conversion from electron-withdrawing boronates to 
electron-donating phenols as an “on/off switch” mechanism.91  Fluorescein analogues have 
been used in a variety of imaging and labelling studies of biomolecules as they are highly 
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responsive, generally possess high quantum yields ( ) in aqueous environments and are 
excitable at longer wavelengths (which are convenient for confocal microscopy using 
Ar/ion lasers and causes less damage to biological components) than many other 
fluorophores.
101
   
 
 
Fig.24 and Table 1: H2O2 selective sensors developed by Chang and co-workers 
R R’ X   
B(Pinacol)   PF1 80 
OMe   PF2 81 
OH   PF3 82 
NH2   PE1 83 
NEt2   PY1 84 
N(CH2CH2)2N(CH2)4PPh3I   MitoPY1 85 
 B(Pinacol) NH PR1 86 
 B(Pinacol) C(O) PX1 87 
 O N PC1 88 
 
MitoPY1 79 is a mitochondria-targeted variant which allows mitochondrial H2O2 levels to 
be probed.  A further advantage of using arylboronates/arylboronic acids in to study 
endogenous ROS produced by mitochondria is that the active oxidant is the conjugate base 
of H2O2 (pKa = 11.62 at 25 °C).  Consequently the reaction of this trigger mechanism with 
H2O2 is faster in the mitochondrial matrix (pH ~8.0-8.3) compared to the cytosol (pH ~7.2-
7.4) resulting in improved selectivity and conversion rates. 
 
A problem with the fluorescent probes discussed above is that fluorescence only occurs 
after reaction with H2O2, while it is often desirable to be able to monitor the probe prior to, 
as well as after reaction (ie. they are not ratiometric).  To this end ratio-peroxyfluor-1 
(RPF1 89, Scheme 25) was developed by incorporating a fluorescent coumarin marker.  
RPF1 89 absorbs and emits predominantly from the coumarin moiety with λabs and λem 
maxima at 420 and 464 nm respectively, consistent with coumarin based emission and 
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minimal fluorescence resonance energy transfer (FRET) to the closed fluoran acceptor.  
After reaction with H2O2 the major λem maximum shifted to 517 nm with a minor λem at 
461 nm consistent with the proposed FRET process and emission by the open fluorescein 
90.  RPF1 89 reacts selectively with H2O2 over other biologically relevant ROS tested and 
gave an ~8-fold increase in the ratio of fluorescein-type and coumarin-type emission 





Scheme 25: RPF1 89 opening allows FRET 
 
RPF1 89 successfully allowed the detection and ratiometric quantification of H2O2 levels 
in isolated mitochondria from yeast (Saccharomyces cerevisiae) inhibited with antimycin 
A, a complex III inhibitor, to produce endogenous ROS including H2O2 after dismutation 
of O2
•−
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4.2 Superoxide detection 
 
To date non-fluorescent hydroethidium (HE) 91 and its mitochondria-targeted analogue 
MitoHE 92 (MitoSOX) are the most widely used probes to detect superoxide (O2
•−
).  In the 
presence of O2
•−














A major problem HE 91 and MitoHE 92 is that literature reports indicate that they are 
susceptible to oxidisation by a variety of biological species other than O2
•−
 and are oxidised 
rapidly in air.
103,104,105





proteins (cytochrome c, haemoglobin, myoglobin) or manganese porphyrins of HE 91 give 
E
+
 103 or associated dimers HE-HE 105, HE-E
+




 109 (Scheme 27).  MitoHE 
92 undergoes analogous oxidations to give MitoE
+
 104 and dimers MitoHE-MitoHE 106, 
MitoHE-MitoE
+




 110.  Furthermore all of these products are 





109 (and likely analogue 110) is significantly lower due to intramolecular quenching.  
Thus identifying the exact species present and in what ratios in any given mixture by 
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fluorescence techniques alone is not possible. For a clearer indication of O2
•−
 presence, 
HPLC-fluorescence or LC-MS would be required to analyse product distributions. 
 
 




The red-fluorescence of the phenanthridinium compounds above are significantly 
quenched in aqueous environments due to the water molecules in the solvation shell.  
However upon interchelation to DNA, water molecules are displaced and fluorescence is 
restored.
106
  DNA interchelation raises potential toxicity issues in vivo although E
+
 103 has 
been used as a stain for DNA and RNA in vitro.
107
  Thus if fluorescence is used as the read 
out, HE 91 and MitoSOX 92 are inefficient identification or quantitative tools for 
intracellular O2
•−
 levels and are instead more suited to assessing the overall redox state of 
cells.  However, to date MitoSOX 92 displays the best selectivity profile for O2
•−
 and 
although the above species are indistinguishable from each other via fluorescence, using 
MS techniques should allow each species to be readily identified and quantified. 
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4.3  Nitric oxide sensors 
 
Molecular probes designed to detect nitric oxide (
•
NO) predominantly use the conversion 
of 1,2-dianilines 111 into 1,2,3-benzotriazoles 112 by 
•
NO under aerobic conditions.
108
  
The exact reactive species and mechanism involved has not been confirmed but it is most 
likely that the reactive species is a nitrosonium (NO
+
) ion equivalent produced by auto-
oxidation of species such as N2O3.  This can form a diazonium intermediate which closes 
to give a benzotriazole (Scheme 28).  This is a highly selective reaction which gives a 
single, generally stable product.  Although an indirect measurement of 
•
NO, the 
concentrations of any NO
+
 containing species are directly related to the concentrations of 
precursors molecules 
•





Scheme 28: Proposed 1,2-diamines react with nitrosonium ions 
 
In recent years Nagano and co-workers have developed families of diaminofluoresceins 
(DAFs 113-118, Fig.25, Table 2), diaminorhodamines (DARs, 119-121, Fig.25, Table 2) 
as well as BODIPY based systems (Fig.26) to detect 
•
NO as these fluorophores possess 
high quantum yield ( ).109,110,111,112  In all cases the formation of the electron poor 
benzotriazole stops photon-electron transfer (PET) and therefore restores fluorescence.  
This approach behaves as a fluorescence “on/off switch” analogous to the boronate probes 
designed to detect H2O2 developed by Chang and co-workers.
91,102
  Several other groups 
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Fig.25 and Table 2: Nitric oxide sensing fluorophores by Nagano 
X Y Z R R’ R’’ R’’’   
H OH O H H NH2 NH2 DAF-1 113 
H OH O H NH2 NH2 H DAF-2 114 
H OH O NH2 NH2 H H DAF-3 115 
Cl OH O H H NH2 NH2 DAF-4 116 
Cl OH O H NH2 NH2 H DAF-5 117 
Cl OH O NH2 NH2 H H DAF-6 118 
H Et2N Et2N
+
 H H NH2 NH2 DAR-1 119 
H Et2N Et2N
+
 H NH2 NH2 H DAR-2 120 
H Et2N Et2N
+
 H NH2 NHMe H DAR-M 121 
 
 
Fig.26: BODIPY based nitric oxide sensing fluorophores by Nagano 
 
Monosubstitution of the dianiline moiety in DAR-M 121 and TMAPABODIPY 123 will 
likely improve the selectivity towards 
•
NO by preventing 1,2-dicarbonyls found in 
biological systems (eg. glyoxal) from forming quinoxaline derivatives.  In these cases the 
less favourable, higher energy and likely reversible quinoxalinium derivatives would form. 
 
A number of metal-based fluorescent 
•
NO sensors have also been developed which take 
advantage of the reactions of 
•
NO either directly at the metal centre or at ligand sites close 
to the metal.  A number of paramagnetic or heavy metals such as Fe(II), Co(II), Cu(II), 
Ru(II) and Rh(II) can been used to quench fluorophore fluorescence until reduced and/or 
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released by reaction with 
•
NO by one of three mechanisms (Scheme 29).
114
  Fluorophores 
ligated to the metal centres can be directly displaced (A) or the metal centre can be reduced 
with or without fluorophore displacement (B or C) resulting in fluorescence. 
 
 
Scheme 29: Metal based nitric oxide probe fluorescence “on/off” mechanisms 
L = ligand or metal-metal bond  
 
Although many of these metals are not suitable for biological applications due to toxicity 
issues, Lippard and co-workers have recently reported the potential for a number of Cu(II) 
based 
•
NO probes such as CuFL 124 (Scheme 30)
115,116,117,118
 as have other groups with 
probes such as MNIP-Cu 126 (Scheme 31).
119
  These probes display excellent selectivity 
towards 
•
NO over other RNS/ROS and rely on the generation of an N-nitrosamine and 
displacement of a ligated metal ion to moderate fluorophore fluorescence.  Incorporating a 




Scheme 30: CuFL 124 reaction with nitric oxide 
 
 
Scheme 31: MNIP 126 reaction with nitric oxide 
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) is associated with elevated 
•
NO production and its 
diffusion to sites of O2
•−
 formation, where the two react together at close to diffusion rates 








  The generally low steady state concentrations and high 
reactivity of this short-lived species make identification and quantification difficult 
although concentrations are markedly increased under certain circumstances, such as 
during bacterial infection resulting from elevated 
•
NO production by iNOS.  ONOO
−
 (pKa 
6.8) can cause oxidation and nitration and can be converted into other ROS and RNS via 
peroxynitrous acid (ONOOH, ~20% under physiological conditions).
121
  This makes 
obtaining reaction selectivity for ONOO
− 
over more abundant and longer-lived ROS and 






A number of groups have used oxidation of dihydrorhodamine-123 128 (DHR-123, Fig.27) 
or dichlorodihydrofluorescein (DCDHF) 129 to detect ONOO
−
 but these molecules suffer 
from non-peroxynitrite specific oxidation from other ROS and RNS or by light.
121,122
  The 





  Although the photostability is greater and detection limits are lower than for 
DHR-123 128 and DCDHF 129, this approach again suffers from non-peroxynitrite 









To date two notable attempts at developing ONOO
−
 sensing fluorescent probes have been 
made.  Although both employ a BODIPY fluorophore with modulation of an aromatic 
pendant acting as an “on/off switch”, the approaches look to harness different types of 




The group of Nagano have used an analogous approach to their 
•
NO sensors previously 




  NiSPY-3 130 relies 
on nitration of the benzene moiety by peroxynitrite to activate fluorescence (Scheme 32) 
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by the removal of PET between the aryl and BODIPY moieties.  NiSPY-3 130 showed a 
linear response towards ONOO
−
 and high selectivity for this RNS over other ROS and 




NO, singlet oxygen and hypochlorite).  The 
carboxylic acid group is incorporated to improve aqueous solubility and could potentially 
aid cellular retention, however no studies were reported. 
 
 
Scheme 32: Nitration of ONOO
−
 detector NiSPY-3 130 
 





  Oxidation of ketone 132 to hemi-acetal 133 gives a large 
increase in fluorescence through removal of PET.  This probe gives a linear response 
towards ONOO
−
 and high selectivity for this RNS over other ROS and RNS tested, but 
showed a lower selectivity (~3 fold) over HO
•
.  In vitro studies (murine macrophage cell 
lines) using lipopolysaccharide, interferon-γ and phorbol myristate acetate to trigger ROS 
and RNS formation via iNOS led to the predicted increase in fluorescence while the use of 





.  Reaction of HKGreen-2 132 with ONOO
−
 alone was observed in 
an abiotic system with DMSO suppression of HO
•
.  Unfortunately no reliable routes to in 
vitro suppression of HO
•
 currently exists without impacting ONOO
−
 levels.  Beyond the 
potential selectivity issues with endogenous HO
•
, the probe only fluoresced under 
artificially high ONOO
−
 concentration.  Therefore monitoring of endogenous ONOO
−
 




Scheme 33: HKGreen-2 132 reacts with peroxynitrite to give fluorescent hemi-acetal 133 
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4.5 Limitations of existing fluorescence methods 
 
Although improvements to fluorescent ROS and RNS sensors have been made in recent 
years, a number of underlying problems hinder the usefulness of the field.
105
  One major 
issue regards the selectivity of the probes discussed and the inability to differentiate 
between the various reaction products as well as metabolism or breakdown products 
through fluorescence techniques alone.  Background fluorescence of the unreacted probes 
and cell permeability issues reduce measurement sensitivity which is often amplified by 
slow reactivity of probes with the intended substrates at physiological relevant 
concentrations.  
 
A number of fluorescent sensors are also not compatible with physiological conditions due 
to stability or toxicity issues, while those that are suitable are limited to optically accessible 
environments.  These include studies in vitro, in outer tissue layers or in transparent 
organisms such as zebrafish (Danio rerio) or nematode worms (Caenorhabditis elegans).  
As a result many desirable areas of in vivo study are not accessible and thus it is useful to 
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Chapter 5: Research aims 
 
The underlying aim of the following research (Chapters 6-9) is to develop molecular tools 
to further the understanding of how reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are produced and affect biological systems.  As the main source of 
endogenous ROS, this work focuses predominantly on mitochondrially produced 
ROS/RNS.  Accumulation of damage caused by these species may accelerate the ageing 
process and the onset of age-related disease as defined by the free radical theory of ageing 
(FRTA).  
 
The results discussed herein are broken into three novel classes of mitochondria-targeted 
compounds, designed to allow robust testing of the FRTA: 
 
i)  Mass spectrometry (MS) probes for identification and quantification of ROS/RNS 
ii)  Prodrugs to moderate mitochondrial ROS production rates and oxidative stress at a 
cellular level 
iii) Functional molecules to allow for spatially and temporally resolved delivery of 
biologically active species 
 
Initially these materials will be focused on studying the behaviour and conditions found in 
mitochondria.  However these functional molecules may subsequently be adapted to study 
a range other cellular or non-cellular compartments through modification of the targeting 
systems employed. 
 
The first problem in studying mitochondrial ROS/RNS is that it is difficult to accurately 
identify and quantify these generally short-lived, reactive species that are present in 
complex biological systems.  As a result it is difficult to assess how different chemical, 
biological or environmental changes affect ROS/RNS production and their subsequent 
biological roles. 
 
Existing methods of identifying these species in vitro predominantly utilise fluorescent 
techniques, despite a number of limitations (Chapter 4.5).  In terms of in vivo methods, 
oxidative stress is studied indirectly (excluding the limited number of systems in which 
fluorescent techniques are feasible) through oxidative stress markers such as DNA lesions 
and fatty acid oxidation products.  Using markers of oxidative stress can be inaccurate as it 
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is not possible to study focus solely on a single ROS/RNS of interest and instead must look 
at the overall oxidative state of the cell.  Therefore results of any intervention under study 
could potentially be affected by changes to a plethora of biological processes such as 
ROS/RNS production, capture and repair mechanisms as well as a host of other metabolic 
pathways.  Thus a key goal of this research is to develop a small library of probes that will 
allow for a more accurate identification and quantification of specific ROS/RNS and be 
broadly applicable in vitro and in vivo (Chapter 6). 
 
The second goal of this research is to develop a novel class of prodrugs that once 
administered to an organism will remain inactive until they identify high oxidative stress 
conditions (Chapters 7-8).  These materials will then release biologically active species 
that will modify the biological processes involved in this elevated ROS production.  If the 
FRTA is correct and the accumulation of ROS/RNS damage is the major cause of ageing, 
such compounds could extend lifespan and reduce the onset of age-related disease.  This 
class of compounds will initially look at mitochondria-targeted uncoupling molecules, but 
could easily be adapted to release a wide range of other biologically important species in 
response to elevated ROS levels. 
 
A further problem that exists in the study of mitochondria is that any compound 
administered to a system could equally affect any of the mitochondria present.  Thus it is 
impossible to determine if different mitochondrial subpopulations play varying biological 
roles within a cell and how modifying specific mitochondria may lead to different changes 
to cellular pathways and behaviour.  Therefore the final section of this work will look to 
develop a new class of photo-activatable compounds to allow temporal and spatial 
resolution in the delivery of a range of bioactives such as mitochondrial inhibitors (Chapter 
9).  The intention of this work is to develop a library of such compounds which would 
allow any molecule of interest to be delivered to mitochondria and selectively released, 
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Chapter 6: Mitochondria-targeted mass spectrometry probes 
 
I set out to develop a range of mitochondria-targeted ratiometric mass spectrometry probes 
to allow the identification and quantification of particular mitochondrial ROS/RNS to 
overcome limitations of fluorescence based probes.  Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) allows the quantification of ROS/RNS levels present in vitro or 
in vivo by analysis of the ion count ratios between the probe and its selective ROS/RNS 
reaction product, which can be distinguished by differences in mass to charge (m/z) ratios.   
 
All of the probes retain certain features such as a TPP targeting group to deliver the probes 
to the mitochondrial matrix.  An additional benefit of the TPP moiety is that the inherent 
positive molecular charge in the starting probe and reaction products facilitates sensitive 
detection by MS and mild ionisation procedures (electrospray ionisation, ESI) that help to 
minimise compound fragmentation.  Indeed conjugation to TPP groups has been used to 
augment detection limits in MS
126
 and this sensitive technique allows low concentrations 
(pM) of the compounds to be detected in tissue homogenates.  The ratio of compound 
conversion can be determined through the use of deuterated internal standards to account 
for any variability in extraction or detection between the probe and its reaction product. 
 
Another major benefit of using a MS based approach is that it allows the study of whole 
organisms by chemical extraction instead of being limited to studies in cultured cells or 
tissue surfaces, as is the case for the optical approaches previously discussed (Chapter 4). 
 
6.1 Hydrogen peroxide: MitoB and MitoP 
 
To detect and quantify mitochondrial H2O2, the conversion of either an arylboronic acid or 
arylboronate ester into a phenol, as used in the previously discussed fluorescent H2O2 
sensors (Chapter 4.1) would be used.  To assess levels of mitochondrial H2O2, the MS 
probe MitoBoronic acid (MitoB) 134 and its selective H2O2 reaction product, MitoPhenol 





Fig.28: Proposed MS probe and reaction product for mitochondrial H2O2  
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MitoB 134 contains two key moieties.  The triphenylphosphonium DLC incorporated 
targets the probe to mitochondria and is both non-toxic and inert to biological 
environments while the boronic acid unit is selectively converted by endogenous H2O2 into 
the probes phenolic form (Scheme 34).  This conversion leads to a specific change in mass 
(~28 g mol
-1
) which allows both species to be identified from a mixture by ESI-MS.  
Known quantities of deuterated analogues of both MitoB and MitoP (135 and 137) would 
be added prior to extractions as internal standards, so that the unlabelled compounds in the 
extracts could be readily quantified.  Endogenous levels of H2O2 could then be calculated 
from the ratios of the two compounds present. 
 
 
Scheme 34: Proposed structural features and reaction of Mito B 134  
 
As a result of the probe accumulating in mitochondria, the probe will predominantly be 
converted by mitochondrial H2O2.  The probe and its reaction product will distribute 
throughout an organism and as such will measure the average mitochondrial H2O2 levels.  
Assuming comparable metabolism and excretion rates, the ratio of the two compounds is 
dependant upon H2O2 concentration and incubation time.   
 
6.1.1 Synthesis of MitoB and MitoP 
 
Previous work within the Hartley research group had led to the development of MitoB 
pinacol ester 141 and MitoP 136 (Scheme 35) in a moderately yielding three step synthesis 
with benzylic bromide 140 as the key intermediate for all target compounds. 
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Scheme 35: Previous synthesis of MitoB pinacol ester 141 and MitoP 136 
 
Although synthetically convenient, an equilibrium between boronate ester 141 and boronic 
acid 134 is rapidly established in aqueous environments.  The position of this equilibrium 
lies on the side of boronic acid 134, particularly at the low probe concentrations employed 
in living cells.  Therefore boronic acid 134 was the only detectable species by ESI-MS and 
as such it was decided to make this compound directly, which simultaneously reduced the 
length of the synthesis.  MitoB 134 solely in the boronic acid form was synthesised in one 
step from benzylic bromide 143 (Scheme 36). 
 
 
Scheme 36: Synthesis of MitoB 134 and deutero-MitoB 135 
 
The isolated yield for deutero-MitoB 135 was lower than that of the non-deutero-MitoB 
134 for two reasons.  Firstly the cost of the deuterated triphenylphosphine prohibits using a 
large excess of the reagent as can be used in the synthesis of MitoB 134 to drive reaction to 
completion.  Secondly recrystallisation from DMSO/H2O on a small scale leads to 
significant material loss which is not as notable on the larger scale reaction of MitoB 134 
as recrystallisations can be performed in batches which re-use the same DMSO liquor for 
every recrystallisation, resulting in less material loss.  Recrystallisation from DMSO/H2O 
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removed residual traces of toluene and converted small quantities of suspected boroxine 
trimer 144 (
1
H NMR) formed in the reaction into the desired monomer 134 (Scheme 37).  
Subsequent recrystallisation from H2O removed any residual traces of DMSO. 
 
 
Scheme 37: Traces of MitoB trimer 144 are converted into the desired monomer 134 
R = Ph or C6D5 
 
MitoP 136 and its deuterated analogue 137 were initially synthesised in moderate yield 
from phenol 145 (Scheme 38) (Chapter 7.7, Scheme 84 for starting material isolation).  
The instability of the starting material and its tendency to polymerise (from the observed 
formation of a completely insoluble brown gum) reduced reaction yields. 
 
 
Scheme 38: Synthesis of MitoP 136 and deutero-MitoP 137 
 
Adapting the procedure of Dawson et al,
128
 MitoP 136 was also synthesised directly from 
commercially available diol 146 in moderate yield (Scheme 39).  This is a faster, more 
reliable route towards MitoP 136 and is scalable. 
 
 
Scheme 39: Alternative MitoP 136 synthesis 
 
As MitoB 134 was recrystallised from water and contains both TPP and boronic acid 
moieties, it was necessary to assess whether or not the crystalline materials existed as 
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hydrates.  This information is essential to ensure that accurate concentrations of the probes 
could be used in biological tests.  Microanalysis confirmed that neither sets of compounds 
contained any co-ordinated water molecules and this was further confirmed with the crystal 
structure of MitoB 134 (Fig.29) obtained by Dr Louis Farrugia (University of Glasgow). 
 
 
Fig.29: Crystal Structure of MitoB 134
CCDC 900923
 
C = Grey, H = Blue, B = Pink, Br = Red (not covalently bound to structure), 
O = Red (covalently bound to structure), P = Yellow 
 
6.1.2 Biological results 
 
In vivo testing in fruit flies was conducted at University College London (UK) and MS 
analysis, kinetic studies and in vitro tests were carried out at the medical research council 
(MRC) mitochondrial biology unit (Cambridge, UK) by the groups of Partridge and 
Murphy by lead researcher Dr Helena Cochemé.
127,129
  The rates of MitoB 134 to MitoP 
136 conversion by H2O2 were measured by monitoring the rate of change in absorption at 








 at 37 °C and 
25 °C respectively at pH 8.0 are well below that of the dominant mitochondrial peroxidase 






 at physiological 
temperatures.
130
  Therefore MitoB 134 does not affect the overall physiological H2O2 
levels.  This is vital as if MitoB 134 consumed significant amounts of H2O2 this would 
perturb the cellular steady state and affect the signalling processes and other biochemistry, 
resulting in studies being conducted on systems away from their natural states.  Selectivity 
towards mitochondrial H2O2 is achieved due the mitochondria-targeting ability of the 
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probes and is further enhanced as the reaction with MitoB 134 was found to be ~4-fold 
slower at cytosolic pH 7.2 compared to mitochondrial matrix pH 8.0, which is consistent 
with the increased reactivity of the hydroperoxide anion at elevated pH. 
 
MitoB 134 can be given to an organism via either oral or IV administration and is rapidly 
distributed throughout the organism by the circulation.  MitoB 134 equilibrates throughout 
all cellular compartments with predominant accumulation in cell mitochondria (Fig.30) as 
it contains a DLC and gives information about the average mitochondrial H2O2 levels.  
 
      
Fig.30: MitoB 134 mode of action and conversion to MitoP 136 
 
MitoB 134 displayed a high selectivity for reaction with H2O2 over tert-





NO, linoleic acid peroxide or peroxidase enzymes tested.  However, ONOO
−
 does 
convert MitoB 134 into MitoP 136, consistent with rapid rate constants reported for 
ONOO
−








  Although 
acutely sensitive to ONOO
−
, biological concentrations of this species are predicted to be 
very low compared to H2O2 and as such probe conversion will predominantly occur in 
response to H2O2.  This was confirmed during in vitro studies in which NOS inhibitor N-
nitro-L-arginine methyl ester was administered along with MitoB 134 and this showed no 
significant change to MitoP 136/MitoB 134 ratios under a range of test conditions.
127
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Scheme 40: Boronic acids and boronate esters rapidly react with peroxynitrite 
R = alkyl, aryl or vinyl           R’ = H, alkyl or aryl 
 
Initial tests assessed whether or not MitoB 134 would accumulate in isolated rat liver 
mitochondria (Fig.31) using electrodes sensitive to the TPP cation in a KCl medium (pH 
7.2).  Aliquots of MitoB 134 (5   1 µM) were added to establish a calibration curve and 
subsequent addition of de-energized mitochondria leads to a small amount of unspecific 
lipophilic uptake.  Upon addition of succinate the electron transport chain has a substrate 
with which to generate a ΔΨm through succinate dehydrogenase (complex II).  As expected 
a rapid uptake of MitoB 134 by energised mitochondria was observed and de-energizing 
the mitochondria (dissipating ΔΨm) with known mitochondrial uncoupler FCCP 33 
triggered the release of MitoB 134 back into solution.  Similar results are observed for 
MitoP 136 and the deuterated analogues of both compounds (135 and 137).  Uptake levels 






Fig.31: MitoB 134 uptake by energised isolated rat liver mitochondria 
 
In vivo studies discussed herein were conducted in fruit flies (Drosophila melanogaster), 
although similar proof-of-principle studies were successfully conducted in mice and 
nematode Caenorhabditis elegans worms.  MitoB 134 was found to accumulate in higher 
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concentrations in the thorax compared to the head or the abdomen of the fly which is 
consistent with the knowledge that thoracic muscle cells contain larger numbers of 
mitochondria.  MitoB 134 and MitoP 136 underwent the same first-order elimination 
kinetics meaning differences in the MitoP 136/MitoB 134 ratio were due to MitoB 134 
oxidation and not differential excretion rates.  Furthermore no signs of toxicity were 
observed for either of the compounds. 
  
Assessing the MitoP 136/MitoB 134 ratios measured 6 h after injection into female flies 
and 3 h after injection into male flies of varying ages confirmed that in vivo mitochondrial 
H2O2 levels significantly increase with age (Fig.32).   
 
 




To determine whether or not the observed increase in average H2O2 concentrations play a 
role in increased mortality, two well-studied and robust interventions that are known to 
increase the lifespan of Drosophila were studied along with their effects on mitochondrial 
H2O2 concentrations.  Dietary restriction (DR) is a strongly reproducible effect that 
increases lifespan in a number of organisms while reducing female fecundity (Fig.33).  
Cohorts of Drosophila were given standard, increased or decreased calorie diets.  It was 
previously widely hypothesised that reducing the calorific intake of an organism extended 
lifespan by reducing ROS production.  Intuitively, it might seem that less food would lead 
to less metabolism and therefore less ROS.  However, the experiments with MitoB 134 
showed that although average mitochondrial H2O2 levels increase with age, DR in fact has 
no impact on these levels (Fig.34).  Thus the reason for DR extending lifespan must result 
from an alternative mechanism such as having an impact on an organism’s ability to 
scavenge ROS and/or repair oxidative damage. 
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Restricting the physical activity of Drosophila is known to extend lifespan by up to a 
third.
133
  This is achieved by restricting the space inside which the flies are kept such that 
the “inactive” cohorts have no space to fly around and may only walk.  In young flies 
significant differences were found in MitoP 136/MitoB 134 ratios between active and 
inactive cohorts while none were found in older flies consistent with a general decline of 
physical activity with age (Fig.35).  The fact that inactive young flies show higher H2O2 
levels can be explained by these flies not using up their stores of ATP 5.  As a result ΔΨm 









Further studies were conducted in flies to assess the effects on MitoP 136/MitoB 134 ratios 
under a number of conditions known to lead to increased ROS production.  For example 
hyperoxia is known to increase H2O2 levels as the precursor mitochondrial O2
•−
 
concentrations are directly dependent on the O2 concentration.  As expected, hyperoxia as 
well as other interventions such as treatment with redox cycler paraquat, increased MitoP 
136/MitoB 134 ratios. 
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To date MitoB 134 has successfully demonstrated the validity of using a MS approach to 
measure and quantify the average mitochondrial H2O2 levels in cultured cells, flies, worms 
and mice as well as the ability to monitor changes in H2O2 levels in response to a range of 
interventions or environmental changes.  These methods require tissue samples to be taken 
but preliminary mice studies have revealed that MitoB 134 and MitoP 136 are readily 
detectable in urine, raising the possibility of non-invasive measurements of in vivo ROS 
levels in mammals. 
 
6.2 Hydrogen peroxide: ExoCellB 
 
The concept of exocellular boronic acid (ExoCellB) 147 is directly analogous to that of 
MitoB 134 except by existing in an anionic form instead of a cationic form, ExoCellB 147 
would be actively excluded from cells (due to ΔΨp) and mitochondria in particular (due to 
ΔΨm), therefore allowing ratiometric detection of extracellular H2O2 levels.  In this case 




Fig.36: Proposed MS probe and reaction product for extracellular H2O2  
 
The meta-substituted boronate 152 was synthesised (Scheme 41) using the conditions of 
Knochel (Chapter 7.8 for further discussion),
134,135
 as was the para-substituted boronate 
155 (Scheme 42) which was used as an intermediate in the synthesis of mitochondria-
targeted uncoupling molecules (Chapters 7.8-7.10).  Although the yields for the para-
analogue 155 (88-98% depending on scale) were consistent with those reported by Baron 
and Knochel,
134
 the yields for the meta-analogue 152 were consistently lower (32-36%) 
than in the literature and the reason for this is unclear. 
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Scheme 41: Proposed synthesis of ExoCellB 147 and ExoCellP 149 
 
 
Scheme 42: Synthesis of boronate isomer 155 from 1,4-diiodobenzene 154  
 
Magnesiation of aryl iodide 152 followed by reaction with triphenylborane failed to yield 
boronate 153.  This was possibly a result of instability to the mildly acidic work-up 
conditions.  Attempts to synthesise model compound lithium tetraphenylborate from 
triphenylborate and phenyllithium in THF was similarly unsuccessful and it was 
subsequently found that commercially available sodium tetraphenylborane rapidly 
decomposed under acidic conditions through proto-deborylation.  Modifying the 
electronics of the aromatic units to be electron-withdrawing by replacing the phenyl groups 
with pentafluorophenyl or di-/tri-(trifluoromethyl)phenyl groups could slow, or even 
prevent this decomposition.  Further work on developing an extracellular ratiometric MS 
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6.3 Nitric oxide: MitoDA and MitoBT 
 
To quantify mitochondrial 
•
NO levels, the selective conversion of mitochondria-targeted 
1,2-dianiline derivatives 111 under aerobic conditions would be used to give stable 1,2,3-
benzotriazole products 112 (Scheme 43), as used in the 
•
NO fluorescent sensors previously 
discussed (Chapter 4.3, Scheme 28). 
 
 
Scheme 43: Conversion of diamines to benzotriazoles 
 
6.3.1 Synthesis of MitoDA and MitoBT 
 
With the knowledge that monoalkylation of a single amine moiety as seen in DAR-M 121 
should reduce side reactions with 1,2-dicarbonyls such as glyoxal that could otherwise 
form quinoxaline derivatives, MitoDiamine (MitoDA 156) and MitoBenzotriazole 
(MitoBT 158) structures were proposed (Fig.37). 
 
 




The original synthesis of MitoDA 156 and its deuterated analogue 157 began with mono-
TPP salt formation from diiodobutane 160 followed by functional group interconversion to 
give azides 163 and 164 in excellent yields (Scheme 44). 
 
 
Scheme 44: Synthesis of intermediate azides 163 and 164 
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A number of routes to intermediate amine 165 were attempted (Scheme 45).  Standard 
Staudinger reduction conditions were successful at reducing azide 163 but purification 
from the triphenylphosphine oxide and an unknown TPP containing by-product was 
unsuccessful.  Palladium on carbon reduction conditions using ammonium formate as a 
hydrogen source gave no conversion to product while using hydrogen gas itself gave good 
conversion to amine 165 but again led to the formation of an unidentified, inseparable side 
product [~5-10% by 
1
H NMR spectroscopy: triplet at 2.71 ppm, J = 6.8 Hz (400 MHz 
spectrometer) plus a corresponding over-integration of other signals] believed to be some 
form of compound dimer linked through a central nitrogen-bearing unit. 
 
 
Scheme 45: Attempted synthesis of amine 165 
 
Attempts to synthesise amine 165 directly from alkyl iodide 160 using ammonia
136
 were 
partially successful although complete conversion was never achieved and prolonged 
exposure resulted in the formation of small amounts of secondary amine (resulting from 
amine 165 reacting with alkyl iodide 160) which could not be readily separated from the 
desired primary amine 165 (Scheme 46).  Optimisation of this procedure by slowing the 
addition of alkyl iodide 160 to the ammonia saturated methanol solution in which the 
concentrations of alkyl iodide 160 and amine 165 are kept low would likely allow this 
approach to yield the desired product. 
 
 
Scheme 46: Attempted synthesis of amine 165 
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The first synthesis of MitoDA 156 was completed using amine 165 obtained from 
hydrogenation (H2 gas) conditions (Scheme 45).  Carrying forward ~5% of an unknown 
TPP containing impurity through an SNAr reaction to give aniline derivative 166, followed 
by the reduction of the nitro group using sodium dithionite and anion exchange (Appendix 
1) to give the desired diamine 156 in moderate yield over the four steps (Scheme 47). 
 
Purification was achieved using column chromatography on silica after the final step.  The 
methylsulfonate anion was chosen as unlike many other common counter ions (eg. halides, 
triflate, tetrafluoroborate, etc.), it is readily identifiable and quantifiable using 
1
H NMR 
spectroscopy due to the presence of its methyl group. 
 
 
Scheme 47: First synthesis of MitoDA 156 
 
Initial attempts at reducing the nitro group of aniline derivative 166 using standard iron and 
tin reagents were unsuccessful (Scheme 48, Table 3) with no conversion observed under 
any of the test conditions.  Unlike the more common procedures tested, sodium dithionite 
reduction is rapid (complete in under 45 min), conducted at RT and under mildly basic 
conditions making it particularly suited to acid-sensitive or thermally-sensitive molecules.  
Reduction occurs through a series of SET and protonation steps with a number of products 
possible including nitroso and hydroxylamine compounds due to incomplete reduction if 
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Scheme 48 and Table 3: Attempted nitro-group reduction conditions 
Entry Conditions Time (h) Temp. (°C) Conversion (%) 
1 Fe (4 Eq), NH4Cl (5 Eq), EtOH 48 Reflux 0 
2 Fe (8 Eq), EtOH, AcOH 48 Reflux 0 
3 SnCl2.2H2O (4 Eq), EtOH 24 Reflux 0 
 
 
Scheme 49: Sodium dithionite reduction of aryl nitro groups 
 
A modified approach was also employed to synthesise MitoDA 156 and deutero-MitoDA 
157 starting from alkyl bromide 168 (Scheme 50).  TPP formation, followed by 
phthalimide removal by hydrazine yielded amines 171 and 172 after which the route 
follows that of the original synthesis (Scheme 47).  This approach prevents the formation 
of TPP-containing impurities during the synthesis of intermediate amines 171 and 172 
which are difficult to separate from the desired TPP compounds. 
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A further attempt to synthesise MitoDA 156 designed to prevent the need to carry 
phosphonium salts through the entire synthesis started with the SNAr reaction between 
amine 175 and 2-fluoronitrobenzene (Scheme 51) to give alcohol 177 in high yield.  
Subsequent Appel reaction gave iodide 177 and cyclised product 178 in an approximate 
1:1 ratio after purification by column chromatography on silica despite little cyclisation 
product being observed in the crude reaction mixture, indicating that cyclisation occurred 
predominantly during purification.  TPP formation could have been carried out on the 
crude mixture (before or after chromatography) as only alkyl iodide 177 could generate a 
phosphonium salt product which would be readily separable from the cyclised by-product 
178.  However this was not conducted due to the more promising results towards MitoDA 
156 previously discussed (Scheme 50). 
 
 
Scheme 51: Alternative attempted synthesis of MitoDA 156 
 
The first attempted synthesis of MitoBT 158 and deutero-MitoBT 159 began with the 
alkylation of 1,2,3-benzotriazole 179 using the procedure of Cho et al.
137
  This was 
unsuccessful as the sodium salt of the deprotonated benzotriazole is completely insoluble 
in MeCN (or DCM), although the starting materials were readily recovered.  Switching the 
solvent to DMF allowed the reaction to proceed but despite using an excess of alkyl 
diiodide 160 a number of by-products were generated (Scheme 52).  Reaction products 
include mainly single alkylation products 180 and 181, but also not insignificant quantities 
of double alkylation products 182-184 (as well as some other minor products including 
iodide elimination which generated terminal alkenes) the distribution of which indicates 
that the reactivity of the three nitrogen atoms are comparable to each other (~2:1 N1:N2 
alkylation components observed in crude 
1
H NMR).  Assessing the composition of crude 
reaction mixtures was initially difficult as the 
1
H NMR spectra of each N1-alkylation aryl 
component (180, 182 and 183) are almost identical and the same is the case for each N2-
alkylation aryl component (181, 183 and 184).  To make matters worse, alkyl chain proton 
signals from both monoalkylated products (180 and 181) overlap while all dialkylated 
products (182-184) similarly overlap with each other. 
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Scheme 52: Selected products of benzotriazole alkylation 
 
Purification can be achieved by column chromatography on silica although significant 
overlap in product elution is observed.  Compounds containing N1-alkylation have a 
stronger retention on silica than the N2-alkylated analogues with order of elution: N2-
alkylated product 181, N1-alkylated product 180, N2-N2-double alkylation product 184, 
N1-N2-double alkylation product 183 and N1-N1-double alkylation product 182 in 
petroleum ether:EtOAc (1:1).  This is likely to be due to the greater dipole moment in the 
unsymmetrical triazole generated by N1-alkylation 180 compared to the symmetrical 
triazole generated by N2-alkylation 181 and where the free nitrogen lone pairs are less 
likely to interact with silica simultaneously. 
 
An alternative route to alkyl iodide 180 was also assessed (Scheme 53, Table 4).  The first 
attempt to alkylate 1,2,3-benzotriazole 179 using sodium carbonate as a base in MeCN was 
promising in that using only a slight excess (1.2 eq.) of diiodobutane 160 gave only 
monoalkylated products 180 and 181 as well as trace amounts of bis-alkylation product 
185 along with unreacted starting materials (Entry 1).  Increasing the equivalence of the 
alkylating reagent and the reaction temperature (50 °C to reflux), led to a greater number of 
unidentified impurities forming including alkenes generated through iodide elimination, 
with the majority of identifiable material in the bis-alkylated form 185 (Entry 2).  
Reducing the reaction temperature back to 50 °C and extending the reaction time gave 
improved isolated yields of the desired compound.  The predicted 2:1 ratio of the N1-
alkylation 180:N2-alkylation 179 was reduced as the N1-alkylation product 179 is free to 
undergo a second alkylation to give the N1-N3-alkylation product 185.  Other minor 
unidentified reaction products and unreacted benzotriazole 179 were observable in the 
1
H 
NMR spectrum of the crude reaction mixture (Entry 3). 
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Scheme 53 and Table 4: Optimisation of 1,2,3-benzotriazole alkylation 
 
Entry 
Reaction Conditions Conversion/Yield (%) 
Temp. 
(°C) 






N1 and N3 
185 
1 50 18 1.2 eq. 26 13 Trace 
2* Reflux 20 4 eq. Minor Minor Major 
3 50 48 4 eq. 47 32 12 
* Reaction not purified due multiple unidentified reaction products 
 
Alkyl iodide 180 was readily converted into MitoBT 158 and deutero-MitoBT 159 in 
excellent yields using triphenylphosphine and its deuterated analogue respectively 
(Scheme 54).  Prolonged reaction times at relatively low temperatures compared to 
standard TPP formation conditions were employed to prevent any unwanted iodide 
elimination or other side-products. 
 
 
Scheme 54: Synthesis of MitoBT 158 and deutero-MitoBT 159 
 
MitoBT 158 may also be synthesised from the reaction of azide 163 using a benzyne 
generating reagent (Scheme 55).  Due to its high reactivity, benzyne must be produced in 
situ and can be generated from a number of benzyne precursors including under mild 





Scheme 55: MitoBT 158 synthesis using benzyne chemistry 
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Activation of the silyl group by fluoride leads to displacement of the ortho-triflate leaving 
group to generate highly reactive benzyne 187, which undergoes a click-type reaction 
analogous to azide-alkyne Huisgen cycloaddition to generate benzotriazoles (Scheme 56).  
A key factor in benzyne chemistry is to ensure that concentrations of the benzyne species 
is kept low as dimers 188 and trimers 189 will rapidly form if concentrations are too high.  
Although no product was isolated via this route, conversion to benzotriazole 158 is clean 
(as determined by 
1
H NMR spectroscopy) with benzyne derived impurities (eg. 188 and 
189) readily washed out with diethyl ether. 
 
 






Although the benzyne precursor 186 was added slowly in two batches, the presence of a 
full equivalence of a fluoride source (cesium fluoride) in the reaction mixture may have led 
to benzyne formation occurring too quickly.  It is strongly believed that with slower 
addition of fluoride and benzyne precursor, with elevated equivalences of the latter, 
MitoBT 158 could be accessible using this approach.  No attempts at optimising this route 
were made as by this point MitoBT 158 and its deuterated analogue had been successfully 
synthesised by the previously discussed route (Schemes 53-54). 
 
Alternative methods of benzyne 187 formation involve harsher conditions such as the 
decomposition of anthranilic acid 190 derived diazonium salt 191 (Scheme 57).
138
  This 
approach liberates large quantities of carbon dioxide and nitrogen and therefore is 
potentially explosive.  Lithium-halogen exchange of an aryl ortho-dihalides or aryl ortho-
halide-triflate 193 or ortho-lithiation of an aryl fluoride 192, followed by release of the 
ortho-substituent can also be used to generate benzyne, but the necessary lithiation 
reagents are not compatible with TPP-azides 163 or 164 (Scheme 57).
138
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Scheme 57: Alternative methods of benzyne formation 
 
To assess if MitoDA 156 could be converted into MitoBT 158 by the proposed reaction 
mechanism (Schemes 28 and 43), 
•
NO was released in situ by the thermal decomposition 
of NONOate sodium salt 194 under pseudo-physiological [KHE buffer (Appendix 2), pH 
7.4, 37 °C] aerobic conditions (Scheme 58).  The crude mixture was subsequently analysed 
by positive mode ESI-MS with the only observed cations corresponding to MitoDA 156 
and MitoBT 158.  Therefore this strongly supports the concept of MitoDA 156 as a 
potential biological 
•
NO quantification tool by its clean conversion into MitoBT 158.  
Biological testing is currently underway at the MRC mitochondrial biology unit 
(Cambridge, UK) by the group of Murphy. 
 
 
Scheme 58: Conversion of MitoDA 156 into MitoBT 158 
 
6.4 Superoxide: MitoSOX 
 
The aim of this project was to develop a ratiometric mitochondria-targeted O2
•−
 probe to 
allow the accurate determination of endogenous O2
•−
 levels inside mitochondria.  The 
proposed probe design was based on mitochondria-targeted superoxide fluorescent sensor 
MitoSOX 92 (Chapter 4.2) as to date this molecule displays the best reaction selectivity for 
O2
•−





 195 along with their respective O2
•−
 reaction products 2-OH-MitoSOX 102 and 
deuterated analogue 197 (Scheme 59).  The phenanthridinium probes 104 and 195 will be 
reduced using sodium borohydride immediately prior to use so that they are responsive to 
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O2
•−
 (or may be reduced in advance if stored under anaerobic conditions) as the tertiary 
amines 92 and 196 will rapidly re-oxidise in air to phenanthridiniums 104 and 195.   
 
 




Although MitoSOX 92 is commercially available, no complete synthesis has been reported 
in the literature.  To enable the subsequent selective alkylation of the phenanthridine core 
nitrogen atom, both amine moieties of diaminophenanthridine 198 were Boc protected.  
This was initially achieved in a low yield similar to that obtained by Ross et al,
139
 using a 
comparable method and purification by column chromatography on silica (Scheme 60, 
Table 5, Entry 1).  Conversion in this reaction was very high, although a significant 
amount of material was lost during purification.  Changing the procedure to enable product 




Scheme 60 and Table 5: Bis-amine protection conditions to give dicarbamate 199 
Entry Conditions Temp. (°C) Time (h) Isolated Yield (%) 
1 Boc2O, CHCl3 RT 66 20 
2 Boc2O, THF:H2O (10:1), K2CO3 RT 96 85 
 
Alkylation of phenanthridines using alkyl halides has previously been reported by a 
number of groups but none of the alkylation conditions tested gave any signs of alkylation 
product (Scheme 61, Table 6).
140,141
  It is possible that reversible alkylation was occurring, 
with the liberated iodide quickly displacing the phenanthridine to regenerate starting 
materials.  AgNO3 was used as an additive to trap any iodide generated as AgI which 
would precipitate out of solution and drive the reaction to completion, but again no signs of 
alkylation were observed. 
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Scheme 60 and Table 6: Attempted alkylation to give alkyl iodide 200 
Entry Solvent AgNO3 Temp. (°C) Time (d) Yield (%) 
1 THF N/A Reflux 10 0 
2 THF 1 eq. Reflux 7 0 
3 PhNO2 N/A RT 5 0 
4 PhNO2 1 eq. Reflux 3 0 
 
Triflates have also been employed to alkylate phenanthridines
139,142
 and to date have been 
employed within the Hartley research group with limited success due to purification issues.  
Ongoing work on this project is focussed on synthesising the complete phenanthridinium 
core, pre-alkylated from mono-aryl precursor fragments which will allow a family of 
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Chapter 7: Mitochondrial uncoupling 
7.1 Mitochondrial uncoupling molecules 
 
In mitochondrial biology, uncoupling refers to the process of detaching the workings of the 
respiratory chain from the oxidative phosphorylation of ATPase, principally as a result of 
dissipating ΔΨm.  The electron transport chain responds to uncoupling by upregulating 
protein turnover (complexes I to IV) in an attempt to maintain the protomotive force while 
ATP 5 synthesis is slowed.  In strongly uncoupling conditions ATPase can reverse, with 
the energy released from the conversion of ATP 5 back into ADP 4 being used to pump 
protons into the IMS to maintain ΔΨm.   
 
An increase in ΔΨm leads to an increase in ROS production
6
 and mild mitochondrial 
uncoupling can reduce the markers of oxidative stress through the lowering of this 
potential gradient
143,144
 as this reduces ROS production, allowing the organism’s natural 
defences such as anti-oxidants to regain control of the system.  To date five transmembrane 
uncoupling proteins (UCPs) have been identified.  These have evolved to protect an 
organism from excessive ROS production in times of elevated ΔΨm.  Dissipation of ΔΨm 
through uncoupling processes leads to thermogenesis which is used by a number of 
animals to maintain body temperature during hibernation.  
 
Small molecule mitochondrial uncouplers
145,146
 predominantly act as proton translocators 
(protonophores) that catalytically cycle protons from the IMS into the mitochondrial 
matrix (Figs.38 and 39), although a few can uncouple through interactions with certain 
transmembrane protein pores.  As the ΔΨm is reduced, there is no way to power ATPase 
and so the mitochondria stop producing ATP 5 as well as lowering ROS production.  
Uncoupling molecules must be lipophilic enough to diffuse passively through lipid bilayers 
in both the neutral and anionic forms as well as possess a suitable pKa so as to be 
sufficiently protonated in the IMS and deprotonated in the mitochondrial matrix.  The most 
commonly used uncoupling molecules are 2,4-dinitrophenol (DNP) 201 and carbonyl 





 respectively.  Both possess suitable lipophilicity, pKa, and stability for biological 
testing and also possess characteristic UV/VIS spectra making them extremely simple to 
identify in solution.   
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Fig.38: Mitochondrial uncoupling mechanism via proton translocation 
 
 
Fig.39: DNP 201 and FCCP 33 with corresponding DNP
–




DNP 201 was successfully used in the 1930’s to treat obesity as it uncouples mitochondrial 
ATP 5 production from the energy obtained from oxidation of fuel sources such as fatty 
acids and sugars.  Mitochondria respond to the reduced efficiency of ATP 5 production by 
increasing the rate at which they metabolise fatty acids stored in adipose tissue in order to 
maintain a sufficient energy supply for the organism.  However, as calories are dissipated 
as heat the differences in therapeutic and toxic doses proved insufficient for DNP 201 (and 
many other uncoupling molecules) to continue to be used in the treatment of obesity with 
extreme cases of mitochondrial uncoupling leading to hyperthermia, cell necrosis and 
death.
149
  The second issue with excessive uncoupling is that at a ΔΨm of below ~120 mV, 
ATP 5 synthesis stops and reversal of ATPase attenuates any further drop in ΔΨm.  This 
diminishes ATP 5 stores by conversion into ADP 4, which can result in insufficient energy 
stores to maintain cellular functions (eg. heart muscle contraction).  Thus, uncoupling 
molecules delivered unselectively have severe limitations. 
 
Many molecules have been examined for their abilities to uncouple mitochondria and have 
been found to uncouple to different extents (Fig.40).
145,146,149
  Such molecules can act as 
mitochondrial uncouplers behaving as proton translocators as previously discussed, or by 
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interacting with mitochondrial membrane proteins such as adenosine nucleotide 
translocase (ANT) (ie. benzoic acid 204), or a combination of both [ie. butylated 
hydroxytoluene (BHT) 205].  ANT is a common MIM protein that facilitates the import of 
ADP 4 and the export of ATP 5 during oxidative phosphorylation.  Interactions with ANT 
have been seen to increase the uncoupling ability of several uncoupling molecules 
including DNP 201.  The mode of action for certain molecules which possess some (albeit 
low) degree of uncoupling ability such as fatty acids is not fully understood,
150
 and 
research in the field is ongoing. 
 
 
Fig.40: Examples of small molecule mitochondrial uncouplers 
 
Benzoic acid 24 is a weak uncoupler as it displays only limited interactions with ANT and 
cannot behave as a proton translocator as its anionic form (pKa 4.2) is insufficiently 
lipophilic to cross the MIM.
149
  Carbonylcyanide m-chlorophenylhydrazone (CCCP) 207 is 
a stronger uncoupler than FCCP 33 with the former known to be a proton translocator as 
well as acting on ANT.  It is assumed that FCCP 33 would similarly interact with ANT 
although confirmation of this has not been reported to date.  Malonoben 208 acts as an 
uncoupler directly analogous to CCCP 207 but is a more potent.
146
  Diarylamines with 
suitably electron withdrawing and lipophilic substituents such as fentrifanil 209 (a more 
potent uncoupler than CCCP 207), can behave as weak acids and therefore uncouple 
mitochondria through a protonophore mechanism.
151
  Derivatisations of the 
carbonylcyanide phenyl hydrazone and BHT 205 backbones have previously been made to 
modify properties such as pKa, lipophilicity and hydrophilicity, which has led to many 
variants such as butylated hydroxyanisole 206.  Many molecules such as pentafluorophenol 
(pKa 5.5)
152
 have pKa values between that of DNP 201 and FCCP 33 and would be 
expected to be sufficiently lipophilic to cross phospholipid membranes.  The ability of 
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pentafluorophenol to uncouple isolated rat skeletal muscle mitochondria was assessed, but 
no uncoupling behavior was observed (experimental observation, data not shown).  It is 
possible that the physiochemical properties required for mitochondrial uncoupling are 
more complex than these two characteristics alone or perhaps this molecule was simply too 
lipophilic, resulting in it becoming membrane bound and therefore unable to cycle protons.  
Regardless of the reasoning, it was decided that for the following studies, established 
uncouplers DNP 201 and FCCP 33 would be used.  
 
7.2 Mitochondria-targeted caged selective uncoupling molecules 
 
The primary aim of this project was to produce the first mitochondria-targeted, selective 
uncoupling molecules (MitoSUMs) that would be able to reduce ΔΨm and therefore ROS 
production selectively in response to excess endogenous H2O2.  The MitoSUMs would 
accumulate in all mitochondria but only release uncoupling molecules where there was 
significant oxidative stress, as signalled by high levels of H2O2.  Rather than working as an 
antioxidant simply mopping up the oxidant, the uncoupler would shut down the conditions 
that gave rise to the elevated ROS production. 
 
The advantage of mitochondrial accumulation is that the uncouplers would be released 
directly at the site of action, maximising effect and reducing dosage requirements to obtain 
an effective concentration.  Concentration of the uncoupler present in the cell as a whole 
would be low as diffusion away from the mitochondrion in which it was released would 
lead to significant dilution and because very little of the uncoupler would be released in the 
cytosol directly due to the low concentration of the MitoSUM in this region.  Therefore 
MitoSUMs would modulate misbehaving mitochondria while well-behaved mitochondria 
would be unaffected.  The MitoSUMs would be used both as a molecular probe to test the 
free radical theory of ageing and as a prototype drug for combating oxidative stress arising 
from mitochondria-generated ROS. 
 
The proposed target compounds must be non-toxic and comprise three moieties (Fig.41); 
i)  A targeting group to allow accumulation inside the mitochondrial matrix to 
maximise efficiency through a high localised concentration at the site of action. 
ii)  A H2O2-selective trigger mechanism that is stable to in vivo conditions ie. pH, 
temperature, enzymes, etc. 
iii)  An inactive, caged mitochondrial uncoupler that will become active only after the 
trigger mechanism is initiated. 
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Fig.41: Proposed 3 moiety probes and mode of action 
 
A TPP targeting group was chosen as the probe is designed to reduce ROS produced by 
mitochondria with elevated ΔΨm.  Therefore harnessing the ΔΨm to drive uptake may 
provide some degree of selectivity towards high ROS producing mitochondria over healthy 
mitochondria.  Mitochondria-targeting will enable significant reduction in the 
concentrations required to obtain uncoupling benefits by releasing the uncoupling molecule 
inside the matrix (ie. at the site of action), reducing any non-mitochondria specific 
interactions and any effects on mitochondria not producing significant amounts of H2O2. 
 
The chosen H2O2 selective trigger mechanism will employ a simple boronate ester and will 
be converted into a phenol by reaction with H2O2.  The change in the functional group 
electronics from an electron withdrawing boronate to an electron donating 
phenol/phenoxide will trigger molecular fragmentation, and hence payload molecule 
release. 
 
Uncoupling molecules such as DNP 201 are designed to be caged in a manner to prevent 
their uncoupling function (ie. through the phenol moiety of DNP 201) prior to release by 
H2O2.  This will help reduce their toxicity profile due to excessive uncoupling as only very 
low concentrations of the free uncoupling molecule will be present in any cell at any time 
and also only in those cells with elevated ROS levels.   
 
Utilising a carbonate or carbamate linker as used by Chang
100
 as well as Lo and Chu
97
 
introduces an increased driving force for fragmentation with the liberation of a stable 
carbon dioxide molecule in addition to being entropically favoured (Chapter 4.1, Scheme 
24).  However, these linkers will likely increase molecule instability due to potential 
hydrolysis, particularly in vivo where these units are potential substrates for esterase 
enzymes.  For this reason, initial studies looked at the viability of using a simplified linker 
relying on direct release from the triggering unit without carbamate fragmentation.  
 
  93 
7.3 Synthesis of DNP-SUM and FCCP-SUM 
 
The initial project aim was to optimise the synthesis of two untargeted SUM molecules, 
DNP-SUM 210 and FCCP-SUM 211, developed within the Hartley research group to 
release DNP
–
 202 or FCCP
–
 203 respectively in response to H2O2 and to assess the 






Scheme 60: Release mechanism for H2O2 SUMs carrying caged DNP 201 
 
 
Scheme 61: Release mechanism for H2O2 SUMs carrying caged FCCP 33 
 
The initial synthetic steps towards boronate ester 210 from aryl bromide 212 via acetal 
protection of the benzylic alcohol moiety, lithium-halogen exchange to introduce the 
boronate group and acid catalysed alcohol deprotection were all achieved in moderate to 
high yields (Scheme 62).   
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Scheme 62: Synthesis of DNP-SUM 210 (DNB = Dinitrobenzene) 
 
Isolated yields of DNP-SUM 210 using standard SNAr conditions using triethylamine as a 
base were repeatedly low due to poor conversion even when neat reagents were used.  A 
number of attempts to optimise this reaction step were made.  Attempts to increase the 
electrophilicity of 1-fluoro-2,4-dinitrophenol by generating an aryl chromium tricarbonyl 
complex (Scheme 63) were unsuccessful and gave only insoluble material which could not 
be identified.  Mesylation of benzylic alcohol 215 followed by SN2 displacement by 
sodium 2,4-dinitrophenoxide (generated from DNP 201 and NaH) was similarly 
unsuccessful.  Switching to sodium hydride as a base to deprotonate benzylic alcohol 215 
resulted in an excellent conversion and a significantly increased isolated yield.  It is 
possible that introducing 15-crown-5 to this reaction could allow yields to be increased 
further through the sequestering of Na
+
 ions, resulting in a more nucleophilic aryloxy-
anion, although this was not tested. 
 
 
Scheme 63: Attempted synthesis of aryl chromium tricarbonyl complex 217 
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To begin the synthesis of FCCP-SUM 211, the boronate trigger mechanism was introduced 
to aryl bromide 218 via lithium-halogen exchange in excellent yield on a multi-gram scale.  
Intermediate benzylic bromide 220 had been previously synthesised in the Hartley research 
group utilising a low yielding (34%) radical bromination of the benzylic carbon atom of 
boronate 219 (Scheme 64), but isolating the product was unsuccessful during this project. 
 
 
Scheme 64: Attempted synthesis of benzylic bromide 220 
 
The radical reaction was initiated by the thermal homolytic cleavage of benzoyl peroxide 
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Unreacted starting material 219 and both monobromide 220 and dibromide 225 (Table 7) 
were identified by 
1
H NMR spectroscopy.  Although tribromide 226 is another potential 
product of over bromination, no unambiguous confirmation of this species presence was 
made.  The mixtures proved inseparable by column chromatography on silica and 
recrystallisation was unsuccessful in my hands.  Some degree of optimisation was achieved 
by re-initiating the radical reaction after 24 h (Entry 4), although a previous attempt to 
restart the reaction (Entry 3) led to over bromination. 
 
Table 7: Radical bromination of dioxaborolane 219  






















1 1 0.02 1.2 6 24 80 20 0 
2 1 0.02 1.2 6 48 80 20 0 
3* 1 0.02 1.2 6 24 0 56 44 




6 48 8 84 8 
* Entry 3 used crude product mixture from entry 2 
** After 24 h 
 
The radical bromination method was discontinued in favour of a more reliable approach to 
synthesise benzylic bromide 220.  Following the procedure of De Filippis et al,
154
 benzylic 
alcohol 215 was readily converted into benzylic bromide 220 (Scheme 66).  This step was 
unoptimised but yielded sufficient material to allow completion of the synthetic route.  An 
Appel reaction (triphenylphosphine and carbon tetrabromide) could also have been 
employed to achieve this functional group interconversion.  Dinitrile 227 was synthesised 
using an excess of malononitrile to prevent formation of the doubly-reacted product in 
which deprotonated dinitrile 227 reacts with a second equivalent of benzylic bromide 220.  
The diazonium salt prepared from p-(trifluoromethoxy)aniline and sodium nitrite under 
acidic conditions was reacted with dinitrile 227 under basic conditions to complete the 
synthesis of FCCP-SUM 211 in moderate yield. 
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Scheme 66: Synthesis of FCCP-SUM 211 
 
7.3.1 Kinetic studies of DNP-SUM and FCCP-SUM 
 
Kinetic experiments using DNP-SUM 210 and FCCP-SUM 211 were carried out using a 
JASCO V-550 UV/VIS spectrophotometer with the assistance of Professor Nicholas Price 
and Dr Linsey Robertson, University of Glasgow.
153
  The expected reaction for each probe 
(Chapter 7.3, Schemes 60 and 61) would release one molecule of quinone methide 74 for 
each molecule of probe reacting in a 1:1 stoichiometry with H2O2.  This by-product would 




The aim of these experiments was to assess the rates of conversion of DNP-SUM 210 and 
FCCP-SUM 211 into free DNP 201 and FCCP 33 respectively, under pseudo-
physiological conditions in the presence of known H2O2 concentrations to derive the 
limiting change in A410/A385 (Alim) and the pseudo-first order rate constants (k1).  Using a 
10- or 20-fold excess of SUMs 210 or 211 over the H2O2 concentration allow the standard 
bimolecular second order rate equation (Fig.42) to be simplified to the pseudo-first order 
rate equation (Fig.43) where the concentration of the caged uncoupler is regarded as 
constant. 
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d[Uncoupler
–
]/dt = k2[Caged Uncoupler][H2O2] 





]/dt = k1[H2O2] 
Fig.43: Pseudo-first order rate equation 
 
Experiments were conducted at 37 C in 50% DMF, 50% aqueous solution.  Physiological 
pH 8.3 (mimicking the pH of the mitochondrial matrix) was obtained using a 140 mM 
NaHCO3 aqueous solution.  It was observed that DMF alone caused a slow, steady 
decomposition of probe DNP-SUM 210 and so this compound was included in both 
reference and sample cells to account for this spontaneous release of DNP 201.  No such 
decomposition was observed in 100% water.  Kinetic validity is unaffected by this slow 
decomposition (less than 3% after 2000 s) as the concentration of DNP-SUM 210 (200 
M) was in a large excess compared to H2O2 concentrations studied (10 and 20 M). 
 
Absorption was monitored at 410 nm as free DNP 201 displays a characteristic absorption 
maximum (λabs) at this wavelength that does not overlap significantly with the absorption 
spectrum observed from the caged uncoupler 201.  The λabs is maintained across the pH 
range of 7.4 to 8.3 which were assessed.  Furthermore pHs outside this range are expected 
to maintain the maximum λabs at 410 nm absorption peak across a broad range of pHs 
above the pKa of DNP 201 (4.1).  From earlier studies within the Hartley research group, it 
was known that the A410 of 20 M DNP 201 in the DMF/buffer mixture was 0.4097.  Thus 
this absorption level would be observed at 100% reaction of 20 M H2O2 based on a 1:1 
reaction stoichiometry between H2O2 and DNP-SUM 210. 
 
The reactions were monitored over a 2000 s time course, and results averaged over 3 
replicates.  For 10 M H2O2, calculated Alim = 0.122 (±0.01), i.e. 5.96 M DNP 201 was 
formed or a yield of 60% relative to the H2O2 added.  The average k1 is 0.00216 s
-1
, which 






For 20 M H2O2, calculated Alim = 0.220 (±0.006), i.e. 10.73 M DNP 201 was formed 
or a yield of 54% relative to the H2O2 added.  The average k is 0.00185 s
-1
, which when 






  99 
H2O2 Triggered DNP Release






























Fig.44: H2O2 triggered DNP 201 release from DNP-SUM 210 (Scheme 60) 
 
The overall conversion yields averaged over the 2 sets of runs are 57 (± 3)% and the 




.  The incomplete conversion of the probe 
may be a result of competing reactions resulting in the consumption of H2O2.  For 
example, as the hydroperoxide anion (HOO
–
) is the most nucleophilic species present, the 
quinone methide by-product 74 could react with a second equivalent H2O2 molecule, 
instead of becoming trapped by water to form diol 75. 
  
The rate of reaction between DNP-SUM 210 and peroxynitrite at pH 7.4 was determined 
by the group of Kalyanaraman using stopped-flow measurements.  The calculated rate 





These results prove that the boronate ester trigger and subsequent fragmentation 
mechanisms through a benzylic aryl ether linker can successfully be used to release active 
uncoupler molecules from inactive precursors, in the presence of H2O2.  Similarly 
successful results were obtained by Dr Linsey Robertson for FCCP-SUM 211 (50 μM), 
measured in the same pseudo-physiological conditions over a 1000 s run time (Fig.45).  
The overall conversion yields averaged over both H2O2 concentrations tested (5 and 10 
M) were 58 (± 2)% and the second-order rate constant is 64.8 (± 0.6) M-1 s-1.  Overall 
conversion of both probe analogues are comparable suggesting a similar side-reaction may 
be involved which results in the consumption of similar levels of H2O2.  The rates of FCCP 
33 release from FCCP-SUM 211 by either reaction with H2O2 or background probe 
breakdown were both significantly higher than the rates of DNP 201 release from DNP-
SUM 210 due to the former being a better leaving group. 
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H2O2 Triggered FCCP Release





























Fig.45: H2O2 triggered FCCP 33 release from FCCP-SUM 211 (Scheme 61) 
 
The above results therefore confirm that the proposed mechanism of uncoupling molecule 
release in response to H2O2 works as designed in probes 210 and 211, with the successful 
release from benzylic attachment sites without the need for a fragmentable carbonate or 
carbamate linker. 
 
7.4 Synthesis of TPP salts 
 
Next, targeting of the SUMs to mitochondria was investigated.  MitoSUMs were designed 
to employ the TPP targeting approach previously discussed (Chapter 2.1).  Introduction of 
TPP moieties is generally achieved through SN2 displacement of a leaving group such as a 
halide, triflate or mesylate.  Using this approach a number of TPP compounds with ready-
to-attach linkers were synthesised (Schemes 67-70).  TPP formation from short linear 
chain (n = 1-4; where n = number of methylene units) dihaloalkanes in toluene allows 
rapid synthesis and straight-forward isolation by collection of the precipitated product 
(Scheme 67).  Increasing alkyl chain lengths above n = 4 results in partial solubility and so 
mixtures of mono-TPP 228 and di-TPP 229 compounds are produced which are difficult to 
separate from each other.  Similar mono- and di-TPP compound mixtures arise regardless 
of the choice of halide leaving group (Cl, Br or I).  
 
Switching solvents to diethyl ether slows reaction rates due to the reduction in maximum 
obtainable temperatures, but allows the straight-forward synthesis of TPP-alkyl halides up 
to at least n = 6 228 (Scheme 67) due to the poor solubility profile of TPP compounds in 
ethereal solvents.  When n = 10, partial solubility returns due to increased lipophilicity and 
therefore di-TPP compounds 231 once again began to form.  This can be minimised by 
  101 
using a large excess of the dihalodecane but the overall concentration must be kept low as 
the desired mono-TPP product 230 is partially solubilised by the alkylating agent itself 
which leads to the bis-salt 231 being generated.  Further work is required to optimise the 
synthesis of these longer-chain TPP-alkyl halides. 
 
 
Scheme 67: Synthesis of TPP-alkyl halides 
 
A range of other ready-to-attach linkers were also synthesised to enable the simple 
introduction of TPP groups.  To improve the rates of subsequent alkylation reactions 
compared to the linear TPP-alkyl halides above, a TPP-benzylic bromide analogue 233 
was prepared from α,α’-dibromoxylene 232 (Scheme 68).  No reaction was observed when 
attempting to synthesise the direct nitrogen analogue 234 using triphenylamine, due to the 
differences in size of phosphorus and nitrogen atoms.  The smaller nitrogen atom is more 
sterically hindered and the overlap of its lone pair with the aromatic rings is better than in 
the case of phosphorus, resulting in a significantly poorer nucleophile. 
 
 
Scheme 68: Synthesis of TPP-benzylic bromide 233 
 
A carboxylic acid bearing variant 236 was synthesised to allow attachment via esters or 
amides (Scheme 69) either through the use of coupling agents or through the formation of 
an acid chloride intermediate.  Through functional group interchange this compound could 
also potentially be used to access to the alcohol and aldehyde analogues and further 
derivatives thereof if necessary. 
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Scheme 69: Synthesis of TPP-carboxylic acid 236 
 
An attempt was also made to examine the possibility of introducing TPP groups through 
click chemistry (Scheme 70).  Alkyl halides are readily converted into azides in near 
quantitative yields using sodium azide in refluxing aqueous alcohols.  A subsequent trial 
click reaction to couple TPP-azide 238 with propargylic alcohol 239 was unsuccessful, 
although a thorough optimisation of conditions was not completed in this case.  This 
approach has since been successfully used within the Hartley research group (albeit with 
reversal of azide/alkyne moieties in relation to the TPP group) using a CuI catalysed click 
reaction in DMF to introduce TPP moieties via a biologically stable triazole unit. 
 
 
Scheme 70: Attempted TPP introduction using click-chemistry 
 
7.5 Initial attempts towards MitoDNP-SUM and MitoFCCP-SUM 
 
Initial synthetic approaches towards MitoSUMs focussed on modifying the boronate ester 
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Scheme 71: Original proposed route to MitoSUMs 
A: R = p-(C6H4)CH2ODNB B: R = p-(C6H4)CH2FCCP X = Br or OMs 
 
Adapting the procedure of Li and Burgess
155
 alkyne-triol 242 was synthesised, isolated and 
characterised for the first time.  A literature reduction of crude alkyne-triol 242 used 
hydrogen over Raney nickel.  Attempted reduction using hydrogen over Pd/C caused 
significant decomposition with multiple quartets observed in the 
1
H NMR spectrum of the 
crude mixture.  These could only arise after hydroxyl group loss and/or intramolecular 
methyl group migration.  Although originally the aim was to use a saturated linker 243, an 
alternative might be to use alkyne-triol 242 instead which would ensure the remoteness of 
the free hydroxyl to prevent potential mixtures of boronate esters forming (eg. 7- or 8-
membered boronate ring formation). 
 
Before either triol 242 or triol 243 could be coupled to form a boronate ester, conversion of 
DNP-SUM 210 or FCCP-SUM 211 to their corresponding boronic acids would be 
required.  Boronate esters of 1,2-diols such as pinacol and boronic acids exist in 
equilibrium favouring the boronate ester due to the chelate effect.  Sodium periodate was 
employed to convert free pinacol into acetone driving the equilibrium to the boronic acid 
side (Scheme 72).  It was found that hydrolysis of DNP-SUM 210 or FCCP-SUM 211 to 
their boronic acid analogues was difficult to drive to completion above 80-85% 
conversion, despite repeated reaction attempts, with increased duration and sodium 
periodate excess. 
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Scheme 72: NaIO4 reaction with 1,2-diols 
R = p-(C6H4)CH2ODNB or p-(C6H4)CH2FCCP 
 
Alternative methods of boronate ester to boronic acid conversion not attempted employ 
transesterification using an excess of boron trichloride or a polymer-bound boronic acid as 
reported by Pennington et al.
156
  Crude boronic acid 247 (~83:17 247:210 by 
1
H NMR) 
was coupled to alkyne-triol 242 with magnesium sulfate as a drying agent to drive the 
reaction to completion.  
1
H NMR spectroscopy indicated clean coupling of the two partners 
to give boronate 248, however upon attempted purification by column chromatography on 
silica the compound decomposed. 
 
 
Scheme 73: Proposed boronate ester hydrolysis/formation 
 
A test coupling reaction between alkyne-triol 242 and phenylboronic acid 249 appeared 
similarly successful by crude 
1
H NMR spectroscopy but purification by column 
chromatography on silica again led to total decomposition of the alcohol 250 (Scheme 74). 
 
 
Scheme 74: Model boronic acid coupling to alkyne-triol 242 
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Due to stability issues along with the potential loss of the targeting group via reversible 
hydrolysis of the boronate ester in aqueous environments, alternative structures for 
MitoSUMs were proposed. 
 
7.6 Revised approach towards MitoDNP-SUM 
 
The second synthetic MitoSUM target proposed would be directly analogous to DNP-SUM 
210 but would include attachment of a TPP group through a stable ether linker attached 
directly to the aryl ring (Fig.46). 
 
 
Fig.46: Revised structure for mitochondria-targeted DNP-SUM 251 
 
Phenol 252 was iodinated using the procedure of Whiting and Pilling
157
 in moderate yield 
(Scheme 75).  Esterification under acidic conditions and the following 
diisobutylaluminium hydride (DIBALH) reduction to benzylic alcohol 255 were both 
completed in near quantitative yield.  On top of the two equivalences of DIBALH required 
to complete the reduction, a sacrificial equivalence is also required due to reagent co-
ordination to the free phenol. 
 
 
Scheme 75: Synthesis of diol 255 
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Originally LiAlH4 was employed to reduce ethyl ester 254 but this led to a mixture of 
products including dehalogenated phenol 146 (Scheme 76).  The significant halogen loss 
was probably a result of aluminium co-ordination by the phenoxyl moiety directing 
hydride transfer onto the carbon bearing the iodine atom.  A similar mixture including 
iodide loss was observed upon the attempted reduction of carboxylic acid 253 with 
THF.BH3 to give benzylic alcohol 255. 
 
 




Conversion of diol 255 into bis-acetal 257 was quantitative with no trace of phenol 256 
present in the crude reaction mixture (
1
H NMR).  However, after purification by column 
chromatography on silica, partial loss of the phenolic acetal was observed indicating its 
higher lability under mildly acidic conditions compared to the benzylic acetal.  No sign of 
any benzylic alcohol deprotection was detected.  Isolated phenol 256 could be readily 
converted back into bis-acetal 257 through resubmission to protection conditions although 
this was never attempted as sufficient bis-acetal 257 had been obtained as a 1:1 mixture of 
diastereomers to continue the synthesis (Scheme 77). 
 
 
Scheme 77: Protection of diol 255 
 
Lithium-halogen exchange and borylation to give boronate ester 258 was less efficient than 
previously found for boronate esters 214 and 219 due to the increased steric bulk adjacent 
to the borylation site (Scheme 78).  Bis-deprotection was readily achieved using 
aluminium trichloride although approximately 10% of material underwent proto-
deborylation to give diol 146.  The crude mixture was taken forward to introduce the TPP 
group to the phenol moiety.  Differentiation between hydroxyl groups could be achieved 
by differences in pKa values between the phenol (~10) and the benzylic alcohol (~15).  
However, upon phenoxide 262 formation by cesium carbonate, complete proto-
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deborylation occurred as the directly conjugated oxyanion promotes protonation of the 
carbon attached to boron atom (Scheme 79).  If the targeting group attachment had been 
successful, introduction of the uncoupling molecule would have completed the synthesis. 
 
 
Scheme 78: Proposed route towards MitoSUM 251 
 
 
Scheme 79: Proto-deborylation occurs under acidic or basic conditions  
(The boronate cleavage step is likely to go via a step-wise mechanism) 
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In an attempt to prevent proto-deborylation by increasing the rate of the alkylation step an 
excess of α,α’-dibromoxylene 232 was used along with an anhydrous, aprotic solvent 
(Scheme 80).  Significant loss of the boronate group was still observed indicating that this 
decomposition is significantly faster than the attempted alkylation reaction.  Attempted 
targeting group introduction was unsuccessful. 
 
 
Scheme 80: Alternative proposed route to MitoSUM intermediate 
 
Synthetic steps were reversed to allow the introduction of the boronate trigger in the final 
step to prevent the problem of proto-deborylation (Schemes 81-83).  MOM protection of 
previously synthesised ethyl ester 254 was achieved in high yield.  As observed during the 
reduction of the unprotected ethyl ester 254, reduction with lithium aluminium hydride 
gave a mixture of products including dehalogenated products 266 and 267 (Scheme 81).  
Therefore it appears that the methoxymethyl ether protecting group can sufficiently co-
ordinate to aluminium to assist in directing hydride attack to the carbon atom attached to 
the iodine atom.  The use of a bulky, non-co-ordinating phenol protecting group such as a 
tert-butyldimethylsilyl group could potentially prevent iodide loss by removing any 
directing effects and by sterically hindering hydride attack on the iodine-bearing carbon 
atom.  However DIBALH was successfully employed due to its lower reactivity and 
greater steric bulk to reduce ethyl ester 264 to selectively give benzylic alcohol 265 in 63% 
yield. 
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Scheme 81: Intermediate route towards MitoSUMs 
The uncoupling molecule payload was incorporated using the standard SNAr conditions 
(Scheme 82).  Phenol deprotection was achieved in high yield under strongly acidic 
conditions after the same transformation had been attempted using the mild conditions of 
Breton.
158
  NaHSO4 supported on silica gave low but clean conversion to phenol 269  with 
addition of excess reagent unsuccessful at driving the reaction to completion.  Phenol 
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The final step introduction of the pinacol boronate ester group via a Miyaura borylation 
reaction was unsuccessful with no sign of borylation and significant compound 
degradation observed (Scheme 83).  At this stage it was unclear if this degradation resulted 
from thermal decomposition and/or from the breakdown of the compound after palladium 
insertion.   
  
 
Scheme 83: Attempted Miyaura borylation 
 
Other methods of introducing boronate esters are not compatable with the other 
functionality in aryl iodide 270.  A phosphorus ylide could form under basic conditions 
while the nitro groups of the DNP 201 moiety rule out lithiation procedures.  Furthermore 
DNP 201 is a good leaving group precluding the use of many nucleophilic reagents or 
Grignard conditions.  With this in mind and with only limited amounts of aryl iodide 270 
in hand, further modifications to the structure of DNP-bearing MitoSUMs were made 
(Chapters 7.8-7.10). 
 
7.7 Attempts towards MitoBHT-SUM 
 
MitoBHT-SUM 278 was proposed and investigated in tandem with the DNP analogue 251 
discussed previously.  Initial esterification of carboxylic acid 252, introduction of the 
methoxymethyl ether protecting group and ester reduction steps were all achieved in high 
yield on a multi-gram scale.  Attempted functional group conversion of the benzylic 
alcohol 274 into the desired benzylic bromide 275 using the method previously used to 
generate benzylic bromide 220, instead yielded deprotected benzylic bromide 145.  This is 
not unprecedented as acetal-type ethers have previously been reported by Kim et al
159
 to be 
cleaved by soft nucleophiles such as bromide (eg. MgBr2) or thiols in certain solvent 
systems.  Benzylic bromide 145 had previously only been reported in the literature as an 
intermediate crude, unstable oil or as a purified brown solid with incomplete 
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characterisation.
130
  The isolated crystals were indeed found to be unstable in light at RT.  
Whether one or both of these factors promote decomposition is unclear, although both are 
potentially a contributing factor.  The solid itself appears to be stable for prolonged periods 
if stored in the dark at –18 °C.  Upon decomposition the solid turns brown/black indicating 
bromide loss and becomes poorly soluble in organic solvents indicating polymerisation. 
 
 
Scheme 84: Proposed synthesis of MitoBHT-SUM 278 
 
Conversion of benzylic alcohol 274 into benzylic bromide 275 could potentially be 
achieved using Appel reaction conditions or via mesylation followed by bromide 
displacement if an alternative protecting group was chosen.  However, severe proto-
deborylation issues observed during the parallel attempted synthesis of boronate 260 would 
be expected to occur similarly in MitoBHT-SUM 278 due to the closely related structures.  
Therefore no further efforts were made at completing this synthesis via this route. 
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7.8 Attempts towards AmidoMitoDNP-SUM and AmidoMitoFCCP-SUM 
 
The new synthetic targets switched the targeting group attachment site away from the aryl 
ring bearing the boronate trigger to the same attachment site as the uncoupler molecule 
payload itself.  Thus the newly proposed AmidoMitoDNP-SUM 279 and 
AmidoMitoFCCP-SUM 280 have the uncoupler attached to a secondary rather than a 
primary carbon atom (Fig.47).  Although introducing an amide which is a potential site for 
metabolism by enzyme-catalysed hydrolysis that could result in targeting group loss, these 
structural modifications would remove the previous proto-deborylation issues and should 
have improved water solubility. 
 
 
Fig.47: Proposed AmidoMito-SUMs 
 
Phthalimido-aldehyde fragment 283 was readily synthesised from 3-aminopropan-1-ol 281 
by phthalimide protection of the amino group under Dean-Stark conditions followed by 
Swern oxidation of alcohol 282 (Scheme 85).   
 
 
Scheme 85: Synthesis of phthalimido-aldehyde fragment 283 
 
Aryl iodide 155 was readily synthesised in excellent yield using the conditions of Knochel 
and co-workers (Scheme 86).
134,135 
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Scheme 86: Synthesis towards AmidoMito-SUMs 279 and 280 
 
The presence of LiCl breaks up the 
i
PrMgCl dimer 290 or oligomer aggregates in solution 
to form an intermediate 
i
PrMgCl.LiCl 291 complex that is more reactive than the parent 





Scheme 87: Catalysis of Mg-halogen exchange reaction with LiCl 
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Employing identical Grignard conditions as for the previous step, but instead using 
aldehyde 283 as the electrophile gave key intermediate alcohol 284 in moderate yield 
(Scheme 86).  Using LiCl in this second step prevents formation of the isopropylboronate 
resulting from Grignard attack at boron.
135
  At this point the synthesis diverged towards the 
two synthetic targets and the subsequent two steps towards each AmidoMito-SUM were 
successful. 
 
Mesylation and conversion to bromide 285 was followed by SN2 displacement by 
malononitrile to take the synthesis towards AmidoMitoFCCP-SUM 280.  A small amount 
of elimination product 287 was observed in both steps and isolated after the latter. 
 
Hydrazine deprotection of phthalimide 284 and amide formation using water-soluble 
coupling reagent N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC.HCl) and preformed TPP-carboxylic acid 236 gave alcohol 289 in yields of 85% and 
74% respectively, one step from completion of AmidoMitoDNP-SUM 279.   
 
A number of attempts to complete the synthesis of AmidoMitoDNP-SUM 279 using the 
previously used SNAr reaction conditions were unsuccessful (Scheme 88).  The target 
compound was produced by the reaction but none of the conditions used gave complete 
conversion to product despite repeated attempts.  Isolation attempts using column 
chromatography on silica and HPLC were unsuccessful at separating the different TPP salt 
components in the mixture. 
  
 
Scheme 88: Attempted synthesis of AmidoMitoDNP-SUM  279 
 
It is proposed that AmidoMitoFCCP-SUM 280 (Scheme 89) synthesis would be completed 
by reaction of phthalimide 286 with hydrazine followed by amide formation to introduce 
the TPP targeting group as before.  FCCP 33 moiety formation via the diazonium salt of p-
(trifluoromethoxy)aniline would complete the synthesis. 
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Scheme 89: Proposed end to AmidoMitoFCCP-SUM 280 
 
7.9 Synthesis of 1
st
 generation MitoDNP-SUM 
 
From the findings obtained during the previously unsuccessful MitoSUM attempts 
(Chapters 7.5-7.8) regarding synthetic approach, TPP attachment methods and position, a 





 Generation MitoDNP-SUM 
 
Esterification of carboxylic acid 293 followed by methoxymethyl ether protection of the 
phenol moiety, reduction to a primary alcohol and Swern oxidation gave aldehyde 297 in 
excellent yields on multi-gram scales (Scheme 90). 
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Scheme 90: Synthesis of aldehyde fragment 297 
 
Once again employing the Grignard conditions of Knochel
134,135
 with aldehyde 297 as the 
electrophile (and as the limiting reagent) gave secondary alcohol 298 in excellent yield 
(Scheme 91).  The propionaldehyde derivative 297 intermediate was chosen, as E2 
elimination in alcohol 298 or ethers 292 or 299 would be less favourable as the aromatic 
rings would be sufficiently separated to prevent direct conjugation between the aryl units 
in the alkene product.  Originally the SNAr and MOM deprotection steps were conducted 
separately, however after incorporating the DNP 201 moiety, instability on silica and 
alumina led to reduced yields each time the purification was attempted.  Furthermore the 
desired boronate ester form of phenol 299 was more readily separable from its boronic acid 
analogue than was the case for the intermediate boronate ester 300 and boronic acid 301 
(Fig.49).  Boronate ester 300 and boronic acid 301 were however identified in the crude 
1
H 
NMR to monitor the reaction progress before the deprotection step is carried out.  Thus 
combining these steps saved time and improved the overall yield. 
 
Introduction of the TPP targeting group through mild alkylating conditions (cesium 
carbonate and benzylic bromide 233) completed the synthesis of MitoDNP-SUM(1) 292. 
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Scheme 91: Synthesis of MitoDNP-SUM(1) 292 
 
 
Fig.49: Intermediate mixture after SNAr reaction with alcohol 298 
 
A small-scale assessment of the reversal of the final steps was made (Scheme 92).  Phenol 
298 deprotection yielded diol 302 in moderate yield followed by selective alkylation of the 
phenol over the secondary alcohol, again in moderate yield.  An attempt to complete 
MitoDNP-SUM(1) 292 by an SNAr reaction was unsuccessful although optimisation of this 
route could potentially allow it to be used to yield MitoSUMs in the future.  At this point 
the target probe was completed via the original route (Scheme 91) and so no further 
experiments on this alternative route were conducted. 
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Scheme 92: Alternative proposed synthesis of MitoDNP-SUM(1) 292 
 
7.10 Synthesis of 2
nd
 generation MitoDNP-SUM 
 
A more compact, less lipophilic version of MitoDNP-SUM(1) 292 was designed to remove 






 Generation MitoDNP-SUM 
 
Initial attempts looked at making an analogue with an aliphatic linker with one carbon 
shorter than MitoDNP-SUM(2) 304 (as carboxylic acid 235 was to hand) via an adaption 
of the method of Xu et al.
160
  However using this aryl zincation method gave only 
dimerisation product 306 (Scheme 93).  Introduction of a TPP moiety to alkyl bromide 305 
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followed by ketone reduction with NaBH4 and finally DNP 201 introduction by the 
standard SNAr mechanism previously discussed would have completed the synthesis. 
 
 
Scheme 93: Attempted synthesis of intermediate ketone 305 using aryl zincation 
 
Synthesis of MitoDNP-SUM(2) 304 was completed via the direct modification of the 
MitoDNP-SUM(1) 292 route (Schemes 90 and 91) in which aldehyde 309 (Scheme 94) 
replaces aldehyde 297 as the electrophile in the second Grignard reaction (Schemes 91 and 
95).  Desymmetrisation of hexan-1,6-diol 307 by mono-acetal protection and subsequent 
Swern oxidation gave aldehyde 309 in excellent yield on a multi-gram scale.   
  
 
Scheme 94: Synthesis of aldehyde 309 
 
A subsequent Grignard reaction gave secondary alcohol 310 as a 1:1 mixture of 
diastereomers in high yield.  DNP coupling and immediate deprotection under acidic 
conditions gave primary alcohol 311 in moderate yield, while diol 312 and secondary 
alcohol 313 were also isolated as minor by-products from this reaction (Scheme 95).   
 
 
Scheme 95: Synthesis towards MitoDNP-SUM(2) 304 
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The originally envisaged conversion of alcohol 311 directly into TPP salt 304 via an 
intermediate mesylate or triflate was unsuccessful.  Appel reactions were employed to give 
alkyl halides 314 and 315 using CBr4 and CI4 respectively (Scheme 96).
161,162
   
 
 
Scheme 96: Completion of MitoDNP-SUM(2) 304 synthesis 
   
Direct TPP salt formation from bromide 314 failed under a number of conditions.  Direct 
SN2 displacement with triphenylphosphine heated under reflux in MeCN was sluggish and 
resulted in partial DNP 201 loss.  Use of AgNO3 as an additive to drive the reaction to 
completion through the precipitation of the silver bromide by-product led to no TPP 
formation and only gave a by-product, presumed to be the nitrate displacement product as 
identified by the shift in the adjacent CH2 signal from ~3.4 ppm to ~4.4 ppm in 
1
H NMR.  
The use of AgClO4 gave more encouraging preliminary results with TPP formation 
occurring slowly but cleanly.  However by this point synthesis was completed via iodide 
315 by SN2 displacement in diethyl ether.  Although slow, the reaction can be accelerated 
by using a large excess of triphenylphosphine which is simply removed from the desired 
TPP salt product by precipitation of the salt product from stirring diethyl ether.  
Interconversion of bromide 314 into iodide 315 failed using the conditions of Firouzabadi 
et al (ZrCl4 and NaI)
163
 but was achieved in high yield using standard Finkelstein reaction 
conditions. 
 
TPP salt formation was also observed in the reaction of bromide 314 with 
triphenylphosphine in MeCN under microwave conditions but the conversion was low and 
prolonged exposure to microwave energy led to many unidentified decomposition and/or 
side products.  Therefore this approach was not explored any further. 
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7.11 Diastereotopicity in MitoDNP-SUMs  
 
Once DNP 201 is attached, MitoDNP-SUM(1) 292, MitoDNP-SUM(2) 304 and their 
caged-DNP containing precursors 299, 311, 314 and 315, display diastereotopic pinacol 
methyl groups.  In the precursor enantiomeric secondary alcohols 298 and 303 or 
diastereomeric alcohol 310, no difference in chemical shift is observed.  Once the large 
DNP 201 group is added the chiral centre is able to influence the chemical shifts of these 
distant groups. 
   
As a result, geminal dimethyl groups become inequivalent and give rise to two 6H singlets 
in 
1
H NMR spectra and two singlets in 
13
C NMR.  Distal methyl groups (ie. MeA and MeA’ 
in Fig.51) remain equivalent due to free rotation about the boron-carbon bond while the 
proximal methyl groups (ie. MeA and MeB in Fig.51) which are equivalent in the 
precursors, become inequivalent due to the addition of this large group extending the 
influence of the chiral centre after the removal of the molecular mirror plane. 
 
 
Fig.51: Diastereotopicity in MitoDNP-SUMs 292/304 and caged-DNP precursors 
 
Surprisingly, chemical shift differences due to the presence of the chiral centre are also 
apparent in the remote methylene unit directly attached to phosphorus in MitoDNP-
SUM(1) 292.  As this phenomenon is not observed in any of the other linking units, this 
must result from the manner in which the molecule folds in solution.  An explanation for 
this is that the TPP group is held close enough to the chiral centre for the diastereotopicity 
to be observed, in a conformation perhaps resulting from a combination of the DNP unit π-
stacking with the xylyl group and of dipole-dipole interactions between TPP and the 
oxygen atoms of the nitro groups of the DNP moiety.  This may result in differential 
folding of the TPP unit towards either the front or rear faces of the DNP moiety which 
could potentially be influenced by π-stacking interactions between aryl units (Fig.52).   
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Fig.52: Possible folding in MitoDNP-SUM(1) 292 
 
7.12 SUM and MitoSUM stabilities and responsiveness to H2O2 
 
The abilities of MitoDNP-SUMs 292 and 304 to release DNP 201 in response to H2O2 was 
assessed under pseudo-physiological conditions at both cytosolic pH (7.4) and 
mitochondrial matrix pH (8.0) at 37 ºC and were compared to the response of the 
untargeted DNP-SUM 210.  The stabilities of the three compounds under testing 
conditions were also assessed. 
 
Initially the linearity of DNP 201 absorption (λabs = 410 nm) with increasing concentration 
was assessed in KHE buffer (Appendix 2):MeCN (3:1) at pHs 7.4 and 8.0 (Figs.53-55) and 
found to hold up to and including 60 μM DNP 201.  Towards 100 μM DNP 201, 
absorption approaches 1 and linearity is lost.  As a result, the maximum concentration of 
DNP 201 that could be released in the following experiments (assuming a 1:1 reaction 
stoichiometry and 100% conversion of H2O2) was kept below 60 μM.  At both pHs the vast 
majority of DNP 201 is present in its anionic form and thus no significant difference in 
absorption is observed with a linear regression slope of 0.00946 ± 0.00008 for pH 7.4 and 
0.00953 ± 0.00026 for pH 8.0 (Fig.55).  Furthermore the presence of two equivalents of 
H2O2 had no impact on the absorption of DNP 201 (Orange and yellow graph lines, 
Figs.53 and 54).  Absorption spectra graphs are truncated at 250 nm due to strong MeCN 
absorption below this wavelength. 
 
 
  123 
DNP Absorption (pH 7.4)


















DNP Absorption (pH 8.0)



























DNP Absorption at 410nm































Figs.53-55: Linearity of DNP 201 absorption in KHE/MeCN buffer systems (n = 1) 
 
In the following studies all time courses (TCs) were conducted over 2000 s with a full 
absorption spectrum scanned over 7 mins (100 nm min
-1
, 900-200 nm) immediately 
afterwards.  The following data presented are graphs of the spectral scans after each TC to 
monitor DNP 201 release.  Corresponding TC graphs for MitoDNP-SUM(1) 292 and 
MitoDNP-SUM(2) 304 decomposition can be found in appendix 3 (Figs.83-86).  
Subsequent TCs began straight after completion of the preceding spectral scans.  Probe 
concentrations of 200 μM were used to give pseudo-first order conditions.  Additions of 
H2O2 noted in figure legends were added from freshly titrated stock solutions, followed by 
short inversion mixing prior to commencing TCs. 
 
It was found that no decomposition of DNP-SUM 210 was observed at either pH 7.4 or 
8.0, as spectra after TC1 and TC2 perfectly overlap (~1.4 h total incubation time, red and 
orange graph lines, Figs.56 and 57).  Upon addition of H2O2, DNP 201 release was 
observed by monitoring the increased absorption at 410 nm while there was a decrease in 
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probe absorption maximum at 297 nm.  The initial rapid jump in DNP 201 release slowed 
down over time as H2O2 was consumed. 
 
DNP-SUM Decomposition Spectra (pH 7.4)
























DNP-SUM Decomposition Spectra (pH 8.0)
























Figs.56 and 57: DNP-SUM 210 decomposition and reaction with H2O2 
 
At pH 7.4, MitoDNP-SUM(1) 292 showed only very minor decomposition while 
MitoDNP-SUM(2) 304 gave a slow but steady, spontaneous release of DNP 201 (Figs.58 
and 59, TCs 1-4).  It is hypothesised that the greater instability of MitoDNP-SUM(2) 304 
is due to the close proximity of the TPP moiety which can assist the leaving of the DNP 
anion 202 by stabilising the  charge generated in the transition state.  After more than 2.5 h 
incubation, both compounds still gave a rapid DNP 201 release upon addition of H2O2, the 
rate of which slowed as H2O2 was consumed (Fig.58, TCs 5 and 6) or gave an 
approximately linear step increase upon a subsequent H2O2 addition (Fig.59, TCs 5 and 6).  
Both probes display a λabs maximum at 300 nm which decreases as the reaction with H2O2 
proceeds. 
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MitoDNP-SUM(1) Decomposition Spectra (pH 7.4)


























Fig.58: MitoDNP-SUM(1) 292 decomposition and reaction with H2O2 
 
MitoDNP-SUM(2) Decomposition Spectra (pH 7.4)










After TC5 (+ 20 µM H2O2)















Fig.59: MitoDNP-SUM(2) 304 decomposition and reaction with H2O2 
 
Significant decomposition of both MitoDNP-SUMs 292 and 304 occurred at pH 8.0 
(Figs.60 and 61).  Decomposition rates remained steady for the duration of the tests (over 
2.5 h) and were faster than the corresponding rates measured at pH 7.4.  
 
MitoDNP-SUM(1) Decomposition Spectra (pH 8.0)
























Fig.60: MitoDNP-SUM(1) 292 decomposition 
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MitoDNP-SUM(2) Decomposition Spectra (pH 8.0)
























Fig.61: MitoDNP-SUM(2) 304 decomposition 
 
From the apparent pH dependence of non-H2O2 initiated breakdown, it was therefore 
hypothesised that the spontaneous DNP 201 release is occurring due to the reversible 
attack at boron from hydroxide (Scheme 97), which is at a higher concentration at elevated 
pH.  This would convert the electron-withdrawing boronate group into an electron-
donating group with sufficient electron density to allow unimolecular fragmentation to 
occur, releasing DNP 201 in its anionic form 202.  The methylene group adjacent to the 
uncoupling molecule attachment site may stabilise the cationic character formed in the 
intermediate through hyperconjugation.  This appears to be important for breakdown as no 
decomposition is observed in the case of the primary attachment site (DNP-SUM 210, 
Fig.57).  Therefore future MitoSUM target molecules would be envisaged to incorporate a 
primary attachment site for the leaving group with the targeting moiety attached via a short 
aliphatic chain linked to the aryl ring of the arylboronate unit. 
 
 
Scheme 97: pH dependent breakdown of MitoSUMs 
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MitoDNP-SUMs 292 and 304 were also assessed to determine as to whether or not they 
could react proportionally in response to varying levels of H2O2.  Probes were exposed to 
specified concentrations of H2O2 and incubated for 2000 s after which a full spectral scan 
was taken.  To account for spontaneous decomposition, MitoDNP-SUMs 292 or 304 were 
included in the reference cuvette throughout.  Even with the elevated decomposition at pH 
8.0, both probes responded to H2O2 addition and as predicted, with increasing H2O2 
leading to an increased DNP 201 release (Fig.62 and 63). 
 
Response of MitoDNP-SUM(1) to H2O2 (pH 8.0)






After 5 µM H2O2
After 10 µM H2O2 A
After 10 µM H2O2 B
After 20 µM H2O2 A
After 20 µM H2O2 B















Fig.62: Responsiveness of MitoDNP-SUM(1) 292 to H2O2 
 
Response of MitoDNP-SUM(2) to H2O2 (pH 8.0)
























Fig.63: Responsiveness of MitoDNP-SUM(2) 304 to H2O2 
 
Therefore MitoDNP-SUMs 292 and 304 have been shown to release DNP 201 upon 
reaction with H2O2 and are responsive to H2O2 concentrations under pseudo-physiological 
conditions.  The above data are preliminary results with further replicates required for 
statistical analyses to be conducted. 
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It is proposed that mitochondria-targeted arylboronate esters containing a para-leaving 
group analogous to the MitoSUMs discussed above could potentially be used as a slow 
release mechanism for drugs designed to target mitochondria.  The compounds would be 
more stable in the circulation and cytosol but slowly release their payload molecules in the 
mitochondrial matrix due to the elevated pH.  For example, one such application may be 
the targeting of anti-cancer agents as cancer cells almost ubiquitously have elevated ΔΨm 
and some also have elevated ΔΨp, which could be used to derive some degree of selectivity 
for delivery of chemotherapy agents to cancer cells over healthy cells.
164
  It is also thought 
that perturbing this increased ΔΨm may be a way to combat uncontrolled cell division, in 
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Chapter 8:  MitoDNP-SUMs : Preliminary biological results 
 
Biological studies were conducted at the Buck Institute for Research on Aging (Novato, 
CA, USA) in the laboratory of Professor Martin Brand with the assistance of Dr Casey 
Quinlan. 
 
All of the biological tests herein were conducted on mitochondria isolated from rat skeletal 
muscle (Appendix 4).  Muscle tissue is commonly chosen for studies on isolated 
mitochondria as it contains large numbers of mitochondria compared to many other tissue 
types, due to the need for sufficient local energy stores to allow the muscle to respond 
quickly to the need to perform work.  Furthermore, alternatives such as liver mitochondria 
possess heightened levels of peroxidase enzymes which could result in the breaking down 
of H2O2 prior to its reaction with MitoDNP-SUMs 292 or 304 which could affect the 
results of these studies.  All tests were conducted at physiological temperature (37 ºC) in 
either potassium (KHE) or sucrose based buffers (MAS1 or SHEP, Appendix 2).  
 
Over the course of biological studies, the abilities of MitoDNP-SUMs 292 or 304 to 
behave as designed in a physiological environment were investigated.  For example, could 
the probes: 
 
i) Accumulate within the matrix of isolated mitochondria as a result of ΔΨm. 
ii) React with endogenous H2O2 resulting in the release of the mitochondrial 
uncoupling molecule DNP 201. 
iii) Release sufficient DNP 201 to uncouple mitochondria. 
iv) Reduce ROS production by reducing ΔΨm as a result of mitochondrial uncoupling. 
v) Self-limit DNP 201 release.  Firstly as reducing ROS production would reduce 
H2O2 production which is required to trigger DNP 201 release and secondly by 
reducing ΔΨm, the compound could redistribute out of the mitochondrial matrix, 
reducing the rate of the trigger activation reaction. 
vi) Control ROS production to reduce oxidative stress at a cellular level, slowing the 
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In initial biological testing, MitoDNP-SUM(2) 304 exhibited a poor stability profile in the 
biological systems, consistent with results previously discussed (Chapter 7.12, Figs.59 and 
61).  Therefore, the data presented hereafter relates solely to MitoDNP-SUM(1) 292 which 
was sufficiently stable for an evaluation of probe functions to be made. 
 
A number of biologically active compounds are incorporated into the following biological 
experiments to modify the behaviour of the electron transport chain, including rotenone 
316 (complex I inhibitor), antimycin A 317 (complex III inhibitor), oligomycin A 318 
(ATPase inhibitor) and nigericin 319 (proton and potassium ion antiporter) (Fig.64).  
Rotenone 316 inhibits complex I by preventing electron transfer from the Rieske iron-
sulphur centres to coenzyme Q 1 by reversibly binding to the ubiquinone binding site.  
Antimycin A 317 inhibits complex III by binding irreversibly to the Qi site, preventing 
ubiquinone reduction.  The inhibition of complex I or III impacts the ability to generate 
ΔΨm as protons are no longer pumped into the IMS by the inhibited protein complex.  
Oligomycin A 318 inhibits ATPase by blocking the proton channel.  Nigericin 319 




 ions across the MIM, resulting in 
the removal of the pH gradient component of the protomotive force. 
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8.1  Mitochondrial uptake of MitoDNP-SUM(1) 
 
An assessment of MitoDNP-SUM(1) 292 uptake into energised mitochondria was 
conducted using a MTPP (methyltriphenylphosphonium, aka TPMP) electrode which 
measures the voltage in the buffer across a semi-permeable membrane.  The experimental 
set-up also allows for simultaneous measurements of oxygen concentration to be taken by 
a Clark electrode.  Initial studies were conducted using potassium based buffer (KHE) but 
later repeated in a simplified sucrose based buffer (SHEP). 
 
Analogous to the uptake experiment previously shown for MitoB 134 (Fig.31) or reference 
MTPP (Fig.65), MitoDNP-SUM(1) 292 would be added portionwise (five additions) to 
obtain a logarithmic calibration curve.  This could be done with or without isolated 
mitochondria being present in the system from the start of the experimental calibration.  In 
the latter case, the addition of mitochondria mid-experiment gives an indication of the level 
of non-specific lipophilic uptake (drop in voltage).  In either case, the initiation of the 
electron transport chain via the addition of a substrate such as succinate or glycerol 
phosphate establishes a ΔΨm and any lipophilic cations would accumulate in the 
mitochondrial matrix, resulting in a corresponding drop in voltage readings as the cations 
are removed from the bulk buffer.  Using the calibration curve it is possible to determine 
the level of cation uptake into the mitochondrial matrix.  Finally the addition of the strong 
mitochondrial uncoupling molecule FCCP 33 would dissipate the ΔΨm, releasing the 
cations back into the buffer solution.  Experiments are generally run in a closed-system in 
which a finite amount of oxygen is present, allowing mitochondrial respiration rates to be 
monitored at different stages of the experiment.  However in a closed system, mitochondria 
must be present throughout the entire experiment as late addition is not possible. 
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Fig.65: Representative of an optimal TPP salt uptake experiment graph (Closed system) 
 
The MTPP electrode gave a very slow response to MitoDNP-SUM(1) 292 additions 
(particularly at higher doses) (Figs.66 and 67) compared to the reference MTPP (Fig.65) 
itself (min vs s).  Lower additions (0.1-0.5 µM) gave significantly sharper responses, 
however the reduced magnitude of the voltage change resulted in increased signal noise.  
Addition of DNP 201 or FCCP 33 should release the probe by depleting the ΔΨm, however 
upon uncoupler addition the voltage readings gave an inconsistent response (falling/rising/ 
falling then rising/having no change).  This phenomenon is likely related to the high 
lipophilicity of the probe and its binding to the electrode, experimental cell walls and/or 
the mitochondrial membranes, although the exact reasons were not confirmed.  Similar 
issues have been observed by other research groups using this experimental set-up with 
lipophilic compounds, including Asin-Cayuela et al during the investigation of lipophilic 
analogues of MitoQ 29.
60
  Furthermore MTPP-electrode drift issues with these handmade 
electrodes are not uncommon and can change direction and magnitude between runs or 
even within a single run.   
 
Once mitochondria are isolated from cells, their health deteriorates and can be used for 4-6 
h after isolation if stored in highly concentrated stock solutions on ice.  Once in dilute 
buffer solutions this degradation is accelerated which can affect test results.  As the 
electrodes took a relatively long time to settle after MitoDNP-SUM(1) 292 additions, an 
experiment was run in an open system to allow mitochondria to be added during the 
experiment to prevent significant deterioration due to prolonged periods spent in the dilute 
buffer at 37 °C while the electrode stabilised.  This allowed the observation of both initial 
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lipophilic uptake of MitoDNP-SUM(1) 292, followed by active uptake after mitochondrial 
energisation by succinate (Fig.66).  This showed that the probe was driven into the 
mitochondrial matrix by the ΔΨm as designed but release upon de-energisation using 
mitochondrial uncoupler FCCP 33 was unsuccessful. 
 
 
Fig.66: Open system: KHE buffer, 0.25 mg mL
-1
 protein, 1% BSA, pH 7.4, 
5 μM rotenone 316, 1 μg mL-1 oligomycin A 318, 1 μM nigericin 319. 
 
Next, a closed system experiment was conducted in which mitochondria were present from 
the start (Fig.67).  As a result of the slow electrode response to probe additions, only two 
calibration steps were made to prevent extensive mitochondrial deterioration.  Upon 
energisation, ΔΨm driven uptake was again observed.  In this experiment the mitochondria 
present are allowed to consume all of the oxygen in the system.  The resulting anaerobic 
conditions cause the mitochondria to become de-energised and this was observed to trigger 
probe release from the mitochondrial matrix.   
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Fig.67: Closed system: KHE buffer, 0.25 mg mL
-1
 protein, 0.5% BSA, pH 7.4, 
5 μM rotenone 316, 1 μg mL-1 oligomycin A 318, 110 nM nigericin 319. 
 
These uptake experiments have shown that MitoDNP-SUM(1) 292 is actively taken up into 
energised mitochondria due to the DLC targeting group and that depletion of the ΔΨm 
caused by oxygen depletion releases the probe back into the buffer as designed. 
 
8.2 The impact of MitoDNP-SUM(1) on mitochondrial ROS production rates 
 
Experiments to determine the impact of MitoDNP-SUM(1) 292 on mitochondrial ROS 
production rates were conducted measuring changes in fluorescence using an Amplex 
UltraRed (Invitrogen, 50 μM, λex = 563 nm, λem = 587 nm) and horseradish peroxidise 




  Amplex UltraRed is a fluoregenic substrate for HRP, an 
enzyme which utilises H2O2 in a 1:1 stoichiometry to oxidise the substrate into Amplex 
UltroxRed, leading to a large increase in fluorescence at the λem.  The exact structures of 
Amplex UltraRed and Amplex UltroxRed are unpublished but will likely be closely related 
to the structures of Amplex Red 320 (Invitrogen) and its oxidisation/deacetylation product 
resorufin 321 (Scheme 98).  These fluorophores are particularly suited to biological 
systems as they emit red-fluorescence, resulting in little interference from blue or green 
autofluorescence occuring from natural biomolecules. 
 
 
Scheme 98: Oxidation and fluorescence activation of Amplex Red 320 by HRP/H2O2 
 
  135 
As the above system reports solely on H2O2 concentrations, excess superoxide dismutase 
(25 U mL
-1
) was added to rapidly convert any O2
•−
 generated by the system into H2O2 
through a disproportionation reaction, to give a more accurate read on overall ROS 
production levels. 
 
8.2.1 Membrane potential dependent ROS production 
 
The following ROS experiments (Chapters 8.2.1 and 8.2.2) were conducted in SHEP 
buffer (pH 7.4), with 0.3 mg/mL protein (2 mL total cuvette volume) at 37 °C and used 
succinate (5 mM) as the mitochondrial substrate.  Succinate addition after 1-2 min is 
readily observable by the immediate sharp increase in fluorescence (Figs.68-70 and 72) 
and MitoDNP-SUM(1) 292 or DNP 201 additions are subsequently made to the relevant 
runs between 4-5 min.  After this any changes in the rate of fluorescence increase can be 
observed in the change in slope of the signal.  All results in chapters 8.2.1 and 8.2.2 are 
preliminary and require further replication to obtain statistically analysed data sets. 
 
Initially the ability of MitoDNP-SUM(1) 292 to reduce mitochondrial membrane 
dependent ROS production (combined O2
•−
 and H2O2 production monitored as H2O2 using 
SOD/HRP/Amplex UltraRed system) as designed was assessed.  In this experiment 
succinate would generate the ΔΨm causing probe uptake into the mitochondrial matrix.  
Dissipation of the ΔΨm through ATPase is prevented through inhibition by oligomycin A 
318 (14.5 μg mL-1).  Therefore any significant lowering of ΔΨm would result solely from 
DNP 201 released from MitoDNP-SUM(1) 292 uncoupling the mitochondria.  Rotenone 
316 inhibits electron transfer between Fe-S centres of complex I, resulting in a build up of 
electrons on FMNH2 co-factors (the proportion of which is set by the NADH/NAD
+
 ratio), 




  H2O2 
generated by SOD would react with the boronate moiety of the probe, triggering DNP 201 
release which would then reduce ΔΨm and therefore ROS production. 
 
It was found that under these conditions MitoDNP-SUM(1) 292 reduced ROS production 
rates as seen by the reduced rates of fluorescence increase (Fig.68).  Furthermore 
increasing the MitoDNP-SUM(1) 292 dose, increased the drop in ROS production rates 
consistent with increased mitochondrial uncoupling due to an increased DNP 201 
concentration being released into the system. 
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Impact of MitoDNP-SUM(1) on ΔΨm Dependent ROS 


























Figs.68: Impacts of MitoDNP-SUM(1) 292 on ΔΨm dependent ROS 
 
In comparison, the ability of free DNP 201 to moderate ΔΨm was found to be significantly 
lower (Fig.69) than that of MitoDNP-SUM(1) 292 (Fig.68) under these conditions even at 
elevated concentrations.  This is because the bulk of the DNP 201 will remain in the buffer 
as there is no force driving the uncoupler to the site of action while in the case of 
MitoDNP-SUM(1) 292, DNP 201 is released directly into the mitochondrial matrix where 
it acts as an uncoupler. 
 
Impact of DNP on ΔΨm Dependent ROS 
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8.2.2 Membrane potential independent ROS production 
 
To confirm that the reduction in ROS production rates previously observed through 
MitoDNP-SUM(1) 292 addition resulted solely from mitochondrial uncoupling and not 
from an unpredicted inhibition of mitochondrial machinery, two control experiments were 
conducted.  Firstly an experiment was set up containing rotenone 316 (2 μM) and 
anitmycin A 317 (2 μM) to generate ROS, predominantly from complex III after succinate 
oxidation.  As both complexes I and III are inhibited, no ΔΨm can be established as protons 
cannot be pumped into the IMS.  Therefore the ROS produced by this system is 
independent of ΔΨm.  Addition of MitoDNP-SUM(1) 292 was found to have no impact on 
ROS production rates (Fig.70), even at concentrations higher than previously used. 
 
Impact of MitoDNP-SUM(1) on ΔΨm Independent ROS 


























Fig.70: MitoDNP-SUM(1) 292 has no impact on ΔΨm independent ROS 
 
Secondly, to ensure that the lack of impact that MitoDNP-SUM(1) 292 had on the 
membrane potential independent ROS system above was not simply due to lack of 
compound uptake, ΔΨm was generated via the reverse running of ATPase while using the 
same ROS producing conditions (Fig.71).  This system converts excess ATP 5 into ADP 4 
with the concomitant pumping of three protons from the mitochondrial matrix through 
ATPase into the IMS for each molecule of ATP 5 hydrolysed, establishing ΔΨm.  To set up 
these conditions, excess ATP 5 (1 mM) is added while the additions of creatine kinase (20 
U mL
-1
) and an excess of phosphocreatine 322 (10 mM) regenerate ATP 5 from any ADP 
4 produced (Scheme 99), which can then be rehydrolysed by ATPase to maintain ΔΨm.   
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Fig.71: Reverse running of ATPase can be used to generate a ΔΨm 
 
 
Scheme 99: Creatine Kinase and excess phosphocreatine 322 maintain high ATP 5 levels 
 
As predicted under these conditions, MitoDNP-SUM(1) 292 was once again found to have 
no impact on ΔΨm independent ROS production rates (Fig.72) despite probe uptake into 
the mitochondrial matrix. 
 
Impact of MitoDNP-SUM(1) on ΔΨm Independent ROS 


























Fig.72: MitoDNP-SUM(1) 292 has no impact on ΔΨm independent ROS 
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8.2.3  High versus low level ROS production  
 
A key design of the MitoSUMs is that they should only modulate misbehaving 
mitochondria with high ROS production, but not uncouple healthy mitochondria.  An 
investigation into the ability of MitoDNP-SUM(1) 292 to produce different levels of 
uncoupling depending on to varying levels of endogenous ROS was conducted by Dr 
Casey Quilan using a Seahorse XF24 analyzer.  This microplate reader allows for the 
simultaneous monitoring of oxygen concentration and pH over the course of an 
experiment.   
 
Parallel experiments with mitochondria possessing identical ΔΨm (to ensure equal probe 
uptake) but varying in their ROS production rates were required to show any performance 
differences for the probe between high and low ROS conditions.  To do this, the reverse 
ATPase system discussed previously (Chapter 8.2.2) was employed to maintain ΔΨm while 
conditions with or without succinate yielded high (~1.4 nmol H2O2/min/mg protein) and 
low (~0.05 nmol H2O2/min/mg protein) ROS producing systems respectively. 
 
During ATP 5 hydrolysis, protons are liberated resulting in a net acidification of the 
system.  A greater degree of mitochondrial uncoupling results in increased ATP 5 
hydrolysis and hence increased acidification of the system.  Therefore the level of 
uncoupling resulting from any DNP 201 released from MitoDNP-SUM(1) 292 following 
reaction with H2O2 can be monitored as the rate of acidification of the buffer medium. 
 
MitoDNP-SUM(1) 292 exhibited a dose dependent uncoupling response at both low and 
high ROS conditions (Fig.74).  At low concentrations (10 μM) there was no difference 
between the differing ROS levels or from the DNP 201 control.  This could potentially 
result from a number of factors such as free DNP 201 being present in the stock solution, 
or a high sensitivity to either low amounts ROS or to the mitochondrial matrix conditions 
(ie. pH, enzymes or biomolecules).  However at higher concentrations (20 or 40 μM) 
MitoDNP-SUM(1) 292 exhibited a significant ROS-dependent uncoupling profile in line 
with DNP 201 controls, suggesting that high ROS conditions can lead to complete release 
of the uncoupler from the MitoSUM construct with only partial release in low ROS 
conditions.  40 μM DNP 201 was found to give the maximum uncoupling rates under these 
test conditions. 
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A number of the tenets proposed for the MitoSUMs project (Chapters 7-8) have been 
successfully proven.  Firstly, it has been shown that MitoDNP-SUM(1) 292 will 
accumulate in the matrix of isolated energised mitochondria in response to ΔΨm (as a result 
of the DLC targeting group) and that it will be subsequently be released upon de-
energisation brought about by oxygen depletion (Chapter 8.1). 
 
Secondly it has been demonstrated through spectrometric techniques that Mito-SUMs 292 
and 304 react with exogenous H2O2 to release the uncoupling molecule DNP 201 in a dose 
dependent manner under pseudo-physiological conditions (Chapter 7.12).  It was observed 
that the stability of both probes, particularly MitoDNP-SUM(2) 304, deteriorates in 
increasingly basic environments but that this issue may be overcome by a structural 
modification to a primary benzylic attachment site for the uncoupling molecule (as in 
DNP-SUM 210) instead of a secondary centre. 
 
Furthermore, biological testing has confirmed that MitoDNP-SUM(1) 292 will release its 
uncoupling molecule cargo in response to endogenous ROS production, again in a dose 
dependent manner and that the level of DNP 201 released is sufficient to uncouple 
mitochondria as measured by acidification rates (Chapter 8.2.3). 
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Preliminary studies have indicated that the rates of mitochondrial ROS production can be 
attenuated by addition of MitoDNP-SUM(1) 292 (Chapters 8.2.1-8.2.2) and that this is 
more effective than free DNP 201 due to targeted delivery of the uncoupling molecule.  An 
impact on ROS production rates was observed on ΔΨm dependent ROS, consistent with 
this affect resulting from the modulation of ΔΨm by the released uncoupling molecule.  
However, either a Clark electrode experiment measuring the rates of oxygen consumption 
during respiration or a fluorescence experiment that directly monitor ΔΨm (ie. Safranin O 
66, Chapter 3.3) should be conducted to confirm this. 
 
To date no evidence has been generated to indicate that the release of DNP 201 from the 
current MitoSUM constructs is self-limiting and no longer term studies into the affects that 
MitoSUMs might have on the onset of oxidative stress driven age-related diseases have 
been conducted.  For the next round of MitoSUM compounds it is proposed that the 
uncoupling molecule attachment site is modified to a primary centre to improve alkaline 
stability and that a more potent uncoupler such as FCCP 33 be incorporated to reduce 
concentrations and therefore any potential undesired side-effect caused by high 
mitochondrial concentrations of DLCs or probe reaction by-products.  Finally compound 
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Chapter 9: Mitochondria-targeted photo-activatable functional molecules 
9.1 Project aims and photo-activation 
 
Although the TPP delivery mechanism can robustly target materials to mitochondria, the 
challenge of delivering materials selectively to individual mitochondria within cells or 
tissues at any specific time persists.  This is of particular interest as localised 
subpopulations of mitochondria within cells potentially play unique roles in various 
cellular mechanisms.
167
  Furthermore temporal control of compound delivery to specific 
mitochondria is vital in developing a detailed understanding for a wide range of cellular 
pathways and interactions. 
 
Compounds were designed that would accumulate in all mitochondria using the standard 
TPP delivery mechanism, but would only release their payload molecule after targeted 
stimulation.  This would be achieved by laser induced photo-activation so that caged 
functional molecules in specific mitochondrial regions of interest could be activated while 
leaving others unaffected.  A number of photo-cleavable protecting groups have been 
developed,
168





 325 photo-activatable units. 
 
 
Fig.75: NB-type 324 and coumarin-type 325 photo-cleavable protecting groups 
(X = Leaving group) 
 
Photo-activatable caged molecules can be irreversibly activated by light irradiation 
whereby the photo-labile group is permanently cleaved from a payload functional molecule 
of interest.
168,171
  For use in biological systems the ideal caged precursors should be water 
soluble, stable to hydrolysis and both the probe itself and any photo-activation by-products 
should be non-toxic.  Furthermore photo-activation should occur in high   and at 
wavelengths >300 nm to minimise light-induced damage to cells.  
 
NB-type 324 linkers are the most extensively employed photo-activatable caging groups 
and have been used for over three decades in both organic synthesis
174
 and biochemistry 
applications.
175
  The λabs for NB-type 324 units range between ~260-370 nm depending on 
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aryl substitution patterns with more electron-rich aryl units absorbing at the longer 
wavelengths albeit with reduced  .172,173  As normal laser excitation wavelengths range 
from approximately 330-385 nm, the maximum λabs for many NB-type 324 molecules 
(particularly those with electron poorer aromatics) are outside this range. 
 
The exact nature of all photolysis intermediates have not been fully elucidated but it is 
known that upon irradiation, hydrogen atom abstraction from the benzylic position by the 
ortho-nitro group is followed by rapid tautomerisation (Scheme 100).
171
  Subsequent loss 
of a leaving group is the rate determining step, resulting in the formation of a nitroso-
carbonyl by-product 326. 
 
 
Scheme 100: Proposed NB-type 324 photo-cleavage mechanism 
(R = H, alkyl    X = Leaving group) 
 
Commonly coumarin-type 325 photo-activatable units often suffer from a low   but 
benefit from high absorption co-efficients, rapid photo-release and λabs ranges (~325-400 
nm) that extend into the visible region of the electromagnetic spectrum.
171
  As a result 
coumarin-type 325 linkers can be activated by one-photon photolysis using lower energy 
irradiation than required for NB-type 324 groups and are also potential candidates for 
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multiple-photon photolysis cleavage probes.
172,176
  Activation by multiple photons in the IR 
region could be beneficial for a number of reasons.  Firstly these low energy photons result 
in less damage to biological systems (in particular DNA) and have greater penetration due 
to their longer wavelength.  In single-photon excitation, any absorbing molecule in the 
photons path will be excited regardless of depth until the light is completely absorbed and 
the probability of any scattered light resulting in a photo-activation event is high.  In 
contrast, two-photon excitation will only occur at the focal point of both photon beams at 
which the combined energy is sufficient to activate the molecule (Fig.76, orange regions 
represent emission or uncaging events).
177
   
 
 
Fig.76: Two-photon excitation gives increased spatial precision for photo-activation 
 
This could allow significant improvements in spatial selectivity in releasing bioactives as 
has been used for fluorescence based studies.  The success of any such system will rely on 
the uncaging cross  section of the molecule which is a product of the cross-section for two-
photon absorption and the subsequent quantum yield of the uncaging process.
170
  
Unfortunately there currently are no reliable rules which dictate structural requirements for 
the two-photon excitation and uncaging processes. 
 
However, MitoPhoto-DNP 328 was recently synthesised within the Hartley research group 
incorporating an NB-type 324 photo-linker and TPP targeting group (Scheme 101).
167
  
MitoPhoto-DNP 328 was shown to accumulate in the mitochondria of isolated smooth 
muscle cells and selective photo-activation (irradiated at 355 nm, probe maximum λabs = 
306 nm in aqueous buffer with 0.1% DMSO) was found to successfully uncouple specific 
localised mitochondria after the probe released its uncoupling molecule payload (DNP 
201).  The synthetic strategy employed allowed for the final step diversification of the 
probe by attaching a chosen payload molecule to benzylic alcohol 327 (Scheme 101).  
Therefore this general approach should allow a library of compounds containing alcohols 
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Scheme 101: Final step in the synthesis of MitoPhoto-DNP 328 
 
The long-term aims of this project were to: 
i) Develop the scope of bioactive substrates that can be selectively delivered and 
released inside mitochondria using this targeted photo-release approach. 
ii) Optimise the NB-type 324 photo-linker properties to so that the maximum λabs 
more closely matches the excitation wavelength used. 
iii) Assess how various selectively released bioactives could impact mitochondria, as 
well as wider biological behaviour. 
iv) Develop two-photon excitation analogues for increased spatial control of payload 
release. 
 
The ether linker used in MitoPhoto-DNP 328 could easily be adapted into an ester to allow 
the attachment of molecules boasting carboxylic acid moieties, or into a carbamate to allow 
the attachment of any amine or amide containing compound.  Two such examples would 
be for the selective delivery and release of reversible complex I inhibitor amobarbital
178
 
329 or irreversible complex II inhibitor 3-nitropropionic acid (NPA)
179
 331 delivered as 
MitoPhoto-Amytal 331 and MitoPhoto-NPA 332 (Fig.77). 
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Fig.77: MitoPhoto probes to deliver carbamate or ester bound bioactives 
 
It was proposed to further broaden the synthetic strategy to allow the selective delivery of 
bioactives through a photo-activatable acetal linker, analogous to the photo-labile 
protecting group for aldehydes and ketones developed by Hébert, Gravel and 
colleagues.
180,181
  These would allow for the selective mitochondrial release of bioactive 
molecules containing aldehydes or ketones with general acetal structure 333 (Fig.78).  A 
number of options are available for the spacer between the TPP and photo-activatable 
moieties as long as the chosen group does not quench the desired photo-cleavage 
mechanism.  Initially, a butyl chain directly analogous to MitoPhoto-DNP 328 will be used 
as this has previously been successful. 
 
 
Fig.78: Proposed photo-activatable acetals to deliver aldehydes/ketones to mitochondria 
 
9.2 Initial attempts towards mitochondria-targeted photo-labile acetals 
 
The initial target for the acetal-project was to synthesise a mitochondria-targeted photo-
activatable version of reversible isoflavonoid complex I inhibitor rotenone, as MitoPhoto-
Rotenone 334 (Fig.79).  The R-configuration assigned to the acetal centre stereochemistry 
is based on the curvature of the rotenone molecule which would likely block the formation 
of the alternative S-configuration.  
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Fig.79: Proposed mitochondria-targeted photo-activatable version of  rotenone 316 
 
The synthesis would begin with the conversion of aldehyde 335 into triol 337 using 
methylenation and dihydroxylation conditions (Scheme 102).  The subsequent order of 
targeting group and payload molecule attachment could be reversed (depending on the ease 
of synthesis) with a number of potential choices available for each.  Ideally the bioactive 
molecule would be attached as the final step to access one common intermediate 338, 
which would allow single-step diversification to a range of products.  However the 
purification of desired TPP compounds from TPP containing starting materials (eg. 333 
and 338) or by-products with similar physical properties (dominated by the presence of the 
TPP group) can be problematic.  It is however generally slightly easier to separate TPP 
compounds with significant differences in the sizes of attached organic substituents (eg. 
161 and 333) and it is simple to separate non-TPP compounds by precipitation (eg. 339) 
from ethereal solvents. 
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Scheme 102: Proposed general route to MitoPhoto-Acetals 
 
Methylenation of aldehyde 335 (Scheme 103, Table 8) using standard Wittig conditions 
(Entry 1) or by titanium-based conditions developed in the Hartley research group for the 
methylenation of esters
182
 (Entry 2) both gave complete conversion to alkene 336 as 
determined by 
1
H NMR.  However purification from the triphenylphosphine oxide by-
product and excess MTPP bromide (Entry 1) or from titanium containing impurities (Entry 
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BuLi, Ph3PMe.Br (2 eq.), THF 
ii) Aldehyde 335, THF 
–78 °C to RT 43 
2 i) Nysted Reagent 341 (1.5 eq.), Cp2TiCl2, (3 
eq.), THF 
ii) Aldehyde 335, THF 
–78 °C to RT 39 
3 Aldehyde 335, Nysted Reagent 341 (1.5 eq.), 
BF3.OEt2 (1.2 eq.), THF 
0 °C to RT 99 
 
Ultimately using the geminal dizinc Nysted reagent 341 (Fig.80) under Lewis acid 
promoted conditions (Entry 3) again gave clean and complete conversion to the product 
with purification simplified (filtration through a short pad of Celite), giving the alkene 336 
in a near quantitative yield.  Furthermore this methylenation procedure is rapid and 
removes the need to cool to –78 °C or handle pyrophoric materials (nBuLi).  The Nysted 
reagent is often used to chemoselectively methylenate aldehydes and ketones in the 
presence of esters, to methylenate sterically hindered carbonyls or when basic Wittig 





Fig.80: Nysted methylenation reagent 
 
Preliminary attempts to isolate triol 337 after dihydroxylation of alkene 336 using catalytic 
osmium tetroxide with N-morpholine N-oxide (NMO) as the stoichiometric co-oxidant 
were unsuccessful, in part due to the partial water solubility of the product.  Acetate 342 
was synthesised in an attempt to make the dihydroxylation product simpler to isolate.  
Moreover it would help prevent the suspected polymerisation observed upon 
recrystallisation of alkene 336 during its initial synthesis, caused be phenol attack at the 
  150 




Scheme 104: Attempted dihydroxylation step towards MitoPhoto-Acetals 
 
9.3  Revised synthetic targets  
 
New synthetic targets were proposed in which the TPP component would be attached prior 
to setting up the bioactive attachment site to aid isolation.  Simultaneously it was decided 
to optimise the absorption properties of the photo-activatable linker to more aptly match 
the intended excitation wavelength based on the laser that would be used for cell studies 
(355 nm).  To red-shift the maximum λabs of the NB-type 324 photo-activatable probes, the 
target structures were modified to incorporate an additional electron-donating methoxy-
group in the photo-excitable unit.
170,172
  The greater absorption would go someway to 
compensate for the resultant drop in uncaging   but photo-linker properties could be 
further optimised at a later date once a benchmark level of bioactive release had been 
achieved and their biological impacts assessed.  
  
Revised targets included a direct analogue of MitoPhoto-DNP 328 (MethoxyMitoPhoto-
DNP 344) as well as MethoxyMitoPhoto-NPA 345 and MethoxyMitoPhoto-Rotenone 
conjugates 346. 
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Fig.81: Revised mitochondria-targeted photo-activatable targets 
 
9.3.1  Attempted synthesis of MethoxyMitoPhoto-DNP and MethoxyMitoPhoto-NPA 
 
Firstly the chosen photo-activatable core had to be synthesised from vanillin 347 with the 
nitro group and bioactive leaving group attachment sites in an ortho-orientation.  As 
expected, the direct nitration of vanillin 347 yielded solely the most electronically favoured 
product 348 in which the groups are in a meta-orientation (Scheme 105).  Conversion was 
almost quantitative and was aldehyde 348 isolated in a moderate yield after 
recrystallisation.  This reaction was attempted as all materials used were very cheap and 
readily scalable.  Therefore, even if the desired aldehyde 350 could have generated and 




Scheme 105: Nitration of vanillin 347 
 
Modifying the procedure of Tsai and Klinman,
169
 benzyl protection of vanillin 347 
followed by nitration and subsequent deprotection gave aldehyde 350 with 
recrystallisations occurring between each step (Scheme 106).  The change in nitration 
selectivity predominantly results from the change in ring electronics due to the reduced 
electron-donating ability of the phenol moiety, although increased steric interactions 
around the phenolic position are likely to also play a role in the observed selectivity. 
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Scheme 106: Synthesis of photo-activatable probe core 350 
 
The recrystallisation of each step from hot EtOH as described by Tsai and Klinman
169
 is 
not optimal as the crystallisation is hindered by the partial formation of the corresponding 
diethyl acetal and ethyl hemiacetal.  It was found that recrystallisation from acetone is 
found to be more successful.  Phenol protection, nitration and deprotection steps also were 
achieved in a slightly elevated overall yield with just a single recrystallisation after the 
third step which reduced the time taken to obtain aldehyde 350.  It is possible that this 
yield could be increased by further recrystallisations of the crude material, however due to 
time constraints, the initial ~10 g of the photo-activatable linker 350 obtained was 
sufficient to take the synthesis forward. 
 
Direct alkylation of phenol 350 with alkyl iodide 161 proved unsuccessful (Scheme 107).  
This is most likely because of the poor nucleophilicity of the phenoxide due to the electron 
withdrawing effects of the nitro-group and the directly conjugated carbonyl.  Therefore the 
step-wise synthesis of aldehyde 352 was accomplished by alkylation using an excess of 
1,4-diiodobutane 160 at elevated temperatures followed by standard conversion to a TPP 
group.  Yields for each step were reduced due to partial iodide elimination which gave the 
terminal alkene analogue of alkyl iodide 351.  This was particularly an issue in the 
alkylation step due to the presence of base which promoted this side-reaction. 
 
 
Scheme 107: Synthesis of a mitochondria-targeted photo-activatable core 
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The final steps towards MethoxyMitoPhoto-DNP 344 synthesis were attempted using 
identical procedures as had been used for the original MitoPhoto-DNP 328 synthesis 
(Scheme 108).
167
  Reduction to benzylic alcohol 353 was readily achieved using sodium 
borohydride but instability similar to that noted during the original MitoPhoto-DNP 328 
synthesis was observed.  This instability could potentially occur through thermal and/or 
photo-activated decomposition to the related nitroso-aldehyde species, although the exact 
structures of breakdown products were not confirmed in this project. 
 
 
Scheme 108: Attempted completion of a MethoxyMitoPhoto-DNP 344 
 
Aldehyde reduction followed by immediate SNAr coupling to 1-fluoro-2,4-dinitrobenzene 
gave significant and relatively clean conversion, with MethoxyMitoPhoto-DNP 344 as the 
major reaction product as determined by 
1
H NMR.  Partial purification was achieved by 
precipitation from diethyl ether to remove non-TPP salt impurities.  Although significantly 
more stable than the precursor benzylic alcohol 353, analogous to the findings from the 
synthesis of MitoPhoto-DNP 328,
167
 purification was not successful due to decomposition 
of the compound during column chromatography.  It was noted that gradual but significant 
loss of DNP 201 occurred on both silica and alumina.  It is likely that having the electron-
donating ether moiety in direct conjugation, para- to the leaving group is sufficient to 
accelerate decomposition by stabilising the transition state.  A small quantity of 
MethoxyMitoPhoto-DNP 344 was separated containing only a DNP 201 impurity.  
Attempts to wash this out with aqueous NaHCO3 led to complete decomposition of 
remaining ether 344.  Due to issues isolating MethoxyMitoPhoto-DNP 344, attention was 
turned to MethoxyMitoPhoto-NPA 345.  However attempts using the EDC.HCl coupling 
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agent and catalytic DMAP were unsuccessful and no coupling to NPA 330 was observed 
by 
1
H NMR (Scheme 109). 
 
 
Scheme 109: Attempted synthesis of MethoxyMitoPhoto-NPA 345 
 
For each photo-activatable probe, a number of control molecules would be required for 
biological testing, to confirm that the specific roles that individual compound features play 
in uptake, photo-activation and release mechanisms are working as proposed 354-357 
(Fig.82).
167
  TPP 354 lacks the nitro group and therefore would assist in the identification 
of any non-photo-induced release of the bioactives due to interactions with, or general 
instability towards the biological environments under study.  This control molecule would 
also be used to confirm that the uncaging mechanism requires the nitro group for 
activation.  As the removal of the nitro group significantly changes the aromatic core 
electronics, this molecule would have to be assessed at the optimal λabs of both the 
MitoPhoto compound under study and of the control molecule itself.  TPP compounds 355 
and 356 have no cleavable unit or cleave a biologically innocuous molecule respectively 
and would be used to determine if any observed biological affects were being driven by 
photo-activation process or its by-products.  Finally ether 357 would allow the 
confirmation as to whether or not the DLC driven mitochondria-targeting was playing a 
vital role in any observed effects. 
 
 
Fig.82: Proposed control molecules 
R = caged bioactive, R’ = biologically inactive molecule 
 
Aldehyde 358 is a key intermediate towards the nitro group free control molecules for both 
the proposed photo-activatable ether and acetal compounds depending on the subsequent 
synthetic steps employed (Scheme 110).  Vanillin 347 alkylation was achieved in moderate 
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yield using the conditions that had previously been unsuccessful for the more electron-
deficient nitro analogue 352. 
 
 
Scheme 110: Preliminary step towards control molecules 354 and 359 
 
9.3.2  Attempted synthesis of MethoxyMitoPhoto-Acetals 
 
Previously synthesised aldehyde 352 was the key intermediate at which point synthesis 
would diverge to attach various payload molecules.  Reduction to benzylic alcohol 353 
could be followed by attachments via ether, ester, carbamate or carbonate linkers as 
described above while the targeted delivery of bioactive molecules containing aldehydes or 
ketones via acetals could be achieved after methylenation and subsequent dihydroxylation 
procedures.   
 
Methylenation was attempted using the Nysted reagent 341 which gave slow and clean 
conversion of aldehyde 352 into styrene 360 as determined by 
1
H NMR (Scheme 111), but 
complete conversion was never achieved.  Resubmission of the reaction crude mixture to 
identical reaction conditions drove the reaction further towards completion (~50% in total) 
with aldehyde 352 and styrene 360 being the only products in the mixture.  The failure to 
obtain complete conversion is possibly because TPP compounds are insoluble in THF (in 
which the Nysted suspension is purchased) and using DCM as a co-solvent led to a 
destabilisation of the Nysted reagent 341 which requires ethereal solvents for stabilisation.  
Nonetheless it is likely that using a larger excess of Nysted reagent 341 or the optimisation 
of the co-solvent system could be used to give complete methylenation in the presence of 
the TPP salt to yield styrene 360. 
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Scheme 111: Attempted methylenation of aldehyde 352 
 
Wittig methylenation conditions would be incompatible with aldehyde 352 as this could 
lead to the corresponding phosphonium ylide being generated, while Tebbe or Petasis 
conditions were not attempted.  However an alternative approach in which aldehyde 352 is 
epoxidised by trimethylsulfoxonium iodide by a Corey-Chaykovsky reaction followed by 
epoxide opening and acetal formation was investigated (Schemes 112 and 113). 
 
 
Scheme 112: Proposed final steps to MethoxyMitoPhoto-Acetals 
 
 
Scheme 113: Corey-Chaykovsky reaction mechanism 
 
This epoxidation procedure rapidly generated the desired epoxide 361 but also oxidised the 
TPP moiety to a diphenylphosphine oxide when an excess of the sulfoxonium reagent was 
used.  When stoichiometric reagent was used, a mixture of the epoxidation and phosphorus 
oxidation products were observed indicating comparable reaction rates. 
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Although anhydrous DMSO was used as a solvent, it is unclear as to whether or not 
phosphorus oxidation is occurring as a result of reaction with the oxygen from the 
trimethylsulfoxonium iodide reagent directly, or simply by hydroxide (Chapter 2.1, 
Scheme 17) generation from small amounts of residual moisture present in the small scale 
reactions.  If hydroxide had been the cause it would be expected that some epoxide 
opening to diol 362 would have been observed, but this was not the case.  Additionally, 
increasing the equivalences of the sulfoxonium reagent would not be expected to have any 
impact on the amount of phosphorus oxidation, unless this reagent was the source of 
moisture.  If any of TPP 352 had been deprotonated by either residual base or the 
deprotonated sulphur reagent to form a phosphonium ylide, a much messier crude mixture 
would be expected after undergoing a Wittig reaction with a further molecule of aldehyde 
352.  Oxidation caused by trimethylsulfoxonium iodide itself could be confirmed or ruled 
out by using an 
18
O radiolabelled version of the reagent and assessing if any of the labelled 
oxygen becomes incorporated in the phosphorus oxidation products. 
 
An alternative route reversing the methylenation and targeting group attachment steps was 
started (Scheme 114).  Alkene 362 was readily isolated in good yield using an excess of 
Nysted reagent to account for any lost through co-ordination of the zinc reagent to the free 
phenol.  Alkene 362 could then be used to complete the synthesis of MitoPhoto-Acetals via 








A number of steps towards new generations of mitochondria-targeted photo-activatable 
probes have been made.  Most significantly, the synthesis of a mitochondria-targeted core 
352 that could potentially be used as a common precursor for the delivery of a plethora of 
bioactive molecules linked through ethers, esters, carbamates and acetals was achieved.  It 
is possible that with further optimisation of the final reaction steps and with increased 
experience handling light unstable materials, that new probes to investigate mitochondria 
could be developed based on this synthetic route. 
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Chapter 10: Research conclusions and future work 
 
Over the course of the above projects (Chapters 6-9), a number of novel functional 
molecules have been produced that assist in advancing the understanding of mitochondrial 
behaviour and the free radical theory of ageing.   
 
10.1  Ratiometric mass spectrometry probes for ROS/RNS quantification 
 
The first ratiometric mass spectrometry (MS) probe (MitoB 134) has been produced and 
allows the levels of H2O2 to be accurately measured in vivo (also applicable in vitro) for 
the first time, via the conversion of a boronic acid to a phenol moiety.
127,129
  To date 
studies require a tissue sample to be taken, but preliminary studies suggest that further 
optimisation of this technique will allow for the first completely non-invasive 
measurements in larger organisms through urine sampling. 
 
For the first time, a plethora of biological interventions and environmental conditions can 
be assessed directly for their impacts on H2O2 concentrations in whole organisms.  This 
begins to allow studies to look at separating a whole host of ROS production, 
detoxification and repair pathways from each other. 
 
For example, the widely held theory that dietary restriction extended lifespan as a result of 
reducing ROS levels has been now been shown to be incorrect.  Conformation of the 
increasing H2O2 level in an organism as it ages has been found to be independent of 
lifespan, suggesting that the concentration may be a result of ageing rather than causative.  
The influence of many other chemical or environmental factors such as oxygen 
concentration, paraquat addition, differing levels of physical activity, etc. can now also be 
probed.  This approach will ultimately allow for the development of a ranking table in 
which the various factors that modify H2O2 concentration can be ranked and assessed 
against each other and against different organism/cell types.  In particular, optimising the 
procedures may allow for many behavioural and dietary variables such as smoking or 
alcohol consumption (which are known to lead to accelerated ageing and disease) to be 
studied for their impacts on ROS production in whole organisms, such as humans. 
 
This approach is also applicable to in vitro studies complementing existing fluorescent 
techniques, or replacing them where necessary.  This method has a broad scope as it could 
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be used in the detection and quantification of many biologically relevant species as long as 
the reaction between the probe and the species in question can be sufficiently selective and 
yield a stable, MS identifiable product.  For example, the assessment of the analogous 
nitric oxide MS probe (MitoDA 156, Chapter 6.3) in biological systems is underway and 
the development of further ROS/RNS MS probes is ongoing within the Hartley research 
group.  Once biologically suitable, selective probe transformations have been established 
for each ROS/RNS of interest, alterations of the targeting group will allow this ratiometric 
MS approach to give quantification of these species in cellular compartments other than 
the mitochondria (eg. as discussed in ExoCellB 147, Chapter 6.2).  
 
10.2 Prodrugs activated in response to endogenous ROS 
 
A novel class of compounds, mitochondria-targeted selective uncoupling molecules 
(MitoSUMs) have been developed and their impact on isolated mitochondria assessed.  In 
line with the project aims, MitoSUMs were shown to accumulate in the matrix of isolated 
energised mitochondria in response to ΔΨm and release uncoupling molecules in a dose 
dependent manner in response to elevated mitochondrial ROS production, leading to a 
reduction in ROS production rates.  Additionally these constructs were shown to be 
significantly more potent than untargeted uncoupler, which would reduce any unwanted 
side-effects of DNP 201 interaction with biological systems outside of the mitochondria. 
 
These molecules are a new class of prodrug that with further payload molecule variation, 
could be used to selectively release a wide range of biologically active compounds inside 
mitochondria in response to elevated H2O2 production.  This could allow the biological 
effects of many compounds to be studied in vitro in relation to ROS production rates, 
detoxification or repair mechanisms.   
 
Further studies are required to assess whether or not prolonged exposure to MitoSUMs in 
whole organisms can lead to a reduction in the onset of age-related disease resulting from 
oxidative stress, as proposed in the free radical theory of ageing.  For the next round of 
MitoSUM compounds it is proposed that modifications of the payload molecule, 
uncoupling molecule attachment site and trigger electronics/sterics could be made to 
optimise compound stability, reactivity and potency.  Theoretically the trigger mechanism 
could be altered so as to give selective payload molecule release in response to some other 
biologically produced species of interest.  Similarly, the targeting group could be modified 
to target different cellular compartments.   
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10.3 Photo-activatable constructs for highly controlled bioactive release 
 
A future goal of this research is to produce mitochondria-targeted compounds that will 
allow temporal and spatial selectivity with regards to bioactive release following targeted 
photo-activation.  This would allow theories related to localised mitochondria 
subpopulations to be investigated and a greater understanding of the roles individual 
mitochondria play to be developed.  The scope of this research following on from the first 
such probe developed within the Hartley research group, MitoPhoto-DNP 328,
167
 is vast.  
Of particular interest is the possibility of selectively releasing respiratory chain inhibitors 
so as to monitor the effects of altering biological pathways of specific mitochondria and 
assessing how this impacts the cell and organism as a whole.   
 
A number of steps towards novel mitochondria-targeted photo-activatable probes have 
been made.  These include the synthesis of a mitochondria-targeted core 352 precursor that 
could allow for the delivery of bioactive molecules linked through ethers, esters, 
carbamates and acetals.  Completion of this synthetic route (Schemes 106 and 107) will 
lead to a library of targeted bioactives that may be selectively released inside mitochondria 
of interest that may be used in a wide range of potential studies.  Three key areas of 
optimisation for these molecules exist.  Firstly, optimisation of the photo-activatable core 
may be required to allow these functional molecules to more aptly match the preferred 
wavelengths of lasers used by different research groups and improve stability in the visible 
light region if required.  Secondly, changing of the targeting group will allow studies to 
examine bioactive molecule interactions with areas of an organism other than 
mitochondria.  Finally developing a range of new photo-activatable cores which are 
suitable for two-photon excitation will allow improved spatial resolution, which will be 
hugely beneficially for in vivo studies.  This is particularly useful as the lower energy, 
longer wavelength photons required can penetrate tissues more readily and cause less 
damage to cells.  One such application may be to selective release apoptosis inducing 
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Chapter 11: Experimental 
11.1 General experimental 
 
All reactions under an inert atmosphere were carried out using oven-dried or flame-dried 
glassware. Solutions were added via syringe or canula.  Acetonitrile, diethyl ether, 
tetrahydrofuran, dichloromethane, and toluene were dried where necessary using a solvent 
drying system, Puresolv
TM
, in which solvent is pushed from its storage container under low 
nitrogen pressure through two stainless steel columns containing activated alumina and 
copper.  Acetone was dried by distillation from calcium sulphate and dimethylformamide 
was dried by distillation from calcium hydride or purchased anhydrous from commercial 
suppliers.  Reagents were obtained from commercial suppliers and used without further 










P NMR spectra were obtained 
on a Bruker DPX/400 spectrometer operating at 400, 100, 128, 376 and 162 MHz 
respectively or on a Bruker AVIII spectrometer operating at 500, 126, 160, 470 and 202 
MHz respectively.  All coupling constants are measured in Hz.  DEPT was used to assign 
the signals in the 
13
C NMR spectra as C, CH, CH2 or CH3. COSY, NOESY, HMBC and 
HSQC NMR were used to confirm assignments where required.  Aromatic carbons directly 
attached to boron are not observed in 
13





B.  Standard abbreviations for signal multiplicities are used (eg. s, d, t, q, dd, dt, m, 
etc.).  
1
H NMR data for partially deuterated aromatic rings P(C6D4H) are reported and 
integrated relative to other 
1
H NMR signals unless the signals are otherwise obscured by 
other aromatic region signals.  Proton assignments in THP ethers are as described by 
Abraham et al, with protons assigned to the major ring conformer in which the 2-oxo 
substituent is axial due to the anomeric effect.
184
  Mass spectra (MS) were recorded on a 




 and certain CI
+
 analyses, which 
were recorded on a Thermofisher LTQ Orbitrap XL.  Infra-red (IR) spectra were obtained 
on a Shimadzu FTIR-8400S spectrometer using attenuated total reflectance (ATR) so that 
the IR spectrum of the compound (solid or liquid) could be directly detected (thin layer) 
without any sample preparation.  Rf values for phosphonium salts and carboxylic acids are 
concentration dependant and are reported as the maximum observed Rf.  Microanalyses 
were obtained on an Exeter Analytical CE440.  This instrument cannot distinguish between 
hydrogen and deuterium and the percentage H and D found in deuterated compounds are 
calculated from raw data with any deviation from theoretical appearing in the percentage 
D. 
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11.2 Synthesis 




3-(Bromomethyl)phenylboronic acid 143 (400 mg, 95%, 1.77 mmol) and 
triphenylphosphine (513 mg, 1.96 mmol) were heated at reflux in toluene (10 mL) for 6 h 
during which a white precipitate formed.  The mixture was concentrated under reduced 
pressure and the residue was recrystallised from minimal DMSO-toluene.  The solid was 
dissolved in hot H2O (400 mL) and H2O was removed under reduced pressure until 
precipitation began, upon which the mixture was allowed to cool to RT and crystallise 
slowly.  The mixture was centrifuged, and solvent pipetted off.  Crystals were washed with 
a little ice-cold H2O (5 mL) and dried under reduced pressure to yield phosphonium 
bromide 134 as needles.  Further phosphonium bromide 134 was obtained by multiple 
repetitions of the recrystallisation and centrifugation processes with material obtained by 
concentration of the combined aqueous liqueur (Combined yield 732 mg, 87%). Mp: 304-
305 °C (H2O). max (ATR): 3322 (OH), 2928 (CH), 2882 (CH), 2789 (CH), 1549 (Ar), 
1485 (Ar), 1435 (Ar) cm
–1
. H (400 MHz, d6–DMSO): 7.94 [2H, s, B(OH)2], 7.92-7.86 
(3H, m, 3   p-H PPh3), 7.77-7.69 (7H, m, 6   o-H PPh3 and H-4), 7.68-7.60 (6H, m, 6   
m-H PPh3), 7.46 (1H, broad s, H-2), 7.17 (1H, t, J = 7.5 Hz, H-5), 6.96 (1H, broad d, J = 
7.4 Hz, H-6), 5.14 (2H, d, J = 15.6 Hz, CH2). C (100 MHz, d6–DMSO): 136.88 (d, J = 5.6 
Hz, CH), 134.94 (d, J = 2.4 Hz, CH), 133.93 (d, J = 9.8 Hz, CH), 133.78 (d, J = 3.6 Hz, 
CH), 132.25 (d, J = 5.2 Hz, CH), 129.95 (d, J = 12.5 Hz, CH), 127.60 (d, J = 2.8 Hz, CH), 
126.67 (d, J = 8.5 Hz, C), 117.75 (d, J = 85.5 Hz, C), 28.15 (d, J = 46.5 Hz, CH2). P (162 
MHz, d6–DMSO): 23.52-22.76 (broad s).P {
1
H} (162 MHz, d6–DMSO): 23.15 (s). 
LRMS (ESI
+
): 397 (cation, 100%). HRMS: 397.1518 and 396.1557. C25H23
11
BO2P 
requires cation, 397.1524 and C25H23
10
BO2P requires cation, 396.1560. Microanalysis: 
C25H23BBrO2P requires C: 62.93% H: 4.86%, found C: 62.90% H: 4.80%. Structure 
confirmed by x-ray crystallography: Cambridge Crystalographic Data Centre deposition 












A stirring solution of 3-(bromomethyl)phenylboronic acid 143 (155 mg, 95%, 0.69 mmol) 
and tri(pentadeuterophenyl)phosphine (200 mg, 0.72 mmol) was heated at reflux in toluene 
(4 mL) for 6 h during which a white precipitate formed.  The mixture was concentrated 
under reduced pressure and the residue was recrystallised from DMSO-toluene, followed 
by recrystallisation from hot H2O.  The mixture was centrifuged, and solvent pipetted off. 
Crystals were washed with a little ice-cold H2O and dried under reduced pressure to yield 
phosphonium bromide 135 as needles.  The solvent pipetted off after centrifugation and the 
aqueous washings were concentrated under reduced pressure until further crystallisation 
was observed to begin and the crystallisation and centrifugation processes repeated to yield 
further phosphonium bromide 135 (Combined yield 179 mg, 50%). The compound was 
isolated as a 92:8 mixture of H8D15:H9D14. Mp: 303-304 °C (H2O). max (ATR): 3236 
(OH), 2928 (CH), 2882 (CH), 1543 (Ar), 1485 (Ar), 1424 (Ar,) cm
–1
. H (400 MHz, d6–
DMSO): 7.96 [2H, s, B(OH)2], 7.72 (1H, broad d, J = 7.4 Hz, H-4), 7.46 (1H, broad s, H-
2), 7.17 (1H, t, J = 7.6 Hz, H-5), 6.94 (1H, broad d, J = 7.6 Hz, H-6), 5.12 (2H, d, J = 15.6 
Hz, CH2). C (100 MHz, d6–DMSO): 137.02 (d, J = 5.6 Hz, CH), 135.08-134.22 (m, CD), 
133.92 (d, J = 2.7 Hz, CH), 134.22-133.12 (m, CD), 132.43 (d, J = 5.5 Hz, CH), 130.05-
129.15 (m, CD), 127.75 (d, J = 2.6 Hz, CH), 126.84 (d, J = 8.6 Hz, C), 117.67 (d, J = 85.4 
Hz, C), 28.27 (d, J = 46.5 Hz, CH2). P (162 MHz, d6–DMSO): 23.01 (broad t, J = 15.5 
Hz).P {
1
H} (162 MHz, d6–DMSO): 23.12-22.94 (broad s). LRMS (ESI
+
): 412 (cation, 
100%). HRMS: 412.2460 and 411.2479. C25H8D15
11
BO2P requires cation, 412.2465 and 
C25H8D15
10
BO2P requires cation, 411.2501. Microanalysis: C25H8D15BBrO2P requires C: 
61.00% H: 1.64% D: 6.14%, found C: 60.90% H: 1.64% D: 6.17%. 
 





A stirring solution of benzylic bromide 145 (134 mg, 0.72 mmol) and triphenylphosphine 
(200 mg, 0.76 mmol) was heated at reflux in toluene (4 mL) for 24 h during which a white 
precipitate formed.  The reaction mixture was concentrated under reduced pressure and the 
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resultant solid recrystallised from EtOH-hexane.  The solid was washed with a little ice-
cold H2O and dried under reduced pressure to yield phosphonium bromide 136 as an 
amorphous solid (190 mg, 59%). Mp: >290 °C (Decomp.) [Lit.
128
 290.5-291.5 °C (EtOH)]. 
max (ATR): 3079 (OH), 2889 (CH), 2858 (CH), 2787 (CH), 1611 (Ar), 1568 (Ar) cm
–1
. H 
(400 MHz, d6–DMSO): 9.54 (1H, s, OH), 7.94-7.86 (3H, m, 3   p-H PPh3), 7.78-7.70 (6H, 
m, 6   o-H PPh3), 7.70-7.60 (6H, m, 6   m-H PPh3), 7.00 (1H, t, J = 7.8 Hz, H-5), 6.68 
(1H, broad d, J = 8.0 Hz, H-4), 6.41 (1H, broad s, H-2), 6.36 (1H, broad d, J = 7.1 Hz, H-
6), 5.06 (2H, d, J = 15.6 Hz, CH2). C (100 MHz, d6–DMSO): 157.54 (d, J = 3.2 Hz, C), 
135.10 (d, J = 1.9 Hz, CH), 134.03 (d, J = 9.8 Hz, CH), 130.11 (d, J = 12.5 Hz, CH), 
129.75 (d, J = 2.2 Hz, CH), 129.05 (d, J = 8.3 Hz, C), 121.39 (d, J = 5.5 Hz, CH), 117.98 
(d, J = 85.6 Hz, C), 117.83 (d, J = 5.6 Hz, CH), 115.33 (d, J = 3.1 Hz, CH), 28.13 (d, J = 
46.6 Hz, CH2). P (162 MHz, d6–DMSO): 23.38-22.70 (broad s).P {
1
H} (162 MHz, d6–
DMSO): 23.03 (s). LRMS (ESI
+
): 369 (cation, 100%). HRMS: 369.1399. C25H22OP 
requires cation, 369.1403. Microanalysis: C25H22BrOP requires C: 66.83% H: 4.94%, 
found C: 66.89% H: 4.98%. 
1





Adapting the procedure of Dawson et al.
128
  PBr3 (0.95 mL, 1.0 M in DCM, 3.50 mmol) 
and anhydrous pyridine (150 µL, 1.85 mmol) were added to anhydrous MeCN (1 mL) at –
8 °C under argon and stirred for 5 min.  A solution of 3-hydroxybenzyl alcohol 146 (1.00 
g, 8.06 mmol) and anhydrous pyridine (50 µl, 0.62 mmol) in anhydrous MeCN (2.5 mL) 
was added slowly and the resulting solution stirred for 10 min at –8 °C under argon.  The 
solution was allowed to warm to RT and stirred at 20 C for 15 h before being 
concentrated under reduced pressure.  H2O (10 mL) was added and extracted with DCM (2 
  10 mL).  The extracts were eluted through a short silica column with EtOAc-DCM (1:19 
then 1:9).  Toluene (8 mL) was added to the crude yellow, unstable oil (1.13 g) followed 
by triphenylphosphine (3.58 g, 13.6 mmol) and stirred at reflux for 16 h.  After cooling to 
RT the precipitate was collected by filtration, washed with hot toluene, then Et2O and dried 
under reduced pressure.  Slow recrystallisation from EtOH yielded phosphonium bromide 
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A stirring solution of benzylic bromide 145 (128 mg, 0.68 mmol) and 
tri(pentadeuterophenyl)phosphine (200 mg, 0.72 mmol) was heated at reflux in toluene (4 
mL) for 24 h during which a white precipitate formed.  The reaction mixture was 
concentrated under reduced pressure and the resultant solid recrystallised from EtOH-
hexane.  The solid was washed with a little ice-cold H2O and dried under reduced pressure 
to yield phosphonium bromide 137 as an amorphous solid (153 mg, 48%). The compound 
was isolated as a 92:8 mixture of H7D15:H8D14. Mp: >290 °C (Decomp.). max (ATR): 3080 
(OH), 2889 (CH), 2858 (CH), 2787 (CH), 1617 (Ar), 1609 (Ar), 1587 (Ar) cm
–1
. H (400 
MHz, d6–DMSO): 9.55 (1H, s, OH), 7.00 (1H, t, J = 7.8 Hz, H-5), 6.69 (1H, broad d, J = 
8.0 Hz, H-4), 6.42 (1H, broad s, H-2), 6.36 (1H, broad d, J = 7.2 Hz, H-6), 5.08 (2H, d, J = 
15.7 Hz, CH2). C (100 MHz, d6–DMSO): 157.54 (d, J = 3.1 Hz, C), 134.90-134.23 (m, 
CD), 134.08-133.12 (m, CD), 130.08-129.20 (m, CD), 129.73 (d, J = 3.4 Hz, CH), 128.57 
(d, J = 8.6 Hz, C), 121.39 (d, J = 5.6 Hz, CH), 117.85 (d, J = 5.5 Hz, CH), 117.76 (d, J = 
85.4 Hz, C), 115.32 (d, J = 3.4 Hz, CH), 28.16 (d, J = 46.6 Hz, CH2). P (162 MHz, d6–
DMSO): 22.92 (broad t, J = 15.4 Hz).P {
1
H} (162 MHz, d6–DMSO): 23.08-22.74 (broad 
s). LRMS (ESI
+
): 384 (cation, 100%). HRMS: 384.2336. C25H7D15OP requires cation, 
384.2344. Microanalysis: C25H7D15BrOP requires C: 64.66% H: 1.52% D: 6.51%, found 
C: 64.69% H: 1.52% D: 6.69%. 
1
H NMR data for partially deuterated aromatic ring 
P(C6D4H) integrated relative to other signals in 
1
H NMR: 7.90 (0.018H, d, J = 0.9 Hz, p-H 
PPh3), 7.74 (0.030H, d, J = 3.0 Hz, m-H PPh3), 7.65 (0.032H, d, J = 12.5 Hz, o-H PPh3). 
 
3-Hydroxybenzyl bromide 145 
 
A stirring solution of benzylic alcohol 274 (3.00 g, 17.8 mmol) and anhydrous 
triethylamine (3.7 mL, 27 mmol) in anhydrous DCM (90 mL) were degassed with argon 
for 10 min.  The solution was cooled to 0 °C and methanesulfonyl chloride (1.8 mL, 23.2 
mmol) was added dropwise.  The solution was stirred at 0 °C for 1 h and then allowed to 
warm to RT over 1 h.  The solution was washed with H2O (2   20 mL), dried over MgSO4 
and concentrated under reduced pressure.  Anhydrous acetone (90 mL) and anhydrous 
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LiBr (15.85 g, 178 mmol) were added to the residual oil and the resulting mixture stirred 
for 22 h at reflux under argon.  The mixture was concentrated under reduced pressure and 
the residue redissolved in DCM (80 mL).  Organics were washed with H2O (2   30 mL), 
dried over MgSO4 and concentrated under reduced pressure to give a brown gum.  Column 
chromatography [SiO2, petroleum ether-EtOAc (3:2)] yielded benzylic bromide 145 as 
needles (1.14 g, 34%). Rf [SiO2, petroleum ether-EtOAc (3:2)]: 0.71. Mp: 61-62 °C. max 
(ATR): 3248 (OH), 2955 (CH), 2851 (CH), 1586 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.21 
(1H, t, J = 7.9 Hz, H-5), 6.96 (1H, d, J = 7.9 Hz, H-6), 6.89-6.86 (1H, m, H-2), 6.77 (1H, 
ddd, J = 8.1, 2.5 and 0.8 Hz, H-4), 5.04 (1H, broad s, OH), 4.34 (2H, s, CH2). C (100 
MHz, CDCl3): 155.62 (C), 139.42 (C) 130.07 (CH), 121.47 (CH), 115.90 (CH), 115.53 




























Anhydrous THF (25 mL) was added under argon to 1,3-diiodobenzene 151 (1.50 g, 4.55 
mmol) and anhydrous LiCl (212 mg, 5.00 mmol).  The stirring mixture was cooled to –78 
°C and 
i
PrMgCl (2.0 M in THF, 2.5 mL, 5.00 mmol) was added dropwise and stirred for 3 
h.  2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (930 μL, 4.6 mmol) was added 
dropwise and the solution allowed to warm slowly to RT overnight.  Saturated aqueous 
NH4Cl (2 mL) was added to quench.  The resulting mixture was stirred until the precipitate 
settled before being filtered through a pad of Celite and washed through with Et2O.  
Organics were dried over MgSO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (9:1)] yielded dioxaborolane 152 as an 
amorphous solid (545 mg, 36%). Rf [SiO2, petroleum ether-EtOAc (9:1)]: 0.54. Mp: 70-71 
°C [Lit.
134
 71.1-71.9 °C (Et2O)]. H (500 MHz, CDCl3): 8.14 (1H, broad t, J = 1.2 Hz, H-
2’), 7.78 (1H, ddd, J = 7.9, 1.9 and 1.2 Hz, H-4’ or H-6’), 7.75 (1H, td, J = 7.4 and 1.1 Hz, 
H-4’ or H-6’), 7.10 (1H, td, J = 7.6 and 0.3 Hz, H-5’), 1.33 (12H, s, 4   Me). C (126 
MHz, CDCl3): 143.39 (CH), 140.06 (CH), 133.62 (CH), 129.62 (CH), 94.50 (C), 84.10 
(C), 24.84 (CH3).
 11




H} (160 MHz, CDCl3): 30.27 















Anhydrous THF (500 mL) was added to 1,4-diiodobenzene 154 (25.00 g, 75.8 mmol) and 
anhydrous LiCl (3.48 g, 82.1 mmol) under argon.  The stirring mixture was cooled to –78 
°C and 
i
PrMgCl (2.0 M in THF, 41 mL, 82 mmol) was added dropwise over 50 min.  After 
stirring for 3 h at –78 °C, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15.5 ml, 
75.8 mmol) was added dropwise and the mixture allowed to warm slowly to RT overnight.  
Saturated aqueous NH4Cl (50 mL) was added to quench.  The resulting mixture was stirred 
until the precipitate settled before being filtered through a pad of Celite and washed 
through with Et2O.  Organics were dried over MgSO4 and concentrated under reduced 
pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (9:1)] yielded 
dioxaborolane 155 as a solid (24.58 g, 98%). Rf [SiO2, petroleum ether-EtOAc (9:1)]: 0.45. 
Mp: 95-96 °C [Lit.
134
 93.9-98.4 °C (Et2O)]. H (400 MHz, CDCl3): 7.72 (2H, d, J = 8.2 Hz, 
H-2’ and H-6’), 7.51 (2H, d, J = 8.1 Hz, H-3’ and H-5’), 1.33 (12H, s, 4   Me). C (100 













Pd/C (281 mg, 10% Pd on C, 0.26 mmol) was added to a solution of azide 163 (950 mg, 
1.9 mmol) in MeOH (12 mL) and H2 (g) was bubbled through for 24 h.  The mixture was 
filtered and concentrated until reduced pressure.  The crude oil was dissolved in anhydrous 
MeCN (15 mL) under argon.  1-Fluoro-2,4-dinitrobenzene (0.6 mL, 5.9 mmol) and 
anhydrous triethylamine (0.9 mL, 6.3 mmol) were added and the solution stirred at 40 °C 
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for 18 h before concentrating under reduced pressure.  The residue was dissolved in CHCl3 
(8 mL) and the salt was precipitated by adding the solution dropwise to vigourously 
stirring Et2O (300 mL).  The precipitate was collected by filtration, washed with Et2O and 
dried under reduced pressure.  The crude orange glass was dissolved in EtOH:H2O (35 
mL:25 mL).  NaHCO3 (727 mg, 8.7 mmol) and Na2S2O4 (1.84 g, 82%, 8.7 mmol) were 
added and the solution stirred at 30 °C for 1 h.  A further Na2S2O4 (1.84 g, 82%, 8.7 mmol) 
was added and the mixture stirred at 30 °C for a further 1 h.  The mixture was filtered and 
the precipitate washed with CHCl3.  The filtrate was concentrated under reduced pressure 
and column chromatography [SiO2, DCM-EtOH (1:0) to (4:1)] gave the target phophonium 
salt with a mixture of anions.  The mixed salt was washed through an ion-exchange resin 
(7 g) loaded with methanesulfonate anions (Appendix 1) in a MeOH-H2O (1:1) solution.  
Concentration of the eluent under reduced pressure yielded phosphonium 
methanesulfonate 156 as a sticky light brown glass (189 g, 23%). The compound was 
stored under argon. Rf [SiO2, DCM-EtOH (9:1)]: 0.17. max (ATR): 3358 (NH2), 3059 
(CH), 2932 (CH), 2870 (CH), 1651 (Ar), 1591 (Ar), 1520 (Ar), 1180 (S=O)  cm
–1
. H (400 
MHz, CDCl3): 7.79-7.71 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.69-7.62 (6H, m, 6   
m-H PPh3), 6.63 (1H, td, J = 7.5 and 1.5 Hz, H-5’), 6.58 (1H, dd, J = 7.6 and 1.6 Hz, H-
3’), 6.53 (1H, td, J = 7.4 and 1.1 Hz, H-4’), 6.48 (1H, dd, J = 7.8 and 1.0 Hz, H-6’), 3.68 
(3H, broad s, NH and NH2), 3.67-3.59 (2H, m, 2   H-1), 3.44 (2H, broad t, J = 5.9 Hz, 2   
H-4), 2.06-1.98 (2H, m, 2   H-3), 1.85-1.75 (2H, m, 2   H-2). C (100 MHz, CDCl3): 
136.57 (C), 134.91 (d, J = 3.0 Hz, CH), 134.86 (C), 133.60 (d, J = 9.8 Hz, CH), 130.44 (d, 
J = 12.7 Hz, CH), 118.94 (CH), 118.48 (d, J = 85.7 Hz, C), 117.68 (CH), 115.28 (CH), 
110.75 (CH), 42.97 (CH2), 39.55 (CH3), 28.70 (d, J = 6.4 Hz, CH2), 21.84 (d, J = 50.2 Hz, 
CH2), 20.61 (d, J = 4.2 Hz, CH2).P {
1
H} (162 MHz, CDCl3): 24.14 (s). LRMS (ESI
+
): 







EtOH (0.9 mL) and H2O (0.9 mL) were added to a stirring mixture of phosphonium 
bromide 173 (40 mg, 75 μmol), NaHCO3 (44 mg, 524 μmol) and Na2S2O4 (112 mg, 82%, 
527 μmol) under argon.  The resulting mixture was stirred at RT for 45 min before 
concentrating under reduced pressure.  Extracts from the solid residue were made with 
CHCl3 (2   5 mL).  Combined organic extracts were dried over Na2SO4 and concentrated 
under reduced pressure.  Flash column chromatography [SiO2, DCM-EtOH (1:0) to (4:1)] 
yielded the target phophonium salt with a mixture of anions.  The mixed salt was washed 
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through an ion-exchange resin (7 g) loaded with methanesulfonate anions (Appendix 1) in 
a MeOH-H2O (1:1) solution.  Concentration of the eluent under reduced pressure yielded 
phosphonium methanesulfonate 156 as a sticky light brown glass (16.1 mg, 41%). 
Characterisation as previous. 
 
{4-[(2’-Aminophenyl)amino]but-1’-yl}tri(pentadeuterophenyl)phosphonium 
methanesulfonate (MitoDA-d15) 157 
 
EtOH (0.9 mL) and H2O (0.9 mL) were added to a stirring mixture of phosphonium 
bromide 174 (40 mg, 73 μmol), NaHCO3 (37 mg, 440 μmol) and Na2S2O4 (55 mg, 82%, 
438 μmol) under argon.  The resulting mixture was stirred at RT for 45 min before 
concentrating under reduced pressure.  Extracts from the solid residue were made with 
CHCl3 (2   5 mL).  Combined organic extracts were dried over Na2SO4 and concentrated 
under reduced pressure.  Flash column chromatography [SiO2, DCM-EtOH (1:0) to (4:1)] 
yielded phophonium salt with a mixture of anions.  The mixed salt was washed through an 
ion-exchange resin (7 g) loaded with methanesulfonate anions (Appendix 1) in a MeOH-
H2O (1:1) solution.  Concentration of the eluent under reduced pressure yielded 
phosphonium methanesulfonate 157 as a sticky light brown glass (22.0 mg, 57%).  The 
compound was stored under argon. Rf [SiO2, DCM-EtOH (9:1)]: 0.17. max (ATR): 3362 
(NH), 2992 (CH), 2932 (CH), 2866 (CH), 2274 (CD), 2234 (CD), 1649 (Ar), 1597 (Ar), 
1519 (Ar), 1182 (S=O) cm
–1
. H (500 MHz, CDCl3): 6.63 (1H, td, J = 7.4 and 1.7 Hz, H-
5’), 6.58 (1H, dd, J = 7.6 and 1.7 Hz, H-3’), 6.53 (1H, td, J = 7.4 and 1.3 Hz, H-4’), 6.47 
(1H, dd, J = 7.8 and 1.2 Hz, H-6’), 3.97 (3H, broad s, NH and NH2), 3.81-3.65 (2H, m, 2   
H-1), 3.24 (2H, broad t, J = 5.6 Hz, 2   H-4), 2.72 (3H, s, Me), 2.10-1.98 (2H, m, 2   H-
3), 1.88-1.74 (2H, m, 2   H-2). C (126 MHz, CDCl3): 136.35 (C), 135.12 (C), 134.64-
134.11 (m, CD), 133.53-132.94 (m, CD), 130.25-129.60 (m, CD), 118.61 (CH), 118.35 (d, 
J = 85.3 Hz, C), 117.45 (CH), 114.93 (CH), 110.38 (CH), 42.91 (CH2), 39.60 (CH3), 28.53 
(d, J = 16.4 Hz, CH2), 21.87 (d, J = 49.9 Hz, CH2), 20.70 (d, J = 4.0 Hz, CH2). P {
1
H} 
(162 MHz, CDCl3): 24.46-24.02 (m). LRMS (ESI
+
): 440 (cation, 100%). HRMS: 







NMR data for partially deuterated aromatic ring P(C6D4H) integrated relative to other 
signals in 
1
H NMR: 7.78 (0.031H, d, J = 12.7 Hz, o-H PPh3), 7.75 (0.018H, d, J = 1.8 Hz, 
p-H PPh3), 7.65 (0.028H, d, J = 3.4 Hz, m-H PPh3). 
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[4-(1’H-1’,2’,3’-benzotriazol-1’-yl)but-1-yl]triphenylphosphonium iodide (MitoBT) 
158 
 
A solution of alkyl iodide 180 (135 mg, 0.45 mmol) and triphenylphosphine (1.18 g, 4.5 
mmol) in DCM (1.2 mL) was stirred at 30 °C for 48 h.  CHCl3 (2.5 mL) was added and the 
salt precipitated by adding the solution dropwise to vigouously stirring Et2O (80 mL).  
After filtering, the residue was loaded onto a pad of silica in CHCl3, washed with EtOAc 
before CHCl3-EtOH (9:1) was used to elute the product.  Drying under reduced pressure 
yielded phophonium iodide 158 as a sticky glass (240 mg, 95%). max (ATR): 3053 (CH), 
3009 (CH), 2990 (CH), 2920 (CH), 2895 (CH), 1613 (Ar), 1587 (Ar) cm
–1
. H (500 MHz, 
CDCl3): 7.96 (1H, broad d, J = 8.4 Hz, H-4’), 7.81 (1H, broad d, J = 8.4 Hz, H-7’), 7.79-
7.72 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.68-7.62 (m, 6   m-H PPh3), 7.46 (ddd, J 
= 8.4, 7.0 and 0.9 Hz, H-6’), 7.34 (ddd, J = 8.4, 6.9 and 0.9 Hz, H-5’), 4.87 (2H, t, J = 6.5 
Hz, 2   H-4), 3.89-3.77 (2H, m, 2   H-1), 2.55-2.45 (2H, m, 2   H-3), 1.86-1.72 (2H, m, 
2   H-2). C (126 MHz, CDCl3): 145.78 (C), 135.16 (d, J = 3.0 Hz, CH), 133.65 (d, J = 
10.1 Hz, CH), 132.97 (C), 130.54 (d, J = 12.3 Hz, CH), 127.55 (CH), 124.01 (CH), 119.52 
(CH), 117.72 (d, J = 86.2 Hz, C), 110.39 (CH), 46.98 (CH2), 29.32 (d, J = 17.1 Hz, CH2), 
22.28 (d, J = 51.2 Hz, CH2), 19.49 (d, J = 3.6 Hz, CH2). P {
1
H} (202 MHz, CDCl3): 24.30 
(s). LRMS (ESI
+










A solution of alkyl iodide 180 (181 mg, 0.60 mmol) and tri(pentadeuterophenyl)phosphine 
(200 mg, 0.72 mmol) in DCM (0.5 mL) was stirred at 30 °C for 72 h.  CHCl3 (1.5 mL) was 
added and the salt precipitated by adding the solution dropwise to vigouously stirring Et2O 
(60 mL).  After filtering, the residue was loaded onto a pad of silica in CHCl3, washed with 
EtOAc before CHCl3-EtOH (9:1) was used to elute the product.  Drying under reduced 
pressure yielded phophonium iodide 159 as a sticky glass (302 mg, 87%). max (ATR): 
2918 (CH), 2868 (CH), 2793 (CH), 2255 (CD), 2191 (CD), 1613 (Ar), 1549 (Ar) cm
–1
. H 
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(500 MHz, CDCl3): 7.99 (1H, broad d, J = 8.4 Hz, H-4’), 7.80 (1H, broad d, J = 8.4 Hz, H-
7’), 7.48 (1H, ddd, J = 8.4, 7.0 and 0.8 Hz, H-6’), 7.35 (1H, ddd, J = 8.4, 6.9 and 0.8 Hz, 
H-5’), 4.89 (2H, t, J = 6.4 Hz, 2   H-4), 3.94-3.84 (2H, m, 2   H-1), 2.58-2.48 (2H, m, 2 
  H-3), 1.69-1.59 (2H, m, 2   H-2). C (126 MHz, CDCl3): 145.86 (C), 134.88-134.14 (m, 
CD), 133.59-132.94 (m, CD), 132.99 (C), 130.35-129.69 (m, CD), 127.58 (CH), 124.01 
(CH), 119.58 (CH), 117.62 (d, J = 86.1 Hz, C), 110.35 (CH), 46.88 (CH2), 29.14 (d, J = 
17.3 Hz, CH2), 22.40 (d, J = 51.1 Hz, CH2), 19.42 (d, J = 3.6 Hz, CH2). P {
1
H} (202 
MHz, CDCl3): 24.53-24.20 (m). LRMS (ESI
+
): 451 (cation, 100%). HRMS: 451.2867. 






H NMR data for 
partially deuterated aromatic ring P(C6D4H) integrated relative to other signals in 
1
H NMR: 
7.76 (d, J = 12.9 Hz, o-H PPh3), 7.65 (0.031H, d, J = 3.4 Hz, m-H PPh3).  The p-H PPh3 
signal and the integration for the o-H PPh3 obscured due to other aromatic signals. 
 
(4-Iodobutyl)triphenylphosphonium iodide 161 
 
1,4-Diiodobutane 160 (3.0 mL, 22.7 mmol) was added to a solution of triphenylphosphine 
(3.00 g, 11.4 mmol) in toluene (30 mL) and the resulting solution stirred at 95 °C for 48 h.  
After cooling to RT the precipitate was collected by filtration, washed with Et2O (30 mL) 
and residual solvent removed under reduced pressure to yield phosphonium iodide 161 as 
an amorphous solid (6.46 g, 99%).  A portion of the solid was dissolved in minimal CHCl3 
and allowed to re-crystallise slowly through evaporation to give phosphonium iodide 161 
as needles. Mp: 168-169 °C (Needles). max (ATR): 3074 (CH), 3052 (CH), 3007 (CH), 
2952 (CH), 2889 (CH), 2858 (CH), 2785 (CH), 1587 (Ar), 1484 (Ar) cm
–1
. H (400 MHz, 
CDCl3): 7.90-7.79 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7375-7.69 (6H, m, 6   m-H 
PPh3), 3.88-3.78 (2H, m, 2   H-1), 3.35 (2H, t, J = 6.2 Hz, 2   H-4), 2.28-2.19 (2H, m, 2 
  H-2), 1.88-1.76 (2H, m, 2   H-3). C (100 MHz, CDCl3): 135.24 (d, J = 3.0 Hz, CH), 
133.76 (d, J = 10.1 Hz, CH), 130.63 (d, J = 12.5 Hz, CH), 117.90 (d, J = 86.1 Hz, C), 
32.52 (d, J = 17.0 Hz, CH2), 23.23 (d, J = 3.6 Hz, CH2), 21.98 (d, J = 51.2 Hz, CH2), 7.41 
(CH2). P {
1
H} (162 MHz, CDCl3): 24.34 (s). LRMS (ESI
+
): 445 (cation, 100%), 289 (18). 
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(4-Iodobut-1-yl)tri(pentadeuterophenyl)phosphonium iodide 162 
 
1,4-Diiodobutane 160 (0.57 mL, 4.3 mmol) was added to a solution of 
tri(pentadeuterophenyl)phosphine (300 mg, 1.1 mmol) in toluene (5 mL).  The resulting 
solution was stirred at 80 °C for 24 h under argon.  After cooling to RT the precipitate was 
collected by filtration, washed with Et2O and residual solvent removed under reduced 
pressure to yield phosphonium iodide 162 as an amorphous solid (574 mg, 88%). Mp: 169-
170 °C. max (ATR): 2929 (CH), 2889 (CH), 2857 (CH), 2784 (CH), 1547 (Ar) cm
–1
. H 
(400 MHz, CDCl3): 3.78-3.66 (2H, m, 2   H-1), 3.31 (2H, t, J = 6.5 Hz, 2   H-4), 2.30-
2.18 (2H, m, 2   H-3), 1.90-1.77 (2H, m, 2   H-2). C (100 MHz, CDCl3): 135.06-134.27 
(m, CD), 133.55-132.61 (m, CD), 130.54-129.52 (m, CD), 117.31 (d, J = 86.0 Hz, C), 
32.60 (d, J = 16.9 Hz, CH2), 23.09 (d, J = 3.5 Hz, CH2), 21.75 (d, J = 51.4 Hz, CH2), 7.18 
(CH2). P (162 MHz, CDCl3): 23.90-23.49 (m). LRMS (ESI
+
): 460 (cation, 100%). HRMS 
(ESI
+







NMR data for partially deuterated aromatic ring P(C6D4H) integrated relative to other 
signals in 
1
H NMR: 7.88 (0.031H, d, J = 12.6 Hz, o-H PPh3), 7.87 (0.019H, d, J = 2.5 Hz, 
p-H PPh3), 7.77 (0.030H, d, J = 3.5 Hz, m-H PPh3). 
 
(4-Azidobut-1-yl)triphenylphosphonium iodide 163 
 
A solution of alkyl iodide 161 (3.25 g, 5.7 mmol) and NaN3 (741 mg, 11.4 mmol) in EtOH 
(20 mL) and H2O (20 mL) was stirred at 70 °C for 18 h.  After cooling to RT, extracts 
were made with CHCl3 (2   50 mL).  Combined organics were dried over Na2SO4 and 
concentrated under reduced pressure to yield phophonium iodide 161 as an amorphous 
solid (2.74 g, 99%). Mp: 145-146 °C. max (ATR): 3053 (CH), 3007 (CH), 2945 (CH), 
2893 (CH), 2868 (CH), 2789 (CH), 2097 (N3), 1993 (N3), 1587 (Ar), 1574 (Ar) cm
–1
. H 
(400 MHz, CDCl3): 7.88-7.79 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.78-7.70 (6H, m, 
6   m-H PPh3), 3.79-3.66 (2H, m, 2   H-1), 3.45 (2H, t, J = 6.3 Hz, 2   H-4), 2.06-1.96 
(2H, m, 2   H-3), 1.83-1.70 (2H, m, 2   H-2). C (100 MHz, CDCl3): 135.04 (d, J = 2.9 
Hz, CH), 133.43 (d, J = 10.1 Hz, CH), 130.43 (d, J = 12.5 Hz, CH), 117.60 (d, J = 86.2 Hz, 
C), 50.35 (CH2), 29.06 (d, J = 16.6 Hz, CH2), 22.30 (d, J = 51.1 Hz, CH2), 19.61 (d, J = 3.9 
Hz, CH2). P (162 MHz, CDCl3): 24.02 (broad s). LRMS (ESI
+
): 847 [(2   cation) + I
–
, 
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6%], 360 (cation, 100), 332 (28), 289 (65). HRMS (ESI
+
): 360.1622. C22H23N3P requires 






(4-Azidobut-1-yl)tri(pentadeuterophenyl)phosphonium iodide 164 
 
A solution of alkyl iodide 162 (250 mg, 0.43 mmol) and NaN3 (55 mg, 0.85 mmol) in 
EtOH (1.5 mL) and H2O (1.5 mL) was stirred at 70 °C for 18 h.  H2O (2 mL) was added 
and extracts made with CHCl3 (2   5 mL).  Combined organics were dried over Na2SO4 
and concentrated under reduced pressure to yield phophonium iodide 164 as an amorphous 
solid (210 mg, 98%). Mp: 153-154 °C. max (ATR): 2940 (CH), 2893 (CH), 2868 (CH), 
2797 (CH), 2247 (CD), 2153 (CD), 2095 (N3), 1547 (Ar) cm
–1
. H (400 MHz, CDCl3): 
3.79-3.65 (2H, m, 2   H-1), 3.44 (2H, t, J = 6.4 Hz, 2   H-4), 2.10-1.96 (2H, m, 2   H-3), 
1.86-1.72 (2H, m, 2   H-2). C (100 MHz, CDCl3): 134.31-133.54 (m, CD), 132.78-
131.94 (m, CD), 129.72-128.87 (m, CD), 116.64 (d, J = 86.0 Hz, C), 49.70 (CH2), 28.44 
(d, J = 16.6 Hz, CH2), 21.68 (d, J = 51.2 Hz, CH2), 18.93 (d, J = 3.7 Hz, CH2). P {
1
H} 
(162 MHz, CDCl3): 23.82-22.90 (m). LRMS (ESI
+
): 375 (cation, 100%). HRMS: 







data for partially deuterated aromatic ring P(C6D4H) integrated relative to other signals in 
1
H NMR: 7.86 (0.031H, d, J = 12.7 Hz, o-H PPh3), 7.86 (0.018H, d, J = 1.5 Hz, p-H PPh3), 
7.76 (0.031H, d, J = 3.4 Hz, m-H PPh3). 
 
[4-(N-Phthalimido)but-1-yl]triphenylphosphonium bromide 169 
 
N-(4-Bromobut-1-yl)phthalimide 168 (600 mg, 2.1 mmol) and triphenylphosphine (7.4 g, 
28 mmol) in toluene (50 mL) were stirred at 95 °C for 24 h during which a white 
precipitate formed.  After cooling to RT, toluene was decanted off.  The residue was 
dissolved in (5 mL) CHCl3 and the salt precipitated by adding the solution dropwise to 
vigouously stirring Et2O (80 mL).  The precipitate was collected by filtration, washed with 
Et2O and dried under reduced pressure to yield phophonium bromide 169 as an oil (521 
mg, 45%). max (ATR): 3048 (CH), 2953 (CH), 2872 (CH), 2799 (CH), 1705 (C=O), 1624 
(Ar), 1610 (Ar), 1586 (Ar) cm
–1
. H (500 MHz, CDCl3): 7.88-7.81 (6H, m, 6   o-H PPh3), 
7.79-7.71 (7H, m, 3   p-H PPh3 and 4   H Phthal), 7.70-7.64 (6H, m, 6   m-H PPh3), 
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4.03-3.92 (2H, m, 2   H-1), 3.76 (2H, t, J = 6.3 Hz, 2   H-4), 2.20-2.10 (2H, m, 2   H-3), 
1.67-1.53 (2H, m, 2   H-2). C (126 MHz, CDCl3): 167.73 (C), 134.52 (d, J = 2.5 Hz, 
CH), 133.77 (CH), 133.08 (d, J = 10.0 Hz, CH), 130.99 (C), 129.09 (d, J = 12.5 Hz, CH), 
122.56 (CH), 117.34 (d, J = 86.0 Hz, C), 35.64 (CH2), 27.92 (d, J = 16.8 Hz, CH2), 21.05 
(d, J = 50.9 Hz, CH2), 18.81 (d, J = 2.9 Hz, CH2). P {
1
H} (162 MHz, CDCl3): 24.36 (s). 
LRMS (ESI
+











, 100).   
 
[4-(N-Phthalimido)but-1-yl]tri(pentadeuterophenyl)phosphonium bromide 170 
 
N-(4-Bromobutyl)phthalimide 169 (183 mg, 0.65 mmol) and 
tri(pentadeuterophenyl)phosphine (150 mg, 0.54 mmol) in toluene (6 mL) were stirred at 
95 °C for 24 h during which a white precipitate formed.  After cooling to RT, toluene was 
decanted off.  The residue was dissolved in CHCl3 and the salt precipitated by adding the 
solution dropwise to vigouously stirring Et2O (80 mL).  The precipitate was collected by 
filtration, washed with Et2O and dried under reduced pressure to yield phophonium 
bromide 170 as an oil (169 mg, 56%). max (ATR): 2915 (CH), 2251 (CD), 1703 (C=O), 
1613 (Ar), 1549 (Ar) cm
–1
. H (500 MHz, CDCl3): 7.77-7.70 (4H, m, 4   Phthalimide), 
4.07-3.98 (2H, m, 2   H-1), 3.77 (2H, t, J = 6.3 Hz, 2   H-4), 2.20-2.12 (2H, m, 2   H-3), 
1.66-1.57 (2H, m, 2   H-2). C (126 MHz, CDCl3): 168.33 (C), 134.72-134.28 (m, CD), 
134.06 (CH), 133.75-133.08 (m, CD), 131.82 (C), 130.28-129.60 (m, CD), 123.15 (CH), 
117.34 (d, J = 86.0 Hz, C), 36.40 (CH2), 28.50 (d, J = 16.8 Hz, CH2), 21.69 (d, J = 50.8 
Hz, CH2), 19.47 (d, J = 3.8 Hz, CH2). P {
1
H} (162 MHz, CDCl3): 24.93-24.53 (m). LRMS 
(ESI
+










, 100). HRMS: 479.2707. 
C30H12D15NO2P requires cation, 479.2715. 
 
(4-Aminobut-1-yl)triphenylphosphonium bromide 171 
 
N2H4.H2O (31 µL, 64%, 0.41 mmol) was added to a stirring solution of phthalimide 169 
(150 mg, 0.33 mmol) in MeOH (0.2 mL) and the resultant solution was stirred overnight at 
RT.  After concentrating under reduced pressure, CHCl3 (5 mL) was added followed by 
Na2SO4.  The suspension was filtered and the filtrate concentrated under reduced pressure 
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to yield amine 171 as a pale yellow oil (165 mg, 89%). max (ATR): 3368 (NH2), 2985 
(CH), 2924 (CH), 2864 (CH), 1614 (Ar), 1589 (Ar) cm
–1
. H (500 MHz, CDCl3): 7.88-7.77 
(9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.77-7.68 (6H, m, 6   m-H PPh3), 3.76-3.61 
(2H, m, 2   H-1), 2.78 (2H, t, J = 6.7 Hz, 2   H-4), 2.34 (2H, broad s, NH2), 1.94-1.83 
(2H, m, 2   H-3), 1.81-1.78 (2H, m, 2   H-2). C (126 MHz, CDCl3): 135.02 (d, J = 3.0 
Hz, CH), 133.45 (d, J = 10.0 Hz, CH), 130.41 (d, J = 12.6 Hz, CH), 117.91 (d, J = 86.0 Hz, 
C), 40.79 (CH2), 32.85 (d, J = 7.6 Hz, CH2), 22.62 (d, J = 50.1 Hz, CH2), 19.97 (d, J = 3.9 
Hz, CH2). P (162 MHz, CDCl3): 24.06 (s). LRMS (ESI
+
): 334 (cation, 100%). HRMS 
(ESI
+













(4-Aminobut-1-yl)tri(pentadeuterophenyl)phosphonium iodide 172 
 
N2H4.H2O (35 µL, 64%, 0.46 mmol) was added to a stirring solution of phthalimide 170 
(160 mg, 0.29 mmol) in MeOH (0.3 mL) and the resultant solution was stirred overnight at 
RT.  After concentrating under reduced pressure, CHCl3 (5 mL) was added followed by 
Na2SO4.  The suspension was filtered and the filtrate concentrated under reduced pressure 
to yield amine 172 a pale yellow oil (116 mg, 94%). max (ATR): 3358 (NH2), 2916 (CH), 
2870 (CH), 1589 (Ar) cm
–1
. H (500 MHz, CDCl3): 3.84-3.73 (2H, m, 2   H-1), 2.79 (4H, 
broad s, 2   H-4 and NH2), 1.96-1.83 (2H, m, 2   H-3), 1.81-1.67 (2H, m, 2   H-2). C 
(126 MHz, CDCl3): 134.96-134.20 (m, CD), 133.66-132.94 (m, CD), 130.44-129.68 (m, 
CD), 118.06 (d, J = 85.8 Hz, C), 40.74 (CH2), 32.88 (d, J = 7.6 Hz, CH2), 22.58 (d, J = 
50.0 Hz, CH2), 20.05 (d, J = 4.1 Hz, CH2). P (162 MHz, CDCl3): 24.29-23.82 (m). LRMS 
(ESI
+
): 349 (cation, 100%). HRMS (ESI
+













H NMR data for partially 
deuterated aromatic ring P(C6D4H) integrated relative to other signals in 
1
H NMR: 7.83 
(0.032H, d, J = 12.7 Hz, o-H PPh3), 7.80 (0.018H, d, J = 1.8 Hz, p-H PPh3), 7.71 (0.030H, 
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{4-[(2’-Nitrophenyl)amino]but-1-yl}triphenylphosphonium bromide 173 
 
1-Fluoro-2-nitrobenzene (85 μL, 0.81 mmol) was added to a stirring solution of amine 171 
(110 mg, 0.3 mmol) in anhydrous MeCN (0.5 mL) under argon.  Anhydrous triethylamine 
(120 μL, 0.86 mmol) was  added dropwise and the resulting solution stirred at 40 °C 
overnight.  After cooling to RT the solution was concentrated under reduced pressure then 
re-dissolved in CHCl3 (3 mL).  The solution was added dropwise to vigourously stirring 
Et2O (90 mL) and the precipitate collected by filtration.  The solid was dissolved in CHCl3 
(8 mL) and washed with H2O (5 mL).  Organics were dried over Na2SO4 and concentrated 
under reduced pressure to yield phosphonium bromide 173 as an orange glass (135 mg, 
95%). Rf [SiO2, DCM-EtOH (9:1)]: 0.48. max (ATR): 3377 (NH), 3053 (CH), 3007 (CH), 
2866 (CH), 2793 (CH), 1614 (Ar), 1570 (Ar), 1352 (NO2) cm
–1
. H (500 MHz, CDCl3): 
8.07 (1H, dd, J = 8.6 and 1.5 Hz, H-3’), 7.92 (1H, broad t, J = 5.1 Hz, NH), 7.89-7.81 (6H, 
m, 6   o-H PPh3), 7.81-7.74 (3H, m, 3   p-H PPh3), 7.72-7.64 (6H, m, 6   m-H PPh3), 
7.43 (1H, ddd, J = 8.5, 7.0 and 1.3 Hz, H-5’), 6.99 (1H, dd, J = 8.6 and 0.6 Hz, H-6’), 6.60 
(1H, ddd, J = 8.6, 6.9 and 1.1 Hz, H-4’), 4.03-3.87 (2H, m, 2   H-1), 3.51 (2H, td, J = 6.4 
and 5.6 Hz, 2   H-4), 2.21-2.08 (2H, m, 2   H-3), 1.89-1.73 (2H, m, 2   H-2). C (126 
MHz, CDCl3): 145.47 (C), 136.61 (CH), 135.08 (d, J = 2.8 Hz, CH), 133.68 (d, J = 10.0 
Hz, CH), 131.66 (C), 130.52 (d, J = 12.7 Hz, CH), 126.56 (CH), 118.11 (d, J = 85.8 Hz, 
C), 115.41 (CH), 114.56 (CH), 41.84 (CH2), 29.07 (d, J = 16.4 Hz, CH2), 22.34 (d, J = 
50.6 Hz, CH2), 19.92 (d, J = 3.8 Hz, CH2). P {
1
H} (162 MHz, CDCl3): 24.40 (s). LRMS 
(ESI
+












1-Fluoro-2-nitrobenzene (0.2 mL, 1.9 mmol) was added to a stirring solution of amine 172 
(102 mg, 0.24 mmol) in anhydrous MeCN (0.5 mL) under argon.  Anhydrous triethylamine 
(150 μL, 1.1 mmol) was added dropwise and the resulting solution stirred at 40 °C 
overnight.  After cooling to RT the solution was concentrated under reduced pressure then 
re-dissolved in CHCl3 (3 mL).  The solution was added dropwise to vigourously stirring 
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Et2O (80 mL) and the precipitate collected by filtration.  The solid was dissolved in CHCl3 
(8 mL) and washed with H2O (5 mL).  Organics were dried over Na2SO4 and concentrated 
under reduced pressure to yield phosphonium bromide 174 as an orange glass (118 mg, 
83%). max (ATR): 3377 (NH), 2866 (CH), 2793 (CH), 2251 (CD), 1616 (Ar), 1570 (Ar), 
1352 (NO2) cm
–1
. H (500 MHz, CDCl3): 8.06 (1H, dd, J = 8.7 and 1.6 Hz, H-3’), 7.91 
(1H, broad t, J = 5.1 Hz, NH), 7.42 (1H, ddd, J = 8.6, 7.1 and 1.4 Hz, H-5’), 6.98 (1H, 
broad d, J = 8.7 Hz, H-6’), 6.60 (1H, ddd, J = 8.6, 7.0 and 1.1 Hz, H-4’), 3.98-3.89 (2H, m, 
2   H-1), 3.51 (2H, broad td, J = 6.5 and 5.7 Hz, 2   H-4), 2.18-2.10 (2H, m, 2   H-3), 
1.86-1.76 (2H, m, 2   H-2). C (126 MHz, CDCl3): 145.46 (C), 136.60 (CH), 134.97-
134.25 (m, CD), 133.63-132.94 (CD), 131.65 (C), 130.46-129.66 (m, CD), 126.55 (CH), 
117.87 (d, J = 85.8 Hz, C), 115.40 (CH), 114.56 (CH), 41.85 (CH2), 29.08 (d, J = 16.5 Hz, 
CH2), 22.36 (d, J = 50.6 Hz, CH2), 19.90 (d, J = 3.8 Hz, CH2). P {
1
H} (162 MHz, CDCl3): 
24.46-24.02 (m). LRMS (ESI
+
): 470 (cation, 100%). HRMS: 470.2819. C28H13D15N2O2P 













data for partially deuterated aromatic ring P(C6D4H) integrated relative to other signals in 
1
H NMR: 7.85 (d, J = 12.7 Hz, o-H PPh3), 7.65 (0.021H, d, J = 1.8 Hz, p-H PPh3).  The m-





4-Aminobutan-1-ol 175 (340 μL, 3.3 mmol) was added to a stirring solution of 1-fluoro-2-
nitrobenzene (300 μL, 3.3 mmol) in MeCN (1.5 mL) followed by the dropwise addition of 
triethylamine (680 μL, 4.9 mmol).  The resulting solution was stirred at 50 °C overnight.  
After cooling to RT the solution was concentrated under reduced pressure.  The residue 
was dissolved in DCM and flushed through a short pad of silica with DCM followed by 
DCM-EtOH (19:1) to elute the product.  Concentration under reduced pressure yielded 
alcohol 176 as orange needles (572 mg, 84%). Rf (SiO2, DCM): 0.10.  Mp: 42-43 °C 
(Lit.
185
 40-41 °C). max (ATR): 3378 (NH and OH), 2936 (CH), 2863 (CH), 1616 (Ar), 
1571 (Ar), 1507 (NO2), 1351 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.14 (1H, ddd, J = 8.6, 
1.6 and 0.3 Hz, H-3’), 8.08 (1H, broad t, J = 4.0 Hz, NH), 7.42 (1H, dddd, J = 8.6, 7.0, 1.6 
and 0.6 Hz, H-5’), 6.85 (1H, dd, J = 8.7 and 1.2 Hz, H-6’), 6.62 (1H, ddd, J = 8.6, 6.9 and 
1.2 Hz, H-4’), 3.72 (2H, t, J = 6.2 Hz, 2   H-1), 3.34 (2H, td, J = 6.9 and 5.4 Hz, 2   H-
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4), 2.21 (1H, broad s, OH), 1.87-1.78 (2H, m, 2   H-3), 1.76-1.67 (2H, m, 2   H-2). C 
(100 MHz, CDCl3): 145.56 (C), 136.31 (CH), 131.62 (C), 126.83 (CH), 115.17 (CH), 
113.81 (CH), 62.18 (CH2), 42.80 (CH2), 29.98 (CH2), 25.41 (CH2). LRMS (CI
+
): 211 [(M 
+ H)
+






Anhydrous MeCN (40 mL) was added to a stirring mixture of 1H-1,2,3-benzotriazole 179 
(1.00 g, 8.4 mmol) and K2CO3 (1.07 g, 10.1 mmol) followed by 1,4-diiodobutane 160 (4.4 
mL, 33.6 mmol) under argon.  The resultant mixture stirred at 50 °C for 48 h.  After 
cooling to RT the mixture was concentrated under reduced pressure.  CHCl3 (60 mL) was 
added and the mixture washed with H2O (2   30 mL).  Organics were dried over Na2SO4 
and concentrated under reduced pressure.  Column chromatography [SiO2, petroleum 
ether-EtOAc (1:0) to (1:1)] yielded alkyl iodide 180 as a pale yellow oil (1.56 g, 46%). Rf 
[SiO2, petroleum ether-EtOAc (1:1)]: 0.53. max (ATR): 3062 (CH), 2941 (CH), 2852 
(CH), 1614 (Ar), 1589 (Ar) cm
–1
. H (400 MHz, CDCl3): 8.06 (1H, broad dt, J = 8.4 and 
0.8 Hz, H-4), 7.55 (1H, broad dt, J = 8.3 and 1.0 Hz, H-7), 7.50 (1H, ddd, J = 8.3, 6.7 and 
0.9 Hz, H-6), 7.38 (1H, ddd, J = 8.1, 6.7 and 1.2 Hz, H-5), 4.67 (2H, t, J = 6.9 Hz, 2   H-
1’), 3.20 (2H, t, J = 6.7 Hz, 2   H-4’), 2.20-2.11 (2H, m, 2   H-2’), 1.90-1.81 (2H, m, 2   
H-3’). C (100 MHz, CDCl3): 145.97 (C), 132.78 (C), 127.36 (CH), 123.92 (CH), 120.05 











Column chromatography of the mixture that produced alkyl iodide 180 above also gave 
alkyl iodide 181 (814 mg, 32%) as an oil that solidified on standing. Rf [SiO2, petroleum 
ether-EtOAc (1:1)]: 0.67. Mp: 45-46 °C. max (ATR): 2955 (CH), 2930 (CH), 2862 (CH), 
1568 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.86 (2H, dd, J = 6.5 and 3.1 Hz, H-4 and H-7), 
7.37 (2H, dd, J = 6.5 and 3.1 Hz, H-5 and H-6), 4.75 (2H, t, J = 6.8 Hz, 2   H-1’), 3.19 
(2H, t, J = 6.8 Hz, 2   H-4’),  2.28-2.19 (2H, m, 2   H-2’), 1.89-1.80 (2H, m, 2   H-3’). 
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C (100 MHz, CDCl3): 144.28 (C), 126.26 (CH), 117.93 (CH), 55.18 (CH2), 30.66 (CH2), 
30.06 (CH2), 5.14 (CH2). LRMS (CI
+
): 302 [(M + H)
+
, 100%], 189 (72), 133 (42). HRMS: 






By-product isolated during the attempted synthesis of alkyl iodide 180.  NaH (88 mg, 60% 
in mineral oil, 2.2 mmol) was added to a stirring solution of 1H-1,2,3-benzotriazole (250 
mg, 2.1 mmol) and 1,4-diiodobutane (1.1 mL, 8.4 mmol) in anhydrous DMF (4 mL) at 0 
°C.  The resultant solution was stirred at RT for 2 h.  H2O (8 mL) was added and extracted 
with CHCl3 (3   8 mL).  Combined organics were dried over Na2SO4 and concentrated 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (1:0) to 
(1:1)] yielded benzotriazole 182 as an amorphous off-white solid (3 mg, <1%). Rf [SiO2, 
petroleum ether-EtOAc (1:1)]: 0.15. H (500 MHz, CDCl3): 8.06 (2H, broad dt, J = 8.4 and 
0.7 Hz, H-4 and H-4’’), 7.50-7.47 (4H, m, H-6, H-7, H-6’’ and H-7’’), 7.37 (2H, ddd, J = 
8.2, 5.6 and 1.4 Hz, H-5 and H-5’’), 4.72-4.66 (4H, m, 2   H-1’ and 2   H-4’), 2.09-2.04 
(4H, m, 2   H-2’ and 2   H-3’). LRMS (CI+): 293 [(M + H)+, 100%]. HRMS: 293.1510. 






Column chromatography of the experiment that yielded bis(benzotriazole) 182 above also 
gave bis(benzotriazole) 183 as an amorphous solid (14 mg, 2%). Rf [SiO2, petroleum ether-
EtOAc (1:1)]: 0.33. Mp: 77-78 °C. max (ATR): 3055 (CH), 2947 (CH), 2878 (CH), 1614 
(Ar), 1589 (Ar), 1568 (Ar) cm
–1
. H (500 MHz, CDCl3): 8.06 (1H, d, J = 8.4 Hz, H-4), 7.85 
(2H, dd, J = 6.5 and 3.1 Hz, H-4’’ and H-7’’), 7.51-7.43 (2H, m, H-6 and H-7), 7.39 (2H, 
dd, J = 6.5 and 3.1 Hz, H-5’’ and H-6’’), 7.36 (1H, ddd, J = 8.0, 6.6 and 1.4 Hz, H-5), 4.79 
(2H, t, J = 6.6 Hz, 2   H-4’), 4.68 (2H, t, J = 6.9 Hz, 2   H-1’), 2.22-2.14 (2H, m, 2   H-
3’), 2.09-2.02 (2H, m, 2   H-2’). C (126 MHz, CDCl3): 146.13 (C), 144.40 (C), 132.91 
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(C), 127.34 (CH), 126.42 (CH), 123.90 (CH), 120.16 (CH), 117.98 (CH), 109.13 (CH), 
55.46 (CH2), 47.20 (CH2), 26.96 (CH2), 26.50 (CH2). LRMS (CI
+
): 293 [(M + H)
+
, 100%]. 




1,3-Bis(4’-iodobut-1-yl)-1H-1,2,3-benzotriazol-3-ium iodide 185 
 
Column chromatography of the mixture that produced alkyl iodide 180 above also gave 
alkyl iodide 185 as an amorphous yellow solid (617 mg, 12%). Rf [SiO2, DCM-EtOH 
(9:1)]: 0.04. Mp: 114-115 °C. max (ATR): 3032 (CH), 2999 (CH), 2934 (CH), 2891 (CH), 
2862 (CH), 1603 (Ar) cm
–1
. H (400 MHz, CDCl3): 8.55 (2H, dd, J = 6.6 and 3.0 Hz, H-4 
and H-7), 7.96 (2H, dd, J = 6.6 and 3.0 Hz, H-5 and H-6), 5.28 (4H, t, J = 7.2 Hz, 4   H-
1’), 3.28 (4H, t, J = 6.6 Hz, 4   H-4’),  2.39-2.30 (4H, m, 4   H-2’), 2.10-2.01 (4H, m, 4 
  H-3’). C (100 MHz, CDCl3): 144.28 (C), 126.26 (CH), 117.93 (CH), 55.18 (CH2), 
30.66 (CH2), 30.06 (CH2), 5.14 (CH2). LRMS (ESI
+
): 484 (cation, 100%). HRMS: 












THF (10 mL) was added to 3,8-diamino-6-phenylphenanthridine 198 (500 mg, 1.8 mmol) 
and potassium carbonate (969 mg, 7.0 mmol) followed by H2O (1 mL).  Di-tert-butyl 
dicarbonate (1.53 g, 7.0 mmol) was added drop-wise to the vigourously stirring biphasic 
solution.  After stirring for 96 h at RT, the precipitate was collected by filtration, washed 
with THF (3 mL) and H2O (3 mL) and dried under reduced pressure to yield dicarbamate 
199 as an amorphous yellow solid (724 mg, 85%). Mp: 209-210 °C. max (ATR): 3323 
(NH), 3009 (CH), 2981 (CH), 2833 (CH), 1695 (C=O), 1622 (Ar), 1583 (Ar), 1573 (Ar), 
1549 (Ar) cm
–1
. H (400 MHz, d6-DMSO): 9.75 (1H, s, NH), 9.71 (1H, s, NH), 8.71 (1H, 
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d, J = 9.1 Hz, H-10), 8.60 (1H, d, J = 9.0 Hz, H-1), 8.21 (1H, d, J = 1.5 Hz, H-7), 8.19 (1H, 
d, J = 2.0 Hz, H-4), 8.01 (1H, broad d, J = 8.4 Hz, H-9), 7.81 (1H, d, J = 9.0 and 2.2 Hz, 
H-2), 7.72-7.67 (2H, m, 2   m-H Ph), 7.62-7.54 (3H, m, 2   o-H Ph and p-H Ph), 1.53 
(9H, s, Boc), 1.45 (9H, s, Boc). C (100 MHz, d6-DMSO): 160.27 (C), 152.81 (C), 152.76 
(C), 143.25 (C), 139.58 (C), 139.55 (C), 138.17 (C), 129.59 (CH), 128.61 (CH), 128.22 
(CH), 128.08 (C), 124.33 (C), 123.02 (CH), 122.82 (CH), 122.58 (CH), 118.94 (CH), 
118.29 (C), 116.35 (CH), 115.00 (CH), 79.41 (C), 79.18 (C), 28.15 (CH3), 28.07 (CH3). 
LRMS (CI
+
): 1457 {[(3   M) + H]
+
, 1%}, 971 {[(2   M) + H]
+
, 32], 486 [(M + H)
+
, 100]. 
HRMS: 1456.6966, 971.4698 and 486.2380. C87H94N9O12 requires [(3   M) + H]
+
, 
1456.7016, C58H63N6O8 requires [(2   M) + H]
+










3,8-Diamino-6-phenylphenanthridine 198 (700 mg, 2.45 mmol) in CHCl3 (16 mL) was 
added slowly to stirring di-tert-butyl dicarbonate (1.07 g, 4.91 mmol) in CHCl3 (6 mL) 
under argon.  The resulting orange solution was stirred at RT for 66 h before concentrating 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (1:1)] 
yielded dicarbamate 199 as an amorphous yellow solid (226 mg, 20%). Rf [SiO2, petroleum 








Benzylic alcohol 215 (200 mg, 0.85 mmol) was mixed with 1-fluoro-2,4-dinitrobenzene 
(0.5 mL, 4.1 mmol) and 3 drops of anhydrous triethylamine added.  The reaction mixture 
was stirred overnight at RT and then concentrated under reduced pressure.  The mixture 
was dissolved in DCM (15 mL) and washed with NaHCO3 (2   20 mL), H2O (2   10 mL) 
and brine (10 mL).  Organics were dried over MgSO4 and concentrated under reduced 
pressure to give a yellow oil.  Column chromatography [SiO2, petroleum ether-EtOAc 
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(4:1)] gave an oil, which was triturated with hexane.  The mixture was heated until the 
solid whitened, then the hexane was removed by pipette.  The hexane washings were then 
concentrated under reduced pressure and the resulting oil treated in the same way.  The 
process was repeated until no further solid was collected.  The solid residues were 
combined to yield DNP-SUM 210 as an amorphous solid (54 mg, 16%). Rf [SiO2, 
petroleum ether-EtOAc (4:1)]: 0.23. Mp: 143-145 °C. max (ATR): 2981 (CH), 2931 (CH), 
2894 (CH), 1604 (Ar), 1521 (NO2), 1342 (NO2) cm
–1
. H (CDCl3, 400 MHz): 8.74 (1H, d, 
J = 2.8 Hz, H-3’’), 8.34 (1H, dd, J = 9.3 and 2.8 Hz, H-5’’), 7.85 (2H, d, J = 8.1 Hz, H-2’ 
and H-6’), 7.44 (2H, d, J = 8.1 Hz, H-3’ and H-6’), 7.21 (1H, d, J = 9.3 Hz, H-6’’), 5.39 
(2H, s, ArCH2), 1.35 (12H, s, 4   Me). C (CDCl3, 100 MHz): 156.21 (C), 140.23 (C), 
139.24 (C), 136.90 (C), 135.39 (CH), 128.95 (CH), 126.15 (CH), 121.96 (CH), 114.98 
(CH), 84.01 (C), 71.98 (CH2), 24.86 (CH3). LRMS (CI
+
): 401 [(M + H)
+





 95], 219 (100), 145 (43). HRMS: 401.1521 and 400.1564. 
C13H22
11
BN2O7 requires (M + H)
+
, 401.1520 and C13H22
10






NaH (28 mg, 60% in mineral oil, 0.69 mmol) was added to stirring benzylic alcohol 215 
(125 mg, 0.53 mmol) and 1-fluoro-2,4-dinitrobenzene (135 µL, 1.1 mmol) in anhydrous 
DCM (1.5 mL) under argon.  The resulting mixture was stirred at RT for 16 h.  H2O (8 
mL) was added to quench and extracts made with DCM (2   5 mL).  Organics were dried 
over Na2SO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (1:0) to (1:1)] yielded DNP-SUM 210 as an amorphous solid (134 







A solution of NaNO2 (25 mg, 0.36 mmol) in H2O (0.3 mL) was cooled to 0 °C and added 
dropwise to a stirring solution of 4-trifluoromethoxyaniline (62.8 mg, 0.36 mmol) and HCl 
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(1.5 M, 1.7 mL) at 0 °C.  The resulting solution was stirred for 5 min and then added 
dropwise to a stirring solution of boronate ester 227 (100 mg, 354 mol) and NaOAc (116 
mg, 1.42 mmol) in a mixture of H2O (1.3 mL), MeOH (1.5 mL) and EtOH (1.5 mL) at 0 
°C.  The resultant solution was stirred at 0 °C for 1 h and then overnight at RT.  The 
precipitate was filtered, washed with ice-cold H2O (4 mL) and dried under reduced 
pressure to yield FCCP-SUM 211 as an amorphous yellow solid.  Further material was 
obtained by concentration of the filtrate under reduced pressure and extraction with DCM.  
Concentration under reduced pressure followed by column chromatography [SiO2, 
petroleum ether-EtOAc (9:1)] yielded further FCCP-SUM 211 (Combined yield 77 mg, 
46%). Rf [SiO2, petroleum ether-EtOAc (9:1)]: 0.34. Mp: 120-122 °C. max (ATR): 2937 
(CH), 2162 (CN), 1614 (Ar) cm
–1
. H (CDCl3, 400 MHz): 7.90 (2H, d, J = 9.0 Hz, H-2’’’ 
and H-6’’’), 7.82 (2H, d, J = 8.0 Hz, H-3’ and H-5’), 7.39-7.36 (4H, m, H-2’, H-6’, H-3’’’ 
and H-5’’’), 3.69 (2H, s, 2   H-3), 1.34 (12H, s, 4   Me). F (CDCl3, 376 MHz): –57.58 
(s). C (CDCl3, 100 MHz): 153.08 (C), 147.71 (C), 135.51 (CH), 132.86 (C), 130.15 (CH), 
125.81 (CH), 121.48 (CH), 120.38 (q, J = 259.2 Hz, CF3), 111.85 (C), 84.17 (C), 69.35 
(C), 36.62 (CH2), 24.99 (CH3). LRMS (CI
+




B), 11%], 446 (39), 337 
(40), 283 (95), 219 (91), 189 (F3COArN2
+
, 100). HRMS: 471.1821. C23H23
11
BF3N4O3 






A solution of 4-bromobenzyl alcohol 212 (13.00 g, 69.5 mmol), 2,3-dihydrofuran (6.3 mL, 
83.5 mmol) and para-toluene sulfonic acid monohydrate (20 mg, 0.1 mmol) in DCM (50 
mL) was stirred at RT for 1.5 h.  The reaction mixture was then washed with H2O (2   100 
mL) and saturated aqueous NaHCO3 (100 mL).  Organics were dried over MgSO4 and 
concentrated under reduced pressure to yield acetal 213 as a yellow oil (17.17 g, 96%). 
max (ATR): 2982 (CH), 2951 (CH), 2882 (CH), 1487 (Ar) cm
–1
. H (CDCl3, 400 MHz): 
7.45 (2H, d, J = 8.3 Hz, H-3’ and H-5’), 7.20 (2H, d, J = 8.3 Hz, H-2’ and H-6’), 5.19 (1H, 









), 3.95-3.84 (2H, m, 2   H-5), 2.07-1.80 (4H, m, 2   H-3 and 2   H-4). C 
(CDCl3, 100 MHz): 137.44 (C), 131.41 (CH), 129.43 (CH), 121.29 (C), 103.17 (CH), 




















, 100), 71 (C4H7O
+
, 
















A stirring solution of aryl bromide 213 (12.00 g, 46.7 mmol) in anhydrous THF (130 mL) 
was cooled to –78 °C and degassed with argon for 15 min.  Under argon, nBuLi (1.68 M in 
hexanes, 31.7 mL, 56.0 mmol) was added dropwise over 3 h and the mixture allowed to 
stir for 15 min.  2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11.4 mL, 56.0 
mmol) was added dropwise and the resulting solution allowed to stir for 2 h –78 °C before 
warming to RT.  The reaction was quenched with H2O (100 mL) and the product extracted 
with DCM (3   100 mL).  Combined organics were washed with brine (100 mL), dried 
over MgSO4 and concentrated under reduced pressure to give a yellow oil.  Impurities 
were removed by Kugelrohr distillation to yield acetal 214 as a yellow oil, which solidified 
on standing (11.87 g, 84%). Mp: 41-44 °C. max (ATR): 2978 (CH), 2932 (CH), 2882 
(CH), 1614 (Ar) cm
–1
. H (CDCl3, 400 MHz): 7.78 (2H, d, J = 7.7 Hz, H-2’ and H-5’), 7.34 









), 3.97-3.86 (2H, m, 2   H-5), 
2.09-1.83 (4H, m, 2   H-3 and 2   H-4), 1.34 (12H, s, 4   Me). C (CDCl3, 100 MHz): 
141.60 (C), 134.86 (CH), 126.99 (CH), 103.09 (CH), 83.73 (C), 68.60 (CH2), 67.02 (CH2), 
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[4-(4’,4’,5’,5’-Tetramethyl-1’,3’,2’-dioxaborolan-2’-yl)phenyl]methanol 215153, 154 
 
Adapting the procedure of De Filippis et al,
154
 aluminium trichloride (40 mg, 0.30 mmol) 
was added to a stirring solution of acetal 214 (1.00 g, 3.29 mmol) in anhydrous EtOH (10 
mL) under argon.  The mixture was stirred overnight at RT and then concentrated under 
reduced pressure.  The residue was dissolved in Et2O and filtered.  The filtrate was 
concentrated under reduced pressure and redissolved in anhydrous EtOH (10 mL) under 
argon.  Aluminium chloride (30 mg, 0.22 mmol) was added and the solution was stirred 
overnight at RT.  The residue was concentrated under reduced pressure, dissolved in Et2O 
and filtered.  The filtrate was concentrated under reduced pressure to yield the benzylic 
alcohol 215 as an oil (517 mg, 67%). max (ATR): 3312 (OH), 2978 (CH), 2930 (CH), 
2880 (CH), 1614 (Ar) cm
–1
. H (CDCl3, 400 MHz): 7.78 (2H, d, J = 7.6 Hz, H-3 and H-5), 
7.33 (2H, d, J = 7.7 Hz, H-2 and H-6), 4.66 (2H, s, ArCH2), 2.34 (1H, broad s, OH), 1.33 
(12H, s, 4   Me). C (CDCl3, 100 MHz): 144.07 (C), 134.99 (CH), 126.06 (CH), 83.82 



























BuLi (2.5 M in hexanes, 33.7 mL, 84.2 mmol) was added dropwise to a stirred solution of 
4-bromotoluene 218 (12.00 g, 70.2 mmol) in anhydrous THF (200 mL) under argon at –78 
°C over 3 h and the reaction was stirred for a further 15 min.  2-Isopropoxy-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (17.2 mL, 84.2 mmol) was added dropwise and the 
reaction stirred for a further 1.5 h at –78 ºC, before being allowed to warm to RT 
overnight.  The reaction mixture was quenched with H2O (100 mL) and extracted with 
EtOAc (2   100 mL).  Combined organics were washed with brine (100 mL), dried over 
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MgSO4 and concentrated under reduced pressure.  Impurities were removed by Kugelrohr 
distillation to yield boronate ester 219 as an oil, which solidified on standing (14.89 g, 
97%). Mp: 38-40 C. max (ATR): 2978 (CH), 2924 (CH), 2864 (CH), 1611 (Ar) cm
–1
. H 
(400 MHz, CDCl3): 7.71 (2H, d, J = 7.7 Hz, H-2’ and H-6’), 7.17 (2H, d, J = 7.6 Hz, H-3’ 
and H-5’), 2.35 (3H, s, Me), 1.33 (12H, s, 4   Me). C (100 MHz, CDCl3): 141.42 (C), 




















Following the procedure of De Filippis et al,
154
 stirring benzylic alcohol 215 (500 mg, 2.14 
mmol) in anhydrous DCM (15 mL) was degassed with argon for 15 min.  The solution was 
cooled to 0 °C and anhydrous triethylamine (324 mg, 3.20 mmol) was added.  
Methanesulfonyl chloride (0.2 mL, 2.56 mmol) was added and the solution was allowed to 
stir for 1 h.  Organics were washed with H2O (3   4 mL), dried over MgSO4 and 
concentrated under reduced pressure.  The resultant solid was dissolved in anhydrous 
acetone (15 mL) and degassed with argon for 15 min.  Anhydrous LiBr (1.90 g, 21.4 
mmol) was added and the resultant solution was heated at reflux overnight.  The solution 
was concentrated under reduced pressure and the residue dissolved in DCM (15 mL) and 
washed with H2O (8 mL).  Organics were dried over MgSO4 and concentrated under 
reduced pressure.  Column chromatography [SiO2, hexane-EtOAc (3:1)] yielded benzylic 
bromide 220 as an amorphous solid (413 mg, 63%). Rf [SiO2, hexane-EtOAc (3:1)]: 0.64. 
Mp: 76-78 °C (Lit.154 76-78 °C). max (ATR): 2976 (CH), 2930 (CH), 2872 (CH), 1613 
(Ar) cm
–1
. H (400 MHz, CDCl3): 7.79 (2H, d, J = 7.7 Hz, H-2’ and H-6’), 7.39 (2H, d, J = 
7.7 Hz, H-3’ and H-5’), 4.49 (2H, s, CH2), 1.34 (12H, s, 4   Me). C (100 MHz, CDCl3): 

















































Malononitrile (0.12 mL, 2.3 mmol) in anhydrous THF (2 mL) and anhydrous DMF (1.6 
mL) was added dropwise to a stirring suspension of NaH (70 mg, 80% in mineral oil, 2.3 
mmol) in anhydrous THF (16 mL) at RT under argon.  The reaction was stirred at RT for 
30 min then cooled to 0 °C.  A solution of benzylic bromide 220 (329 mg, 1.1 mmol) in 
anhydrous THF (4 mL) was added dropwise and stirred overnight allowing to warm to RT.  
Saturated aqueous NH4Cl (40 mL) was added to quench the reaction and the mixture 
extracted with EtOAc (3   20 mL).  Combined organics were washed with H2O (3   20 
mL), dried over MgSO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, hexane-EtOAc (4:1)] yielded boronate ester 227 as an amorphous 
solid. (281 mg, 90%). Rf [SiO2, hexane-EtOAc (4:1)]: 0.13. Mp: 135-137 °C. max (ATR): 
2982 (CH), 2361 (CN), 1614 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.84 (2H, d, J = 7.1 Hz, H-
3’ and H-5’), 7.32 (2H, d, J = 7.2 Hz, H-2’ and H-6’), 3.94 (1H, t, J = 6.8 Hz, H-2), 3.26 
(2H, d, J = 6.8 Hz, 2   H-3), 1.34 (12H, s, 4   Me). C (100 MHz, CDCl3): 135.86 (C), 
135.61 (CH), 128.46 (CH), 112.19 (C), 84.00 (C), 77.30 (CH), 36.66 (CH2), 24.85 (CH3). 
LRMS (CI
+




B), 100%]. HRMS: 283.1613. C16H20
11





(6-Iodohexyl)triphenylphosphonium iodide 228 
 
1,6-Diiodohexane (3 mL, 18.19 mmol) was added to a solution of triphenylphosphine (1.19 
g, 4.55 mmol) in Et2O (10 mL) and the resulting solution allowed to stand at RT for 6 d.  
Crystals were collected by filtration, washed with Et2O and dried under reduced pressure.  
The filtrate was allowed to evaporate to ~5 mL and further crystals were collected as above 
after 5 d standing at RT.  This process was repeated one more time to yield 228 as needles 
(Combined yield 2.24 g, 83%). Mp: 128-129 °C. max (ATR): 3040 (CH), 3006 (CH), 2929 
(CH), 2858 (CH), 2794 (CH), 1587 (Ar), 1483 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.89-7.78 
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(9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.74-768 (6H, m, 6   m-H PPh3), 3.85-3.76 
(2H, m, 2   H-1), 3.17 (2H, t, J = 6.8 Hz, 2   H-6), 1.82-1.61 (6H, m, 2   H-2, 2   H-3 
and 2   H-5), 1.47-1.37 (2H, m, 2   H-4). C (100 MHz, CDCl3): 135.14 (d, J = 3.0 Hz, 
CH), 133.74 (d, J = 10.1 Hz, CH), 130.58 (d, J = 12.5 Hz, CH), 118.18 (d, J = 85.9 Hz, C), 
32.86 (CH2), 29.96 (CH2), 29.24 (d, J = 16.0 Hz, CH2), 23.12 (d, J = 50.1 Hz, CH2), 22.51 
(d, J = 4.4 Hz, CH2), 7.52 (CH2). P {
1
H} (162 MHz, CDCl3): 24.34 (s). LRMS (ESI
+
): 473 







[4-(Bromomethyl)benzyl]triphenylphosphonium bromide 233 
 
A solution of triphenylphosphine (100 mg, 0.38 mmol) in anhydrous toluene (1.25 mL) 
was added dropwise to a stirring solution of , ’-para-dibromoxylene 232 (604 mg, 2.3 
mmol) in anhydrous toluene (2.5 mL) at 95 °C under argon and stirred for 1 h.  A further 
solution of triphenylphosphine (100 mg, 0.38 mmol) in anhydrous toluene (2.5 mL) was 
added dropwise and the resulting mixture was stirred for 5 h at 95 °C under argon.  The hot 
mixture was filtered and the precipitate washed with hot toluene and then Et2O.  The solid 
was dried under reduced pressure to yield phosphonium bromide 233 as an amorphous 
solid (391 mg, 98%). Mp: >220 °C (Decomp.). max (ATR): 3054 (CH), 3010 (CH), 2990 
(CH), 2965 (CH), 2887 (CH), 2850 (CH), 2779 (CH), 1604 (Ar), 1588 (Ar), 1572 (Ar). H 
(400 MHz, CD3CN): 7.91-7.84 (3H, m, 3   p-H PPh3), 7.72-7.64 (6H, m, 6   o-H PPh3), 
7.61-7.51 (6H, m, 6   m-H PPh3), 7.27 (2H, d, J = 7.7 Hz, H-3 and H-5), 6.94 (2H, dd, J = 
7.9 and 1.8 Hz, H-2 and H-6), 4.68 (2H, d, J = 14.3 Hz, CH2P), 4.52 (2H, s, CH2Br). C 
(100 MHz, CD3CN): 138.89 (d, J = 4.6 Hz, C), 134.95 (d, J = 2.9 Hz, CH), 133.89 (d, J = 
9.8 Hz, CH), 131.01 (d, J = 5.4 Hz, CH), 129.77 (d, J = 12.6 Hz, CH), 129.29 (d, J = 3.0 
Hz, CH), 127.21 (d, J = 7.8 Hz, C), 117.06 (d, J = 86.0 Hz, C), 32.36 (s, CH2), 29.16 (d, J 
= 48.3 Hz, CH2).P {
1
H} (162 MHz, CD3CN): 22.71 (s). LRMS (ESI
+
): 447 [cation (
81
Br), 
100%], 445 [cation (
79
Br), 93]. HRMS: 447.0683 and 445.0707. C26H26
81
BrP requires 
cation, 447.0695 and C26H26
79





















5-Bromovaleric acid 235 (6.00 g, 33.1 mmol) and triphenylphosphine (9.56 g, 36.5 mmol) 
were dissolved in anhydrous MeCN (15 mL) and stirred at 80 °C under argon for 70 h.  
After cooling to RT, the mixture was concentrated under reduced pressure.  The resulting 
solid was triturated with Et2O, liquid removed via pipette and the solid dried under reduced 
pressure to yield phosphonium bromide 236 as an amorphous solid (14.69 g, 100%). Mp: 
199-200 °C. H (400 MHz, CDCl3): 10.44 (1H, broad s, CO2H), 7.84-7.75 (9H, m, 6   o-H 
PPh3 and 3   p-H PPh3), 7.74-7.67 (6H, m, 6   m-H PPh3), 3.70-3.59 (2H, m, 2   H-1), 
2.64 (2H, t, J = 7.0 Hz, 2   H-4), 1.94 (2H, quintet, J = 6.9 Hz, 2   H-3), 1.78-1.67 (2H, 
m, 2   H-2). C (100 MHz, CDCl3): 175.06 (C), 135.20 (d, J = 2.9 Hz, CH), 133.63 (d, J = 
9.9 Hz, CH), 130.61 (d, J = 12.5 Hz, CH), 118.00 (d, J = 86.1 Hz, C), 33.76 (CH2), 25.54 
(d, J = 17.1 Hz, CH2), 22.31 (d, J = 51.3 Hz, CH2), 21.54 (d, J = 4.2 Hz, CH2).P {
1
H} 
(162 MHz, CDCl3): 23.67 (s). LRMS (ESI
+
): 363 (cation, 100%). HRMS (ESI
+
): 





















A solution of (3-bromopropyl)triphenylphosphonium bromide 237 (500 mg, 1.08 mmol) 
and NaN3 (105 mg, 1.62 mmol) in EtOH (3 mL) and H2O (3 mL) was stirred at 72 °C for 
18 h.  Extracts were made with DCM (3   4 mL).  Combined organics were dried over 
MgSO4 and concentrated under reduced pressure to yield phosphonium bromide 238 as an 
amorphous solid (441 mg, 99%). Mp: 161-162 °C (Lit.
188
 181-182 °C). max (ATR): 3079 
(CH), 3004 (CH), 2991 (CH), 2890 (CH), 2869 (CH), 2801 (CH), 2286 (N3), 2112 (N3), 
1587 (Ar) cm
–1
. H (500 MHz, CDCl3): 7.88-7.79 (9H, m, 6   o-H PPh3 and 3   p-H 
PPh3), 7.75-7.69 (6H, m, 6   m-H PPh3), 4.04-3.96 (2H, m, 2   H-1), 3.84 (2H, dt, J = 6.3 
and 0.9 Hz, 2   H-3), 1.95-1.86 (2H, m, 2   H-2). C (126 MHz, CDCl3): 135.18 (d, J = 
3.0 Hz, CH), 133.67 (d, J = 10.1 Hz, CH), 130.59 (d, J = 12.6 Hz, CH), 118.00 (d, J = 86.3 
Hz, C), 50.74 (d, J = 18.3 Hz, CH2), 22.71 (d, J = 3.2 Hz, CH2), 20.07 (d, J = 52.7 Hz, 
CH2). P {
1
H} (202 MHz, CDCl3): 24.52 (s). LRMS (ESI
+
): 346 (cation, 100%). HRMS 
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(ESI
+
























Adapting the procedure of Li and Burgess,
155
 KOH (7.71 g, 137.4 mmol) and H2O (5 ml) 
were added to propargyl alcohol 239 (4.0 mL, 68.7 mmol) in Et2O (200 mL).  The resultant 
mixture stirred for 1 h at 25 °C.  3-Hydroxy-3-methyl-2-butanone 241 (3.35 mL, 32.7 
mmol) was added and the reaction stirred overnight at 25 °C.  The solution was 
concentrated under reduced pressure, acidified with H2SO4 (1 M, 68.7 mL) and 
concentrated under reduced pressure. Eextracts were made with EtOAc, filtered and 
concentrated under reduced pressure to yield triol 242 as an oil (3.559 g, 71%). max 
(ATR): 3351 (OH) cm
–1
. H (400 MHz, CDCl3): 4.29 (2H, s, 2   H-1), 4.11 (3H, broad s, 
3   OH) 1.43 (3H, s, Me), 1.37 (3H, s, Me), 1.27 (3H, s, Me). C (100 MHz, CDCl3): 
88.04 (C), 82.78 (C), 75.67 (C), 73.93 (C), 50.44 (CH2), 25.57 (CH3), 24.40 (CH3), 22.79 
(CH3). LRMS (CI
+
): 141 [(M + H)
+
 – H2O, 100%], 123 [(M + H)
+
 – (2   H2O), 47]. 
HRMS: 141.0914. C8H13O2 requires [(M + H)
+
 – H2O], 141.0916. Compound reported in 





Propargyl alcohol 239 (0.32 mL, 6.62 mmol) in anhydrous THF (10 mL) was degassed 
with argon for 15 min.  NaH (370 mg, 80% in mineral oil, 12.3 mmol) was added and the 
mixture stirred for 1 h under argon at 25 C.  3-Hydroxy-3-methyl-2-butanone 241 (0.32 
mL, 2.9 mmol) in anhydrous THF (10 mL) was added and the reaction stirred overnight at 
25 °C under argon. Saturated aqueous NH4Cl (15 mL) was added to quench and the 
resultant mixture concentrated under reduced pressure.  The solid residue was washed with 
EtOAc, filtered and concentrated under reduced pressure to yield triol 242 as an oil (368 
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3-(4’,5’,5’-Trimethyl-2’-phenyl-1’,3’,2’-dioxaborolan-4’-yl)prop-2-yn-1-ol 250 
 
Phenylboronic acid 249 (200 mg, 1.63 mmol) and molecular sieves (4Å, 815 mg) were 
added to triol 242 (259 mg, 1.63 mmol) in anhydrous THF (10 mL).  The resultant mixture 
was stirred for 72 h at 25 °C. The mixture was filtered and concentrated under reduced 
pressure to yield the crude boronate ester 250 as an oil.  Attempted purification by column 
chromatography (SiO2) resulted in decomposition.  Selected data from crude: H (400 
MHz, CDCl3): 7.82 (2H, d, J = 6.8 Hz, H-2’’ and H-6’’), 7.47 (1H, t, J = 7.4 Hz, H-4’’), 
7.37 (2H, t, J = 7.3 Hz, H-3’’ and H-5’’), 4.32 (2H, d, J = 5.9 Hz, 2   H-1), 2.06 (1H, 
broad s, OH) 1.60 (3H, s, Me), 1.55 (3H, s, Me), 1.39 (3H, s, Me). C (100 MHz, CDCl3): 
134.90 (CH), 131.64 (CH), 127.77 (CH), 85.00 (C), 85.42 (C), 84.25 (C), 81.00 (C), 51.07 






Following the procedure of Whiting and Pilling,
157
 a solution of I2 (23.40 g, 92 mmol) and 
KI (18.26 g, 110 mmol) in H2O (100 mL) was added dropwise to a stirring solution of 3-
hydroxybenzoic acid 252 (13.95 g, 100 mmol) in concentrated aqueous NH3 (200 mL) 
over 1.5 h at RT.  The resultant green solution was stirred for 30 min before cooling to 0 
°C.  Concentrated HCl (180 mL) was added slowly during which a precipitate formed.  
After cooling to RT, the precipitate was filtered off and washed with ice-cold H2O (40 
mL).  The precipitate was recrystallised from H2O-EtOH (5:1) and washed with ice-cold 
H2O (40 mL) before drying under reduced pressure to yield carboxylic acid 253 as an 
amorphous solid (18.82 g, 69%). Mp: 222-224 °C [H2O-EtOH (5:1)] [Lit.
157
 224-225 C 
H2O-EtOH (5:1)].max (ATR): 3547 (OH), 3302 (very broad, CO2H) 1680 (C=O) cm
–1
. H 
(400 MHz, CDCl3): 13.00 (1H, s, CO2H), 10.68 (1H, s, OH), 7.80 (1H, d, J = 8.1 Hz, H-5), 
7.42 (1H, d, J = 1.9 Hz, H-2), 7.14 (1H, dd, J = 8.1 and 1.9 Hz, H-6). C (100 MHz, 
CDCl3): 166.80 (C), 156.70 (C), 138.98 (CH), 131.99 (C), 121.39 (CH), 114.90 (CH), 
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90.84 (C). LRMS (CI
+
): 265 [(M + H)
+
, 79%], 264 (46), 157 (59), 139 (65), 79 (100). 













Carboxylic acid 253 (10.91 g, 41.3 mmol) in EtOH (40 mL) was cooled to –8 °C and 
thionyl chloride (9.3 mL, 0.13 mol) was added dropwise.  The solution was then stirred at 
reflux for 3 h before cooling to RT.  The solution was concentrated under reduced 
pressure.  The resultant solid was dissolved in DCM (100 mL), washed with saturated 
aqueous NaHCO3 (2   50 mL) and H2O (50 mL).  Organics were dried over MgSO4 and 
concentrated under reduced pressure.  Recrystallisation from EtOAc-hexane yielded ethyl 
ester 254 as plates (11.90 g, 99%). Mp: 118-119 °C (EtOAc-hexane) [Lit.
191
 119-120 C 
(toluene)]. max (ATR): 3374 (broad OH), 1694 (C=O) cm
–1
. H (400 MHz, CDCl3): 7.75 
(1H, d, J = 8.2 Hz, H-5), 7.65 (1H, d, J = 1.7 Hz, H-2), 7.33 (1H, dd, J = 8.2 and 1.7 Hz, 
H-6), 5.81 (1H, s, OH), 4.37 (2H, q, J = 7.1 Hz, CH2), 1.39 (3H, t, J = 7.1 Hz, CH3). C 
(100 MHz, CDCl3): 166.00 (C), 155.09 (C), 138.53 (CH), 132.55 (C), 122.99 (CH), 115.77 




, 79%], 247 [M
+• – EtO• 









3-Hydroxy-4-iodobenzyl alcohol 255 
 
Ethyl ester 254 (2.20 g, 7.53 mmol) in anhydrous Et2O (40 mL) was degassed with argon 
for 15 min.  The stirring solution was cooled to –78 °C and diisobutylaluminium hydride 
(22.6 mL, 1.0 M in hexanes, 22.6 mmol) was added dropwise. The resultant solution 
stirred at –78 °C for 1 h and then stirred overnight, allowing to warm to RT.  Saturated 
aqueous NH4Cl (15 mL) and Et2O (60 mL) were added and the resulting solution stirred 
for 1.5 h until the precipitate settled.  The Et2O layer was filtered through a Celite pad and 
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washed through with Et2O.  Organics were dried over MgSO4, and concentrated under 
reduced pressure to yield diol 255 as an amorphous solid (1.84 g, 98%). Mp: 107-109 °C. 
max (ATR): 3406 (OH), 3134 (CH), 3086 (CH), 1589 (Ar) cm
–1
. H (400 MHz, MeOD): 
7.60 (1H, d, J = 7.8 Hz, H-5), 6.86 (1H, s, H-2), 6.58 (1H, d, J = 7.8 Hz, H-6), 4.49 (2H, s, 
CH2). C (100 MHz, MeOD): 158.07 (C), 144.91 (C), 140.19 (CH), 120.75 (CH), 114.25 




, 100%), 123 (M
+• – I•, 27), 95 (91). 






By-product isolated during the synthesis of diacetal 257.  Diol 255 (2.61 g, 10.4 mmol) in 
anhydrous Et2O (50 mL) was degassed with argon for 15 min.  The solution was cooled to 
0 °C and 2,3-dihydrofuran (0.96 mL, 12.5 mmol) and para-toluene sulfonic acid 
monohydrate (19 mg, 0.1 mmol) were added.  The solution was stirred at 0 ºC for 1 h 
before 2,3-dihydrofuran (0.96 mL, 12.5 mmol) was added followed by stirring at 0 ºC for 1 
h then at RT for a further 1 h.  The solution was concentrated under reduced pressure and 
the resultant yellow oil taken up in DCM (40 mL).  Organics were washed with saturated 
aqueous NaHCO3 (25 mL) and H2O (2   20 mL), dried over MgSO4 and concentrated 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (4:1)] 
yielded phenol 256 as an amorphous solid (1.32 g, 40%).  This reaction also yielded 
diacetal 257 as an oil (1.60 g, 39%).  Mp: 60-61 °C. Rf [SiO2, petroleum ether-EtOAc 
(4:1)]: 0.23. max (ATR): 3201 (OH), 2980 (CH), 2945 (CH), 2907 (CH), 1589 (Ar) cm
–1
. 
H (400 MHz, CDCl3): 7.60 (1H, d, J = 8.1 Hz, H-3), 6.96 (1H, s, H-6), 6.65 (1H, d, J = 









), 4.01-3.83 (2H, m, 2   H-5’), 2.10-1.79 
(4H, m, 2   H-3’ and 2   H-4’). C (100 MHz, CDCl3): 154.07 (C), 141.22 (C), 138.16 
(CH), 121.65 (CH), 114.25 (CH), 103.20 (CH), 84.00 (C), 67.82 (CH2), 67.15 (CH2), 32.34 
(CH2), 23.41 (CH2). LRMS (CI
+
): 321 [(M + H)
+
, 62%], 71 (C4H7O
+
, 100). HRMS: 
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2-(Tetrahydrofuran-2’-yloxy)-4-(tetrahydrofuran-2’’-yloxymethyl)iodobenzene 257 
 
Diol 255 (1.97 g, 7.87 mmol) and 2,3-dihydrofuran (1.8 mL, 32.6 mmol) in anhydrous 
Et2O (30 mL) were degassed with argon for 10 min.  para-Toluene sulfonic acid 
monohydrate (20 mg, 0.11 mmol) was added and the resulting solution degassed with 
argon for a further 10 min before stirring at RT for 24 h.  The solution was washed with 
saturated aqueous NaHCO3 (10 mL) and H2O (2   10 mL).  Organics were dried over 
MgSO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (4:1)] yielded diacetal 257 as an oil in a 1:1 mixture of 
diastereomers (X and Y) (1.63 g, 53%). Rf [SiO2, petroleum ether-EtOAc (4:1)]: 0.44 and 
0.50. max (ATR): 2978 (CH), 2947 (CH), 2886 (CH), 1574 (Ar) cm
–1
. H (400 MHz, 
CDCl3): 7.69 (1H, d, J = 8.0 Hz, H-6), 7.11 (1H, s, H-3), 6.73 (1H, d, J = 8.0 Hz, H-5), 









), 4.09 (1H, dt, J = 8.0, 5.6 Hz, 
H
A
-5’), 4.00-3.83 (3H, m, HB-5’ and 2   H-5’’), 2.37-2.18 (2H, m, 2   H-3’), 2.17-1.78 
(6H, m, 2   H-4’, 2   H-3’’ and 2   H-4’’). C (100 MHz, CDCl3): 155.97 (C), 140.31 
(C), 140.25 (C), 138.89 (CH), 122.69 (CH), 115.05 (CH), 103.17 (CH), 103.12 (CH), 
86.65 (C), 86.61 (C), 68.29 (CH2), 68.09 (CH2), 66.99 (CH2), 32.76 (CH2), 32.29 (CH2), 




, 100%), 320 (M
+•
 – C4H6O, 51), 234 
(M
+•
 – C4H6O and – C4H6O2, 100), 71 (C4H7O
+








Aryl iodide 257 (1.63 g, 4.18 mmol) was dried by azeotrope with toluene (3) and dried 
under reduced pressure.  Anhydrous THF (20 mL) was added and the resulting stirring 
solution degassed with argon for 20 min.  The solution was cooled to –78 °C and nBuLi 
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(1.6 M in hexanes, 3.14 mL, 5.02 mmol) was added dropwise over 2 min.  The resulting 
solution was stirred for a further 10 min before 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (1.02 mL, 5.02 mmol) was added dropwise.  This solution was stirred at –78 
°C for 1.5 h and then was allowed to warm to RT overnight.  The reaction was quenched 
with H2O (10 mL) and extracted with EtOAc (4   25 mL).  Column chromatography 
[SiO2, petroleum ether-EtOAc (4:1)] yielded diacetal 258 as an oil as a 1:1 mixture of 
diastereomers (924 mg, 57%). Rf [SiO2, petroleum ether-EtOAc (4:1)]: 0.28. max (ATR): 
2976 (CH), 2955 (CH), 2886 (CH), 1611 (Ar). H (400 MHz, CDCl3): 7.61 (1H, d, J = 7.5 
Hz, H-6’), 7.08 (1H, s, H-3’), 6.97 (1H, d, J = 7.5 Hz, H-5’), 5.80 (1H, t, J = 4.3 Hz, H-
2’’), 5.19 (1H, dd, J = 4.5 and 1.4 Hz, H-2’’’), 4.68 (1H, d, J = 12.5 Hz, ArCHAHB), 4.47 




), 4.14-4.06 (1H, m, H
A
-5’’), 3.98-3.84 (3H, m, HB-5’’ and 
2   H-5’’’), 2.31-2.14 (2H, m, 2   H-3’’), 2.11-1.77 (6H, m, 2   H-4’’, 2   H-3’’’ and 2 
  H-4’’’), 1.33 (12H, s, 4   Me). C (100 MHz, CDCl3): 161.91 (C), 143.08 (C), 143.05 
(C), 136.34 (CH), 120.86 (CH), 120.83 (CH), 115.69 (CH), 115.64 (CH), 103.40 (CH), 
103.34 (CH), 103.09 (CH), 83.23 (C), 68.52 (CH2), 67.96 (CH2), 67.00 (CH2), 32.68 
(CH2), 32.33 (CH2), 24.86 (CH3), 23.43 (CH2), 23.21 (CH2). LRMS (CI
+
): 391 [(M + H)
+
, 
19%], 321 [(M + H)
+
 – C4H6O, 100), 303 [(M + H)
+
 – C4H6O and – H2O, 83], 233 [(M + 
H)
+
 – (2   C4H6O) and – H2O, 56], 177 (68), 71 (C4H7O
+
, 57). HRMS: 391.2285. 
C21H32
11






Alumininium trichloride (32 mg, 0.24 mmol) was added to a stirring solution of diacetal 
258 (461 mg, 1.2 mmol) in EtOH (9.5 mL).  The reaction mixture was stirred under argon 
at RT for 45 min.  The solution was concentrated under reduced pressure and the resulting 
grey oil dissolved in Et2O (40 mL) and filtered.  Concentrating under reduced pressure 
yielded diol 259 as a 10:1 mixture with 3-hydroxybenzyl alcohol 146 by-product as the 
minor component (296 mg, 99%). max (ATR): 3436 (OH), 2979 (CH), 2934 (CH), 2869 
(CH), 1629 (Ar). H (400 MHz, CDCl3): 7.85 (1H, broad s, OH), 7.58 (1H, d, J = 7.8 Hz, 
H-3), 6.91-6.70 (2H, m, H-4 and H-6), 4.65 (2H, s, CH2), 2.05 (1H, broad s, OH), 1.36 
(12H, s, 4   Me). C (100 MHz, CDCl3): 163.87 (C), 147.23 (C), 136.01 (CH), 117.79 
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(CH), 113.40 (CH), 84.50 (C), 65.00 (CH2), 24.81 (CH3). LRMS (CI
+
): 251 [(M + H)
+
, 
100%], 233 [(M + H)
+





, 251.1455 and C13H20
10





2’’-yl)benzyl alcohol 262 
 
Cs2CO3 (74 mg, 0.23 mmol) was added to stirring α, α’-para-dibromoxylene 232 (218 mg, 
0.83 mmol) in anhydrous acteone (2 mL) and the mixture degassed with argon for 30 min.  
The mixture was heated to reflux and a degassed solution of phenol 259 (26 mg, 0.11 
mmol) in anhydrous acetone (0.2 mL) and anhydrous THF (0.5 mL) was added dropwise.  
After 45 min anhydrous DMF (0.1 mL) was added to aid solubility.  After a further 1.75 h, 
a further degassed solution of phenol 259 (26 mg, 0.11 mmol) in anhydrous acetone (0.2 
mL) and anhydrous THF (0.3 mL) was added dropwise.   After a further 2.5 h, the reaction 
mixture was cooled to RT.  H2O (15 mL) was added and extracted with Et2O (4   15 mL).  
Combined organics were dried over MgSO4 and concentrated under reduced pressure.  
Column chromatography [SiO2, petroleum ether-EtOAc (4:1)] yielded benzylic bromide 
262 as a semi-pure oil (18 mg, 9%). Selected data from crude:  H (400 MHz, CDCl3): 7.69 
(1H, broad d, J = 7.4 Hz, H-5), 7.61 (2H, d, J = 8.2 Hz, H-2’ and H-6’), 7.40 (2H, J = 8.2 
Hz, H-3’ and H-5’), 6.96 (1H, broad s, H-2), 6.94 (1H, broad d, J = 7.5 Hz, H-6), 5.11 (2H, 
s, ArCH2O), 4.70 (2H, s, CH2OH), 4.52 (2H, s, CH2Br), 1.37 (12H, s, 4   Me). C (100 
MHz, CDCl3): 163.52 (C), 145.88 (C), 137.99 (C), 137.08 (CH), 136.79 (C), 128.90 (CH), 
127.05 (CH), 118.78 (CH), 109.95 (CH), 83.50 (C), 69.38 (CH2), 65.17 (CH2), 33.51 








  197 
Ethyl 3-(methoxymethoxy)-4-iodobenzoate 264 
 
Phenol 254 (1.00 g, 3.4 mmol) and diisopropylethylamine (1.2 mL, 6.9 mmol) in 
anhydrous DCM (25 mL) were degassed with argon for 10 min.  Bromomethyl methyl 
ether (0.62 mL, 6.9 mmol) was added and the solution stirred at reflux for 24 h.  After 
cooling to RT, the mixture was washed with aqueous HCl (1 M, 25 mL) and H2O (50 mL).  
Organics were dried over MgSO4 and concentrated under reduced pressure to give a 
yellow oil.  Column chromatography [SiO2, petroleum ether-EtOAc (9:1)] yielded ethyl 
ester 264 as an oil (984 mg, 86%). Rf [SiO2, petroleum ether-EtOAc (9:1)]: 0.41. max 
(ATR): 2970 (CH), 2919 (CH), 2830 (CH), 1717 (C=O), 1586 (Ar), 1570 (Ar) cm
–1
. H 
(400 MHz, CDCl3): 7.85 (1H, d, J = 8.1 Hz, H-5), 7.66 (1H, d, J = 1.8 Hz, H-2), 7.41 (1H, 
dd, J = 8.1 and 1.8 Hz, H-6), 5.30 (2H, s, OCH2O), 4.37 (2H, q, J = 7.1 Hz, CH2CH3), 3.52 
(3H, s, OMe), 1.39 (3H, t, J = 7.1 Hz, CH2CH3). C (100 MHz, CDCl3): 165.89 (C), 155.97 
(C), 139.48 (CH), 132.01 (C), 124.32 (CH), 114.96 (CH), 94.90 (CH2), 93.61 (C), 61.31 
(CH2), 55.80 (CH3), 14.30 (CH3). LRMS (FAB
+
): 337 [(M + H)
+
, 100%], 336 (96), 291 
[(M + H)
+








A stirring solution of ethyl ester 264 (8.00 g, 23.8 mmol) in anhydrous Et2O (120 mL) was 
degassed with argon for 15 min.  The solution was cooled to –78 °C and 
diisobutylaluminium hydride (1.0 M in THF, 52.4 mL, 52.4 mmol) was added over 20 min 
and the resulting mixture stirred for 2.5 h before warming to RT, followed by 40 min 
further stirring.  Saturated aqueous NH4Cl (80 mL) and Et2O (50 mL) were added and the 
mixture stirred until the precipitate settled.  The organic layer was filtered through a pad of 
Celite and washed through with Et2O (350 mL).  Organics were dried over MgSO4 and 
concentrated under reduced pressure.  Column chromatography [SiO2, petroleum ether-
EtOAc (4:1)] gave alcohol 265 as an oil (4.40 g, 63%). Rf [SiO2, petroleum ether-EtOAc 
(4:1)]: 0.13. max (ATR): 3373 (Broad, OH), 2957 (CH), 2905 (CH), 2827 (CH), 1588 (Ar), 
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1575 (Ar). H [400 MHz, (CD3)2CO]: 7.73 (1H, d, J = 8.0 Hz, H-5), 7.16 (1H, d, J = 1.5 
Hz, H-2), 6.81 (1H, broad dd, J = 8.0 and 1.7 Hz, H-6), 5.27 (2H, s, OCH2O), 4.60 (2H, s, 
CH2OH), 4.33 (1H, broad s, OH), 3.47 (3H, s, OMe). C (100 MHz, CDCl3): 155.78 (C), 
142.89 (C), 139.23 (CH), 121.93 (CH), 113.05 (CH), 94.64 (CH2), 85.54 (C), 64.07 (CH2), 




, 95%), 45 (CH3OCH2
+
, 100). HRMS: 293.9749. 
C9H11IO3 requires M
+•
, 293.9753. Compound is reported in the literature although analysed 






Benzylic alcohol 265 (700 mg, 2.38 mmol), 1-fluoro-2,4-dinitrobenzene (0.3 mL, 2.38 
mmol) and anhydrous triethylamine (3.3 mL, 2.38 mmol) were stirred in anhydrous 
acetone (3.5 mL) at 40 °C under argon for 72 h.  EtOAc (20 mL) was added and the 
mixture washed with saturated aqueous NaHCO3 (15 mL) and H2O (15 mL).  Organics 
were dried over MgSO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (4:1) to (1:1)] yielded aryl iodide 268 as an 
oil (774 mg, 71%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.57. Mp: 137-138 °C. max 
(ATR): 3114 (CH), 3083 (CH), 2964 (CH), 2939 (CH), 2915 (CH), 2868 (CH), 2830 (CH), 
1605 (Ar), 1573 (Ar). H [400 MHz, (CD3)2CO]: 8.77 (1H, d, J = 2.6 Hz, H-3’), 8.53 (1H, 
dd, J = 9.3 and 2.6 Hz, H-5’), 7.86 (1H, d, J = 8.0 Hz, H-6), 7.70 (1H, d, J = 9.3 Hz, H-6’), 
7.33 (1H, s, H-3), 6.99 (1H, d, J = 8.0 Hz, H-5), 5.53 (2H, s, ArCH2), 5.31 (2H, s, 
OCH2O), 3.48 (3H, s, OMe). C [100 MHz, (CD3)2CO]: 157.26 (C), 156.78 (C), 141.29 
(C), 140.53 (CH), 140.18 (C), 138.18 (C), 129.92 (CH), 123.38 (CH), 122.13 (CH), 116.73 





, 26%), 277 (M
+• – (O2N)2C6H3O
•
, 65), 184 (DNP
+•
, 18), 45 (CH3OCH2
+
, 100). 













NaHSO4.SiO2 was synthesised following the procedure of Breton.
158
 NaHSO4.SiO2 (47 
mg) was added to a stirring solution of acetal 268 (80 mg, 0.17 mmol) in DCM (2 mL) at 
RT.  The reaction was monitored via TLC every 30 min.  After 2 h the reaction had ceased 
and was incomplete.  A further 70 mg of NaHSO4.SiO2 was added and stirring continued 
for a further 2.25 h.  With no further change observed by TLC, the mixture was filtered and 
concentrated under reduced pressure.  Column chromatography [SiO2, petroleum ether-
EtOAc (9:1) to (1:1)] yielded phenol 269 as an oil (17.3 mg, 19%). Rf [SiO2, petroleum 
ether-EtOAc (1:1)]: 0.47. Mp: >200 °C (Decomp.). max (ATR): 3439 (OH), 3120 (CH), 
3111 (CH), 3089 (CH), 3074 (CH), 2923 (CH), 2861 (CH), 1607 (Ar), 1571 (Ar). H [400 
MHz, (CD3)2CO]: 8.76 (1H, d, J = 2.8 Hz, H-3’), 8.52 (1H, dd, J = 9.3 and 2.8 Hz, H-5’), 
7.77 (1H, d, J = 8.0 Hz, H-3), 7.67 (1H, d, J = 9.3 Hz, H-6’), 7.12 (1H, d, J = 1.9 Hz, H-6), 
6.82 (1H, dd, J = 8.0 and 1.9 Hz, H-4), 5.47 (2H, s, CH2). C [100 MHz, (CD3)2CO]: 
157.80 (C), 156.78 (C), 141.31 (C), 140.43 (CH), 140.22 (C), 138.19 (C), 129.89 (CH), 





, 10%), 233 [(HO)IC6H3CH2
+






Concentrated HCl (4 mL) in MeOH (16 mL) was added to a stirring solution of acetal 268 
(506 mg, 1.1 mmol) in DCM (10 mL).  A further DCM (8 mL) was added to dissolve a 
resulting precipitate.  After stirring for 4 h at 32 °C, the solution was poured into aqueous 
HCl (1 M, 15 mL) and extracted with DCM (3   20 mL).  Combined organics were dried 
over MgSO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (9:1) to (7:3)] yielded phenol 269 as an oil (413 mg, 90%). 
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{4-[5’-(2’’,4’’-Dinitrophenoxymethyl)-2’-iodophenoxymethyl]benzyl} 
triphenylphosphonium bromide 270 
 
Anhydrous MeCN (3 mL) was added to a mixture of phenol 269 (40 mg, 9.6   10
-5
 mol), 
phosphonium bromide 233 (50.6 mg, 9.6   10
-5
 mol) and Cs2CO3 (31.3 mg, 0.12 mmol).  
The resulting mixture was stirred at 25 °C for 4.5 h under argon, resulting in a yellow 
liquid over a white precipitate.  Liquid was pipetted off and filtered.  Residual solid was 
washed multiple times with anhydrous MeCN and pipetted off and filtered each time until 
only a small residue remained.  Combined MeCN washings were concentrated under 
reduced pressure, redissolved in DCM (3 mL) and washed with H2O (3 mL).  Organics 
were dried over MgSO4 and concentrated under reduced pressure to yield phosphonium 
bromide 270 as a pale yellow solid (79 mg, 95%). Mp: >140 °C (Decomp.). max (ATR): 
3053 (CH), 3110 (CH), 3089 (CH), 2960 (CH), 2892 (CH), 2852 (CH), 2779 (CH), 1607 
(Ar). H (400 MHz, CD3CN): 8.68 (1H, d, J = 2.8 Hz, H-3’’), 8.43 (1H, dd, J = 9.3 and 2.8 
Hz, H-5’’), 7.89-7.82 (4H, m, 3   p-H PPh3 and H-3’), 7.69-7.62 (6H, m, 6   o-H PPh3), 
7.60-7.51 (6H, m, 6   m-H PPh3), 7.43 (1H, d, J = 9.3 Hz, H-6’’), 7.34 (2H, broad d, J = 
7.9 Hz, H-3 and H-5), 7.12 (1H, d, J = 1.6 Hz, H-6’), 6.97 (2H, dd, J = 8.2 and 2.4 Hz, H-2 
and H-6), 6.88 (1H, dd, J = 8.0 and 1.6 Hz, H-4’), 5.33 (2H, s, CH2ODNB), 5.16 (2H, d, J 
= 1.7 Hz, CH2ArCH2P), 4.69 (2H, d, J = 14.7 Hz, CH2P). C (100 MHz, CD3CN): 157.10 
(C), 156.07 (C), 140.24 (C), 139.64 (CH), 138.85 (C), 136.78 (d, J = 3.3 Hz, C), 136.43 
(C), 135.08 (d, J = 2.3 Hz, CH), 134.31 (d, J = 9.8 Hz, CH), 131.57 (d, J = 5.4 Hz, CH), 
130.20 (d, J = 12.6 Hz, CH), 129.50 (CH), 127.40 (d, J = 2.8 Hz, CH), 126.43 (d, J = 9.3 
Hz, C), 121.84 (CH), 121.13 (CH), 117.62 (d, J = 85.8 Hz, C), 115.85 (CH), 111.56 (CH), 
86.43 (C), 71.28 (CH2), 70.17 (CH2), 30.55 (d, J = 46.8 Hz, CH2). P {
1
H} (162 MHz, 
CD3CN): 23.04 (s). LRMS (ESI
+












3-Hydroxybenzoic acid 252 (10.10 g, 72.4 mmol) in EtOH (70 mL) was cooled to –8 ºC 
and thionyl chloride (16.3 mL, 217 mmol) was added dropwise to the stirring solution.  
After stirring at reflux for 3 h the solution was allowed to cool to RT and then concentrated 
under reduced pressure.  The residue was dissolved in DCM (70 mL) and washed with 
saturated aqueous NaHCO3 (25 mL) and H2O (2   50 mL).  Organics were dried over 
MgSO4 and concentrated under reduced pressure.  Recrystallisation from EtOAc-hexane 
yielded ethyl ester 272 as an amorphous solid (10.25 g, 85%). Mp: 71-72 C (EtOAc-
hexane) [Lit.
193
 72-73 °C (EtOH)]. max (ATR): 3318 (OH), 2986 (CH), 1674 (C=O), 1589 
(Ar) cm
–1
. H (400 MHz, CDCl3): 7.64-7.58 (2H, m, H-2 and H-6), 7.31 (1H, t, J = 8.1 Hz, 
H-5), 7.07 (1H, ddd, J = 8.1, 2.5 and 1.2 Hz, H-4), 5.97 (1H, broad s, OH), 4.38 (2H, q, J = 
7.1 Hz, CH2), 1.39 (3H, t, J = 7.1 Hz, CH3). C (100 MHz, CDCl3): 167.05 (C), 155.98 (C), 









Ethyl 3-(methoxymethoxy)benzoate 273 
 
A stirring solution of phenol 272 (6.00 g, 36.1 mmol) in anhydrous DCM (200 mL) was 
degassed with argon for 20 min.  Bromomethyl methyl ether (0.62 mL, 6.9 mmol) was 
added and the solution stirred at reflux for 24 h under argon.  After cooling to RT, the 
mixture was washed with aqueous HCl (1 M, 75 mL) and H2O (2   150 mL).  Organics 
were dried over MgSO4 and concentrated under reduced pressure to give a yellow oil.  
Column chromatography [SiO2, petroleum ether-EtOAc (4:1)] yielded ethyl ester 273 as an 
oil (7.59 g, 94%). Rf [SiO2, petroleum ether-EtOAc (4:1)]: 0.70. max (ATR): 2982 (CH), 
2959 (CH), 2938 (CH), 2905 (CH), 1717 (C=O), 1586 (Ar) cm
–1
. H (400 MHz, CDCl3): 
7.72-7.66 (2H, m, H-2 and H-6), 7.37-7.32 (1H, m, H-5), 7.25-7.19 (1H, m, H-4), 5.21 
(2H, s, OCH2O), 4.37 (2H, q, J = 7.1 Hz, CH2CH3), 3.48 (3H, s, OMe), 1.39 (3H, t, J = 7.1 
Hz, CH2CH3). C (100 MHz, CDCl3): 166.31 (C), 157.13 (C) 131.90 (C), 129.69 (CH), 
123.06 (CH), 120.89 (CH), 117.04 (CH), 94.38 (CH2), 61.07 (CH2), 56.09 (CH3), 14.33 





, 100%), 165 (M
+•
 – EtO• or – CH3OCH2
•
, 48), 45 
(CH3OCH2
+•








A stirring solution of ethyl ester 273 (500 mg, 2.38 mmol) in anhydrous Et2O (20 mL) was 
degassed with argon for 10 min.  The solution was cooled to 0 °C and lithium aluminium 
hydride (332 mg, 8.32 mmol) was added slowly.  The mixture was stirred at 0 °C for 1.5 h 
and then at RT for 4 h.  H2O (1.5 mL) was added dropwise to quench the reaction followed 
by 3 drops aqueous HCl (1 M).  The solution was diluted with H2O (20 mL) and extracted 
with Et2O (3   20 mL).  Combined organics were dried over MgSO4 and concentrated 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (4:1)] 
yielded benzylic alcohol 274 as an oil (393 mg, 79%). Rf [SiO2, petroleum ether-EtOAc 
(4:1)]: 0.13. max (ATR): 3393 (OH), 2934 (CH), 2903 (CH), 2828 (CH), 1587 (Ar) cm
–1
. 
H (400 MHz, CDCl3): 7.25 (1H, t, J = 7.9 Hz, H-5), 7.04-7.00 (1H, m, H-2), 6.96 (1H, d, J 
= 7.6 Hz, H-4 or H-6), 6.93 (1H, dd, J = 8.2 and 2.4 Hz, H-4 or H-6), 5.12 (2H, s, 
CH2OH), 4.60 (2H, s, OCH2O), 3.45 (3H, s, OMe), 2.55 (1H, broad s, OH). C (100 MHz, 
CDCl3): 157.27 (C), 142.74 (C) 129.55 (CH), 120.34 (CH), 115.31 (CH), 114.55 (CH), 









, 15), 45 (CH3OCH2
+•













3-Aminopropan-1-ol 281 (8.0 mL, 105 mmol), phthalic anhydride (15.49 g, 105 mmol) 
and triethylamine (14.6 mL, 105 mmol) were dissolved in anhydrous toluene (150 mL) and 
stirred at reflux using a Dean-Stark apparatus for 5 h.  After cooling to RT organics were 
washed with H2O (80 mL) and dried over Na2SO4.  Concentration under reduced pressure 
yielded alcohol 282 as an amorphous solid (20.80 g, 97%). Mp: 70-71 °C (Lit.
195
 73-75 
°C). max (ATR): 3329 (OH), 2949 (CH), 2941 (CH), 2929 (CH), 2874 (CH), 1699 (C=O), 
1692 (C=O), 1604 (Ar), 1556 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.86 (2H, dd, J = 5.4 and 
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3.1 Hz, H-4’ and H-7’), 7.73 (2H, dd, J = 5.4 and 3.1 Hz, H-5’ and H-6’), 3.86 (2H, t, J = 
6.3 Hz, 2   H-1), 3.62 (2H, t, J = 5.8 Hz, 2   H-3), 2.50 (1H, broad s, OH), 1.89 (2H, tt, J 
= 6.3 and 5.9 Hz, 2   H-2). C (100 MHz, CDCl3): 168.91 (C), 134.11 (CH), 132.00 (C), 
123.37 (CH), 59.06 (CH2), 34.27 (CH2), 31.34 (CH2). LRMS (CI
+
): 206 [(M + H)
+
, 100%], 
188 [(M + H)
+













Oxalyl chloride (10.3 mL, 122 mmol) was added slowly to anhydrous DCM (350 mL) at –
78 °C under argon and stirred for 5 min.  Anhydrous DMSO (20.2 mL, 285 mmol) was 
added slowly and the resulting solution stirred for 30 min.  A solution of alcohol 282 
(16.71 g, 81.4 mmol) in anhydrous DCM (120 mL) was added slowly and the resulting 
solution stirred for 30 min.  Triethylamine (40.9 mL, 293 mmol) was added and after 
stirring for 30 min at –78 °C, the solution was warmed to RT and stirred for a further 1.75 
h.  The reaction mixture was poured into H2O (200 mL) and organics separated.  Organics 
were washed with H2O (2   150 mL), dried over Na2SO4 and concentrated under reduced 
pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (4:1) to (1:1)] yielded 
aldehyde 283 as a viscous oil that solidified on standing (16.54 g, 88%). Rf [SiO2, 
petroleum ether-EtOAc (1:1)]: 0.45. Mp: 119-120 °C (Lit.
195
 119-121 °C). max (ATR): 
2949 (CH), 2926 (CH), 2845 (CH), 2743 (CH), 1702 (C=O), 1677 (C=O), 1613 (Ar) cm
–1
. 
H (400 MHz, CDCl3): 9.83 (1H, t, J = 1.3 Hz, H-1), 7.85 (2H, dd, J = 5.4 and 3.1 Hz, H-4’ 
and H-7’), 7.73 (2H, dd, J = 5.4 and 3.1 Hz, H-5’ and H-6’), 4.04 (2H, t, J = 7.0, 2   H-3), 
2.88 (2H, dt, J = 1.3 and 7.0 Hz, 2   H-2). C (100 MHz, CDCl3): 199.51 (CH), 168.05 





, 16%), 175 [(M
+•
 – CO), 53], 160 (PhthNCH2
+
, 87), 85 (93), 83 (100), 76 (41), 47 



















Anhydrous THF (35 mL) was added to aryl iodide 155 (2.50 g, 7.6 mmol) and anhydrous 
LiCl (385 mg, 9.1 mmol) under argon.  The stirring mixture was cooled to –78 °C and 
i
PrMgCl (2.0 M in THF, 4.6 mL, 9.1 mmol) was added dropwise.  After stirring for 4.5 h, a 
solution of aldehyde 283 (1.54 g, 7.6 mmol) in anhydrous THF (15 mL) and anhydrous 
DCM (8 mL) was added dropwise and the mixture allowed to warm to RT overnight.  
Saturated aqueous NH4Cl (15 mL) was added to quench and the mixture stirred until the 
precipitate settled.  The mixture was filtered through a pad of Celite and washed through 
with Et2O.  Organics were dried over Na2SO4 and concentrated under reduced pressure.  
Column chromatography [SiO2, petroleum ether-EtOAc (9:1) to (1:1)] yielded alcohol 284 
as an oil (1.79 g, 58%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.50. Mp: 126-127 °C. 
max (ATR): 3502 (OH), 3042 (CH), 2994 (CH), 2942 (CH), 2871 (CH), 1699 (C=O), 1610 
(Ar) cm
–1
. H (400 MHz, CDCl3): 7.84 (2H, dd, J = 5.4 and 3.1 Hz, H-4’ and H-7’), 7.74 
(2H, d, J = 8.1 Hz, H-3’’ and H-5’’), 7.71 (2H, dd, J = 5.4 and 3.1 Hz, H-5’ and H-6’), 
7.34 (2H, d, J = 8.0 Hz, H-2’’ and H-6’’), 4.70 (1H, dt, J = 8.5 and 4.4 Hz, H-1), 3.91 (2H, 
dt, J = 6.5 and 1.2 Hz, 2   H-3), 2.91 (1H, broad d, J = 4.2 Hz, OH), 2.15-2.00 (2H, m, 2 
  H-2), 1.33 (12H, s, 4   Me). C (100 MHz, CDCl3): 168.77 (C), 146.72 (C), 134.97 
(CH), 134.02 (CH), 132.04 (C), 124.92 (CH), 123.33 (CH), 83.74 (C), 71.18 (CH), 37.61 




, 72%), 233 
{[(Pinacol)B(C6H4)CHOH]
+
 , 66}, 175 [(PhthNEt)
+•
, 65], 160 (PhthNCH2
+
, 100), 105 
(PhCO
+
, 58), 83 (C6H11
+
, 50) , 77 (Ph
+






















Methanesulfonyl chloride (15 µL, 0.20 mmol) was added to stirring alcohol 284 (67 mg, 
0.17 mmol) in anhydrous DCM (1.1 mL) under argon at 0 °C followed by anhydrous 
triethylamine (34 µL, 0.25 mmol).  After stirring for 1.5 h at RT, DCM (1.6 mL) was 
added and organics washed with H2O (2   1.6 mL).  Organics were dried over Na2SO4 and 
concentrated under reduced pressure.  The residue was dissolved in anhydrous acetone (2 
mL) under argon and anhydrous LiBr (143 mg, 1.65 mmol) added.  The resultant mixture 
was stirred at reflux for 14 h.  After cooling to RT, the mixture was concentrated under 
reduced pressure.  DCM (4 mL) was added and washed with H2O (2   3 mL).  Organics 
were dried over Na2SO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (4:1) to (1:1)] yielded semi-pure bromide 
285 as amorphous solid (49 mg, 63%) (~85:15 bromide 285:alkene 287). Rf [SiO2, 
petroleum ether-EtOAc (1:1)]: 0.58 (bromide 285 and alkene 287).  Selected data for 
bromide 285 from mixture: H (500 MHz, CDCl3): 7.79 (2H, dd, J = 5.4 and 3.1 Hz, H-4 
and H-7), 7.72 (2H, d, J = 8.0 Hz, H-3’’ and H-5’’), 7.68 (2H, dd, J = 5.5 and 3.0 Hz, H-5 
and H-6), 7.39 (2H, d, J = 8.1 Hz, H-2’’ and H-6’’), 5.00 (1H, t, J = 7.5 Hz, H-3’), 3.87-
3.74 (2H, m, 2   H-1’), 2.69-2.60 (2H, m, 2   H-2’), 1.34 (12H, s, 4   Me). C (126 
MHz, CDCl3): 168.08 (C), 143.96 (C), 135.21 (CH), 133.94 (CH), 131.94 (C), 126.51 





Anhydrous DMF (0.2 mL) was added to NaH (8.3 mg, 60% in mineral oil, 0.21 mmol) 
under argon at 0 °C.  Malononitrile (4 drops) was added and and the solution stirred for 30 
min.  A solution of alkyl bromide (40 mg, 85 μmol) 285 in anhydrous DMF (0.4 mL) was 
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added dropwise and washed in with further anhydrous DMF (0.3 mL).  The resultant 
solution was stirred overnight allowing to warm to RT.  After 14.5 h, saturated NH4Cl (2 
mL) was added and extracts made with DCM (3   2 mL).  Combined organics were dried 
over Na2SO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (1:0) to (1:1)] yielded dinitrile 286 as amorphous solid (28 mg, 
73%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.60. H (500 MHz, CDCl3): 7.76 (2H, dd, J 
= 5.5 and 3.0 Hz, H-5’ and H-6’), 7.75 (2H, d, J = 8.2 Hz, H-3’’ and H-5’’), 7.68 (2H, dd, 
J = 5.5 and 3.0 Hz, H-4’ and H-7’), 7.34 (2H, d, J = 8.1 Hz, H-3’’ and H-5’’), 4.07 (1H, d, 
J = 6.2 Hz, H-2), 3.70 (2H, t, J = 6.7 Hz, H-5), 3.32 (1H, dt, J = 10.7 and 6.4 Hz, H-3), 
2.60-2.50 (1H, m, H
A
-4’), 2.37-2.29 (1H, m, HB-4’), 1.33 (12H, s, 4   Me). C (126 MHz, 
CDCl3): 168.08 (C), 138.27 (C), 135.69 (CH), 134.05 (CH), 131.70 (C), 127.14 (CH), 
123.31 (CH), 111.42 (C), 111.39 (C), 83.94 (C), 44.51 (CH), 35.42 (CH2), 30.43 (CH2), 




, 35%), 160 (100), 84 (94). HRMS: 














By-product isolated during the synthesis of dinitrile 286 as a glass (3 mg, 8%). Rf [SiO2, 
petroleum ether-EtOAc (1:1)]: 0.58. H (500 MHz, CDCl3): 7.87 (2H, dd, J = 5.5 and 3.0 
Hz, H-5 and H-6), 7.74-7.71 (4H, m, H-3, H-5, H-4’’ and H-7’’), 7.35 (2H, d, J = 8.1 Hz, 
H-2 and H-6), 6.65 (1H, d, J = 15.9 Hz, CHCHCH2N), 6.32 (1H, dt, J = 15.9 and 6.4 Hz, 
CHCH2N), 4.45 (2H, dd, J = 6.4 and 1.3 Hz, CH2N), 1.33 (12H, s, 4   Me). C (126 MHz, 
CDCl3): 167.97 (C), 138.90 (C), 135.00 (CH), 134.01 (CH), 133.64 (CH), 132.18 (C), 





, 95%), 242 (100), 160 (PhthNCH2
+
, 90), 142 (85), 83 (C6H11
+
, 80). HRMS: 

















N2H4.H2O (50 µL, 64%, 0.66 mmol) was added to phthalimide 284 (200 mg, 0.49 mmol) 
in MeOH (1.5 mL) at 25 °C and stirred for 1.25 h before concentrating under reduced 
pressure.  CHCl3 (3 mL) was added and the residual solid removed by filtration.  Organics 
were dried over Na2SO4 and concentrated under reduced pressure to yield amine 288 as an 
oil (115 mg, 85%). max (ATR): 3365 (NH2 and OH), 2976 (CH), 2927 (CH), 2868 (CH), 
1611 (Ar), 1516 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.79 (2H, d, J = 7.6 Hz, H-3’’ and H-
5’’), 7.39 (2H, d, J = 7.8 Hz, H-2’’ and H-6’’), 4.99 (1H, dd, J = 8.1 and 1.9 Hz, H-1), 
3.13-3.03 (1H, m, H
A
-3), 3.01-2.90 (1H, m, H
B
-3), 1.95 (3H, broad s, NH2 and OH), 1.92-
1.83 (1H, m, H
A
-2), 1.79-1.67 (1H, m, H
B
-2), 1.34 (12H, s, 4   Me). C (100 MHz, 
CDCl3): 148.42 (C), 134.78 (CH), 124.98 (CH), 83.68 (C), 74.63 (CH), 40.67 (CH2), 39.99 




, 24%), 260 
[(M
+•
 – NH3), 39], 231 (30), 177 [(OB(C6H4)CHOHCH2CH2NH2)
+•
, 25], 160 (40), 133 












yl)phenyl]propyl}carbamoyl)butyl]triphenylphosphonium bromide 289 
 
Anhydrous DMF (6 mL) was added to a stirring mixture of amine 288 (388 mg, 1.4 
mmol), carboxylic acid 236 (604 mg, 1.4 mmol), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (314 mg, 1.6 mmol) and 4-dimethylaminopyridine (17 mg, 0.14 mmol) at 25 
°C under argon.  The resulting solution was stirred for 24 h.  DCM (15 mL) was added and 
organics washed with H2O (18 mL), saturated aqueous LiBr (16 mL), dried over Na2SO4 
and concentrated under reduced pressure.  Column chromatography [SiO2, DCM-MeOH 
(1:0) to (9:1)] yielded phosphonium bromide 289 as a glass (713 mg, 74%). Rf [SiO2, 
DCM-MeOH (9:1)]: 0.30.max (ATR): 3329 (OH and NH), 3055 (CH), 2976 (CH), 2932 
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(CH), 2870 (CH), 1643 (C=O), 1613 (Ar), 1543 (Ar) cm
–1
. H (400 MHz, CDCl3): 8.72 
(1H, t, J = 6.2 Hz, NH), 7.84-7.71 (11H, m, 6   o-H PPh3, 3   p-H PPh3, H-3’’ and H-
5’’), 7.70-7.63 (6H, m, 6   m-H PPh3), 7.33 (2H, d, J = 8.0 Hz, H-2’’ and H-6’’), 4.82 
(1H, broad s, OH), 4.70 (1H, broad d, J = 9.7 Hz, H-3’), 3.82-3.50 (3H, m, 2   H-1 and 
H
A
-1’), 3.36-3.25 (1H, m, HB-1’), 2.77-2.61 (2H, m, 2   H-4), 2.06-1.89 (3H, m, 2   H-3 
and H
A
-2’), 1.81-1.62 (3H, m, 2   H-2 and HB-2’), 1.34 (12H, s, 2   Me). C (100 MHz, 
CDCl3): 173.90 (C), 148.28 (C), 135.13 (d, J = 2.9 Hz, CH), 134.63 (CH), 133.60 (d, J = 
10.1 Hz, CH), 130.52 (d, J = 12.6 Hz, CH), 125.05 (CH), 118.04 (d, J = 86.0 Hz, C), 83.61 
(C), 69.88 (CH), 39.41 (CH2), 35.87 (CH2), 34.09 (CH2), 26.04 (d, J = 17.0 Hz, CH2), 
24.88 (CH3), 22.41 (d, J = 51.1 Hz, CH2), 21.07 (d, J = 4.1 Hz, CH2). LRMS (ESI
+
): 622 
(cation, 100%). HRMS (ESI
+
): 622.3236 and 621.3277. C38H46
11
BNO4P requires cation, 
622.3259 and C38H46
10


















Cs2CO3 (178 mg, 0.55 mmol) was added to phenol 299 (178 mg, 0.34 mmol) in anhydrous 
MeCN (1.2 mL) and stirred under argon for 5 min.  Benzylic bromide 233 (180 mg, 0.34 
mmol) in anhydrous DCM (0.4 mL) was added.  The resulting solution was stirred at RT 
for 10.5 h under argon before being concentrated under reduced pressure.  H2O (5 mL) was 
added and the product extracted with CHCl3 (3   5 mL).  Combined organics were dried 
over MgSO4 and concentrated under reduced pressure.  The solid was dissolved in DCM 
and precipitated by adding dropwise to stirring Et2O.  The liquor was pipetted off and the 
solid washed with Et2O.  Column chromatography of the residual solid [SiO2, DCM-EtOH 
(9:1)] yielded phosphonium bromide 292 as an yellow glass (192 mg, 58%). Rf [SiO2, 
DCM-EtOH (9:1)]: 0.20. max (ATR): 3059 (CH), 3051 (CH), 2978 (CH), 2918 (CH), 2868 
(CH), 2853 (CH), 1605 (Ar), 1524 (Ar), 1510 (NO2), 1343 (NO2). H (500 MHz, CDCl3): 
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8.69 (1H, d, J = 2.8 Hz, H-3’’’), 8.14 (1H, dd, J = 9.3 and 2.8 Hz, H-5’’’), 7.82-7.72 (11H, 
m, 6   o-H PPh3, 3   p-H PPh3, H-3 and H-5), 7.66-7.59 (6H, m, 6   m-H PPh3), 7.31 
(2H, d, J = 8.1 Hz, H-3’’’’ and H-5’’’’), 7.19 (2H, d, J = 8.0 Hz, H-2’’’’ and H-6’’’’), 7.13 
(2H, dd, J = 8.3 and 2.8 Hz, H-2 and H-6), 7.05 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.86 
(1H, d, J = 9.4 Hz, H-6’’’), 6.81 (2H, d, J = 8.7 Hz, H-2’ and H-6’), 5.50-5.42 (2H, m, 
CH2P), 5.26 (1H, dd, J = 8.4 and 4.5 Hz, H-3’’), 4.96 (2H, d, J = 2.0 Hz, CH2O), 2.77 (2H, 
t, J = 7.5 Hz, H-1’’), 2.45-2.36 (1H, m, HA-2’’), 2.21-2.12 (1H, m, HB-2’’), 1.324 (6H, s, 2 
  Me), 1.319 (6H, s, 2   Me). C (126 MHz, CDCl3): 156.86 (C), 155.73 (C), 141.79 (C), 
139.77 (C), 139.22 (C), 137.53 (d, J = 4.2 Hz, C), 135.54 (CH), 135.07 (d, J = 2.4 Hz, 
CH), 134.32 (d, J = 9.8 Hz, CH), 133.05 (C), 131.63 (d, J = 5.6 Hz, CH), 130.18 (d, J = 
12.7 Hz, CH), 129.41 (CH), 128.72 (CH), 127.66 (d, J = 3.0 Hz, CH), 126.62 (d, J = 8.6 
Hz, C), 125.14 (CH), 121.59 (CH), 117.61 (d, J = 85.6 Hz, C), 116.32 (CH), 114.95 (CH), 
83.99 (C), 82.10 (CH), 69.29 (CH2), 39.89 (CH2), 30.49 (d, J = 47.3 Hz, CH2), 30.46 
(CH2), 24.86 (CH3), 24.81 (CH3). P {
1
H} (162 MHz, CDCl3): 23.00 (s). LRMS (ESI
+
): 
885 (cation, 100%). HRMS (ESI
+
): 885.3478 and 884.3517. C53H51
11
BN2O8P requires 
cation, 885.3479 and C53H51
10













Ethyl 3-(4’-hydroxyphenyl)propionate 294196 
 
Thionyl chloride (10.54 mL, 144.4 mmol) was added dropwise to a stirring solution of 3-
(4’-hydroxyphenyl)propionic acid 293 (8.00 g, 48.1 mmol) in EtOH (150 mL).  The 
solution was stirred at reflux for 4.5 h.  After cooling to RT, the solution was concentrated 
under reduced pressure to give a crude orange oil.  Column chromatography [SiO2, 
petroleum ether-EtOAc (9:1) to (3:2)] yielded ethyl ester 294 as an oil that solidified on 
standing (9.30 g, 99%). Rf [SiO2, petroleum ether-EtOAc (7:3)]: 0.47. Mp: 42-43 °C. max 
(ATR): 3364 (OH), 2998 (CH), 2981 (CH), 2962 (CH), 2942 (CH), 2904 (CH), 2870 
(CH), 1701 (C=O), 1611 (Ar), 1596 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.04 (2H, d, J = 8.6 
Hz, H-2’ and H-6’), 6.74 (2H, d, J = 8.6 Hz, H-3’ and H-5’), 6.02 (1H, broad s, OH), 4.13 
(2H, q, J = 7.1 Hz, CH2CH3), 2.87 (2H, t, J = 7.9 Hz, 2   H-3), 2.59 (2H, t, J = 7.8 Hz, 2 
  H-2), 1.23 (3H, t, J = 7.2 Hz, CH3). C (100 MHz, CDCl3): 173.75 (C), 154.24 (C), 





, 33%), 149 (M
+•
 – EtO•, 9), 120 (M+• – EtOH and – CO2,
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78), 107 (HOC6H4CH2
+









Ethyl 3-(4’-methoxymethoxyphenyl)propionate 295197 
 
A stirring solution of ethyl ester 294 (27.00 g, 139 mmol) and DIPEA (31.5 mL, 181 
mmol) in anhydrous DCM (400 mL) was degassed with argon for 30 min.  Bromomethyl 
methyl ether (16.5 mL, 90%, 181 mmol) was added dropwise and the resulting solution 
stirred at reflux overnight under argon.  After cooling to RT, the mixture was washed with 
aqueous HCl (1 M, 150 mL), H2O (2   150 mL), dried over MgSO4 and concentrated 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (19:1) to 
(65:35)] yielded ethyl ester 295 as an oil (31.12 g, 94%). Rf [SiO2, petroleum ether-EtOAc 
(4:1)]: 0.49. max (ATR): 2982 (CH), 2955 (CH), 2936 (CH), 2826 (CH), 1732 (C=O), 
1613 (Ar), 1586 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.11 (2H, d, J = 8.7 Hz, H-2’ and H-6’), 
6.94 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 5.13 (2H, s, OCH2O), 4.11 (2H, q, J = 7.1 Hz, 
CH2CH3), 3.45 (3H, s, OMe), 2.88 (2H, t, J = 7.8 Hz, 2   H-3), 2.57 (2H, t, J = 7.9 Hz, 2 
  H-2), 1.22 (3H, t, J = 7.2 Hz, CH2CH3). C (100 MHz, CDCl3): 172.87 (C), 155.72 (C), 
133.98 (C), 129.29 (CH), 116.30 (CH), 94.49 (CH2), 60.33 (CH2), 55.85 (CH3), 36.15 




, 51%), 45 (CH3OCH2
+
, 100). 
HRMS: 238.1209. C13H18O4 requires M
+•







A stirring solution of ethyl ester 295 (8.73 g, 36.6 mmol) in anhydrous Et2O (140 mL) was 
cooled to 0 °C under argon and LiAlH4 (4.17 g, 109.8 mmol) was added portionwise.  The 
solution was stirred at 0 °C under argon for 45 min before being allowed to warm to RT 
overnight.  H2O (25 mL) was added dropwise to quench.  H2O (20 mL) and Et2O (100 mL) 
were added to dilute and the mixture stirred until the precipitate settled.  The organic layer 
was filtered through a pad of Celite and washed through with Et2O.  Organics were dried 
over MgSO4 and concentrated under reduced pressure to yield alcohol 296 as an oil (6.05 
g, 84%). max (ATR): 3347 (OH), 2994 (CH), 2937 (CH), 2902 (CH), 2861 (CH), 2827 
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(CH), 2785 (CH), 1612 (Ar), 1585 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.08 (2H, d, J = 8.7 
Hz, H-2’ and H-6’), 6.94 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 5.11 (2H, s, OCH2O), 3.59 
(2H, broad t, J = 5.9 Hz, 2   H-1), 3.44 (3H, s, OMe), 3.00 (1H, broad s, OH), 2.61 (2H, t, 
J = 7.7 Hz, 2   H-3), 1.86-1.77 (2H, m, 2   H-2). C (100 MHz, CDCl3): 155.31 (C), 
135.36 (C), 129.33 (CH), 116.23 (CH), 94.50 (CH2), 61.81 (CH2), 55.84 (CH3), 34.34 
(CH2), 31.17 (CH2). LRMS (CI
+
): 197 [(M + H)
+
, 46%], 165 [(M + H)
+
 – MeOH, 100]. 






C NMR are in 
agreement with literature, excluding the misreported 
13
C NMR peak at 192.25 ppm 






Oxalyl chloride (1.9 mL, 21.6 mmol) was added to anhydrous DCM (70 mL) at –78 °C 
under argon and stirred for 5 min.  Anhydrous DMSO (2.7 mL, 38.0 mmol) was added and 
the resulting solution stirred at –78 °C for 30 min.  A solution of alcohol 296 (3.00 g, 15.3 
mmol) in anhydrous DCM (20 mL) was added slowly.  After stirring for 30 min, 
anhydrous triethylamine (10.65 mL, 76.4 mmol) was added.  After stirring for a further 30 
min at –78 °C, the solution was allowed to warm to RT and stir for a further 2.5 h.  The 
reaction was concentrated under reduced pressure.  H2O (50 mL) was added and 
extractions were made with DCM (3   30 mL).  Combined organics were dried over 
MgSO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (9:1) to (7:3)] yielded aldehyde 297 as an oil (2.97 g, 94%). Rf 
[SiO2, petroleum ether-EtOAc (4:1)]: 0.44. max (ATR): 2996 (CH), 2957 (CH), 2933 
(CH), 2898 (CH), 2848 (CH), 2826 (CH), 2792 (CH), 1722 (C=O), 1611 (Ar), 1585 (Ar) 
cm
–1
. H (400 MHz, CDCl3): 9.78 (1H, t, J = 1.4 Hz, H-1), 7.10 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 6.96 (2H, d, J = 8.6 Hz, H-3’ and H-5’), 5.13 (2H, s, OCH2O), 3.45 (3H, s, 
OMe), 2.89 (2H, t, 2   H-3, J = 7.5 Hz), 2.73 (2H, broad t, 2   H-2, J = 7.5 Hz). C (100 
MHz, CDCl3): 201.60 (CH), 155.73 (C), 133.72 (C), 129.26 (CH), 116.42 (CH), 94.48 















Anhydrous THF (60 mL) was added to aryl iodide 155 (3.91 g, 11.8 mmol) and anhydrous 
LiCl (552 mg, 13.0 mmol) under argon.  The stirring mixture was cooled to –78 °C and 
i
PrMgCl (2.0 M in THF, 6.5 mL, 13.0 mmol) was added dropwise over 20 min.  After 
stirring for 3.5 h at –78 °C, aldehyde 297 (1.64 g, 8.4 mmol) in anhydrous THF (10 mL) 
was added dropwise and the solution allowed to warm to RT overnight.  Saturated aqueous 
NH4Cl (7 mL) was added to quench.  H2O (40 mL) was added and extractions made with 
Et2O (3   40 mL).  Combined organics were filtered through a pad of Celite and washed 
through with Et2O.  Organics were dried over MgSO4 and concentrated under reduced 
pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (19:1) to (55:45)] 
yielded alcohol 298 as an oil (3.36 g, 93%). Rf [SiO2, petroleum ether-EtOAc (4:1)]: 0.22. 
max (ATR): 3458 (OH), 2979 (CH), 2932 (CH), 2865 (CH), 2826 (CH), 1611 (Ar), 1586 
(Ar) cm
–1
. H (400 MHz, CDCl3): 7.78 (2H, d, J = 8.1 Hz, H-3’’ and H-5’’), 7.32 (2H, d, J 
= 8.0 Hz, H-2’’ and H-6’’), 7.07 (2H, d, J = 8.6 Hz, H-2’ and H-6’), 6.93 (2H, d, J = 8.6 
Hz, H-3’ and H-5’), 5.11 (2H, s, OCH2O), 4.68-4.60 (1H, m, H-1), 3.44 (3H, s, OMe), 
2.70-2.52 (2H, m, 2   H-3), 2.33 (1H, broad s, OH), 2.12-1.87 (2H, m, 2   H-2), 1.33 
(12H, s, 4   Me). C (100 MHz, CDCl3): 155.36 (C), 147.84 (C), 135.15 (C), 134.97 (CH), 
129.34 (CH), 125.24 (CH), 116.25 (CH), 94.53 (CH2), 83.76 (C), 73.60 (CH), 55.85 (CH3), 





, 53%), 380 (M
+•
 – H2O, 43), 233 [(C6H12O2)B(C6H4)CHOH
+
, 33], 230 (60), 165 
[MOMO(C6H4)CH2CH2
+
, 10], 107 (HOC6H4CH2
+
, 45), 45 (CH3OCH2
+


















Anhydrous triethylamine (525 μL, 3.77 mmol) was added to a stirring solution of alcohol 
298 (500 mg, 1.26 mmol) and 1-fluoro-2,4-dinitrobenzene (470 μL, 3.77 mmol) in 
anhydrous acetone (0.2 mL) and under argon.  The resulting solution was stirred at 40 °C 
for 72 h, then concentrated under reduced pressure.  EtOAc (12 mL) was added and 
washed with saturated aqueous NaHCO3 (6 mL) and H2O (2   6 mL).  Organics were 
dried over MgSO4 and concentrated under reduced pressure.  DCM (16 mL) and MeOH 
(16 mL) were added followed by concentrated HCl (4 mL) dropwise.  The resulting 
solution was stirred vigourously at 32 °C for 3.5 h.  Pinacol (35 mg, 296 µmol) was added 
and stirred at RT for 1 h.  The reaction mixture was poured into aqueous HCl (1 M, 12 mL) 
and organics separated before extracts were made with DCM (3   10 mL).  Combined 
organics were dried over MgSO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (9:1) to (2:1)] yielded phenol 299 as an oil 
(417 mg, 64%). Rf [SiO2, petroleum ether-EtOAc (7:3)]: 0.33. max (ATR): 3399 (OH), 
3114 (CH), 3094 (CH), 2980 (CH), 2932 (CH), 2863 (CH), 1606 (Ar), 1528 (NO2), 1514 
(NO2), 1359 (NO2), 1342 (NO2) cm
–1
. H (500 MHz, CDCl3): 8.70 (1H, d, J = 2.8 Hz, H-
3’’), 8.14 (1H, dd, J = 9.3 and 2.8 Hz, H-5’’), 7.80 (2H, d, J = 7.9 Hz, H-3’’’ and H-5’’’), 
7.31 (2H, d, J = 8.0 Hz, H-2’’’ and H-6’’’), 7.02 (2H, d, J = 8.4 Hz, H-3 and H-5), 6.85 
(1H, d, J = 9.4 Hz, H-6’’), 6.74 (2H, d, J = 8.4 Hz, H-2 and H-6), 5.25 (1H, dd, J = 8.4 and 
4.5 Hz, H-3’), 4.81 (1H, broad s, OH), 2.77 (2H, t, J = 7.5 Hz, 2   H-1’), 2.46-2.36 (1H, 
m, H
A
-2’), 2.21-2.11 (1H, m, HB-2’), 1.33 (6H, s, 2   Me), 1.32 (6H, s, 2   Me).  C (126 
MHz, CDCl3): 155.71 (C), 153.96 (C), 141.82 (C), 139.92 (C), 139.40 (C), 135.61 (CH), 
132.59 (C), 129.60 (CH), 128.56 (CH), 125.10 (CH), 121.69 (CH), 116.00 (CH), 115.46 





, 7%), 336 (M
+•
 – DNP, 7), 184 (DNP+•, 10), 107 (HOArCH2
+
, 100), 91 


















Anhydrous triethylamine (210 μL, 1.5 mmol) was added to stirring alcohol 298 (200 mg, 
0.5 mmol), 1-fluoro-2,4-dinitrobenzene (189 μL, 1.5 mmol) and anhydrous acetone (0.1 
mL) at RT under argon.  The resulting solution was stirred at 40 °C for 72 h before being 
concentrated under reduced pressure.  The residue was dissolved in DCM (6 mL) and 
washed with saturated aqueous NaHCO3 (4 mL) and H2O (2   4 mL).  Organics were 
dried over MgSO4 and concentrated under reduced pressure.  Column chromatography 
[SiO2, petroleum ether-EtOAc (95:5) to (5:95)] yielded an approximate 2:1 mixture of 
boronate ester 300 and boronic acid 301.  Selected data for boronate ester 300 from 
mixture: H (400 MHz, CDCl3): 8.69 (1H, d, J = 2.8 Hz, H-3’’’), 8.15 (1H, dd, J = 9.3 and 
2.8 Hz, H-5’’’), 7.81 (2H, d, J = 8.1 Hz, H-2’ and H-6’), 7.07 (2H, d, J = 8.6 Hz), 5.30 
(1H, dd, J = 8.3 and 4.6 Hz, H-1’’), 5.14 (2H, s, OCH2O), 3.47 (3H, s, OMe), 2.78 (2H, t, J 
= 7.4 Hz, 2   H-3’’), 2.47-2.33 (1H, m, HA-2’’), 2.23-2.12 (1H, m, HB-2’’), 1.332 (6H, s, 2 
  Me), 1.327 (6H, s, 2   Me). 
 
Selected data for boronic acid 301 from mixture: H (400 MHz, CDCl3): 8.65 (1H, d, J = 
2.8 Hz, H-3’’), 8.10 (1H, dd, J = 9.3 and 2.8 Hz, H-5’’), 7.51 (2H, d, J = 7.9 Hz), 7.06 (2H, 
d, J = 8.6 Hz), 5.26 (1H, dd, J = 8.1 and 4.9 Hz, H-1’), 5.14 (2H, s, OCH2O), 3.47 (3H, s, 












Concentrated HCl (2 mL) was added dropwise to stirring acetal 298 (250 mg, 0.63 mmol) 
in DCM (8 mL) and MeOH (8 mL).  The resulting solution was stirred at 32 °C for 3.5 h.  
The solution was poured into aqueous HCl (1 M, 5 mL) and extracted with DCM (3   5 
mL).  Combined organics were dried over MgSO4 and concentrated under reduced 
pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (7:3)] gave diol 302 as 
an oil that solidified on standing (137 mg, 62%). Rf [SiO2, petroleum ether-EtOAc (7:3)]: 
0.19. Mp: 120-121 °C. max (ATR): 3352 (OH), 3128 (CH), 3030 (CH), 3018 (CH), 2985 
(CH), 2937 (CH), 2918 (CH), 2855 (CH), 1614 (Ar), 1600 (Ar) cm
–1
. H (400 MHz, 
CDCl3): 7.80 (2H, d, J = 8.0 Hz, H-3’’ and H-5’’), 7.35 (2H, d, J = 8.0 Hz, H-2’’ and H-
6’’), 7.04 (2H, d, J = 8.5 Hz, H-3 and H-5), 6.74 (2H, d, J = 8.5 Hz, H-2 and H-6), 4.84 
(1H, broad s, OH), 4.72-4.65 (1H, m, H-3’), 2.70-2.54 (2H, m, 2   H-1’), 2.14-1.92 (2H, 
m, 2   H-2’), 1.90 (1H, broad s, OH), 1.35 (12H, s, 4   Me). C (100 MHz, CDCl3): 
153.68 (C), 147.67 (C), 135.03 (CH), 133.78 (C), 129.51 (CH), 125.24 (CH), 115.22 (CH), 







 – H2O, 22), 233 [(C6H12O2)B(C6H4)CHOH
+
, 80], 208 (40), 121 (40), 107 
[HO(C6H4)CH2
+













yl}phenoxymethyl)benzyltriphenylphosphonium bromide 303 
 
Cs2CO3 (44 mg, 0.14 mmol) was added to phenol 302 (40 mg, 0.11 mmol) in anhydrous 
MeCN (2 mL).  After stirring under argon for 5 min, benzylic bromide 233 (59.4 mg, 1.1 
mmol) in anhydrous DCM (0.5 mL) was added.  The resulting solution was stirred at RT 
for 4 h under argon before being concentrated under reduced pressure.  H2O (3 mL) was 
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added and extracted with CHCl3 (3   3 mL).  Combined organics were dried over MgSO4 
and concentrated under reduced pressure.  The solid was dissolved in DCM and 
precipitated by adding dropwise to stirring Et2O.  Liquid was pipetted off and the solid 
rinsed with Et2O.  Column chromatography [SiO2, DCM-EtOH (9:1)] yielded 
phosphonium bromide 303 as an amorphous solid (43 mg, 48%). Rf [SiO2, DCM-EtOH 
(9:1)]: 0.20. Mp: >190 °C (Decomp.). max (ATR): 3323 (OH), 3055 (CH), 2976 (CH), 
2926 (CH), 2862 (CH), 2785 (CH), 1611 (Ar), 1587 (Ar). H (400 MHz, CDCl3): 7.80-7.68 
(11H, m, 6   o-H PPh3, 3   p-H PPh3, H-3’’’ and H-5’’’), 7.60 (6H, m, 6   m-H PPh3), 
7.34 (2H, d, J = 8.0 Hz, H-2’’’ and H-6’’’), 7.16 (2H, d, J = 8.0 Hz, H-2 and H-6), 7.13-
7.04 (4H, m, H-3, H-5, H-3’ and H-5’), 6.80 (2H, d, J = 8.6 Hz, H-2’ and H-6’), 5.74 (2H, 
d, J = 14.4 Hz, CH2P), 4.93 (2H, d, J = 1.7 Hz, CH2O), 4.69 (1H, dd, J = 7.6 and 5.4 Hz, 
H-3’’), 2.71-2.54 (2H, m, 2   H-1’’), 2.20 (1H, broad s, OH), 2.13-1.91 (2H, m 2   H-
2’’), 1.34 (12H, s, 4   Me). C (100 MHz, CDCl3): 156.66 (C), 147.99 (C), 137.60 (d, J = 
3.8 Hz, C), 135.06 (d, J = 2.9 Hz, CH), 135.01 (CH), 134.45 (C), 134.43 (d, J = 9.8 Hz, 
CH), 131.74 (d, J = 5.5 Hz, CH), 130.22 (d, J = 12.5 Hz, CH), 129.45 (CH), 127.71 (d, J = 
3.3 Hz, CH), 126.69 (d, J = 8.6 Hz, C), 125.34 (CH), 117.75 (d, J = 85.8 Hz, C), 114.83 
(CH), 83.86 (C), 73.59 (CH), 69.39 (CH2), 40.82 (CH2), 31.09 (CH2), 30.50 (d, J = 47.8 
Hz, CH2), 24.93 (CH3). P {
1
H} (162 MHz, CDCl3): 23.52 (s). LRMS (ESI
+
): 719 (cation, 
100%). HRMS: 718.3476, 719.3436 and 720.3461. C47H49
10
BO4P requires cation, 
718.3492, C47H49
11








dioxaborolan-2’’’-yl)phenyl]hexyltriphenylphosphonium iodide [MitoDNP-SUM(2)] 
304 
 
Alkyl iodide 315 (100 mg, 0.17 mmol) and triphenylphosphine (176 mg, 0.67 mmol) were 
dissolved in Et2O (0.9 mL) and stirred at 30 °C for 3 d.  After concentrating under reduced 
pressure, crude material was dissolved in minimal CHCl3 and added dropwise to 
vigourously stirring Et2O (20 mL).  The precipitate was collected by filtration, washed 
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with Et2O (10 mL) and dried under reduced pressure to yield phosphonium iodide 304 as a 
yellow glass.  Combined Et2O was concentrated under reduced pressure and the above 
isolation procedure was repeated to yield further phosphonium iodide 304 (Combined yield 
130.8 mg, 91%). max (ATR): 3052 (CH), 2978 (CH), 2925 (CH), 2863 (CH), 1604 (Ar), 
1522 (Ar), 1484 (Ar), 1358 (NO2), 1340 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.60 (1H, d, J 
= 2.8 Hz, H-3’), 8.21 (1H, dd, J = 9.4 and 2.8 Hz, H-5’), 7.83-7.77 (9H, m, 6   o-H PPh3 
and 3   p-H PPh3), 7.76 (2H, d, J = 8.1 Hz, H-3’’ and H-5’’), 7.73-7.68 (6H, m, 6   m-H 
PPh3), 7.46 (2H, d, J = 8.0 Hz, H-2’’ and H-6’’), 7.38 (1H, d, J = 9.5 Hz, H-6’), 5.89 (1H, 
dd, J = 7.9 and 5.0 Hz, H-6), 3.77-3.56 (2H, m, 2   H-1), 2.09-1.98 (1H, m, H
A
-5), 1.91-
1.55 (7H, m, 2   H-2, 2   H-3, 2   H-4, and H
B
-5), 1.32 (6H, s, 2   Me), 1.31 (6H, s, 2   
Me). C (100 MHz, CDCl3): 155.88 (C), 142.42 (C), 139.69 (C), 139.14 (C), 135.26 (d, J = 
23.7 Hz, CH), 135.14 (CH), 133.70 (d, J = 9.8 Hz, CH), 130.58 (d, J = 12.4 Hz, CH), 
129.06 (CH), 125.51 (CH), 121.25 (CH), 118.11 (d, J = 86.0 Hz, C), 117.72 (CH), 83.91 
(C), 82.33 (CH), 37.28 (CH2), 29.39 (d, J = 16.3 Hz, CH2), 24.87 (CH3), 24.85 (CH3), 
24.28 (CH2), 22.85 (d, J = 50.4 Hz, CH2), 22.17 (d, J = 4.2 Hz, CH2). P {
1
H} (162 MHz, 
CDCl3): 24.30 (s). LRMS (ESI
+
): 731 (cation, 100%). HRMS: 731.3040 and 730.3081. 
C42H45
11
BN2O7P requires cation, 731.3059 and C42H45
10












By-product isolated during the attempted synthesis of alkyl bromide 305 using the 




PrMgCl (2.0 M in THF, 0.5 mL, 1.0 mmol) was added dropwise 
to a stirring solution of aryl iodide 155 (300 mg, 0.9 mmol) and anhydrous ZnBr2 (246 mg, 
1.1 mmol) in anhydrous N-methylpyrolidinone (1.6 mL) at RT under argon.  The solution 
was stirred at 60 °C for 30 min then at RT for 1 h.  Thionyl chloride (1.8 mL, 24.7 mmol) 
was added to 5-bromovaleric acid (165 mg, 0.9 mmol) at 0 °C and stirred for 5 min.  The 
solution was then stirred at RT for a further 1 h, then concentrated under reduced pressure.  
Pd(dppf)Cl2 (20 mg, 2.7   10
-5
 mol) and anhydrous N-methylpyrolidinone (0.7 mL) were 
added under argon and this solution added to the initial solution via syringe.  After stirring 
at RT for 3 h, H2O (5 mL) was added and extracts made with Et2O (3   5 mL).  Combined 
organics were dried over MgSO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (1:0) to (4:1)] yielded bis-dioxaborolane 
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306 as an amorphous solid (93 mg, 36%). Rf [SiO2, petroleum ether-EtOAc (9:1)]: 0.31. 
Mp: 240-241 °C. max (ATR): 2982 (CH), 2930 (CH), 1605 (Ar), 1501 (Ar) cm
–1
. H (400 
MHz, CDCl3): 7.89 (4H, d, J = 8.3 Hz, H-2’, H-6’, H-3’’ and H-5’’), 7.64 (4H, d, J = 8.3 
Hz, H-3’, H-5’, H-2’’ and H-6’’), 1.36 (24H, s, 8   Me). C (100 MHz, CDCl3): 143.60 
(C), 135.24 (CH), 126.50 (CH), 83.83 (C), 24.86 (CH3). B {
1





, 2   11B, 100%), 405 (M+•, 11B & 10B, 47), 307 (50), 220 (55), 






















1,6-Hexanediol 307 (40.0 g, 339 mmol) was melted at 60 °C under argon.  2,3-Dihydro-
2H-pyran (7.1 mL, 78 mmol) was added slowly to the stirring solution.  p-Toluenesulfonic 
acid monohydrate (3.2 g, 17 mmol) was added and the resulting solution was stirred for 18 
h.  After cooling to RT, DCM (100 mL) was added and washed with H2O (3   200 mL).  
Organics were dried over Na2SO4 and concentrated under reduced pressure.  Column 
chromatography [SiO2, petroleum ether-EtOAc (1:1)] yielded alcohol 308 as an oil (13.97 
g, 88%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.38. H (400 MHz, CDCl3): 4.57 (1H, 
dd, J = 4.5 and 2.7 Hz, H-2’), 3.87 (1H, ddd, J = 11.2, 7.5 and 3.6 Hz, H-6’AX), 3.78-3.69 
(1H, dt, J = 9.6 and 6.8 Hz, H
A
-6), 3.61 (2H, t, J = 6.6 Hz, 2   H-1), 3.54-3.46 (1H, m, H-
6’EQ), 3.43-3.35 (1H, dt, J = 9.6 and 6.6 Hz, HB-6), 2.56 (1H, broad s, OH), 1.87-1.77 (1H, 
m, H-4’AX), 1.75-1.67 (1H, m, H-3’EQ), 1.65-1.47 (8H, m, H-3’AX, H-4’EQ, H-5’AX, H-5’EQ, 
2   H-2 and 2   H-5), 1.45-1.33 (4H, m, 2   H-3 and 2   H-4). C (100 MHz, CDCl3): 
98.89 (CH), 67.56 (CH2), 62.68 (CH2), 62.38 (CH2), 32.69 (CH2), 30.77 (CH2), 29.69 
(CH2), 26.06 (CH2), 25.61 (CH2), 25.49 (CH2), 19.69 (CH2). LRMS (CI
+
): 203 [(M + H)
+
, 











Oxalyl chloride (6.3 mL, 74.1 mmol) was added to anhydrous DCM (250 mL) at –78 °C 
under argon and stirred for 5 min.  Anhydrous DMSO (9.0 mL, 127 mmol) was added and 
the resulting solution stirred at –78 °C for 30 min.  A solution of alcohol 308 (10.71 g, 52.9 
mmol) in anhydrous DCM (50 mL) was added slowly.  After stirring for 45 min 
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triethylamine (10.65 mL, 76.4 mmol) was added slowly.  After stirring for a further 1 h at 
–78 °C, the solution was allowed to warm to RT overnight.  Organics were washed with 
H2O (2   100 mL), dried over Na2SO4 and concentrated under reduced pressure to yield 
aldehyde 309 as an pale brown oil that was taken forward without further purification (9.95 
g, 94%). H (400 MHz, CDCl3): 9.77 (1H, t, J = 1.8 Hz, H-6), 4.57 (1H, dd, J = 4.3 and 2.8 
Hz, H-2’), 3.86 (1H, ddd, J = 11.1, 7.4 and 3.6 Hz, H-6’AX), 3.74 (1H, dt, J = 9.6 and 6.7 
Hz, H
A
-6), 3.53-3.46 (1H, m, H-6’EQ), 3.39 (1H, dt, J = 9.6 and 6.5 Hz, HB-6), 2.45 (2H, 
dt, J = 1.8 and 7.3 Hz, 2   H-2), 1.87-1.77 (1H, m, H-4’AX), 1.75-1.48 (9H, m, H-3’EQ, H-
3’AX, H-4’EQ, H-5’EQ, H-5’AX, 2   H-3 and 2   H-5), 1.47-1.37 (2H, m, 2   H-4). C (100 
MHz, CDCl3): 202.60 (CH), 98.92 (CH), 67.25 (CH2), 62.38 (CH2), 43.83 (CH2), 30.77 
(CH2), 29.51 (CH2), 25.91 (CH2), 24.49 (CH2), 21.93 (CH2), 19.71 (CH2). LRMS (CI
+
): 
201 [(M + H)
+













Anhydrous THF (150 mL) was added to a mixture of aryl iodide 155 (9.47 g, 28.7 mmol) 
and anhydrous LiCl (1.46 g, 34.5 mmol) under argon.  The stirring mixture was cooled to –
78 °C and 
i
PrMgCl (2.0 M in THF, 17.2 mL, 34.5 mmol) was added slowly.  After stirring 
for 45 min, aldehyde 309 (5.75 g, 28.7 mmol) in anhydrous THF (30 mL) was added 
dropwise and the solution allowed to warm to RT overnight.  H2O (25 mL) was added to 
quench and the mixture was stirred until the precipitate settled before being washed 
through a pad of Celite with Et2O.  Organics were dried over Na2SO4 and concentrated 
under reduced pressure.  Column chromatography [SiO2, petroleum ether-EtOAc (4:1) to 
(1:1)] yielded alcohol 310 as an oil in a 1:1 mixture of diastereomers (X and Y) (9.91 g, 
85%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.58. max (ATR): 3442 (OH), 2977 (CH), 
2938 (CH), 1613 (Ar), 1520 (Ar) cm
–1
. H (400 MHz, CDCl3): 7.76 (2H, d, J = 8.1 Hz, H-
3’’ and H-5’’), 7.31 (2H, d, J = 8.0 Hz, H-2’’ and H-6’’), 4.62 (1H, t, J = 6.5 Hz, H-1), 
4.52 (1H, dd, J = 4.2 and 2.6 Hz, H-2’), 3.80 (1H, ddd, J = 11.1, 7.8 and 3.3 Hz, H-6’AX), 
3.67 [1H, td, J = 9.6 and 6.8 Hz, H
A
-6-(X)], 3.65 [1H, td, J = 9.6 and 6.8 Hz, H
A
-6-(Y)], 
3.48-3.41 (1H, m, H-6’EQ), 3.32 (1H, dt, J = 9.6 and 6.5 Hz, HB-2), 2.77 (1H, broad s, OH), 
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1.83-1.72 (2H, m, H-3’EQ and H-4’AX), 1.71-1.61 (2H, m, 2   H-2A), 1.59-1.44 (6H, m, H-
3’AX, H-4’EQ, H-5’EQ, H-5’AX and 2   H-5), 1.42-1.26 (4H, m, 2   H-3 and 2   H-4), 1.32 
(12H, s, 4   Me). C (100 MHz, CDCl3): 148.33 (C), 134.86 (CH), 125.20 (CH), 98.66 
(CH), 83.89 (C), 74.23 (CH), 74.21 (CH), 67.43 (CH2), 67.39 (CH2), 62.14 (CH2), 62.11 
(CH2), 39.05 (CH2), 30.67 (CH2), 29.58 (CH2), 29.56 (CH2), 26.16 (CH2), 26.10 (CH2), 




, 9%), 319 
(83), 233 (100), 99 (63), 85 (C5H9O
+














NaH (206 mg, 60% in mineral oil, 5.1 mmol) was added to a stirring solution of alcohol 
310 (1.30 g, 3.2 mmol) and 1-fluoro-2,4-dinitrobenzene (1.4 mL, 3.9 mmol) in anhydrous 
DCM (8 mL) at 0 °C under argon.  The solution was allowed to slowly warm to RT.  After 
5 h, H2O (10 mL) was added slowly followed by DCM (10 mL).  Organics were separated, 
dried over Na2SO4 and concentrated under reduced pressure.  The residue was redissolved 
in DCM (8 mL) and MeOH (8 mL).  Concentrated HCl (2.6 mL) was added dropwise to 
the vigourously stirring solution, which was then stirred at RT for 2 h.  H2O (15 mL) was 
added and extractions made with DCM (3   15 mL).  Combined organics were dried over 
Na2SO4 and concentrated under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (4:1) to (1:1)] yielded alcohol 311 as a viscous yellow oil (950 mg, 
61%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.29. max (ATR): 3411 (OH), 2979 (CH), 
2936 (CH), 2864 (CH), 1605 (Ar), 1526 (Ar), 1358 (NO2), 1341 (NO2) cm
–1
. H (400 
MHz, CDCl3): 8.67 (1H, d, J = 2.8 Hz, H-3’), 8.18 (1H, dd, J = 9.3 and 2.8 Hz, H-5’), 7.81 
(1H, d, J = 8.0 Hz, H-3’’ and H-5’’), 7.35 (1H, d, J = 8.0 Hz, H-2’’ and H-6’’), 6.97 (1H, 
d, J = 9.4 Hz, H-6’), 5.38 (1H, dd, J = 7.4 and 5.3 Hz, H-6), 3.62 (2H, t, J = 6.4 Hz, 2   H-
1), 2.19-2.03 (2H, m, H
B
-5 and OH), 2.00-1.89 (1H, m, H
A
-5), 1.62-1.51 (3H, m, 2   H-2 
and H
A
-4), 1.48-1.38 (3H, m, 2   H-3 and H
B
-4), 1.331 (6H, s, 2   Me), 1.327 (6H, s, 2   
Me). C (100 MHz, CDCl3): 155.83 (C), 142.01 (C), 139.83 (C), 139.42 (C), 135.56 (CH), 
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128.56 (CH), 125.11 (CH), 121.61 (CH), 116.13 (CH), 84.02 (C), 83.39 (CH), 62.58 
(CH2), 38.06 (CH2), 32.38 (CH2), 25.38 (CH2), 25.02 (CH2), 24.86 (CH3), 24.82 (CH3). 
LRMS (CI
+
): 504 [(M + H)
+
, 55%], 436 (49), 422 (100). HRMS: 504.2509 and 503.2544. 
C24H35
11
BN3O7 requires (M + NH4)
+
, 504.2516 and C24H35
10








Column chromatography of the mixture that produced alcohol 311 above also gave diol 
312 as an oil (122 mg, 12%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.13. max (ATR): 
3372 (OH), 2979 (CH), 2934 (CH), 2861 (CH), 1612 (Ar) cm
–1
. H (400 MHz, CDCl3): 
7.79 (2H, d, J = 8.0 Hz, H-3’ and H-5’), 7.35 (2H, d, J = 7.8 Hz, H-2’ and H-6’), 4.69 (1H, 
dd, J = 7.2 and 5.9 Hz, H-1), 3.61 (2H, t, J = 6.6 Hz, 2   H-6), 1.91 (1H, broad s, OH), 
1.86-1.76 (1H, m, H
A
-2), 1.76-1.66 (1H, m, H
B
-2), 1.61 (1H, broad s, OH), 1.59-1.49 (2H, 
m, 2   H-5), 1.47-1.27 (4H, m, 2   H-3 and 2   H-4) 1.34 (12H, s, 4   Me). C (100 
MHz, CDCl3): 147.21 (C), 133.86 (CH), 124.20 (CH), 82.77 (C), 73.17 (CH), 61.52 (CH2), 





, 36%], 338 [(M+NH4)
+
, 100], 320 [(M+NH4)
+
 – H2O, 31], 303 [(M + H)
+
 – 
H2O, 30]. HRMS: 338.2504 and 337.2539. C18H33
11












Column chromatography of the mixture that produced alcohol 311 above also gave alcohol 
313 as a pale yellow oil (71 mg, 4%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.37. max 
(ATR): 3428 (OH), 3117 (CH), 3087 (CH), 2979 (CH), 2940 (CH), 2862 (CH), 1608 (Ar), 
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1526 (Ar), 1357 (NO2), 1342 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.72 (1H, d, J = 2.7 Hz, 
H-3’), 8.40 (1H, dd, J = 9.3 and 2.8 Hz, H-5’), 7.77 (2H, d, J = 8.0 Hz, H-3’’ and H-5’’), 
7.33 (2H, d, J = 8.0 Hz, H-2’’ and H-6’’), 7.16 (1H, d, J = 9.4 Hz, H-6’), 4.70 (1H, broad t, 
J = 6.5 Hz, H-1), 4.19 (2H, t, J = 6.3 Hz, 2   H-6), 2.16 (1H, broad s, OH), 1.92-1.67 (4H, 
m, 2   H-2 and 2   H-5), 1.62-1.41 (4H, m, 2   H-3 and 2   H-4), 1.34 (12H, s, 4   Me). 
C (100 MHz, CDCl3): 156.87 (C), 147.88 (C), 139.85 (C), 138.88 (C), 134.98 (CH), 
129.05 (CH), 125.18 (CH), 121.84 (CH), 114.27 (CH), 83.82 (C), 74.30 (CH), 70.68 
(CH2), 38.74 (CH2), 28.50 (CH2), 25.56 (CH2), 25.12 (CH3), 24.85 (CH3). LRMS (CI
+
): 
504 [(M + NH4)
+
, 100%]. HRMS: 504.2510 and 503.2545. C24H35
11
BN3O8 requires (M + 
NH4)
+
, 504.2516 and C24H35
10







Alcohol 311 (65 mg, 0.13 mmol) and carbon tetrabromide (53 mg, 0.16 mmol) were stirred 
in anhydrous DCM (0.5 mL) under argon and cooled to 0 °C. A solution of 
triphenylphosphine in anhydrous DCM (0.5 mL) was added dropwise.  After 5 min, the 
solution was allowed to warm to RT and stir for 16 h.  After concentrating under reduced 
pressure, column chromatography [SiO2, petroleum ether-EtOAc (2:1) to (1:1)] yielded 
dioxaborolane 314 as a pale yellow oil (73 mg, 98%). Rf [SiO2, petroleum ether-EtOAc 
(1:1)]: 0.76. max (ATR): 2978 (CH), 2936 (CH), 2863 (CH), 1604 (Ar), 1527 (Ar), 1359 
(NO2), 1341 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.68 (1H, d, J = 2.8 Hz, H-3’’’), 8.18 (1H, 
dd, J = 9.3 and 2.8 Hz, H-5’’’), 7.81 (2H, d, J = 8.1 Hz, H-2’ and H-6’), 7.35 (2H, d, J = 
8.0 Hz, H-3’ and H-5’), 6.96 (1H, d, J = 9.4 Hz, H-6’’’), 5.38 (1H, dd, J = 7.5 and 5.2 Hz, 
H-1’’), 3.39 (2H, t, J = 6.7 Hz, 2   H-6’’), 2.19-2.08 (1H, m, HA-2’’), 2.00-1.90 (1H, m, 
H
B
-2’’), 1.90-1.81 (2H, m, 2   H-5’’), 1.60-1.41 (4H, m, 2   H-3’’ and 2   H-4’’), 1.331 
(6H, s, 2   Me), 1.327 (6H, s, 2   Me). C (100 MHz, CDCl3): 155.75 (C), 141.84 (C), 
139.87 (C), 139.41 (C), 135.59 (CH), 128.55 (CH), 125.07 (CH), 121.63 (CH), 116.08 
(CH), 84.01 (C), 83.23 (CH), 37.90 (CH2), 33.66 (CH2), 32.39 (CH2), 27.66 (CH2), 24.86 
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(CH3), 24.82 (CH3), 24.36 (CH2). MS Analysis was unsuccessful at both the University of 






Alcohol 311 (229 mg, 0.47 mmol), carbon tetraiodide (392 mg, 0.75 mmol) and 
triphenylphosphine (198 mg, 0.75 mmol) were dissolved in anhydrous DCM (1.2 mL) 
under argon and stirred at RT for 18 h.  DCM (5 mL) was added washed with aqueous 
sodium thiosulfate (10%, 4 mL).  Organics were separated, dried over Na2SO4 and 
concentrated under reduced pressure.  Column chromatography [SiO2, petroleum ether-
EtOAc (1:0) to (1:1)] yielded dioxaborolane 315 as a pale yellow oil (208 mg, 74%). Rf 
[SiO2, petroleum ether-EtOAc (1:1)]: 0.86. max (ATR): 2976 (CH), 2931 (CH), 2861 
(CH), 1605 (Ar), 1527 (Ar), 1485 (Ar), 1358 (NO2), 1340 (NO2) cm
–1
. H (400 MHz, 
CDCl3): 8.68 (1H, d, J = 2.8 Hz, H-3’’’), 8.18 (1H, dd, J = 9.3 and 2.8 Hz, H-5’’’), 7.81 
(2H, d, J = 8.0 Hz, H-2’ and H-6’), 7.34 (2H, d, J = 8.0 Hz, H-3’ and H-5’), 6.95 (1H, d, J 
= 9.3 Hz, H-6’’’), 5.37 (1H, dd, J = 7.6 and 5.2 Hz, H-1’’), 3.17 (2H, t, J = 6.9 Hz, 2   H-
6’’), 2.19-2.07 (1H, m, HA-2’’), 2.00-1.89 (1H, m, HB-2’’), 1.87-1.76 (2H, m, 2   H-5’’), 
1.60-1.52 (1H, m, H
A
-3’’), 1.50-1.40 (3H, m, 2   H-4’’ and HB-3’’), 1.331 (6H, s, 2   
Me), 1.326 (6H, s, 2   Me). C (100 MHz, CDCl3): 155.76 (C), 141.84 (C), 139.88 (C), 
139.42 (C), 135.60 (CH), 128.54 (CH), 125.05 (CH), 121.65 (CH), 116.07 (CH), 84.02 
(C), 83.23 (CH), 37.89 (CH2), 33.07 (CH2), 29.97 (CH2), 24.87 (CH3), 24.83 (CH3), 24.14 
(CH2), 6.82 (CH2). LRMS (ESI
+
): 1210 [(2M + NH4)
+
, 50%], 614 [(M + NH4)
+
, 100]. 












BIN2O7.NH4 requires (M + NH4)
+
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Method B: 
Alkyl bromide 314 (215 mg, 0.39 mmol) was dissolved in anhydrous acetone (1.5 mL) 
under argon.  Anhydrous KI (195 mg, 1.17 mmol) was added and the resulting mixture 
stirred at reflux for 3 h.  The mixture was cooled to 0 °C, filtered and the solid washed with 
a little anhydrous acetone.  Concentration under reduced pressure yielded iodide 315 as a 





A stirring solution of Nysted reagent 341 (3.5 mL, 20% wt. suspension in THF, 1.8 mmol) 
was cooled to 0 °C under argon, boron trifluoride diethyl etherate (180 μL, 1.4 mmol) 
added and stirred under argon for 5 min.  5-Hydroxy-2-nitrobenzaldehyde 335 (200 mg, 
1.2 mmol) in anhydrous THF (1.4 mL) was cooled to 0 °C and added dropwise.  After 5 
min the reaction mixture was warmed to RT and stirred for a further 2.25 h.  Aqueous HCl 
(1 M, 6 mL) was added followed by brine (5 mL) and the mixture extracted with DCM (3 
  6 mL).  Combined organics were dried over MgSO4 and concentrated under reduced 
pressure.  The crude material was washed through a short pad of silica using petroleum 
ether-EtOAc (1:1) and concentrated under reduced pressure.  The solid was dissolved in 
CHCl3 and allowed to recrystallise slowly.  Solvent traces were removed under reduced 
pressure yielding alkene 336 as needles (196 mg, 99%). Mp: 90-91 °C (CHCl3). max 
(ATR): 3336 (OH), 3078 (CH), 2924 (CH), 2857 (CH), 2783 (CH), 1601 (Ar), 1576 (Ar), 
1316 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.03 (1H, d, J = 8.9 Hz, H-5), 7.28 (1H, dd, J = 
17.2 and 10.9 Hz, H-1’), 7.00 (1H, d, J = 2.7 Hz, H-2), 6.84 (1H, dd, J = 9.0 and 2.8 Hz, 
H-6), 5.70 (1H, dd, J = 17.2 and 0.9 Hz, H-2’-cis to aryl), 5.47 (1H, dd, J = 10.9 and 0.9 
Hz, H-2’-trans to aryl). C (100 MHz, CDCl3): 159.99 (C), 140.88 (C), 137.21 (C), 133.47 





41%), 148 (58), 136 (44), 120 (37), 107 (41), 84 (55), 77 (100), 65 (78), 63 (49). HRMS: 





Methyltriphenylphosphonium bromide (941 mg, 2.6 mmol) was stirred in anhydrous THF 
(6 mL) under argon.  The mixture was cooled to –78 °C and nBuLi (1.64 mL, 2.6 mmol) 
was added dropwise and the resulting mixture stirred for 30 min.  5-Hydroxy-2-
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nitrobenzaldehyde 335 (200 mg, 1.2 mmol) in anhydrous THF (2 mL) was added and the 
mixture stirred for 1 h before being allowed to warm to RT before stirring at reflux for 2 h.  
After cooling to RT, saturated aqueous NH4Cl (15 mL) was added followed by H2O (15 
mL).  Extractions were made with DCM (4   30 mL).  Combined organic extracts were 
dried over MgSO4 and concentrated under reduced pressure.  Column chromatography 
[SiO2, petroleum ether-EtOAc (4:1)] yielded alkene 336 as an amorphous solid (85 mg 




Nysted reagent 341 (3.5 mL, 20% wt. suspension in THF, 1.8 mmol) was added to stirring 
titanocene dichloride (894 mg, 3.6 mmol) in anhydrous THF (6 mL) under argon and 
stirred at 40 °C for 30 min.  The resulting black/red solution was cooled to –78 °C and a 
solution of 5-hydroxy-2-nitrobenzaldehyde 335 (200 mg, 1.2 mmol) in anhydrous THF (2 
mL) was added dropwise.  The solution was stirred for 10 min before being allowed to 
warm to RT.  Saturated aqueous NaHCO3 (25 mL) was added and extractions made with 
EtOAc (5   20 mL).  The aqueous layer was acidified using aqueous HCl (3 M) and 
extracted with DCM (3   20 mL).  Combined DCM extracts were dried over MgSO4 and 
concentrated under reduced pressure.  Column chromatography [SiO2, petroleum ether-
EtOAc (4:1)] yielded alkene 336 an amorphous solid (77 mg, 39%). Rf [SiO2, petroleum 
ether-EtOAc (4:1)]: 0.21. Characterisation as previous. 
 
4-Nitro-3-vinylphenyl acetate 342 
 
Stirring Nysted reagent 341 (17 mL, 20% wt. suspension in THF, 9 mmol) was cooled to 0 
°C and boron trifluoride diethyl etherate (883 μL, 7.2 mmol) added under argon and stirred 
for 5 min.  5-Hydroxy-2-nitrobenzaldehyde 335 (1.00 g, 6.0 mmol) in anhydrous THF (7 
mL) was cooled to 0 °C and added dropwise.  After 5 min the reaction mixture was 
allowed to warm to RT and stir for a further 2 h.  Aqueous HCl (1 M, 8 mL) was added 
followed by brine (8 mL).  One extract was made with DCM (15 mL) and residual material 
washed through a Celite pad with DCM.  Combined organics were dried over MgSO4 and 
concentrated under reduced pressure.  The crude material was washed through a short pad 
of silica using petroleum ether-EtOAc (1:1) and concentrated under reduced pressure.  
Attempted recrystallisations led to some suspected polymerisation of material upon 
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warming in CHCl3, forming a black, insoluble oil.  The residual yellow material was 
dissolved in acetic anhydride (7 mL) and AcOH (0.3 mL) was added.  The resulting 
solution was stirred at reflux overnight under argon.  Concentration under reduced pressure 
gave a dark residue.  Column chromatography [SiO2, petroleum ether-EtOAc (95:5) to 
(4:1)] yielded acetate 342 as needles (863 mg, 70%). Rf [SiO2, petroleum ether-EtOAc 
(4:1)]: 0.42. Mp: 85-86 °C. max (ATR): 3108 (CH), 3098 (CH), 3081 (CH), 1766 (C=O), 
1613 (Ar), 1579 (Ar), 1519 (NO2), 1343 (NO2) cm
–1
. H (400 MHz, CDCl3): 8.02 (1H, d, J 
= 8.9 Hz, H-5), 7.35 (1H, d, J = 2.5 Hz, H-2), 7.21 (1H, dd, J = 17.2 and 10.9 Hz, H-1’), 
7.17 (1H, dd, J = 8.9 and 2.5 Hz, H-6), 5.74 (1H, dd, J = 17.2 and 0.6 Hz, H-2’-cis to aryl), 
5.53 (1H, dd, J = 11.0 and 0.6 Hz, , H-2’-trans to aryl), 2.35 (3H, s, CH3). C (100 MHz, 
CDCl3): 168.51 (C), 153.94 (C), 144.78 (C), 135.53 (C), 132.11 (CH), 126.29 (CH), 












, 78], 136 (41), 120 (35), 107 (43), 89 (34), 77 
(56), 43 (CH3CO
+








Vanillin 347 (2.50 g, 16.4 mmol) was dissolved in AcOH (35 mL) and cooled to 0 °C 
before HNO3 (2.2 mL, 25 mmol, 70%) was added dropwise.  After stirring for 5 min at 0 
°C and 45 min ant RT, the solution was concentrated under reduced pressure.  The 
resulting solid was recrystallised from acetone to yield aldehyde 348 as a yellow prisms 
(2.19 g, 68%). Mp: 173-174 C (acetone) (Lit.201 176 °C). max (ATR): 3194 (OH), 3078 
(CH), 2984 (CH), 2945 (CH), 2878 (CH), 1684 (C=O), 1611 (Ar), 1576 (Ar), 1545 (Ar), 
1335 (NO2) cm
–1
. H (400 MHz, CDCl3): 11.27 (1H, s, OH), 9.90 (1H, s, CHO), 8.23 (1H, 
d, J = 1.7 Hz, H-6), 7.65 (1H, d, J = 1.7 Hz, H-2), 4.03 (3H, s, Me). C (100 MHz, CDCl3): 
188.86 (CH), 151.22 (C), 151.08 (C), 133.50 (C), 127.95 (C), 121.34 (CH), 113.52 (CH), 




, 41%), 180 (21), 122 (20), 86 (63), 84 (100). 
1
H NMR 












Benzyl bromide (12.3 mL, 104 mmol) was added dropwise to a stirring mixture of vanillin 
347 (10.00 g, 65.7 mmol) and K2CO3 (4.54 g, 32.8 mmol) in anhydrous acetone (150 mL) 
under argon.  The resulting mixture was stirred at reflux for 16 h.  After cooling to RT, 
H2O (500 mL) was added and extracted with DCM (3   150 mL).  Combined organics 
were dried over Na2SO4 and concentrated under reduced pressure.  Recrystallisation from 
hot EtOH yielded aldehyde 349 as plates (11.00 g, 69%). Mp: 60-61 °C (EtOH). max 
(ATR): 3061 (CH), 3034 (CH), 3013 (CH), 2949 (CH), 2839 (CH), 2762 (CH), 1672 
(C=O), 1597 (Ar), 1582 (Ar), 1504 (Ar) cm
–1
. H (500 MHz, CDCl3): 9.84 (1H, s, CHO), 
7.46-7.42 (3H, m, 2   m-H Ph and H-2), 7.41-7.36 (3H, m, 2   o-H Ph and p-H Ph), 7.35-
7.31 (1H, m, H-6), 6.99 (1H, d, J = 8.2 Hz, H-5), 5.25 (2H, s, CH2), 3.95 (3H, s, Me). C 
(126 MHz, CDCl3): 190.93 (CH), 153.59 (C), 150.08 (C), 136.00 (C), 130.29 (C), 128.73 
(CH), 128.22 (CH), 127.20 (CH), 126.62 (CH), 112.38 (CH), 109.33 (CH), 70.87 (CH2), 




, 75%), 91 (PhCH2
+
, 100), 84 (75), 65 (56). HRMS: 















Aldehyde 349 (800 mg, 3.3 mmol) was dissolved in AcOH (7 mL) and cooled to 0 °C.  
Concentrated HNO3 (0.45 mL) was added dropwise to the stirring solution then warmed to 
RT after 5 min.  After stirring overnight, the solution was concentrated under reduced 
pressure.  Recrystallisation from hot EtOH yielded intermediate 4-(benzyloxy)-5-methoxy-
2-nitrobenzaldehyde as a yellow amorphous solid (715 mg).  Selected data for intermediate 
4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde: H (400 MHz, CDCl3): 10.43 (1H, s, 
CHO), 7.67 (1H, s, H-3) 7.49-7.34 (6H, m, Ph and H-6), 5.27 (2H, s, CH2), 4.02 (3H, s, 
Me).  Crystals were re-dissolved in AcOH (4.5 mL) at 85 °C and HBr (48%, 1.4 mL) was 
added dropwise to the stirring solution.  After 1 h the solution was cooled to RT.  The 
precipitate was collected by filtration, washed with hexane and dried under reduced 
pressure.  Recrystallisation from EtOH yielded phenol 350 as an amorphous yellow solid 
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(339 mg, 52%).  Mp: 208-209 °C (EtOH) [Lit.
169
 208-210 °C (EtOH)]. max (ATR): 3129 
(OH), 3061 (CH), 2949 (CH), 1670 (C=O), 1582 (Ar), 1510 (NO2), 1325 (NO2) cm
–1
. H 
(400 MHz, d6–DMSO): 11.10 (1H, broad s, OH), 10.16 (1H, s, CHO), 7.50 (1H, s, H-3), 
7.36 (1H, s, H-6), 3.94 (3H, s, OMe). C (100 MHz, d6–DMSO): 188.39 (CH), 151.83 (C), 
151.03 (C), 143.82 (C), 123.38 (C), 111.05 (CH), 110.65 (CH), 56.36 (CH3). LRMS (CI
+
): 
215 [(M + NH4)
+
, 26%], 198 [(M + H)
+
, 100], 168 [(M + H)
+
 – CHO, 9]. HRMS: 










Benzyl bromide (19.4 mL, 163 mmol) was added slowly to a stirring mixture of vanillin 
347 (20.00 g, 131 mmol) and K2CO3 (9.1 g, 138 mmol) in anhydrous acetone (300 mL) 
under argon.  The resultant mixture stirred at relfux overnight.  After cooling to RT, H2O 
(125 mL) was added and extracted with DCM (3   100 mL).  Combined organics were 
dried over Na2SO4 and concentrated under reduced pressure.  The crude material was 
dissolved in AcOH (100 mL) at RT and HNO3 (24 mL) was added slowly to the stirring 
solution.  The resulting mixture was stirred at reflux for 20 h.  After cooling to RT, H2O 
(80 mL) was added the precipitate collected by filtration.  The yellow solid was washed 
with a little cold H2O before drying under reduced pressure.  The crude was re-dissolved in 
AcOH (200 mL) at 85 °C and HBr (48%, 75 mL) was added slowly.  After 1.75 h the 
solution was cooled to 0 °C.  The precipitate collected by filtration, washed with hexane 
and dried under reduced pressure.  Recystallisation from acetone yielded phenol 350 as an 




1,4-Diiodobutane 160 (1.6 mL, 12.2 mmol) was added to a stirring mixture of aldehyde 
350 (600 mg, 3.0 mmol) and Cs2CO3 (2.48 g, 7.6 mmol) in anhydrous MeCN (15 mL) at 
RT under argon.  The resulting mixture was stirred at 80 °C for 16 h with light excluded 
throughout.  After cooling to RT the mixture was filtered and washed through with DCM 
(20 mL) before concentrating under reduced pressure.  Column chromatography [SiO2, 
petroleum ether-EtOAc (4:1)] gave aldehyde 351 as a semi-pure pale yellow oil which was 
taken forward without further purification (677 mg, 59%). Rf [SiO2, petroleum ether-
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EtOAc (4:1)]: 0.26. H (400 MHz, CDCl3): 10.45 (1H, s, CHO), 7.59 (1H, s, H-6), 7.41 
(1H, s, H-3), 4.19 (2H, t, J = 5.9 Hz, 2   H-1), 4.01 (3H, s, OMe), 3.29 (2H, t, J = 6.5 Hz, 
2   H-4), 2.10-2.01 (4H, m, 2   H-2 and 2   H-3). LRMS (CI
+
): 380 [(M + H)
+
, 100%].  




[4-(4’-Formyl-2’-methoxy-5’-nitrophenoxy)butyl]triphenylphosphonium iodide 352 
 
Alkyl iodide 351 (560 mg, 1.5 mmol ) and triphenylphosphine (1.16 g, 4.4 mmol) were 
dissolved in anhydrous MeCN (7 mL) under argon and stirred at 80 °C overnight.  After 
cooling to RT the solution was concentrated under reduced pressure.  The residue was 
dissolved in minimal CHCl3 and added dropwise to vigourously stirring Et2O (100 mL).  
The precipitate was collected by filtration, washed with Et2O and concentrated under 
reduced pressure.  Column chromatography [SiO2, DCM-EtOH (1:0) to (19:1)] yielded 
phosphonium iodide 352 as a yellow glass (717 mg, 76%). Rf [SiO2, DCM-EtOH (19:1)]: 
0.29. max (ATR): 3053 (CH), 3008 (CH), 2935 (CH), 2866 (CH), 2794 (CH), 1684 (C=O), 
1599 (Ar), 1571 (Ar), 1515 (Ar), 1328 (NO2) cm
–1
. H (400 MHz, CDCl3): 10.31 (1H, s, 
CHO), 7.89-7.81 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.77-7.70 (6H, m, 6   m-H 
PPh3), 7.58 (1H, s, H-6’), 7.32 (1H, s, H-3’), 4.29 (2H, t, J = 5.7 Hz, 2   H-4), 3.88 (3H, s, 
OMe), 3.87-3.78 (2H, m, 2   H-1), 2.40-2.30 (2H, m, 2   H-3), 2.06-1.94 (2H, m, 2   H-
2). C (100 MHz, CDCl3): 187.74 (CH), 153.25 (C), 151.66 (C), 143.81 (C), 135.24 (d, J = 
2.9 Hz, CH), 133.73 (d, J = 10.0 Hz, CH), 130.62 (d, J = 12.6 Hz, CH), 125.38 (C), 118.00 
(d, J = 86.1 Hz, C), 109.91 (CH), 108.49 (CH), 69.12 (CH2), 56.65 (CH3), 29.06 (d, J = 
16.5 Hz, CH2), 22.74 (d, J = 50.9 Hz, CH2), 19.57 (d, J = 3.7 Hz, CH2). P {
1
H} (162 
MHz, CDCl3): 24.28 (s). LRMS (ESI
+
): 546 [(cation + MeOH), 77%), 514 (cation, 100). 
HRMS: 546.2023 and 514.1767. C31H33NO6P  requires (cation + MeOH), 546.2040 and 
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[4-(4’-Formyl-2’-methoxyphenoxy)butyl]triphenylphosphonium iodide 358 
 
Anhydrous MeCN (10 mL) was added to a stirring mixture of alkyl iodide 161 (1.13 g, 2.0 
mmol), vanillin 347 (300 mg, 2.0 mmol) and Cs2CO3 (771 mg, 2.4 mmol) under argon.  
The resulting mixture was stirred at 80 °C for 66 h.  After cooling to RT, the mixture was 
filtered and washed through with CHCl3 before concentrating under reduced pressure.  
Column chromatography [SiO2, DCM-EtOH (1:0) to (19:1)] yielded aldehyde 358 as a 
glass (785 mg, 67%). Rf [SiO2, DCM-EtOH (19:1)]: 0.41.max (ATR): 3057 (CH), 3015 
(CH), 2922 (CH), 1678 (C=O), 1585 (Ar), 1508 (Ar) cm
–1
. H (400 MHz, CDCl3): 9.83 
(1H, s, CHO), 7.89-7.79 (9H, m, 6   o-H PPh3 and 3   p-H PPh3), 7.76-7.68 (6H, m, 6   
m-H PPh3), 7.47 (1H, dd, J = 8.2 and 1.8 Hz, H-5’), 7.37 (1H, d, J = 1.8 Hz, H-3’), 7.11 
(1H, d, J = 8.3 Hz, H-6’), 4.26 (2H, t, J = 5.7 Hz, 2   H-4), 3.89-3.79 (2H, m, 2   H-1), 
3.73 (3H, s, OMe), 2.33-2.24 (2H, m, 2   H-3), 2.05-1.93 (2H, m, 2   H-2). C (100 MHz, 
CDCl3): 190.91 (CH), 153.54 (C), 149.37 (C), 135.19 (d, J = 2.6 Hz, CH), 133.53 (d, J = 
10.0 Hz, CH), 130.55 (d, J = 12.5 Hz, CH), 129.87 (C), 126.85 (CH), 117.82 (d, J = 86.1 
Hz, C), 112.10 (CH), 109.34 (CH), 68.41 (CH2), 55.90, (CH3), 28.82 (d, J = 16.2 Hz, 
CH2), 22.50 (d, J = 50.8 Hz, CH2), 19.70 (d, J = 3.4 Hz, CH2). P {
1
H} (162 MHz, CDCl3): 
23.88 (s). LRMS (ESI
+
): 469 (cation, 100%). HRMS: 469.1918. C30H30O3P requires 










Nysted reagent (3.5 mL, 20% wt. suspension in THF, 1.8 mmol) and boron trifluoride 
diethyl etherate (190 μL, 1.5 mmol) were stirred under argon for 5 min.  A solution of 
aldehyde 350 (150 mg, 0.76 mmol) in anhydrous THF (1.4 mL) was added dropwise and 
the resulting mixture stirred for 3 h at RT.  Aqueous HCl (1 M, 5 mL) was added dropwise 
followed by brine (5 mL) and DCM (5 mL).  After mixing, the mixture was filtered 
through a pad of Celite and washed through with DCM.  Organics were dried over Na2SO4, 
concentrated under reduced pressure and purificatied by flash column chromatography 
[SiO2, petroleum ether-EtOAc (1:1)].  Crystallisation from CHCl3 yielded phenol 362 as 
yellow needles (120 mg, 81%). Rf [SiO2, petroleum ether-EtOAc (1:1)]: 0.51. Mp: 89-90 
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°C. max (ATR): 3358 (OH), 3098 (CH), 3078 (CH), 3011 (CH), 2951 (CH), 2849 (CH), 
1618 (Ar), 1587 (Ar), 1520 (NO2), 1331 (NO2) cm
–1
. H (400 MHz, CDCl3): 7.60 (1H, s, 
H-6), 7.24 (1H, dd, J = 17.1 and 10.8 Hz, H-1’), 6.96 (1H, s, H-3), 5.89 (1H, broad s, OH), 
5.61 (1H, dd, J = 17.2 and 0.9 Hz, H-2’-cis to aryl), 5.40 (1H, dd, J = 10.9 and 0.9 Hz, H-
2’-trans to aryl), 4.02 (1H, s, OMe). C (100 MHz, CDCl3): 150.58 (C), 145.17 (C), 140.83 
(C), 133.48 (CH2), 127.94 (C), 117.15 (CH), 111.11 (CH), 109.26 (CH), 56.45 (CH3). 
LRMS (CI
+
): 213 [(M + NH4)
+
, 36%], 196 [(M + H)
+
, 100], 178 [(M + H)
+
 – H2O,  11]. 
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Appendices 
 
Appendix 1: Anion exchange chromatography procedure 
 
Amberlite IRA-400 ion exchange resin chloride form (7 g) was packed into a column with 
H2O.  An aqueous solution of NaOH (10% w/v) was run through the column until the pH 
of the eluate was 14.  The column was then washed with H2O until the eluate pH was 7 (~6 
column volumes).  An aqueous solution of MeSO3H (10% w/v) was washed through the 
column until the eluate pH was 1 (~2 column volumes) before being washed with H2O 
until the eluate pH was 7 (~6 column volumes).  The desired mixed anion phosphonium 
salt was washed through the column in MeOH:H2O (1:1). 
 
The desired phosphonium methanesulfonate salt was collected either by concentrating the 
eluate under reduced pressure, or by extracting from the eluate with CHCl3 (3   8 mL), 
drying combined organics over Na2SO4, followed by concentration under reduced pressure. 
 
Appendix 2: Buffer solutions 
 
All buffers were adjusted to the desired pH at 37 °C using KOH or HCl.  BSA is included 
in biological testing only. 
 
MAS1 Buffer 
Mannitol  220 mM 
Sucrose  70 mM 
HEPES  1 mM 
EGTA   2 mM 
KH2PO4  10 mM 
MgCl2   5 mM 
BSA (FA free) 0.2% by weight 
 
SHEP Buffer 
Sucrose  290 mM 
HEPES  1 mM 
EGTA   2 mM 
KH2PO4  10 mM 
BSA (FA free) 0.2% by weight 
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KHE Buffer 
KCl   120 mM 
HEPES  5 mM 
EGTA   1 mM 
KH2PO4  5 mM 
BSA (FA free) 0.2% by weight 
 
CP1 Buffer – pH 7.4 at 4 °C (approx 9 mL 10 M HCl) 
KCl    100 mM 
Tris-HCl   50 mM 
EGTA   2 mM 
 
CP2 Buffer – pH 7.4 at 4 °C (approx 2.7 mL 10 M HCl) 
KCl    100 mM 
Tris-HCl   50 mM 
EGTA   2 mM 
BSA(FA free)  0.5% by weight 
MgCl2.6H2O  5 mM 
ATP   1 mM 




CP2 can be made the day before use but BSA, ATP and protease must be added on the day 
of mitochondria isolation.  Check pH and adjust if appropriate prior to use.  Dissolve 
solutions completely before adding MgCl2.6H2O.  Adjust to pH 7.1 at RT, put in fridge 
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Appendix 3: MitoSUM decomposition time course graphs 
 
MitoDNP-SUM(1) Decomposition TC (pH 7.4)


























Fig.83: Time course graph showing linearity of MitoDNP-SUM(1) 292 decomposition 
 
MitoDNP-SUM(2) Decomposition TC (pH 7.4)










TC5 (+ 20 µM H2O2)















Fig.84: Time course graph showing linearity of MitoDNP-SUM(2) 304 decomposition 
 
MitoDNP-SUM(1) Decomposition TC (pH 8.0)
























Fig.85: Time course graph showing linearity of MitoDNP-SUM(1) 292 decomposition 
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MitoDNP-SUM(2) Decomposition TC Spectra (pH 8.0)
























Fig.86: Time course graph showing linearity of MitoDNP-SUM(2) 304 decomposition 
 
Appendix 4: Mitochondria isolation procedure from skeletal muscle tissue 
 
The isolation of the mitochondria was performed in a team each day, with different team 
members performing different steps in the isolation procedure to split the workload.  
Changing the steps that individuals complete each day can lead to result variability and so 
commonly, each person would be involved only in specific steps.  Those without animal 
handling certification can only join the procedure from step 5 onwards.  For one rat 






1. Kill the rat by cervical dislocation.  Cut around the hind legs with sharp scissors, peel 
back the skin with a sharp blade and cut out as much skeletal muscle as possible, 
including some from the back. 
2. Place the tissue immediately into CP1 medium on ice. 
3. Pour away the medium and weigh the tissue (~15-25 g tissue/rat). 
4. Add more CP1 medium immediately to the tissue. 
5. Take one piece of tissue at a time, place on a pre-cooled tile and mince with a sharp 
blade removing as much fat and connective tissue as possible.  Once a piece of tissue is 
minced place it in CP1 medium again. 
6. Repeat until all the tissue has been minced in this way. 
7. Chop the tissue further with scissors and rinse 4-5 times with CP1. 
Add the tissue to CP2 (with protease & ATP 5).  Use 40 mL of CP2 for every 4-5 g 
tissue (It is important not to have a higher dilution, as this causes over digestion of the 
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tissue, resulting in a poor yield of mitochondria).  Leave to stir gently in a 250 mL 
beaker on ice for 5 min (2.5 min for mice). 
8. Divide the tissue into 3 or 4   100 mL plastic beakers. 
9. Polytron the tissue in each beaker separately for 3   3 second bursts. (1   3 s for 
mice). 
 
Use the polytron on a slow speed.  Remove any fat or connective tissue from head                
between bursts.  Over homogenised tissue results in damaged mitochondria so this step 
will vary depending on the homogeniser used. 
 
10. Pour the homogenised tissue back into the 250 mL beaker and leave stirring on ice for 
a further 6 min (3 min for mice). 
11. Split the homogenised tissue between 8   50 mL plastic centrifuge tubes and spin at 4 
°C for 10 min at 500   g. 
12. Filter the supernatant through two layers of muslin into 8 new centrifuge tubes.  Fill up 
the tubes with CP1 if necessary and spin at 4 °C for 10 min at 10,000   g. 
13. Resuspend the pellets in CP1 medium ie. decant off supernatant, remove any white 
outer layer by gentle swirling of the tube by hand and resuspend the mitochondria with 
a resuspending stick in a very small volume of medium.  At this stage combine two 
pellets together. 
14. Fill up the tubes (4) with CP1 medium and spin at 4 °C for 10 min at 10,000   g. 
15. Resuspend the mitochondria as before and again combine two pellets together. 
16. Fill up the tubes with CP1 and spin at 500   g for 5 min. 
17. Transfer the supernatant and spin at 4 °C for 10 min at 10,000   g. 
18. Finally, resuspend and combine the two pellets.  Make up to a final volume of approx 1 
mL with CP1 medium and determine the protein concentration using a Biuret assay 
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